{"docstore/data": {"8a18b715-4d21-4660-899a-d5bacabdd209": {"__data__": {"id_": "8a18b715-4d21-4660-899a-d5bacabdd209", "embedding": null, "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "original_text": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "487df8c4-d11a-4214-b81d-9f434234bcfe", "node_type": "1", "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n", "original_text": "Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call. "}, "hash": "f0449a94763453a2c3c7cd62de4a86d21c25e808e4cf547d00b1a596e7cbbdc0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "487df8c4-d11a-4214-b81d-9f434234bcfe": {"__data__": {"id_": "487df8c4-d11a-4214-b81d-9f434234bcfe", "embedding": null, "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n", "original_text": "Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a18b715-4d21-4660-899a-d5bacabdd209", "node_type": "1", "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "original_text": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c5c376ac1adf29e88dfd0bf6738769911af3254e380e0936c8a307dd7570f92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2f53de9-142f-4ed0-a9df-998a4ad55fc6", "node_type": "1", "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome. ", "original_text": "Today's conference is being recorded. "}, "hash": "f98cec30fa7a0cd57eee2ce37c7e27bfa318dff42c6e33991d789b32d36c034b", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call. ", "start_char_idx": 48, "end_char_idx": 236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2f53de9-142f-4ed0-a9df-998a4ad55fc6": {"__data__": {"id_": "a2f53de9-142f-4ed0-a9df-998a4ad55fc6", "embedding": null, "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome. ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "487df8c4-d11a-4214-b81d-9f434234bcfe", "node_type": "1", "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n", "original_text": "Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0d3c5576d88773fafcfd614c1e9a798ad70128e223eeea6e5fefcc379804306", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64f7b3ea-7c5b-4c6d-b74d-5a18a0cc68ba", "node_type": "1", "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook. ", "original_text": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. "}, "hash": "43631893e8dda7bc04ed979292643b647861b2879d8a37de05f74861cd550081", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 236, "end_char_idx": 274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64f7b3ea-7c5b-4c6d-b74d-5a18a0cc68ba": {"__data__": {"id_": "64f7b3ea-7c5b-4c6d-b74d-5a18a0cc68ba", "embedding": null, "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook. ", "original_text": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2f53de9-142f-4ed0-a9df-998a4ad55fc6", "node_type": "1", "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome. ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdf81a080b0e8721dfeccf5a28f21095b4a81152390c661491bb4267efccfbd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "691f2ff0-f72d-4c90-8f4e-3c87313fbb39", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com. ", "original_text": "Please go ahe ad. \n \n"}, "hash": "41023f0c7b28362c24f6a486337859056c489d61e0f3c996d28c5279858243bd", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "start_char_idx": 274, "end_char_idx": 380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "691f2ff0-f72d-4c90-8f4e-3c87313fbb39": {"__data__": {"id_": "691f2ff0-f72d-4c90-8f4e-3c87313fbb39", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com. ", "original_text": "Please go ahe ad. \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64f7b3ea-7c5b-4c6d-b74d-5a18a0cc68ba", "node_type": "1", "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook. ", "original_text": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "009b3b73d6380207cb8e3a4888bf9649f8ac8614ecf50f42d03e48d4a3346822", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b07050c-a339-4e4b-9c5a-9d195d01b30c", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "original_text": "Kevin Moran:   Good morning, and welcome. "}, "hash": "4ab271b713a167f65f81bbf4b0a15626dfd0ce2d7fb4eaa6ad10491ece23dfd4", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahe ad. \n \n", "start_char_idx": 380, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b07050c-a339-4e4b-9c5a-9d195d01b30c": {"__data__": {"id_": "5b07050c-a339-4e4b-9c5a-9d195d01b30c", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "original_text": "Kevin Moran:   Good morning, and welcome. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "691f2ff0-f72d-4c90-8f4e-3c87313fbb39", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com. ", "original_text": "Please go ahe ad. \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af61927028559bf19b2d81be2b3b02f3da0ee4242e8caadb095e036920381dd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6c0d5c5-cd5e-4c03-adb7-5018488f4c91", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements. ", "original_text": "Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook. "}, "hash": "601228bbda2eba23c9383fceb83ca4ef8d380e94d8d08d6da4df45e7806892d9", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:   Good morning, and welcome. ", "start_char_idx": 401, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6c0d5c5-cd5e-4c03-adb7-5018488f4c91": {"__data__": {"id_": "d6c0d5c5-cd5e-4c03-adb7-5018488f4c91", "embedding": null, "metadata": {"window": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements. ", "original_text": "Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b07050c-a339-4e4b-9c5a-9d195d01b30c", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "original_text": "Kevin Moran:   Good morning, and welcome. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae5f3725c1c038f3ac1108268667ac6d8844975d34811d247ec03e1ab5104065", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "324b16d3-8f12-4bb2-ad4a-e66634fade20", "node_type": "1", "metadata": {"window": "Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied. ", "original_text": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com. "}, "hash": "91fc2ffbca155c15e8824ffd0b09d338cf334c12aac811b44fcae2d8e5cbf285", "class_name": "RelatedNodeInfo"}}, "text": "Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook. ", "start_char_idx": 443, "end_char_idx": 563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "324b16d3-8f12-4bb2-ad4a-e66634fade20": {"__data__": {"id_": "324b16d3-8f12-4bb2-ad4a-e66634fade20", "embedding": null, "metadata": {"window": "Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied. ", "original_text": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6c0d5c5-cd5e-4c03-adb7-5018488f4c91", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements. ", "original_text": "Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddb8f0e4e742ee20c63cbed4f71587e92dfaeb84eb47c1df3a87bb1dffcabda0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a84a070-cb03-4c79-aac8-62e3f2480743", "node_type": "1", "metadata": {"window": "Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties. ", "original_text": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n"}, "hash": "308982416a930d208f455983373f2eb4cecebf575f658ce159ba11d36d1ed7f0", "class_name": "RelatedNodeInfo"}}, "text": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com. ", "start_char_idx": 563, "end_char_idx": 675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a84a070-cb03-4c79-aac8-62e3f2480743": {"__data__": {"id_": "5a84a070-cb03-4c79-aac8-62e3f2480743", "embedding": null, "metadata": {"window": "Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties. ", "original_text": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "324b16d3-8f12-4bb2-ad4a-e66634fade20", "node_type": "1", "metadata": {"window": "Please go ahe ad. \n \n Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied. ", "original_text": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28d6ecf3ecf623dabd7ad0ed432bfd1b8325496f58f5e5a60bb5d6cb99436e00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3bdf4e7-2502-4577-a701-8b4354f0ccf7", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements. "}, "hash": "07e74479564bf2c7c21391d8420c6eea1e3156143a6a78a2e4d51b4fcdd8cb2f", "class_name": "RelatedNodeInfo"}}, "text": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "start_char_idx": 675, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3bdf4e7-2502-4577-a701-8b4354f0ccf7": {"__data__": {"id_": "a3bdf4e7-2502-4577-a701-8b4354f0ccf7", "embedding": null, "metadata": {"window": "Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a84a070-cb03-4c79-aac8-62e3f2480743", "node_type": "1", "metadata": {"window": "Kevin Moran:   Good morning, and welcome.  Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties. ", "original_text": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22a3cda1d604da0a041418b53389c5665d2b86ecd3b89ff22dfe1c72e21b3cbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93c553a6-33aa-4bfe-93fa-c32a0954f7eb", "node_type": "1", "metadata": {"window": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied. "}, "hash": "36fc25eca6811127d7274c80984ce8f37e01a97fe2e159493ef4a21304b286ed", "class_name": "RelatedNodeInfo"}}, "text": "During the call, we will be making forward -looking statements. ", "start_char_idx": 784, "end_char_idx": 848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93c553a6-33aa-4bfe-93fa-c32a0954f7eb": {"__data__": {"id_": "93c553a6-33aa-4bfe-93fa-c32a0954f7eb", "embedding": null, "metadata": {"window": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3bdf4e7-2502-4577-a701-8b4354f0ccf7", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health Second Quarter \nFiscal 2022 results along with an update to our FY  \u201822 outlook.  You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f075f831afc3bd205eb666cf4e004ec40d14ab5090032617fcfe93977e4eb14d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fda7b66-2aba-4ff6-8853-880f6881bef8", "node_type": "1", "metadata": {"window": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties. "}, "hash": "5096f6ea9d6f439067afd7753a2836c8ea7fd9eeb34e14b841825706d976b7d1", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied. ", "start_char_idx": 848, "end_char_idx": 1019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fda7b66-2aba-4ff6-8853-880f6881bef8": {"__data__": {"id_": "5fda7b66-2aba-4ff6-8853-880f6881bef8", "embedding": null, "metadata": {"window": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93c553a6-33aa-4bfe-93fa-c32a0954f7eb", "node_type": "1", "metadata": {"window": "You can find today's press release \nand presentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42f048df7e8eb7e6daba3af085777deb9e690d5cb1f61c628fcd571571f78423", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b23bf48-be79-485b-a7df-c04747663807", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n", "original_text": "Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. "}, "hash": "6039bbb2b834cc3a649e59cdad8ddf291fcb7a7e891a5f98c52f5b0fe1bac2b7", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties. ", "start_char_idx": 1019, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b23bf48-be79-485b-a7df-c04747663807": {"__data__": {"id_": "0b23bf48-be79-485b-a7df-c04747663807", "embedding": null, "metadata": {"window": "During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n", "original_text": "Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fda7b66-2aba-4ff6-8853-880f6881bef8", "node_type": "1", "metadata": {"window": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01acf78a83eea235ef57efaa9e26c21ef9d0af3c5dced43a01b2359621468fa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b937d73-f2d0-4a8b-90bd-bf6cc47d563f", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n"}, "hash": "272efe837ae3f3ebdab9396b8ced06a687afd874f6a7048b810958e02f4612bd", "class_name": "RelatedNodeInfo"}}, "text": "Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "start_char_idx": 1184, "end_char_idx": 1323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b937d73-f2d0-4a8b-90bd-bf6cc47d563f": {"__data__": {"id_": "7b937d73-f2d0-4a8b-90bd-bf6cc47d563f", "embedding": null, "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b23bf48-be79-485b-a7df-c04747663807", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n", "original_text": "Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7131ee94464af3109cc7fe18d4d47e785be0b47517d31a4b0089ca744ff6fe1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c77b890-9816-4c5b-aa91-66e15e9f026b", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago. ", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . "}, "hash": "20d231c27d6d3c3e0ad708dc9bbd1b2c755b58894e3ed659da1b6f41c5adcf5a", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n", "start_char_idx": 1323, "end_char_idx": 1448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c77b890-9816-4c5b-aa91-66e15e9f026b": {"__data__": {"id_": "1c77b890-9816-4c5b-aa91-66e15e9f026b", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago. ", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b937d73-f2d0-4a8b-90bd-bf6cc47d563f", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a782a8b5767ac10956d1c1b9d24c1c4a24e1ebce9c33d5906770295ce116c49e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc5f2b3b-a23a-4324-9710-f6cd84aa0de7", "node_type": "1", "metadata": {"window": "Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n", "original_text": "With that, I'll now turn the call over to Mike.  \n \n"}, "hash": "0c91c36d72db0577ef24d4dc4768ed5484080730f4be283f1173dd2d4b1a498c", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "start_char_idx": 1448, "end_char_idx": 1605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc5f2b3b-a23a-4324-9710-f6cd84aa0de7": {"__data__": {"id_": "bc5f2b3b-a23a-4324-9710-f6cd84aa0de7", "embedding": null, "metadata": {"window": "Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n", "original_text": "With that, I'll now turn the call over to Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c77b890-9816-4c5b-aa91-66e15e9f026b", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslides at the beginning of our presentation for a description of these risks and uncer tainties.  Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago. ", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c28a1abe9b7df9818923ed9e9df3eeebeec8dc6e2afbad499db6526d51c8cd49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac7517dd-cd3d-4be9-b8fb-0039539e15aa", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently. ", "original_text": "Mike Kaufmann:   Thanks, Kevin, and good morning, everyone. "}, "hash": "e41f5bbd87c00dcc56ff13462950f0e2b8d2d5fc6624da95325cff0ae678e1f9", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll now turn the call over to Mike.  \n \n", "start_char_idx": 1605, "end_char_idx": 1657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac7517dd-cd3d-4be9-b8fb-0039539e15aa": {"__data__": {"id_": "ac7517dd-cd3d-4be9-b8fb-0039539e15aa", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently. ", "original_text": "Mike Kaufmann:   Thanks, Kevin, and good morning, everyone. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc5f2b3b-a23a-4324-9710-f6cd84aa0de7", "node_type": "1", "metadata": {"window": "Please \nnote that during the discussion today, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n", "original_text": "With that, I'll now turn the call over to Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "022b314b4361c168a24690d0b7d67ba149ab9fc3f523193a1361936d9f27b9c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7f5187d-7ce8-4661-ad1e-9bede4c0b785", "node_type": "1", "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate . ", "original_text": "Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago. "}, "hash": "9cd1fc7ad62a740e94da94b0987d33c0d0c4d95bc54be7d851573d89540c71ac", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:   Thanks, Kevin, and good morning, everyone. ", "start_char_idx": 1657, "end_char_idx": 1717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7f5187d-7ce8-4661-ad1e-9bede4c0b785": {"__data__": {"id_": "e7f5187d-7ce8-4661-ad1e-9bede4c0b785", "embedding": null, "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate . ", "original_text": "Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac7517dd-cd3d-4be9-b8fb-0039539e15aa", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press r elease.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently. ", "original_text": "Mike Kaufmann:   Thanks, Kevin, and good morning, everyone. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1b094b78747e2536f917d07dd221c846eb0ced8f8c2bbef9b54e6021f0ae970", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa5ccd21-be07-4e1e-8e6e-1b3dcae6c1ca", "node_type": "1", "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n", "original_text": "Let me start with a few high -level \nthoughts.    \n \n"}, "hash": "275891ca9149324668ba039270411dc148648b6118be32258dd66e1d2d8d2d50", "class_name": "RelatedNodeInfo"}}, "text": "Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago. ", "start_char_idx": 1717, "end_char_idx": 1814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa5ccd21-be07-4e1e-8e6e-1b3dcae6c1ca": {"__data__": {"id_": "fa5ccd21-be07-4e1e-8e6e-1b3dcae6c1ca", "embedding": null, "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n", "original_text": "Let me start with a few high -level \nthoughts.    \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7f5187d-7ce8-4661-ad1e-9bede4c0b785", "node_type": "1", "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate . ", "original_text": "Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1b3cc6cb6827cfde4d91088cd2bea4ad10ee88ae5cf6716abd22a69c14def87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f29ad5b1-38b8-4892-b043-eea95b4a5a09", "node_type": "1", "metadata": {"window": "Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned . ", "original_text": "At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently. "}, "hash": "c6a0651a83e6220d3d246dd4a9fc4a0da66ab24838fc241c08743c5d7854598f", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with a few high -level \nthoughts.    \n \n", "start_char_idx": 1814, "end_char_idx": 1867, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f29ad5b1-38b8-4892-b043-eea95b4a5a09": {"__data__": {"id_": "f29ad5b1-38b8-4892-b043-eea95b4a5a09", "embedding": null, "metadata": {"window": "Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned . ", "original_text": "At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa5ccd21-be07-4e1e-8e6e-1b3dcae6c1ca", "node_type": "1", "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n", "original_text": "Let me start with a few high -level \nthoughts.    \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55a7b5380ebababcf21df78e40c7cd07918ee1d0378fdad237135cf0813ce0eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73568e45-f674-46d6-ac4e-d36e876e7967", "node_type": "1", "metadata": {"window": "Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2. ", "original_text": "We continue to \nbelieve the long -term targets we announced in November are a ppropriate . "}, "hash": "170a453ee69c2f28257a768ba7e867fdb79cfe073b1b93dcc302402c3401633e", "class_name": "RelatedNodeInfo"}}, "text": "At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently. ", "start_char_idx": 1867, "end_char_idx": 2062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73568e45-f674-46d6-ac4e-d36e876e7967": {"__data__": {"id_": "73568e45-f674-46d6-ac4e-d36e876e7967", "embedding": null, "metadata": {"window": "Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2. ", "original_text": "We continue to \nbelieve the long -term targets we announced in November are a ppropriate . ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f29ad5b1-38b8-4892-b043-eea95b4a5a09", "node_type": "1", "metadata": {"window": "Mike Kaufmann:   Thanks, Kevin, and good morning, everyone.  Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned . ", "original_text": "At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3619f1ed69e1a027fa4788bb4575cd9d24c37302bf772fba52c3723989e246c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf7dc50b-84e3-45d9-999c-5f8382a0a154", "node_type": "1", "metadata": {"window": "Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n", "original_text": "And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n"}, "hash": "429c35bf77aba8c3dabbaa39c9cefa3f0772b220820d96d8533a6c7c1ba74980", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nbelieve the long -term targets we announced in November are a ppropriate . ", "start_char_idx": 2062, "end_char_idx": 2153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf7dc50b-84e3-45d9-999c-5f8382a0a154": {"__data__": {"id_": "cf7dc50b-84e3-45d9-999c-5f8382a0a154", "embedding": null, "metadata": {"window": "Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n", "original_text": "And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73568e45-f674-46d6-ac4e-d36e876e7967", "node_type": "1", "metadata": {"window": "Today, Jason's  and my comments will \nbe consistent with the update we provided a few weeks ago.  Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2. ", "original_text": "We continue to \nbelieve the long -term targets we announced in November are a ppropriate . ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf9624fe29ab89ac373a4612fcd4c4b83136e2090d974cf4c0293560acbb064b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ac430be-ec22-4401-a355-1698bbcc2e0c", "node_type": "1", "metadata": {"window": "At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business. ", "original_text": "Our Pharma  business  is performing as planned . "}, "hash": "9fe072ac09c3036c087b192b42408971011fdf1520000108357f1c79c29f410d", "class_name": "RelatedNodeInfo"}}, "text": "And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n", "start_char_idx": 2153, "end_char_idx": 2249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ac430be-ec22-4401-a355-1698bbcc2e0c": {"__data__": {"id_": "8ac430be-ec22-4401-a355-1698bbcc2e0c", "embedding": null, "metadata": {"window": "At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business. ", "original_text": "Our Pharma  business  is performing as planned . ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf7dc50b-84e3-45d9-999c-5f8382a0a154", "node_type": "1", "metadata": {"window": "Let me start with a few high -level \nthoughts.    \n \n At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n", "original_text": "And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b25aff73838d7cfcfba58ce4787bd967c3a8ce9db75d611fce86f6620d68dabc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1572aab-24fd-49b4-a652-cb67f7118f59", "node_type": "1", "metadata": {"window": "We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2. "}, "hash": "b54c226dd7957f1e8d9a4417dd2c1277923c63d715593f5359aac6065c7912cd", "class_name": "RelatedNodeInfo"}}, "text": "Our Pharma  business  is performing as planned . ", "start_char_idx": 2249, "end_char_idx": 2298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1572aab-24fd-49b4-a652-cb67f7118f59": {"__data__": {"id_": "b1572aab-24fd-49b4-a652-cb67f7118f59", "embedding": null, "metadata": {"window": "We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ac430be-ec22-4401-a355-1698bbcc2e0c", "node_type": "1", "metadata": {"window": "At an enterprise level , we continue to focus our efforts on 3 strategic priorities : optimizing  our core \nbusinesses, investing for growth , and innovation , and deploying capital efficiently.  We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business. ", "original_text": "Our Pharma  business  is performing as planned . ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5fbe009af5d68816514796a61e30fe3a52d68db6ad0bd5cf73d2f7d403a84d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e12d94b7-9fc8-43c7-993b-938810a830c9", "node_type": "1", "metadata": {"window": "And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n"}, "hash": "f640a30d190ea45b6fc402efedb69b9f8a63ecf29689478467cd0a3e6d9a0953", "class_name": "RelatedNodeInfo"}}, "text": "We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2. ", "start_char_idx": 2298, "end_char_idx": 2409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e12d94b7-9fc8-43c7-993b-938810a830c9": {"__data__": {"id_": "e12d94b7-9fc8-43c7-993b-938810a830c9", "embedding": null, "metadata": {"window": "And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1572aab-24fd-49b4-a652-cb67f7118f59", "node_type": "1", "metadata": {"window": "We continue to \nbelieve the long -term targets we announced in November are a ppropriate .  And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a021afe2aaf1c7e66cf59f8ed24269f5a37e368014d15218d4eb69c9df9fe93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2873620b-8927-4df9-bc15-e7b66315db2c", "node_type": "1", "metadata": {"window": "Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business. "}, "hash": "c37103c859dd5f8b26e30a6b676ceb717ca1ecc30f2dff7cb0eef2d494bae57b", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n", "start_char_idx": 2409, "end_char_idx": 2505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2873620b-8927-4df9-bc15-e7b66315db2c": {"__data__": {"id_": "2873620b-8927-4df9-bc15-e7b66315db2c", "embedding": null, "metadata": {"window": "Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e12d94b7-9fc8-43c7-993b-938810a830c9", "node_type": "1", "metadata": {"window": "And, we remain on track to \nmeet our $750 million enterprise cost savings target by FY  \u201823. \n \n Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "478437202f521b3ccba3484cee2521cc890f0fbf680dd93b5faf8451c8ea48b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "115aaf47-238e-4583-8356-543066f42e63", "node_type": "1", "metadata": {"window": "We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  "}, "hash": "16e0762f1b7e49ee8f87d4dbb0d4621919e76b31fcfbd184841fac326419ed55", "class_name": "RelatedNodeInfo"}}, "text": "In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business. ", "start_char_idx": 2505, "end_char_idx": 2690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "115aaf47-238e-4583-8356-543066f42e63": {"__data__": {"id_": "115aaf47-238e-4583-8356-543066f42e63", "embedding": null, "metadata": {"window": "We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2630bb3a2d8ec54c0d4ef31d68beb39dfb21c176bc36c3a96fb8085c54607910", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2873620b-8927-4df9-bc15-e7b66315db2c", "node_type": "1", "metadata": {"window": "Our Pharma  business  is performing as planned .  We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57336cb921ff77af717cd84f44e230071bf37adb300627175703fc2d116863a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df58a569-e898-4d33-94a8-1d1631e3622f", "node_type": "1", "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n", "original_text": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.  "}, "hash": "49b8040f764062e542d357366c20da9b65801057b1d967ce0f1eb63f4c7f660b", "class_name": "RelatedNodeInfo"}}, "text": "These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "start_char_idx": 2690, "end_char_idx": 2869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df58a569-e898-4d33-94a8-1d1631e3622f": {"__data__": {"id_": "df58a569-e898-4d33-94a8-1d1631e3622f", "embedding": null, "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n", "original_text": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.  ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "115aaf47-238e-4583-8356-543066f42e63", "node_type": "1", "metadata": {"window": "We've  seen volumes continue to improve \nsequentially, and we are encouraged by the growth we saw again in Q2.  Looking ahead, we continue \nto expect Pharma  to realize mid -single digit growth in FY \u201822. \n \n In our Medical  segment , we continue to experience unprecedented inflationary impacts and global \nsupply chain constraints in our core US Medical  and Products Distribution  business.  These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "original_text": "These impacts, \ncombined with lower -than-expected offsets from pricin g actions , will significantly impact Medical  \nsegment profit consistent with our update a few weeks ago.  ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "509c25dceb21968b8c34bbc24cdc7389a19331911c0db96e87c72ac8e9fa322d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3415a12b-2eef-4420-8b8f-8c708ff5f743", "node_type": "1", "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n", "original_text": "Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n"}, "hash": "061c34f25ab9bc812fee8b71632b00046a2715432994fe5bd4daf2320f1a0d06", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.  ", "start_char_idx": 0, "end_char_idx": 131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3415a12b-2eef-4420-8b8f-8c708ff5f743": {"__data__": {"id_": "3415a12b-2eef-4420-8b8f-8c708ff5f743", "embedding": null, "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n", "original_text": "Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df58a569-e898-4d33-94a8-1d1631e3622f", "node_type": "1", "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n", "original_text": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.  ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b257cd9aed6af718268b494ef88e1310c5a3f8855e80b1140ca75f63c49128c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bd77940-a905-4195-a21f-c0d0a83c191a", "node_type": "1", "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.  ", "original_text": "We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers. "}, "hash": "61a0196392eef561b2586b1c11f4cc1b184099a4a08a662f390e1b74b29c2e7f", "class_name": "RelatedNodeInfo"}}, "text": "Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n", "start_char_idx": 131, "end_char_idx": 259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bd77940-a905-4195-a21f-c0d0a83c191a": {"__data__": {"id_": "2bd77940-a905-4195-a21f-c0d0a83c191a", "embedding": null, "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.  ", "original_text": "We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers. ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3415a12b-2eef-4420-8b8f-8c708ff5f743", "node_type": "1", "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n", "original_text": "Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8d4237740b5ebf100e95128a7f01ad6ad44daf60b422ec8b1345431b1b2f809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c40b3b1-cba2-4a8b-9405-555d43484e9d", "node_type": "1", "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n", "original_text": "Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n"}, "hash": "a8b8b496cc8223b5edf5f29414422b4dc11dde7068a97c921bf021900c8ce82c", "class_name": "RelatedNodeInfo"}}, "text": "We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers. ", "start_char_idx": 259, "end_char_idx": 440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c40b3b1-cba2-4a8b-9405-555d43484e9d": {"__data__": {"id_": "3c40b3b1-cba2-4a8b-9405-555d43484e9d", "embedding": null, "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n", "original_text": "Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bd77940-a905-4195-a21f-c0d0a83c191a", "node_type": "1", "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.  ", "original_text": "We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers. ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb27ac6a7a6ff1276ee4c69debdc14edcb7b0d8b8cba0e92365f20862cff6dc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0643812-8bfc-430b-b2bb-cfba089a60f2", "node_type": "1", "metadata": {"window": "Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n", "original_text": "Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n"}, "hash": "ce2fe96149e2d180b6b04e854eb4cfe665d41a76395c6601ca5d966f21cbe3f6", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n", "start_char_idx": 440, "end_char_idx": 610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0643812-8bfc-430b-b2bb-cfba089a60f2": {"__data__": {"id_": "a0643812-8bfc-430b-b2bb-cfba089a60f2", "embedding": null, "metadata": {"window": "Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n", "original_text": "Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c40b3b1-cba2-4a8b-9405-555d43484e9d", "node_type": "1", "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n", "original_text": "Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "827b315f9f9a63f1c0453b73842af24d02f54f6a9741861df12df5b7d082c134", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed32fa9a-92df-41cd-8481-9fd39f1254c6", "node_type": "1", "metadata": {"window": "We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.  ", "original_text": "Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.  "}, "hash": "6b8b72bfd18a52c146d54276741b5f7c0d12019f0982f4bed911c14fb2513d82", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n", "start_char_idx": 610, "end_char_idx": 673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed32fa9a-92df-41cd-8481-9fd39f1254c6": {"__data__": {"id_": "ed32fa9a-92df-41cd-8481-9fd39f1254c6", "embedding": null, "metadata": {"window": "We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.  ", "original_text": "Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.  ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0643812-8bfc-430b-b2bb-cfba089a60f2", "node_type": "1", "metadata": {"window": "Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n", "original_text": "Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8beca54b7e79c56fbe25c8cf398840947273f0ac264f9df252d6fc1d31b241ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2659f564-2e2b-4a0b-949c-ff7ce23f2a57", "node_type": "1", "metadata": {"window": "Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n", "original_text": "Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n"}, "hash": "ef56d18b117f046c40e5e0e64493713661ef479e6182c2b44924ef7da102abbd", "class_name": "RelatedNodeInfo"}}, "text": "Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.  ", "start_char_idx": 673, "end_char_idx": 822, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2659f564-2e2b-4a0b-949c-ff7ce23f2a57": {"__data__": {"id_": "2659f564-2e2b-4a0b-949c-ff7ce23f2a57", "embedding": null, "metadata": {"window": "Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n", "original_text": "Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed32fa9a-92df-41cd-8481-9fd39f1254c6", "node_type": "1", "metadata": {"window": "We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.  ", "original_text": "Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.  ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e95594e6e4b46c675f703b2b7900dd30afb550794b287426c31d7f300201d237", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adfe9e05-4c02-4c00-87f1-ab2f2d39ae42", "node_type": "1", "metadata": {"window": "Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n", "original_text": "Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n"}, "hash": "3d943ad6039bbdcf548ce5a7d4f7c3f0f87093a739bcae5831fb4c32cf78932e", "class_name": "RelatedNodeInfo"}}, "text": "Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n", "start_char_idx": 822, "end_char_idx": 966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adfe9e05-4c02-4c00-87f1-ab2f2d39ae42": {"__data__": {"id_": "adfe9e05-4c02-4c00-87f1-ab2f2d39ae42", "embedding": null, "metadata": {"window": "Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n", "original_text": "Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2659f564-2e2b-4a0b-949c-ff7ce23f2a57", "node_type": "1", "metadata": {"window": "Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n", "original_text": "Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c0408193eb7705352062441fa759162a02e9169cea6870f621571609daeb380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14fc9b48-9e70-4cab-8c67-841447068d25", "node_type": "1", "metadata": {"window": "Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period . ", "original_text": "Second quarter operating earnings were $467 million.  "}, "hash": "8cd7227c63d89538090e1cafb39f55b8e44527852f4289ddbc8c8430f88401b7", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n", "start_char_idx": 966, "end_char_idx": 1157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14fc9b48-9e70-4cab-8c67-841447068d25": {"__data__": {"id_": "14fc9b48-9e70-4cab-8c67-841447068d25", "embedding": null, "metadata": {"window": "Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period . ", "original_text": "Second quarter operating earnings were $467 million.  ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adfe9e05-4c02-4c00-87f1-ab2f2d39ae42", "node_type": "1", "metadata": {"window": "Jason Hollar:   Thanks  Mike, and good morning , everyone.  \n \n Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n", "original_text": "Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "731c71f2875d48478f0e7cb4b8af8bfab1a104c2bafe9b295188256f572dfdda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f54e29a5-9fd2-44c2-8f1e-f8f8759fa234", "node_type": "1", "metadata": {"window": "Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n", "original_text": "Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n"}, "hash": "288eb8d4f3c46a2cbd8218a8620c0754060be7da99207842dd80c0cea7481a93", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter operating earnings were $467 million.  ", "start_char_idx": 1157, "end_char_idx": 1211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f54e29a5-9fd2-44c2-8f1e-f8f8759fa234": {"__data__": {"id_": "f54e29a5-9fd2-44c2-8f1e-f8f8759fa234", "embedding": null, "metadata": {"window": "Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n", "original_text": "Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14fc9b48-9e70-4cab-8c67-841447068d25", "node_type": "1", "metadata": {"window": "Beginning with total company results, second quarter revenue increased 9% to $45 billion , driven by \nsales growth from existing Pharma  customers.   Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period . ", "original_text": "Second quarter operating earnings were $467 million.  ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "162da5be218c63d81c85446392ad3d3fc359a63e3220c0f360eb6619675bc6c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc3bdf0a-85f5-4cfb-8837-8510847fa604", "node_type": "1", "metadata": {"window": "Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases. ", "original_text": "Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n"}, "hash": "a1ddd3ad838720521c8c1bf2495b88b8d565f7b4d6d01c466d1e00dd579d5e93", "class_name": "RelatedNodeInfo"}}, "text": "Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n", "start_char_idx": 1211, "end_char_idx": 1338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc3bdf0a-85f5-4cfb-8837-8510847fa604": {"__data__": {"id_": "fc3bdf0a-85f5-4cfb-8837-8510847fa604", "embedding": null, "metadata": {"window": "Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases. ", "original_text": "Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f54e29a5-9fd2-44c2-8f1e-f8f8759fa234", "node_type": "1", "metadata": {"window": "Total gross margin was $1.6 billion, a decrease of 9% \nprimarily due to the Cordis divestiture and elevated supply chain costs in Medical .  \n \n Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n", "original_text": "Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ac9f5f507a54aa176edc6a5a3286771672af96652d79f6784e9eea1a5c708c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ecadcf5-b601-4fbf-a667-1d6d46502703", "node_type": "1", "metadata": {"window": "Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n", "original_text": "Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period . "}, "hash": "3eb5951d404dbf96229a681ffdfc8e6cc039c5f377fe0dc337c7a79fcc6284e0", "class_name": "RelatedNodeInfo"}}, "text": "Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n", "start_char_idx": 1338, "end_char_idx": 1491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ecadcf5-b601-4fbf-a667-1d6d46502703": {"__data__": {"id_": "9ecadcf5-b601-4fbf-a667-1d6d46502703", "embedding": null, "metadata": {"window": "Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n", "original_text": "Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period . ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc3bdf0a-85f5-4cfb-8837-8510847fa604", "node_type": "1", "metadata": {"window": "Consolidated SG&A was flat to the prior year at $1.2 billion , as the Cordis divestiture and benefits \nfrom cost savin g initiatives offset IT investments and higher operations expenses.  \n \n Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases. ", "original_text": "Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26339e4ff107be2ada9e3d1a54348c8e7baca8f7f6dfde75165b331b4deed16c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "178db19e-8b00-4728-b552-2719cf15e950", "node_type": "1", "metadata": {"window": "Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n", "original_text": "Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n"}, "hash": "8c16472efdcf20e411119ff5522924399cde2a2e71029a86887c59199d3bd026", "class_name": "RelatedNodeInfo"}}, "text": "Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period . ", "start_char_idx": 1491, "end_char_idx": 1683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "178db19e-8b00-4728-b552-2719cf15e950": {"__data__": {"id_": "178db19e-8b00-4728-b552-2719cf15e950", "embedding": null, "metadata": {"window": "Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n", "original_text": "Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ecadcf5-b601-4fbf-a667-1d6d46502703", "node_type": "1", "metadata": {"window": "Second quarter operating earnings were $467 million.   Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n", "original_text": "Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period . ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "060c46d318da68082257c251e9defb5a496dc99990c849049a87eadde76ab79c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e75d9633-8f59-4e31-a3fa-45c44eb13d9b", "node_type": "1", "metadata": {"window": "Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.  ", "original_text": "Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases. "}, "hash": "591acbd968dcac09ff535a24320826235339bcb7a6a276632f10aedd3fc6a7b8", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n", "start_char_idx": 1683, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e75d9633-8f59-4e31-a3fa-45c44eb13d9b": {"__data__": {"id_": "e75d9633-8f59-4e31-a3fa-45c44eb13d9b", "embedding": null, "metadata": {"window": "Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.  ", "original_text": "Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases. ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "178db19e-8b00-4728-b552-2719cf15e950", "node_type": "1", "metadata": {"window": "Outside of the incremental inflationary impacts \nin Medical, these results were generally in line with our expectations.  \n   \n Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n", "original_text": "Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23ba873f9d311fbe1cfa760cb046006974685fd9aaffedad5c1d548abc664f58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18835c64-3fd1-41fb-b106-ddbabc01e082", "node_type": "1", "metadata": {"window": "Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows. ", "original_text": "Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n"}, "hash": "6fc9a5078d7857238d9bec7fad1a8de64ceb99d03542ebd136b7564bb1792aae", "class_name": "RelatedNodeInfo"}}, "text": "Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases. ", "start_char_idx": 1772, "end_char_idx": 1880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18835c64-3fd1-41fb-b106-ddbabc01e082": {"__data__": {"id_": "18835c64-3fd1-41fb-b106-ddbabc01e082", "embedding": null, "metadata": {"window": "Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows. ", "original_text": "Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e75d9633-8f59-4e31-a3fa-45c44eb13d9b", "node_type": "1", "metadata": {"window": "Moving below line, Interest and O ther decreased by 30 % to $24 million , driven primarily by lower \ninterest expense from debt reduction actions.    \n \n Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.  ", "original_text": "Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases. ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "572fb0014a5201c4d9efcdb79ca958f6f2fb83aa2f9ec7a6d3786acea9cf4fb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ce275f5-377a-4daf-b70e-06fa9a8b521e", "node_type": "1", "metadata": {"window": "Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n", "original_text": "The net result for the quarter was EPS of $1.27.  \n \n"}, "hash": "80c242269bf3ab3139fbde12afc4de9bd7e3ddccf87d0d573b066d6d842b34ea", "class_name": "RelatedNodeInfo"}}, "text": "Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n", "start_char_idx": 1880, "end_char_idx": 2059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ce275f5-377a-4daf-b70e-06fa9a8b521e": {"__data__": {"id_": "1ce275f5-377a-4daf-b70e-06fa9a8b521e", "embedding": null, "metadata": {"window": "Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n", "original_text": "The net result for the quarter was EPS of $1.27.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18835c64-3fd1-41fb-b106-ddbabc01e082", "node_type": "1", "metadata": {"window": "Our second quarter effective tax rate finished at 19.4 %, six  percentage points higher than the prior \nyear due to certain discreet  items, which primarily benefited  the prior year period .  Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows. ", "original_text": "Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96f0c937bc425a54da7341890593483505dcbaab34e7e07a3ed52f0388cd6990", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25e3ac0f-441c-4a7e-b030-fd751f9eff63", "node_type": "1", "metadata": {"window": "Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results . ", "original_text": "Second quarter operating cashflow  was strong at $1.2 billion.  "}, "hash": "3c599edf10f7ebc951ca042c54995b2e6d2d33e0ef0e93f7f73aef406b8aee17", "class_name": "RelatedNodeInfo"}}, "text": "The net result for the quarter was EPS of $1.27.  \n \n", "start_char_idx": 2059, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25e3ac0f-441c-4a7e-b030-fd751f9eff63": {"__data__": {"id_": "25e3ac0f-441c-4a7e-b030-fd751f9eff63", "embedding": null, "metadata": {"window": "Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results . ", "original_text": "Second quarter operating cashflow  was strong at $1.2 billion.  ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ce275f5-377a-4daf-b70e-06fa9a8b521e", "node_type": "1", "metadata": {"window": "Additionally, our \nsecond quarter rate this year included some timing favorability.   \n \n Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n", "original_text": "The net result for the quarter was EPS of $1.27.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa1f461ea8962220e9e8c660ae4799d05f064d244e7c485ca69044e1e15146d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55a321bd-fd6b-4373-acec-67641476366d", "node_type": "1", "metadata": {"window": "Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n", "original_text": "As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows. "}, "hash": "063f20730f8695a5611ccd768a6d963368aeff8ca0749fc28b469d0db7755cb7", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter operating cashflow  was strong at $1.2 billion.  ", "start_char_idx": 2112, "end_char_idx": 2176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55a321bd-fd6b-4373-acec-67641476366d": {"__data__": {"id_": "55a321bd-fd6b-4373-acec-67641476366d", "embedding": null, "metadata": {"window": "Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n", "original_text": "As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows. ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25e3ac0f-441c-4a7e-b030-fd751f9eff63", "node_type": "1", "metadata": {"window": "Average diluted shares outstanding were 281 million, 5 % lower than the prior year due to share \npurchases.  Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results . ", "original_text": "Second quarter operating cashflow  was strong at $1.2 billion.  ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c430ab7932148e42c84b8e81afae0f50228f5b0b55729c5e00a453211ac8312", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5dbc850-e99e-433a-833f-96583de3fdf1", "node_type": "1", "metadata": {"window": "The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n"}, "hash": "8ed9bcb2b0af9fd946715319d1d68c0323aefda26bae03ed0bf33aadfdebcad5", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows. ", "start_char_idx": 2176, "end_char_idx": 2274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5dbc850-e99e-433a-833f-96583de3fdf1": {"__data__": {"id_": "a5dbc850-e99e-433a-833f-96583de3fdf1", "embedding": null, "metadata": {"window": "The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55a321bd-fd6b-4373-acec-67641476366d", "node_type": "1", "metadata": {"window": "Of note, we initiated a $300  million share repurchase  program in the quarter, which was \nrecently completed  and brings our total year -to-date repurchases to $800 million.  \n \n The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n", "original_text": "As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows. ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "405798d4e4dfe277342e209e630838c61192b943f3ca1df76576071b6bce1756", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95f06d92-6b27-4220-b9db-3802ad43e6e3", "node_type": "1", "metadata": {"window": "Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results . "}, "hash": "7a2c88f7cda71f9815d16661d4791e99eda7cd6082271bfb17a1b4979592e3f1", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n", "start_char_idx": 2274, "end_char_idx": 2396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95f06d92-6b27-4220-b9db-3802ad43e6e3": {"__data__": {"id_": "95f06d92-6b27-4220-b9db-3802ad43e6e3", "embedding": null, "metadata": {"window": "Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results . ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5dbc850-e99e-433a-833f-96583de3fdf1", "node_type": "1", "metadata": {"window": "The net result for the quarter was EPS of $1.27.  \n \n Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6eec03332258274d30149aaedbdbb8b30f2cf04d236b8ad73efb40265d71cb41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e1100ee-d3db-48aa-b41d-6da34b8484cc", "node_type": "1", "metadata": {"window": "As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n"}, "hash": "6214dc9a1d9f88c213898f6773ccb867ce4f95ea733fcb42c58c8b7b7cef0851", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results . ", "start_char_idx": 2396, "end_char_idx": 2573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e1100ee-d3db-48aa-b41d-6da34b8484cc": {"__data__": {"id_": "8e1100ee-d3db-48aa-b41d-6da34b8484cc", "embedding": null, "metadata": {"window": "As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95f06d92-6b27-4220-b9db-3802ad43e6e3", "node_type": "1", "metadata": {"window": "Second quarter operating cashflow  was strong at $1.2 billion.   As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results . ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "805d2c09a8fcdd3cbd8cd848c29c0dae326a9ef8dad5486a609e1645bba866c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fbc93a5-3f1d-4440-b01f-630c6900560e", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "Now turning to segments, beginning with Pharma  on slide 5\u2026 \n "}, "hash": "dfa80549266744b9048ab19f842f528c95cd94755a04b375d7c1cac1f298923e", "class_name": "RelatedNodeInfo"}}, "text": "This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n", "start_char_idx": 2573, "end_char_idx": 2718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fbc93a5-3f1d-4440-b01f-630c6900560e": {"__data__": {"id_": "7fbc93a5-3f1d-4440-b01f-630c6900560e", "embedding": null, "metadata": {"window": "We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "856c4011-9e85-4d6a-a778-2ec432012364", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6216b9142c9b37a082450b3b063e39d29b86225f6176d02606f80826c40adc37", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e1100ee-d3db-48aa-b41d-6da34b8484cc", "node_type": "1", "metadata": {"window": "As a reminder, the day of the week in \nwhich the quarter ends affects point -in-time cash  flows.  We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2b380165a6f39a60e5033322eb1e52fc7e93d36df5ea559d5c74f8836da950d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21373f1b-42fb-4bf8-8711-f1e56bd4f857", "node_type": "1", "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels . ", "original_text": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n"}, "hash": "b09f89edc14fe4ee22421d1f774a041c4eb4aa935a55030ac8a7745b24dec613", "class_name": "RelatedNodeInfo"}}, "text": "Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "start_char_idx": 2718, "end_char_idx": 2780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21373f1b-42fb-4bf8-8711-f1e56bd4f857": {"__data__": {"id_": "21373f1b-42fb-4bf8-8711-f1e56bd4f857", "embedding": null, "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels . ", "original_text": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fbc93a5-3f1d-4440-b01f-630c6900560e", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of \n$3.2 billion and no outstanding borrowings under our credit facilities.   \n \n In the quarter , we also recorded a $1.3 billion  non-cash , pre-tax goodwill impairment charge related to \nthe Medical  segment, which is excluded from our non -GAAP results .  This accounting charge primarily \nresulted from additional inflationary impacts and global supply chain constraints  I will discuss shortly.  \n \n Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "original_text": "Now turning to segments, beginning with Pharma  on slide 5\u2026 \n ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4c66816ac74c045b3d65fa566be875a032ea5159b06058c7d9930f65326d179", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc563ad6-fd9e-4752-9aff-cba21639e134", "node_type": "1", "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak . ", "original_text": "Segment profit increased 3% to $426 million driven by generics program performance . "}, "hash": "3bc56598b1bc36866762cde3e534962d243cbc078fa6d77e323f1c8f069691a3", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n", "start_char_idx": 0, "end_char_idx": 186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc563ad6-fd9e-4752-9aff-cba21639e134": {"__data__": {"id_": "fc563ad6-fd9e-4752-9aff-cba21639e134", "embedding": null, "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak . ", "original_text": "Segment profit increased 3% to $426 million driven by generics program performance . ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21373f1b-42fb-4bf8-8711-f1e56bd4f857", "node_type": "1", "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels . ", "original_text": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31adbee78dc711847dc9422554465029f8215ec58fa2c30c5f6e5fe9de2d32f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faad391e-873f-460b-9c7b-e8d27dc2f577", "node_type": "1", "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n", "original_text": "This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n"}, "hash": "f2c9f051ad20c951947ed31d260dc925182db8744ad10a49bbd4cf12670d8612", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit increased 3% to $426 million driven by generics program performance . ", "start_char_idx": 186, "end_char_idx": 271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faad391e-873f-460b-9c7b-e8d27dc2f577": {"__data__": {"id_": "faad391e-873f-460b-9c7b-e8d27dc2f577", "embedding": null, "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n", "original_text": "This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc563ad6-fd9e-4752-9aff-cba21639e134", "node_type": "1", "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak . ", "original_text": "Segment profit increased 3% to $426 million driven by generics program performance . ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4a7ff5567407754fcac0aa1c5b24cce8541dbd5683b339a2735204be04063a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31a977e6-353c-4eb5-ae21-8147bc36b2d5", "node_type": "1", "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n", "original_text": "During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels . "}, "hash": "d9694ae9749d3f63602c8a6c5b7b20ca899ab88e65c1f16f62944090300c9058", "class_name": "RelatedNodeInfo"}}, "text": "This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n", "start_char_idx": 271, "end_char_idx": 478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31a977e6-353c-4eb5-ae21-8147bc36b2d5": {"__data__": {"id_": "31a977e6-353c-4eb5-ae21-8147bc36b2d5", "embedding": null, "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n", "original_text": "During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels . ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faad391e-873f-460b-9c7b-e8d27dc2f577", "node_type": "1", "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n", "original_text": "This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1eadb73abcf961082fab0b8e764270aefc0f5ba68716c0d6977308311bf6bd8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaea3f17-e754-4ca9-b6c9-0a73ccbdbec0", "node_type": "1", "metadata": {"window": "Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution. ", "original_text": "Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak . "}, "hash": "ed5990f3968a2fbf0f8f9f129828ec3062aaf292f318325ae043d02f52886405", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels . ", "start_char_idx": 478, "end_char_idx": 705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaea3f17-e754-4ca9-b6c9-0a73ccbdbec0": {"__data__": {"id_": "aaea3f17-e754-4ca9-b6c9-0a73ccbdbec0", "embedding": null, "metadata": {"window": "Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution. ", "original_text": "Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak . ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31a977e6-353c-4eb5-ae21-8147bc36b2d5", "node_type": "1", "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n", "original_text": "During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels . ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0679d60188f992aed2acdc3511f6c40338fdcf980ebaffc64f4f74c8e87a368f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59a89ebc-d15c-4872-b4c9-5a3fdd2f4829", "node_type": "1", "metadata": {"window": "This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n", "original_text": "Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n"}, "hash": "f96e980118bcce49af21759f795670aaf5c3342602dc63eb3b5bb0924aedaa99", "class_name": "RelatedNodeInfo"}}, "text": "Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak . ", "start_char_idx": 705, "end_char_idx": 844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59a89ebc-d15c-4872-b4c9-5a3fdd2f4829": {"__data__": {"id_": "59a89ebc-d15c-4872-b4c9-5a3fdd2f4829", "embedding": null, "metadata": {"window": "This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n", "original_text": "Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaea3f17-e754-4ca9-b6c9-0a73ccbdbec0", "node_type": "1", "metadata": {"window": "Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution. ", "original_text": "Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak . ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5181577678dfd5007fb40955cb6c3ba5c6ed5d124a563d8fc88104c01738de09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c396cdd2-5ada-4d1f-a69a-a532aff6d701", "node_type": "1", "metadata": {"window": "During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.  ", "original_text": "Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n"}, "hash": "17939f868bdddd20ddab5e487967f10f208404bb05df47e5f616c005ae9bc6b5", "class_name": "RelatedNodeInfo"}}, "text": "Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n", "start_char_idx": 844, "end_char_idx": 937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c396cdd2-5ada-4d1f-a69a-a532aff6d701": {"__data__": {"id_": "c396cdd2-5ada-4d1f-a69a-a532aff6d701", "embedding": null, "metadata": {"window": "During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.  ", "original_text": "Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59a89ebc-d15c-4872-b4c9-5a3fdd2f4829", "node_type": "1", "metadata": {"window": "This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n", "original_text": "Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1b0da478a4150e5052ed27e2dbf9c3904bf81514f3a487944c79453565eca50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e777dac-9cd9-4c05-a4d5-ce0b5131034b", "node_type": "1", "metadata": {"window": "Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n", "original_text": "Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution. "}, "hash": "f75d433226d77f44e62f669d55a21a4b966c32408e97a9f2b4bd40a0c18f0539", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n", "start_char_idx": 937, "end_char_idx": 1090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e777dac-9cd9-4c05-a4d5-ce0b5131034b": {"__data__": {"id_": "8e777dac-9cd9-4c05-a4d5-ce0b5131034b", "embedding": null, "metadata": {"window": "Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n", "original_text": "Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution. ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c396cdd2-5ada-4d1f-a69a-a532aff6d701", "node_type": "1", "metadata": {"window": "During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels .  Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.  ", "original_text": "Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "440648e2eec0bad170e9061737caa8ec533f3d25740b71b81eb406f6055076e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "858ef2e5-c70d-4353-9fd9-83c10ad75ee1", "node_type": "1", "metadata": {"window": "Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n", "original_text": "This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n"}, "hash": "7a135f494b2b152b7242626a52c8d08a67d4a99c5273a6a13c258af9d3b72633", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution. ", "start_char_idx": 1090, "end_char_idx": 1240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "858ef2e5-c70d-4353-9fd9-83c10ad75ee1": {"__data__": {"id_": "858ef2e5-c70d-4353-9fd9-83c10ad75ee1", "embedding": null, "metadata": {"window": "Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n", "original_text": "This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e777dac-9cd9-4c05-a4d5-ce0b5131034b", "node_type": "1", "metadata": {"window": "Our generics program continued to experience generally \nconsistent market dynamics, including c ontinued strong performance from Red Oak .  Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n", "original_text": "Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution. ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf094b5f59848102172cd56d4c1e86998b7aea2b24ff56922d54ac969b4b5754", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3177754c-55e9-4b26-87e8-d540e20a9223", "node_type": "1", "metadata": {"window": "Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n", "original_text": "During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.  "}, "hash": "3252e008e0bcabd8ca70a06b4d1cfeb40246788809c324b432cd6a4a112b5f77", "class_name": "RelatedNodeInfo"}}, "text": "This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n", "start_char_idx": 1240, "end_char_idx": 1441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3177754c-55e9-4b26-87e8-d540e20a9223": {"__data__": {"id_": "3177754c-55e9-4b26-87e8-d540e20a9223", "embedding": null, "metadata": {"window": "Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n", "original_text": "During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.  ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "858ef2e5-c70d-4353-9fd9-83c10ad75ee1", "node_type": "1", "metadata": {"window": "Outside of \ngenerics, we've seen brand inflation trending in line with our expectations.  \n \n Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n", "original_text": "This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d50a51aa8e5a4a82bdb3c8cf3a70fef252de876ed0ec14a5eacb870e8b3aa59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed0a2e98-b865-4d90-87e9-ff8c14dc7042", "node_type": "1", "metadata": {"window": "Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n", "original_text": "Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n"}, "hash": "8886f17c7149dcdf7a774bbb55f386c032898d6a1f670c6ad45e04b7916a1419", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.  ", "start_char_idx": 1441, "end_char_idx": 1662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed0a2e98-b865-4d90-87e9-ff8c14dc7042": {"__data__": {"id_": "ed0a2e98-b865-4d90-87e9-ff8c14dc7042", "embedding": null, "metadata": {"window": "Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n", "original_text": "Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3177754c-55e9-4b26-87e8-d540e20a9223", "node_type": "1", "metadata": {"window": "Turning to Medical  on slide 6\u2026 \n \nSecond -quarter revenue decreased 5% to $4.1 billion, primarily due to the divestiture of the Cordis \nbusiness.    \n \n Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n", "original_text": "During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.  ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9789bef0a5ebd15f18c3ceab28a614d24dea6bc740b9420cb560bf7979a6cf28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8afdf7c-4062-4ced-8f25-78305bc55560", "node_type": "1", "metadata": {"window": "This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical . ", "original_text": "I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n"}, "hash": "eeb85d4c426664d91b3a7123abda959dc21094aff8be1748364d030cbca1e1a9", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n", "start_char_idx": 1662, "end_char_idx": 1929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8afdf7c-4062-4ced-8f25-78305bc55560": {"__data__": {"id_": "b8afdf7c-4062-4ced-8f25-78305bc55560", "embedding": null, "metadata": {"window": "This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical . ", "original_text": "I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed0a2e98-b865-4d90-87e9-ff8c14dc7042", "node_type": "1", "metadata": {"window": "Segment profit decreased 79% to $50 million, primarily due to inflationary impacts and global supply \nchain constraints in products and distribution.  This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n", "original_text": "Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e3ced78a7d9182a0d69a1f54661403d053a149c5160e0046598950abf3947c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5174be4e-a826-4536-9175-9187818bdd52", "node_type": "1", "metadata": {"window": "During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n"}, "hash": "d1e81f27df82ccb1920ba28bb7701880522282b34ac618c9a777a8f5814ce886", "class_name": "RelatedNodeInfo"}}, "text": "I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n", "start_char_idx": 1929, "end_char_idx": 2165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5174be4e-a826-4536-9175-9187818bdd52": {"__data__": {"id_": "5174be4e-a826-4536-9175-9187818bdd52", "embedding": null, "metadata": {"window": "During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8afdf7c-4062-4ced-8f25-78305bc55560", "node_type": "1", "metadata": {"window": "This also reflects the timing of selling higher cost PPE, \nincluding  the net positive impact from this dynamic in the prior year, and to a lesser extent, the \ndivestiture of the Cordis business.   \n \n During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical . ", "original_text": "I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0f56500dd68652e3569ae1305bf17845e426c2f22ad47334c47fffdf3340f70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f591d9a-4d8a-43b1-bc06-204d6da7beac", "node_type": "1", "metadata": {"window": "Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n"}, "hash": "77c0c60ec533f9927e83e24d8dd5f83b051c291ce3251a2e6a0ee10942c328e3", "class_name": "RelatedNodeInfo"}}, "text": "With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n", "start_char_idx": 2165, "end_char_idx": 2367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f591d9a-4d8a-43b1-bc06-204d6da7beac": {"__data__": {"id_": "1f591d9a-4d8a-43b1-bc06-204d6da7beac", "embedding": null, "metadata": {"window": "Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5174be4e-a826-4536-9175-9187818bdd52", "node_type": "1", "metadata": {"window": "During the quarter, our products and distribution business continued to be impacted by significant \ninflationary pressures in th e global supply chain, primarily in the areas of polypropylene and \ninternational freight.   Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37648912449fe18ee6529ebce3f11112f807828253a22ec98b58582d9b61ce75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bd99dae-d5c2-4aab-9680-c2e3751639a4", "node_type": "1", "metadata": {"window": "I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical . "}, "hash": "44d8ee658d48b291a676d896b35d24d60381d8635f27db6c3770832dfc00147d", "class_name": "RelatedNodeInfo"}}, "text": "And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n", "start_char_idx": 2367, "end_char_idx": 2552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bd99dae-d5c2-4aab-9680-c2e3751639a4": {"__data__": {"id_": "8bd99dae-d5c2-4aab-9680-c2e3751639a4", "embedding": null, "metadata": {"window": "I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical . ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f591d9a-4d8a-43b1-bc06-204d6da7beac", "node_type": "1", "metadata": {"window": "Additionally, in the quarter we saw broader inflationary impacts across the \nbusiness such as domestic freight and other commodities, as well as global supply chain c onstraints \naffecting the volume of some of our higher margin  Cardinal Health brand  products.  \n \n I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e7483551e31646549418efb93e144c571bdfb4f8600d03704cc17028e8a5a1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d528835-075e-43f9-9b3b-eab6684eaf0d", "node_type": "1", "metadata": {"window": "With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  "}, "hash": "4b4b5a90cae4b4aa411127e2f850f5c489f454f123e4a7b9ac73aa915da42088", "class_name": "RelatedNodeInfo"}}, "text": "Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical . ", "start_char_idx": 2552, "end_char_idx": 2741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d528835-075e-43f9-9b3b-eab6684eaf0d": {"__data__": {"id_": "9d528835-075e-43f9-9b3b-eab6684eaf0d", "embedding": null, "metadata": {"window": "With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2700b55809318b1a05df84e1ee7eefe0fb49c44740c63e47b4c91c18fb1d29ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bd99dae-d5c2-4aab-9680-c2e3751639a4", "node_type": "1", "metadata": {"window": "I'll discuss these impacts with respect to our full year Medical  outlook momentarily , and  Mike will \nelaborate on the actions we are taking to address these macro challenges and drive performance in \nour core Medical  business .  \n \n With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical . ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b83f7e6146008b65da4ca2ec822fd75422fcb2b77d46ca4187862643a36fa999", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4d78b90-57d9-4968-9f3e-5c6518d6f017", "node_type": "1", "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n", "original_text": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook . "}, "hash": "5d01d70b2b5935bcbc38c74d06d1154af0e947a12be39f1209abb56f54720fbf", "class_name": "RelatedNodeInfo"}}, "text": "We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "start_char_idx": 2741, "end_char_idx": 3032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4d78b90-57d9-4968-9f3e-5c6518d6f017": {"__data__": {"id_": "d4d78b90-57d9-4968-9f3e-5c6518d6f017", "embedding": null, "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n", "original_text": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook . ", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d528835-075e-43f9-9b3b-eab6684eaf0d", "node_type": "1", "metadata": {"window": "With respect to COVID -19 and the Omicron variant, we continue  to see strong performance from our \nLab business, including significant testing demand generally consistent with level seen a year ago . \n And, despite some impacts from Omicron in various geographies, demand for surgical products \nrelated to elective procedures was comparable to both the first quarter and prior year.  \n \n Now, transitioning to our updated fiscal 22 outlook on slide 8\u2026 \n \nWe now expect EPS in the range of $5.15  to $5.50 per share, primarily reflecting our updated \nexpectations for Medical .  We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "original_text": "We also now expect an annual effective tax rate in the range of 23 % to \n24.5%, and Interest and O ther in the range of $140 to $160 million , with th e improvement in I&O \nincluding deferred compensation favorability  which , as a reminder, is fully offset above line in \ncorporate  SG&A.  ", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf675cd6052a081cece556224f9bd402f4d7d903d02e2a61fc602c66383bf387", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3f2de65-4b54-4263-a11a-90f40e97e842", "node_type": "1", "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822. ", "original_text": "We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n"}, "hash": "dfbd9de9dee07cf59059a884601ce41acc8b117813274b181e142e37abb0b684", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook . ", "start_char_idx": 0, "end_char_idx": 94, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3f2de65-4b54-4263-a11a-90f40e97e842": {"__data__": {"id_": "a3f2de65-4b54-4263-a11a-90f40e97e842", "embedding": null, "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822. ", "original_text": "We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4d78b90-57d9-4968-9f3e-5c6518d6f017", "node_type": "1", "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n", "original_text": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook . ", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9846619f44743d03f39e682d9fb79e24092edfb0813bc89e080fdd4ba6045b24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fee0308-c83f-406c-8d2e-b375b2355412", "node_type": "1", "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n", "original_text": "For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n"}, "hash": "c83d0f4ed728e69528fab73fbbec15dbe005c58e3d019100129a5dcc3e6270e8", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n", "start_char_idx": 94, "end_char_idx": 200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fee0308-c83f-406c-8d2e-b375b2355412": {"__data__": {"id_": "0fee0308-c83f-406c-8d2e-b375b2355412", "embedding": null, "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n", "original_text": "For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3f2de65-4b54-4263-a11a-90f40e97e842", "node_type": "1", "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822. ", "original_text": "We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23bec7f2ce88addff989689193d2dfe5aacc0e636d48641fd255917c4add26f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c16248e4-3da9-4ee5-8d66-4188f9dd591c", "node_type": "1", "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n", "original_text": "Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n"}, "hash": "f7eae5973e8a61ea881983621d73c7ab3fdcb752ee370a4b5add8293aab5fad1", "class_name": "RelatedNodeInfo"}}, "text": "For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n", "start_char_idx": 200, "end_char_idx": 330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c16248e4-3da9-4ee5-8d66-4188f9dd591c": {"__data__": {"id_": "c16248e4-3da9-4ee5-8d66-4188f9dd591c", "embedding": null, "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n", "original_text": "Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fee0308-c83f-406c-8d2e-b375b2355412", "node_type": "1", "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n", "original_text": "For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b3a42ba8093878a23581be06e29986ec72206c58d870f3995a0fc976e88b30c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7fdcab9-472a-492e-9b76-f2c60f9cf3a0", "node_type": "1", "metadata": {"window": "We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n", "original_text": "This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822. "}, "hash": "837ce51402a119cd7c3f36be5f0a48036db9611c1f0f5f5a76c1f0a3c2615e0d", "class_name": "RelatedNodeInfo"}}, "text": "Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n", "start_char_idx": 330, "end_char_idx": 637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7fdcab9-472a-492e-9b76-f2c60f9cf3a0": {"__data__": {"id_": "e7fdcab9-472a-492e-9b76-f2c60f9cf3a0", "embedding": null, "metadata": {"window": "We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n", "original_text": "This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822. ", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c16248e4-3da9-4ee5-8d66-4188f9dd591c", "node_type": "1", "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n", "original_text": "Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5bb6d53110e1996ac4a79e29c13a4355003c203e482684ff4017ed5998f6544", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ff99423-1bea-413d-bb07-6d85298b2199", "node_type": "1", "metadata": {"window": "For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter. ", "original_text": "While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n"}, "hash": "f681c9378dd124287728da0abad0c0ab746591d476ce9a36f0fe0ace71b500d0", "class_name": "RelatedNodeInfo"}}, "text": "This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822. ", "start_char_idx": 637, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ff99423-1bea-413d-bb07-6d85298b2199": {"__data__": {"id_": "2ff99423-1bea-413d-bb07-6d85298b2199", "embedding": null, "metadata": {"window": "For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter. ", "original_text": "While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7fdcab9-472a-492e-9b76-f2c60f9cf3a0", "node_type": "1", "metadata": {"window": "We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n", "original_text": "This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822. ", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77773bbba0b4492468348590d3409fa310050b9c6e55221459a4f8c223828ff3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c2a6902-8455-4758-9ca2-3db340c81a6c", "node_type": "1", "metadata": {"window": "Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n", "original_text": "While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n"}, "hash": "93aabb82bfccb3ecf3712db9d665955959b7f6487e7acdd4c3730474e8cd2318", "class_name": "RelatedNodeInfo"}}, "text": "While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n", "start_char_idx": 863, "end_char_idx": 1045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c2a6902-8455-4758-9ca2-3db340c81a6c": {"__data__": {"id_": "0c2a6902-8455-4758-9ca2-3db340c81a6c", "embedding": null, "metadata": {"window": "Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n", "original_text": "While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ff99423-1bea-413d-bb07-6d85298b2199", "node_type": "1", "metadata": {"window": "For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter. ", "original_text": "While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7944513ff56e8078ce8ad727bf56892a2b68e2b02d4780f928e901de34cd3464", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40b305cc-c2f4-421e-a9df-4ba483169ea8", "node_type": "1", "metadata": {"window": "This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n", "original_text": "Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n"}, "hash": "19bf7a632e1d391b44f6d81dda0d0d58251fc3a4c3964d6605243c3dc10706ad", "class_name": "RelatedNodeInfo"}}, "text": "While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n", "start_char_idx": 1045, "end_char_idx": 1215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40b305cc-c2f4-421e-a9df-4ba483169ea8": {"__data__": {"id_": "40b305cc-c2f4-421e-a9df-4ba483169ea8", "embedding": null, "metadata": {"window": "This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n", "original_text": "Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c2a6902-8455-4758-9ca2-3db340c81a6c", "node_type": "1", "metadata": {"window": "Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n", "original_text": "While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd35bea7ccd037d654c8df38cc5ce32ca2d1fe81ebdd4429203682c22167cfde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bac86dce-6a31-4a20-8ddf-a5eede2f5bc7", "node_type": "1", "metadata": {"window": "While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n", "original_text": "In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter. "}, "hash": "6ac8af6ea88a07449f613997cf1708e89bbff28bb015198cf163741fa2c705fa", "class_name": "RelatedNodeInfo"}}, "text": "Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n", "start_char_idx": 1215, "end_char_idx": 1573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bac86dce-6a31-4a20-8ddf-a5eede2f5bc7": {"__data__": {"id_": "bac86dce-6a31-4a20-8ddf-a5eede2f5bc7", "embedding": null, "metadata": {"window": "While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n", "original_text": "In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter. ", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40b305cc-c2f4-421e-a9df-4ba483169ea8", "node_type": "1", "metadata": {"window": "This, in addition to our November 9th update regarding the pressures in international freight and \npolypropylene, now reflects a total net incremental headwind of approximately $250 t o $300 million to \nMedical in fiscal \u201822.  While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n", "original_text": "Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30b5e1f9e04034a8ca7e184392283b17cfaf6874fe2aad92d1ca94a83a0afe90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74054057-b06a-41ca-8d5f-e16c1c3e9547", "node_type": "1", "metadata": {"window": "While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n", "original_text": "We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n"}, "hash": "97d334d008122995009defdd711c5e94a32dea5afea7d711030813ea4d102040", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter. ", "start_char_idx": 1573, "end_char_idx": 1776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74054057-b06a-41ca-8d5f-e16c1c3e9547": {"__data__": {"id_": "74054057-b06a-41ca-8d5f-e16c1c3e9547", "embedding": null, "metadata": {"window": "While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n", "original_text": "We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bac86dce-6a31-4a20-8ddf-a5eede2f5bc7", "node_type": "1", "metadata": {"window": "While these impacts have persisted for longer than previously anticipated, we \ncontinue to believe the majority will be temporary as global supply chain pressures eventually abate. \n While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n", "original_text": "In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter. ", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c7c85be7d944b7edf8862aa833c121f7cfe64acaac17abfef52c0cae4785342", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27bfb175-a2c5-4f07-b45f-24bfd77b5770", "node_type": "1", "metadata": {"window": "Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n", "original_text": "Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n"}, "hash": "cec0393db1e693d32a7ae8a071eaf8d5219d3df14de265c06e277fa97ddca1e1", "class_name": "RelatedNodeInfo"}}, "text": "We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n", "start_char_idx": 1776, "end_char_idx": 1871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27bfb175-a2c5-4f07-b45f-24bfd77b5770": {"__data__": {"id_": "27bfb175-a2c5-4f07-b45f-24bfd77b5770", "embedding": null, "metadata": {"window": "Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n", "original_text": "Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74054057-b06a-41ca-8d5f-e16c1c3e9547", "node_type": "1", "metadata": {"window": "While it will take time, we are com mitted to mitigating the impacts of inflationary pressures, and will \ncontinue to work through these dynamics with our customers.  \n \n Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n", "original_text": "We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd2d440b50bcde48fb4e6a71a92bd7b5e711eab82512778cd47b996c775581b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20165d0c-8439-49af-8247-d33f1f560dde", "node_type": "1", "metadata": {"window": "In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n"}, "hash": "f30a18bf927b82415b0bc57d139fdecb74938cc00e2f14725e8b4f72fb01b26b", "class_name": "RelatedNodeInfo"}}, "text": "Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n", "start_char_idx": 1871, "end_char_idx": 2133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20165d0c-8439-49af-8247-d33f1f560dde": {"__data__": {"id_": "20165d0c-8439-49af-8247-d33f1f560dde", "embedding": null, "metadata": {"window": "In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27bfb175-a2c5-4f07-b45f-24bfd77b5770", "node_type": "1", "metadata": {"window": "Now, a few other things to keep in mind in terms of the fiscal \u201822 cadence\u2026  \n \nFor Pharma, we expect the year -over-year growth i n the back half to be heavily weighted to the fourth \nquarter due to the lapping of some prior year items, including higher costs for the deployment of IT \ninvestments, and the general sequencing of our growth initiatives.  \n \n In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n", "original_text": "Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "572899caa7b8db84046f049fd8b0363d75421ca66c9a24ab9a3d17c6ef6b4abf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d924ab7-f2d2-4143-b244-8bdd79a75117", "node_type": "1", "metadata": {"window": "We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n"}, "hash": "7ac83727453a327424ef6abcd6780bee5671b17c728ad9652bcffff5dbed9df4", "class_name": "RelatedNodeInfo"}}, "text": "As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n", "start_char_idx": 2133, "end_char_idx": 2371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d924ab7-f2d2-4143-b244-8bdd79a75117": {"__data__": {"id_": "4d924ab7-f2d2-4143-b244-8bdd79a75117", "embedding": null, "metadata": {"window": "We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20165d0c-8439-49af-8247-d33f1f560dde", "node_type": "1", "metadata": {"window": "In Medical, we continue to expect an unfavorable year -over-year impact due to timing of selling higher \ncost PPE in the second half of fiscal \u201822, though not to same magnitude as in the second quarter.  We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47fd8a3e23f988223712266cee2b458645780c91de69bb48fcdd5b021a71320f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6cbac8f-13e7-4876-bc19-6addfc003f36", "node_type": "1", "metadata": {"window": "Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "With that, I\u2019ll turn it back over to Mi ke. \n \n"}, "hash": "8f1755044f20cdfaf81c0edc8f8c81986920fc71607fba29a4dedf2294cfb311", "class_name": "RelatedNodeInfo"}}, "text": "We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n", "start_char_idx": 2371, "end_char_idx": 2594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6cbac8f-13e7-4876-bc19-6addfc003f36": {"__data__": {"id_": "e6cbac8f-13e7-4876-bc19-6addfc003f36", "embedding": null, "metadata": {"window": "Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "With that, I\u2019ll turn it back over to Mi ke. \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d924ab7-f2d2-4143-b244-8bdd79a75117", "node_type": "1", "metadata": {"window": "We \nalso will be lapping the large prior year PPE inventory reserve in the fourth quarter.  \n \n Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80e0716d7aaee10fcc6ebdb89d03c64c0bd5200b5d9ba0df5a24b7bd2be5e065", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd424dfe-38d3-4eff-be6b-01563c0a4a6f", "node_type": "1", "metadata": {"window": "As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "Mike Kaufmann:   Thanks, Jason.  "}, "hash": "03a6794aa95a18499537186aa5f4e24d980ac29d719db4b7f8f84b38a1f5d13c", "class_name": "RelatedNodeInfo"}}, "text": "With that, I\u2019ll turn it back over to Mi ke. \n \n", "start_char_idx": 2594, "end_char_idx": 2641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd424dfe-38d3-4eff-be6b-01563c0a4a6f": {"__data__": {"id_": "fd424dfe-38d3-4eff-be6b-01563c0a4a6f", "embedding": null, "metadata": {"window": "As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "Mike Kaufmann:   Thanks, Jason.  ", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc3d06cf6f7fff18fe6ee5edb72e4147d690460c39d31d4db9b543228d891596", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6cbac8f-13e7-4876-bc19-6addfc003f36", "node_type": "1", "metadata": {"window": "Finally, to close, a few reminders on capital deployment\u2026  \n \nWe continue to expect to pay down the approximate $280 million of remaining June 2022 notes at \nmaturity, and continue to expect approximately $1 billion in total share repurchases in fiscal \u201822.  \n \n As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "With that, I\u2019ll turn it back over to Mi ke. \n \n", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9da7b2a08180ed7b18968225aaadefc8444b972fb25221b443b6766470cfb656", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ea5d723-eb47-411e-91d6-2758f86aad24", "node_type": "1", "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n", "original_text": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business. "}, "hash": "b07755a1f2c7b42c73f8aeaee7b7882ce72343741d45567c8d5e8c171506007b", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:   Thanks, Jason.  ", "start_char_idx": 2641, "end_char_idx": 2674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ea5d723-eb47-411e-91d6-2758f86aad24": {"__data__": {"id_": "4ea5d723-eb47-411e-91d6-2758f86aad24", "embedding": null, "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n", "original_text": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd424dfe-38d3-4eff-be6b-01563c0a4a6f", "node_type": "1", "metadata": {"window": "As we\u2019ve said, we see our increasing balance sheet flexibility supporting more opportunistic return of \ncapital to shareholders as our debt paydown begins to moderate, enabled by our recent $3 billion \nshare repurchase authorization.  \n \n We continue to believe that capital deployment, along with the future growth that we expect in both \nour segments, will drive the long -term, double -digit combined EPS growth and dividend yield that we \nare targeting.  \n \n With that, I\u2019ll turn it back over to Mi ke. \n \n Mike Kaufmann:   Thanks, Jason.  ", "original_text": "Mike Kaufmann:   Thanks, Jason.  ", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "749734a15ffe387092dc15da20b8b9637fc4ef6678d50cdf0d564f3b6918fe1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5a3fc2e-6b15-47c3-bf74-6f28b124cbe5", "node_type": "1", "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix. ", "original_text": "We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit. "}, "hash": "1118f9581e008be61b328dfa090d3abe3d8fb8b3c03da1eb0d4a5b8803bf705a", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business. ", "start_char_idx": 0, "end_char_idx": 152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5a3fc2e-6b15-47c3-bf74-6f28b124cbe5": {"__data__": {"id_": "c5a3fc2e-6b15-47c3-bf74-6f28b124cbe5", "embedding": null, "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix. ", "original_text": "We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ea5d723-eb47-411e-91d6-2758f86aad24", "node_type": "1", "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n", "original_text": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7a407a4766ac8d58f23973ced2ac6caaffb1f89006b303692c0ed6be921a42e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8d38b99-e09e-49f8-a1ee-c34e2d8cd550", "node_type": "1", "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n", "original_text": "We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses. "}, "hash": "a3686448cc54abc984cc5418da6e53ceffad98302f8eee9ba8bb65213d290f8a", "class_name": "RelatedNodeInfo"}}, "text": "We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit. ", "start_char_idx": 152, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8d38b99-e09e-49f8-a1ee-c34e2d8cd550": {"__data__": {"id_": "a8d38b99-e09e-49f8-a1ee-c34e2d8cd550", "embedding": null, "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n", "original_text": "We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5a3fc2e-6b15-47c3-bf74-6f28b124cbe5", "node_type": "1", "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix. ", "original_text": "We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb566dfaec4ee17fedce7eff39862122ecaf41eda7c896048092e50c9dd7c25a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d864838-7d38-48c3-a65c-937708f63a5e", "node_type": "1", "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change. ", "original_text": "With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n"}, "hash": "91e45769188ce6252e2c1d1007c072d150b3e47bcecf46c5f32b4f08237371d9", "class_name": "RelatedNodeInfo"}}, "text": "We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses. ", "start_char_idx": 339, "end_char_idx": 427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d864838-7d38-48c3-a65c-937708f63a5e": {"__data__": {"id_": "5d864838-7d38-48c3-a65c-937708f63a5e", "embedding": null, "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change. ", "original_text": "With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8d38b99-e09e-49f8-a1ee-c34e2d8cd550", "node_type": "1", "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n", "original_text": "We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db1746dc79d555a612b03ef3ca343e5d4951f2094738b13acf8dfa9899e1b9b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b426a336-8e3f-4d3f-bbe0-b9af04dfbfb7", "node_type": "1", "metadata": {"window": "We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n", "original_text": "To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix. "}, "hash": "4c54c94f0befeb914b91444cf9e307e6f8d4afaa3a2e08135d68f8737b216184", "class_name": "RelatedNodeInfo"}}, "text": "With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n", "start_char_idx": 427, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b426a336-8e3f-4d3f-bbe0-b9af04dfbfb7": {"__data__": {"id_": "b426a336-8e3f-4d3f-bbe0-b9af04dfbfb7", "embedding": null, "metadata": {"window": "We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n", "original_text": "To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d864838-7d38-48c3-a65c-937708f63a5e", "node_type": "1", "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change. ", "original_text": "With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00854f506e4b1658d1f0300bd9d13f28ec1e80232bce305821bc4f4f5b5b5660", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68ac87a8-8c5d-41a7-a188-123c36a5ef72", "node_type": "1", "metadata": {"window": "We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives. ", "original_text": "Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n"}, "hash": "2095c935a5c79efe01c54110c3816fce8bb92cd166d4cf008584bcc462b853d4", "class_name": "RelatedNodeInfo"}}, "text": "To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix. ", "start_char_idx": 525, "end_char_idx": 679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68ac87a8-8c5d-41a7-a188-123c36a5ef72": {"__data__": {"id_": "68ac87a8-8c5d-41a7-a188-123c36a5ef72", "embedding": null, "metadata": {"window": "We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives. ", "original_text": "Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b426a336-8e3f-4d3f-bbe0-b9af04dfbfb7", "node_type": "1", "metadata": {"window": "We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n", "original_text": "To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d11265d95be0fdf7220049a829598a0549563ae314ec1e4f01570798d50ccc34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28f12405-2321-4a5b-9225-47f521d08235", "node_type": "1", "metadata": {"window": "With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n", "original_text": "However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change. "}, "hash": "776abc3cff67e32ee25c379ec5ccb78838f18e77bee62721397b3ed80bd6db5a", "class_name": "RelatedNodeInfo"}}, "text": "Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n", "start_char_idx": 679, "end_char_idx": 811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28f12405-2321-4a5b-9225-47f521d08235": {"__data__": {"id_": "28f12405-2321-4a5b-9225-47f521d08235", "embedding": null, "metadata": {"window": "With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n", "original_text": "However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68ac87a8-8c5d-41a7-a188-123c36a5ef72", "node_type": "1", "metadata": {"window": "We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives. ", "original_text": "Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "585403237fdbddf7ff6cb09ead6176bde34b80df653aa540ce66d34f822be1ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a12ab53-de5b-4423-aa92-be1368415e3b", "node_type": "1", "metadata": {"window": "To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n", "original_text": "We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n"}, "hash": "0c7f89deff11524785d38294f6dbe21ef2ca6b003a78fe63771902134cedac02", "class_name": "RelatedNodeInfo"}}, "text": "However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change. ", "start_char_idx": 811, "end_char_idx": 936, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a12ab53-de5b-4423-aa92-be1368415e3b": {"__data__": {"id_": "7a12ab53-de5b-4423-aa92-be1368415e3b", "embedding": null, "metadata": {"window": "To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n", "original_text": "We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28f12405-2321-4a5b-9225-47f521d08235", "node_type": "1", "metadata": {"window": "With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n", "original_text": "However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c179c5a62e1622f1b6c3de7c0bb3ff08bdd6db0ff8253b19a2b7d45e3055478", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b44fd569-7bdd-4a91-a855-514462d1fdaf", "node_type": "1", "metadata": {"window": "Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform. ", "original_text": "With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives. "}, "hash": "aced14190f11f17ed856b769ccb0b582b3a7da17d4dea95520772443f84ee69f", "class_name": "RelatedNodeInfo"}}, "text": "We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n", "start_char_idx": 936, "end_char_idx": 1097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b44fd569-7bdd-4a91-a855-514462d1fdaf": {"__data__": {"id_": "b44fd569-7bdd-4a91-a855-514462d1fdaf", "embedding": null, "metadata": {"window": "Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform. ", "original_text": "With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a12ab53-de5b-4423-aa92-be1368415e3b", "node_type": "1", "metadata": {"window": "To address the  challenges in our Medical business, we\u2019re focused on 3 things:  \n \nFirst, evolving our commercial contracting strategies and driving mix.  Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n", "original_text": "We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ad26b6ae788d46621fdbd7d88b911b3cc60a4bea8a707b244e0c84fc0c7b9a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea69bdbb-f9e9-4aab-93a5-d276b1e3b7d3", "node_type": "1", "metadata": {"window": "However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n", "original_text": "We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n"}, "hash": "5d1facbf66314c16b72bc374f3301a878dae5e37a868c4793cc5214f01b69d07", "class_name": "RelatedNodeInfo"}}, "text": "With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives. ", "start_char_idx": 1097, "end_char_idx": 1248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea69bdbb-f9e9-4aab-93a5-d276b1e3b7d3": {"__data__": {"id_": "ea69bdbb-f9e9-4aab-93a5-d276b1e3b7d3", "embedding": null, "metadata": {"window": "However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n", "original_text": "We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b44fd569-7bdd-4a91-a855-514462d1fdaf", "node_type": "1", "metadata": {"window": "Historically, costs have been \nrelatively stable and industry participants have committed to longer -term, multi -year con tracts. \n However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform. ", "original_text": "With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231d9e074cf7a69974d34036cf94dbc58fa319e3bf078b0925539d6b1be985b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73803877-2b21-4cbe-a347-851cf6154e82", "node_type": "1", "metadata": {"window": "We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n", "original_text": "Within our Medical products portfolio, we are actively improving our key category product offerings. \n"}, "hash": "726959101cb70a0cf6378753094b785f4b274ecdb7aa7603c0978d06d41b05e3", "class_name": "RelatedNodeInfo"}}, "text": "We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n", "start_char_idx": 1248, "end_char_idx": 1469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73803877-2b21-4cbe-a347-851cf6154e82": {"__data__": {"id_": "73803877-2b21-4cbe-a347-851cf6154e82", "embedding": null, "metadata": {"window": "We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n", "original_text": "Within our Medical products portfolio, we are actively improving our key category product offerings. \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea69bdbb-f9e9-4aab-93a5-d276b1e3b7d3", "node_type": "1", "metadata": {"window": "However, the rapid escalation of today\u2019s inflationary pressures demonstrate  that our contracting \nstrategy needs to change.  We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n", "original_text": "We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b78fa23903cdbf3379a2ad14cb71373b317abd8c1d52ac3ebb4b92e9393626b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2d9068c-a3fd-4742-bca4-da160a406be5", "node_type": "1", "metadata": {"window": "With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n", "original_text": "For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform. "}, "hash": "d70f82f6215569bc04cdbade6c94051a5228b420e86e3227c4b4e2c98f8d81cd", "class_name": "RelatedNodeInfo"}}, "text": "Within our Medical products portfolio, we are actively improving our key category product offerings. \n", "start_char_idx": 1469, "end_char_idx": 1571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2d9068c-a3fd-4742-bca4-da160a406be5": {"__data__": {"id_": "f2d9068c-a3fd-4742-bca4-da160a406be5", "embedding": null, "metadata": {"window": "With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n", "original_text": "For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73803877-2b21-4cbe-a347-851cf6154e82", "node_type": "1", "metadata": {"window": "We are in the process of working with our customers to adjust certain \ncontracts to ensure we have more pricing flexibility fo r factors beyond our control.  \n \n With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n", "original_text": "Within our Medical products portfolio, we are actively improving our key category product offerings. \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb78dc732ea6aaecb76beeac478dff46ad0a0b022321fdce65919f7b0069e3b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1da8b24f-11de-48e1-8448-dd5a39f3338b", "node_type": "1", "metadata": {"window": "We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n", "original_text": "These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n"}, "hash": "6d1f0b1d710dd8f7e39de4b86bd0e6f9220be70b2855ff62f0725f83ff89ce7d", "class_name": "RelatedNodeInfo"}}, "text": "For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform. ", "start_char_idx": 1571, "end_char_idx": 1719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1da8b24f-11de-48e1-8448-dd5a39f3338b": {"__data__": {"id_": "1da8b24f-11de-48e1-8448-dd5a39f3338b", "embedding": null, "metadata": {"window": "We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n", "original_text": "These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2d9068c-a3fd-4742-bca4-da160a406be5", "node_type": "1", "metadata": {"window": "With regards to mix, as I noted in the prior quarter, we have made important changes to align our \ncommercial organization\u2019s structure and incentives.  We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n", "original_text": "For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bcda3fb8f5333b62698ee537f8f50852610b31a69c356709c4e838b19bc36aec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77d4257f-97ba-40b3-9010-4eb9f762600d", "node_type": "1", "metadata": {"window": "Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities. ", "original_text": "Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n"}, "hash": "da9ba40721a8789acdeac43d7753d0b1228fd207810623b2cb6c635c8ec379dc", "class_name": "RelatedNodeInfo"}}, "text": "These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n", "start_char_idx": 1719, "end_char_idx": 1791, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77d4257f-97ba-40b3-9010-4eb9f762600d": {"__data__": {"id_": "77d4257f-97ba-40b3-9010-4eb9f762600d", "embedding": null, "metadata": {"window": "Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities. ", "original_text": "Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1da8b24f-11de-48e1-8448-dd5a39f3338b", "node_type": "1", "metadata": {"window": "We are under -penetrated in Cardinal Health \nbrand mix relative to our potent ial, which remains a significant mid to long term profit opportunity as \nwe move past the pandemic and associated supply chain challenges.  \n \n Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n", "original_text": "These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d32b63649d2298ae92fb80a12e10714c0b9785b6e602d787dd76a4198f16bda4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ee1d6c0-bebe-42d3-a481-dedcde0a9248", "node_type": "1", "metadata": {"window": "For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n", "original_text": "We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n"}, "hash": "ed5feb70aaa9fb83a8afeeefa3ac567420a0dab98996343ebd204c9c692a4ed5", "class_name": "RelatedNodeInfo"}}, "text": "Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n", "start_char_idx": 1791, "end_char_idx": 1889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ee1d6c0-bebe-42d3-a481-dedcde0a9248": {"__data__": {"id_": "7ee1d6c0-bebe-42d3-a481-dedcde0a9248", "embedding": null, "metadata": {"window": "For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n", "original_text": "We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77d4257f-97ba-40b3-9010-4eb9f762600d", "node_type": "1", "metadata": {"window": "Within our Medical products portfolio, we are actively improving our key category product offerings. \n For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities. ", "original_text": "Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "509d3f061cb510c06f78cc8d1a34571946982f4c21428c3add9cbcb41b1da0e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82568a9a-755a-49e3-90c8-374a4e6b69ac", "node_type": "1", "metadata": {"window": "These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n"}, "hash": "6fc464297b62f262733e538169062e3dbb72a5585d7d75c3dba89dee76c40dbd", "class_name": "RelatedNodeInfo"}}, "text": "We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n", "start_char_idx": 1889, "end_char_idx": 2038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82568a9a-755a-49e3-90c8-374a4e6b69ac": {"__data__": {"id_": "82568a9a-755a-49e3-90c8-374a4e6b69ac", "embedding": null, "metadata": {"window": "These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ee1d6c0-bebe-42d3-a481-dedcde0a9248", "node_type": "1", "metadata": {"window": "For example, in  our Incontinence product line we have launched a new Cardinal Health brand stretch \nbrief and a comprehensive breathable platform.  These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n", "original_text": "We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c41e1910459a65f9622ee547d74df7ce66d4773f744760df8d9c97edc5a87f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e91d9c7b-edd8-43bd-af88-efb8289b6ff0", "node_type": "1", "metadata": {"window": "Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities. "}, "hash": "c39dfb00a1276c6cfda7d9801c4561ad6ba2dadec31c832776155e2b67f0c84a", "class_name": "RelatedNodeInfo"}}, "text": "We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n", "start_char_idx": 2038, "end_char_idx": 2267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e91d9c7b-edd8-43bd-af88-efb8289b6ff0": {"__data__": {"id_": "e91d9c7b-edd8-43bd-af88-efb8289b6ff0", "embedding": null, "metadata": {"window": "Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82568a9a-755a-49e3-90c8-374a4e6b69ac", "node_type": "1", "metadata": {"window": "These enhancements directly support and meet our \ncustomers\u2019 needs.  \n \n Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4849a00d2c7b4faeabac302abc341c91b64e9769e27114eababd2e0052fbb4a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c86291e-b51b-45fe-9ae1-7833011504e8", "node_type": "1", "metadata": {"window": "We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n"}, "hash": "be0003900dfc0e63d9ca63921980097c6621fcc256c91dc7ac1e60bd3140b1e0", "class_name": "RelatedNodeInfo"}}, "text": "We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities. ", "start_char_idx": 2267, "end_char_idx": 2593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c86291e-b51b-45fe-9ae1-7833011504e8": {"__data__": {"id_": "6c86291e-b51b-45fe-9ae1-7833011504e8", "embedding": null, "metadata": {"window": "We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e91d9c7b-edd8-43bd-af88-efb8289b6ff0", "node_type": "1", "metadata": {"window": "Second, we are simplifying our operating model, and optim izing our international footprint.   \n \n We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "314eacb060d600ff99fd3fce0bf5206ee0abaa3742736a308ecfc8002bfd32d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f528f00a-cac6-454c-badb-c7373a2f2379", "node_type": "1", "metadata": {"window": "We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n "}, "hash": "74474039f9f69719c2f4cae88f117b34257a570a736f42dea75b0fed38de098e", "class_name": "RelatedNodeInfo"}}, "text": "Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n", "start_char_idx": 2593, "end_char_idx": 2760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f528f00a-cac6-454c-badb-c7373a2f2379": {"__data__": {"id_": "f528f00a-cac6-454c-badb-c7373a2f2379", "embedding": null, "metadata": {"window": "We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a890dff1-9362-49d1-8301-69bcddb1f082", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11d42600c652009d8fe38f28aba8ba643eb2afd619d07dc356fe6e0bda0ae09b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c86291e-b51b-45fe-9ae1-7833011504e8", "node_type": "1", "metadata": {"window": "We remain on track regarding the timing of the previously -announced exits in certain commercial \nmarkets, with 35 of the 36 completed to -date.  \n \n We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dfc804e819e8db508dc74b6ba83cee4d7bfa6691d2113acd43e751fd54072f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "721e79ba-2399-43f9-b912-9fe0c55bea14", "node_type": "1", "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions. ", "original_text": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home. "}, "hash": "a74f25c950390aabe88b54e8a87cf3e6be0586faa6825a3e65705c1545b6ce06", "class_name": "RelatedNodeInfo"}}, "text": "Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "start_char_idx": 2760, "end_char_idx": 2999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "721e79ba-2399-43f9-b912-9fe0c55bea14": {"__data__": {"id_": "721e79ba-2399-43f9-b912-9fe0c55bea14", "embedding": null, "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions. ", "original_text": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f528f00a-cac6-454c-badb-c7373a2f2379", "node_type": "1", "metadata": {"window": "We are also focused on the modernization of our distribution facilities, in cluding breaking ground on a \nnew distribution center in the Midwest with nearly triple the space of the existing facility enabling \nfuture growth .  \n \n We believe that a diverse, global sourcing network is important to remain competitive on cost, and are \ninves ting in additional self -manufacturing capabilities, including increases in annual production of \nsafety needles and syringes, isolation gowns, and surgical and procedure masks in our own North \nAmerican facilities.  Specifically for surgical gowns, we have ef forts underway that will double our \nNorth American finished goods production and enhance our supply chain resiliency.  \n \n Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "original_text": "Third, we continue to invest across the Medical segment, including in our growth businesses, at -\nHome Solutions and Medical Services, whic h are aligned with industry trends and positioned to grow \ndouble -digits in FY '22 and beyond.  \n ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01df1af4740b63a3de25efdc8383b768f1656756284f04cb221931bf868e0891", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb3e4932-54cf-4df6-810e-8ba11abdc4cf", "node_type": "1", "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses. ", "original_text": "We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care. "}, "hash": "972956fc823d64949d85a727bc42f0fb02d72e33c48e08c04180bc409a4cf4a5", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home. ", "start_char_idx": 0, "end_char_idx": 115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb3e4932-54cf-4df6-810e-8ba11abdc4cf": {"__data__": {"id_": "cb3e4932-54cf-4df6-810e-8ba11abdc4cf", "embedding": null, "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses. ", "original_text": "We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "721e79ba-2399-43f9-b912-9fe0c55bea14", "node_type": "1", "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions. ", "original_text": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc6c1be6a73d315896360bab438ea658fa3dd9ac537cc34404c9e30d7908efab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3ab288a-3a9e-4761-bbd8-9ffad020c776", "node_type": "1", "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics. ", "original_text": "Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n"}, "hash": "f6521a2da022d236915f92097cd67cd26ecfd7434b03faaebf36af7cbf69661d", "class_name": "RelatedNodeInfo"}}, "text": "We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care. ", "start_char_idx": 115, "end_char_idx": 379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3ab288a-3a9e-4761-bbd8-9ffad020c776": {"__data__": {"id_": "d3ab288a-3a9e-4761-bbd8-9ffad020c776", "embedding": null, "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics. ", "original_text": "Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb3e4932-54cf-4df6-810e-8ba11abdc4cf", "node_type": "1", "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses. ", "original_text": "We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1883d4bd565184d1b7041f21c2df03e835bd3ddd53ed59efbeb48087393c4739", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94c7cef1-8999-45cf-820d-d7a310d7da9e", "node_type": "1", "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n", "original_text": "And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions. "}, "hash": "e0db6be512c5ae6ad12d078c93f39dfaec3e2667a3c2f97e88255724c08e3158", "class_name": "RelatedNodeInfo"}}, "text": "Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n", "start_char_idx": 379, "end_char_idx": 536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94c7cef1-8999-45cf-820d-d7a310d7da9e": {"__data__": {"id_": "94c7cef1-8999-45cf-820d-d7a310d7da9e", "embedding": null, "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n", "original_text": "And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3ab288a-3a9e-4761-bbd8-9ffad020c776", "node_type": "1", "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics. ", "original_text": "Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7199066b80dc19f51f250dde1189d6ca8a1d756f9d11e862a70780d2c5720093", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2964809d-5ac1-4624-965f-4e9e3e23d62e", "node_type": "1", "metadata": {"window": "We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks. ", "original_text": "We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses. "}, "hash": "774881b0af97c3af0c1a5d61b0f12e8c0166f0be474e8c154256436e1ed7a80b", "class_name": "RelatedNodeInfo"}}, "text": "And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions. ", "start_char_idx": 536, "end_char_idx": 798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2964809d-5ac1-4624-965f-4e9e3e23d62e": {"__data__": {"id_": "2964809d-5ac1-4624-965f-4e9e3e23d62e", "embedding": null, "metadata": {"window": "We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks. ", "original_text": "We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94c7cef1-8999-45cf-820d-d7a310d7da9e", "node_type": "1", "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n", "original_text": "And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2b9306d5ab604ecf1f04af03a5d32198c49deff60fa6f78f666cce2c9837646", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "741b2d65-3824-4a09-b6da-3ecf5922d3cb", "node_type": "1", "metadata": {"window": "Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n", "original_text": "In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics. "}, "hash": "03f14d15b8934e975f7a20d84a81f19019bc31c64f896d3d7cd1ddf3fda0104e", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses. ", "start_char_idx": 798, "end_char_idx": 898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "741b2d65-3824-4a09-b6da-3ecf5922d3cb": {"__data__": {"id_": "741b2d65-3824-4a09-b6da-3ecf5922d3cb", "embedding": null, "metadata": {"window": "Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n", "original_text": "In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2964809d-5ac1-4624-965f-4e9e3e23d62e", "node_type": "1", "metadata": {"window": "We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks. ", "original_text": "We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0f8443304bc8b63f7e223b25451e6ba1b2d0aa4c9cca66503bfe55fa1fb87db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "329d4c9e-9058-40f5-9b3c-d186325a8844", "node_type": "1", "metadata": {"window": "And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822. ", "original_text": "These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n"}, "hash": "8d60874bde121e2cd694ea18a0fdd6315be2098289bb65dd1946f8aac05063c7", "class_name": "RelatedNodeInfo"}}, "text": "In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics. ", "start_char_idx": 898, "end_char_idx": 1162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "329d4c9e-9058-40f5-9b3c-d186325a8844": {"__data__": {"id_": "329d4c9e-9058-40f5-9b3c-d186325a8844", "embedding": null, "metadata": {"window": "And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822. ", "original_text": "These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "741b2d65-3824-4a09-b6da-3ecf5922d3cb", "node_type": "1", "metadata": {"window": "Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n", "original_text": "In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d8fcf1e04d45c7f8a1abaaae69d96d43f7ca539d1be664006f019abd79c841", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51bcb97d-6a93-49ed-b8ae-d0c7fdbfdb7f", "node_type": "1", "metadata": {"window": "We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business. ", "original_text": "In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks. "}, "hash": "2a367c584d2eb84cfef04964c45b9378f1332b481e969f9738f568e9a02324dd", "class_name": "RelatedNodeInfo"}}, "text": "These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n", "start_char_idx": 1162, "end_char_idx": 1256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51bcb97d-6a93-49ed-b8ae-d0c7fdbfdb7f": {"__data__": {"id_": "51bcb97d-6a93-49ed-b8ae-d0c7fdbfdb7f", "embedding": null, "metadata": {"window": "We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business. ", "original_text": "In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "329d4c9e-9058-40f5-9b3c-d186325a8844", "node_type": "1", "metadata": {"window": "And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions.  We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822. ", "original_text": "These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3db711fd8ec46208f03d0ed3bff8c8e60d83d09482f56e27caed02bdac58b4b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "212275ec-db62-427d-ac0c-5395ea088470", "node_type": "1", "metadata": {"window": "In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program. ", "original_text": "This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n"}, "hash": "ad650558c241ef2c2d27edec015a31a7474bfbd1a5560d3dadea37959ab90795", "class_name": "RelatedNodeInfo"}}, "text": "In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks. ", "start_char_idx": 1256, "end_char_idx": 1408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "212275ec-db62-427d-ac0c-5395ea088470": {"__data__": {"id_": "212275ec-db62-427d-ac0c-5395ea088470", "embedding": null, "metadata": {"window": "In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program. ", "original_text": "This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51bcb97d-6a93-49ed-b8ae-d0c7fdbfdb7f", "node_type": "1", "metadata": {"window": "We\u2019ve invested in additional \ntechnology capabilities to increase our offerings in both businesses.  In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business. ", "original_text": "In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f34cbb7c64b47551ab39291c32f7775c47bf97d6c6fb4d40a87853a6675e20d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ffa74d2-c536-4bd6-b5a9-1860e834f41f", "node_type": "1", "metadata": {"window": "These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs. ", "original_text": "Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822. "}, "hash": "7ae22e5a8f164bfa83178bd6481747bf47012dcbf77adc2f31b40dd303a187bc", "class_name": "RelatedNodeInfo"}}, "text": "This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n", "start_char_idx": 1408, "end_char_idx": 1530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ffa74d2-c536-4bd6-b5a9-1860e834f41f": {"__data__": {"id_": "4ffa74d2-c536-4bd6-b5a9-1860e834f41f", "embedding": null, "metadata": {"window": "These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs. ", "original_text": "Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "212275ec-db62-427d-ac0c-5395ea088470", "node_type": "1", "metadata": {"window": "In OptiFreight\u00ae, we\u2019ve invested \nin additional technology capab ilities focused on building automated, technology -driven solutions that \ninnovate the way healthcare supply chain leaders manage shipping spend and take control over their \ntransportation logistics.  These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program. ", "original_text": "This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eea43b93005c74f0a415707b320d7a9a000ba4086984ad21036c74108fe3cfcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "349426f2-0907-4b6b-b869-6bad66cb1012", "node_type": "1", "metadata": {"window": "In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track. ", "original_text": "We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business. "}, "hash": "704d4266781eccc5e69ff5662aed4a6cf138acfbee10d33567b24410e28ac531", "class_name": "RelatedNodeInfo"}}, "text": "Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822. ", "start_char_idx": 1530, "end_char_idx": 1614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "349426f2-0907-4b6b-b869-6bad66cb1012": {"__data__": {"id_": "349426f2-0907-4b6b-b869-6bad66cb1012", "embedding": null, "metadata": {"window": "In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track. ", "original_text": "We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ffa74d2-c536-4bd6-b5a9-1860e834f41f", "node_type": "1", "metadata": {"window": "These efforts are connecting suppliers and customers at ove r 22,000 shipping \nlocations.  \n \n In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs. ", "original_text": "Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "321213228ba60c9fc11cfe1f39ba1638ef71ea9af4ea194c46010586a3c3d803", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bca876a-5602-41f1-a069-db912d029f7a", "node_type": "1", "metadata": {"window": "This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n", "original_text": "This quarter\u2019s segment profit was \ndriven by the performance in our generics program. "}, "hash": "81173b59cb525202868dce489225fbae9f223e79c568915f1c6aa33f45b827e1", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business. ", "start_char_idx": 1614, "end_char_idx": 1745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bca876a-5602-41f1-a069-db912d029f7a": {"__data__": {"id_": "7bca876a-5602-41f1-a069-db912d029f7a", "embedding": null, "metadata": {"window": "This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n", "original_text": "This quarter\u2019s segment profit was \ndriven by the performance in our generics program. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "349426f2-0907-4b6b-b869-6bad66cb1012", "node_type": "1", "metadata": {"window": "In WaveMarkTM, we launched a cutting -edge supply automation solution for clinical labs, which \nautomates previously manual inventory management tasks.  This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track. ", "original_text": "We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42018a37bff5fc23d3f6bcffb3ac774cd22d25f2c5d64ecbbef30378a4dd5073", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8959190-322d-4f35-b26c-97adb59afbb7", "node_type": "1", "metadata": {"window": "Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "original_text": "Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs. "}, "hash": "f8c3cfdfdc10a27b7add005bb595949ed077a1fe2f1698c71afe71083e62977d", "class_name": "RelatedNodeInfo"}}, "text": "This quarter\u2019s segment profit was \ndriven by the performance in our generics program. ", "start_char_idx": 1745, "end_char_idx": 1831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8959190-322d-4f35-b26c-97adb59afbb7": {"__data__": {"id_": "d8959190-322d-4f35-b26c-97adb59afbb7", "embedding": null, "metadata": {"window": "Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "original_text": "Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bca876a-5602-41f1-a069-db912d029f7a", "node_type": "1", "metadata": {"window": "This enables clinical lab staff to focus on \npatient care and better manage increased testing demand due to COVID -19. \n \n Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n", "original_text": "This quarter\u2019s segment profit was \ndriven by the performance in our generics program. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8953df0dd527972a274f344a8198c703f49b80217d8d23dcad91e404849fd2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac8e606b-ff42-45a2-8ca9-999a8898ef94", "node_type": "1", "metadata": {"window": "We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "original_text": "In addition, our multi -year technology investment \nto modernize our systems is on track. "}, "hash": "03100afe6f4c3da88a5d44b6fd4d5bdd45c9a8a789ab13cec64cd5c813fa6923", "class_name": "RelatedNodeInfo"}}, "text": "Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs. ", "start_char_idx": 1831, "end_char_idx": 2025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac8e606b-ff42-45a2-8ca9-999a8898ef94": {"__data__": {"id_": "ac8e606b-ff42-45a2-8ca9-999a8898ef94", "embedding": null, "metadata": {"window": "We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "original_text": "In addition, our multi -year technology investment \nto modernize our systems is on track. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8959190-322d-4f35-b26c-97adb59afbb7", "node_type": "1", "metadata": {"window": "Our Pharma business remains on track to deliver mid -single digit growth in FY \u201822.  We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "original_text": "Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3787a004f66d1038a544ad5cd63b50cc07426239d2b8654d2200b14b2339ce7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed8e9ef7-75b0-4699-8cce-8f6b56c0b06f", "node_type": "1", "metadata": {"window": "This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines. ", "original_text": "We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n"}, "hash": "dce6db354d4661ca5edadda7368b0f0187996114da66a8ade30004de4e139e5a", "class_name": "RelatedNodeInfo"}}, "text": "In addition, our multi -year technology investment \nto modernize our systems is on track. ", "start_char_idx": 2025, "end_char_idx": 2115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed8e9ef7-75b0-4699-8cce-8f6b56c0b06f": {"__data__": {"id_": "ed8e9ef7-75b0-4699-8cce-8f6b56c0b06f", "embedding": null, "metadata": {"window": "This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines. ", "original_text": "We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac8e606b-ff42-45a2-8ca9-999a8898ef94", "node_type": "1", "metadata": {"window": "We continue to \nmake progress on our 2 primary objectives:  \n \nFirst, strengthening our core Pharma Distribution, or PD, business.  This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "original_text": "In addition, our multi -year technology investment \nto modernize our systems is on track. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce11185c8e01694743ed491415ca148d22172d05e9b3835d62dc42a79589d93b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aeaa93a-ba13-459b-86c9-86e7f0cd60fc", "node_type": "1", "metadata": {"window": "Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain. ", "original_text": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n"}, "hash": "6288f2692c7bde227c71d9dd05e65be65c61cd16d91c118a125a816e498b60af", "class_name": "RelatedNodeInfo"}}, "text": "We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n", "start_char_idx": 2115, "end_char_idx": 2243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aeaa93a-ba13-459b-86c9-86e7f0cd60fc": {"__data__": {"id_": "3aeaa93a-ba13-459b-86c9-86e7f0cd60fc", "embedding": null, "metadata": {"window": "Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain. ", "original_text": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed8e9ef7-75b0-4699-8cce-8f6b56c0b06f", "node_type": "1", "metadata": {"window": "This quarter\u2019s segment profit was \ndriven by the performance in our generics program.  Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines. ", "original_text": "We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3ac214c2d0bfb4dfd00c3fc636dc198bc91ea2c2e34194b367ccd8cfce6f33b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f731da7c-3197-4619-b1bc-1bb43d22501f", "node_type": "1", "metadata": {"window": "In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually. ", "original_text": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. "}, "hash": "4cc003cd2044b2d8b069a3f7af9d02c9110fdfd9ffb04ba762773248248aa684", "class_name": "RelatedNodeInfo"}}, "text": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "start_char_idx": 2243, "end_char_idx": 2326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f731da7c-3197-4619-b1bc-1bb43d22501f": {"__data__": {"id_": "f731da7c-3197-4619-b1bc-1bb43d22501f", "embedding": null, "metadata": {"window": "In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually. ", "original_text": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3aeaa93a-ba13-459b-86c9-86e7f0cd60fc", "node_type": "1", "metadata": {"window": "Our generics program is anchored by the scale \nand expertise of Red Oak Sourcing, a partnership we also recently extended through FY \u201829, and \nwhich positions us w ell to meet customers\u2019 needs.  In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain. ", "original_text": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17277ca885c05fdc929392cfee488a2e23a222fcdde3fee3ba10215752ab6fd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2d7e07d-18ca-44c5-bde4-ead54894f792", "node_type": "1", "metadata": {"window": "We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n", "original_text": "Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines. "}, "hash": "ead6ad7a91c26bc2e1a7799ee17641cf7509e51b3d246d7d718fa277423f60b7", "class_name": "RelatedNodeInfo"}}, "text": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "start_char_idx": 2326, "end_char_idx": 2496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2d7e07d-18ca-44c5-bde4-ead54894f792": {"__data__": {"id_": "a2d7e07d-18ca-44c5-bde4-ead54894f792", "embedding": null, "metadata": {"window": "We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n", "original_text": "Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f731da7c-3197-4619-b1bc-1bb43d22501f", "node_type": "1", "metadata": {"window": "In addition, our multi -year technology investment \nto modernize our systems is on track.  We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually. ", "original_text": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "540d13c33fed66abf5464dadc17e35c781ed47b749a931a55b08f9e207f0da13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca1af714-972d-416c-bec6-34d03839a18e", "node_type": "1", "metadata": {"window": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826. ", "original_text": "As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain. "}, "hash": "83dc4f21df833c3e7514a2c3ccc22155cd7c9746ff2eaa938d8eb8fbe43db7fa", "class_name": "RelatedNodeInfo"}}, "text": "Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines. ", "start_char_idx": 2496, "end_char_idx": 2677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca1af714-972d-416c-bec6-34d03839a18e": {"__data__": {"id_": "ca1af714-972d-416c-bec6-34d03839a18e", "embedding": null, "metadata": {"window": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826. ", "original_text": "As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2d7e07d-18ca-44c5-bde4-ead54894f792", "node_type": "1", "metadata": {"window": "We plan to complete the roll -out by the beginning of our Q4 and \nlook to benefit from the conversion in FY \u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n", "original_text": "Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46978df74618a1f05284871632378410e96d73f72300806bdd7ff01bcf3df640", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c72a4a32-bdaf-4cfa-bebf-c500fc1b1be0", "node_type": "1", "metadata": {"window": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually. "}, "hash": "62d9e49ace1e611d780585e85617879c83310ca7ad3ebddbc03d7b59f0014d9d", "class_name": "RelatedNodeInfo"}}, "text": "As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain. ", "start_char_idx": 2677, "end_char_idx": 2869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c72a4a32-bdaf-4cfa-bebf-c500fc1b1be0": {"__data__": {"id_": "c72a4a32-bdaf-4cfa-bebf-c500fc1b1be0", "embedding": null, "metadata": {"window": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca1af714-972d-416c-bec6-34d03839a18e", "node_type": "1", "metadata": {"window": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826. ", "original_text": "As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "563d078c87a533623dbffd1240e91d49a7a4e19ef240858420bdd718e51a723a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f471b982-3655-462a-b883-b084bb6e43a2", "node_type": "1", "metadata": {"window": "Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n"}, "hash": "4a5238dcaf2873c9306b4b30faf905c784fd52bb44f7f5a020124e67c386282a", "class_name": "RelatedNodeInfo"}}, "text": "This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually. ", "start_char_idx": 2869, "end_char_idx": 2977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f471b982-3655-462a-b883-b084bb6e43a2": {"__data__": {"id_": "f471b982-3655-462a-b883-b084bb6e43a2", "embedding": null, "metadata": {"window": "Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c72a4a32-bdaf-4cfa-bebf-c500fc1b1be0", "node_type": "1", "metadata": {"window": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2eef4bad227edd84a52bd6ac5774f1523a57594ec78774c472aa90c8288b18f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cf4ff4b-e207-4d92-b2bb-a4cd92655dbe", "node_type": "1", "metadata": {"window": "As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826. "}, "hash": "1ca1294c8aa4ab7db18a81edf34b24aacadf4df12792b042337cad1fb393e3a6", "class_name": "RelatedNodeInfo"}}, "text": "And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n", "start_char_idx": 2977, "end_char_idx": 3132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cf4ff4b-e207-4d92-b2bb-a4cd92655dbe": {"__data__": {"id_": "3cf4ff4b-e207-4d92-b2bb-a4cd92655dbe", "embedding": null, "metadata": {"window": "As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f471b982-3655-462a-b883-b084bb6e43a2", "node_type": "1", "metadata": {"window": "Just th is week, we announced a \npartnership with Ember Technologies to offer the world\u2019s first self -refrigerated, cloud -based shipping \nbox for temperature -sensitive medicines.  As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "987bc116a02c6461a218979c8765c556c2dbf5c90faa9727b48d055dd4a381f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43b8e7d5-c4b3-4865-bd71-53cf1da83a01", "node_type": "1", "metadata": {"window": "This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support "}, "hash": "e54052adfac21fb7baf5f3132aa4867a4200b8119bf50a84be27062c8b813d9d", "class_name": "RelatedNodeInfo"}}, "text": "In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826. ", "start_char_idx": 3132, "end_char_idx": 3269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43b8e7d5-c4b3-4865-bd71-53cf1da83a01": {"__data__": {"id_": "43b8e7d5-c4b3-4865-bd71-53cf1da83a01", "embedding": null, "metadata": {"window": "This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415655dd4629355cc8d123e00b5e72d4fb080b76cfa9bc89a91aef781a893ed0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cf4ff4b-e207-4d92-b2bb-a4cd92655dbe", "node_type": "1", "metadata": {"window": "As Biopharma continues bringing cold -chain biologic \nproducts to market, including cell a nd gene therapies, this partnership will help ensure product \nintegrity throughout the supply chain.  This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adcb77ebaf0b497fb2ecf01b467230d03c28e7384bcf6c66c9bb0926aed18b0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f330ef66-a7ad-4e82-8b58-3d49b7458a5f", "node_type": "1", "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n", "original_text": " \nPage 7 of 13 \n \nrobust PET diagno stics. "}, "hash": "ddd2f2c2ca1dfb9bd28279785a1a39a8a98f7309b2d0ad1569787f7e8115ce15", "class_name": "RelatedNodeInfo"}}, "text": "We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "start_char_idx": 3269, "end_char_idx": 3531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f330ef66-a7ad-4e82-8b58-3d49b7458a5f": {"__data__": {"id_": "f330ef66-a7ad-4e82-8b58-3d49b7458a5f", "embedding": null, "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n", "original_text": " \nPage 7 of 13 \n \nrobust PET diagno stics. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43b8e7d5-c4b3-4865-bd71-53cf1da83a01", "node_type": "1", "metadata": {"window": "This is a differentiated offering, and one that will reduce landfill \nwaste by millions of pounds annually.  And with biosimilars, we are well positioned to s upport the next \nphase of growth as biosimilars expand into new therapeutic areas and sites of care.  \n \n In Nuclear, we expect continued double digit profit growth, which would result in a doubling of our \nprofits in this business by FY \u201826.  We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "original_text": "We continue to buil d out our multimillion -dollar Center for \nTheranostics Advancement in Indianapolis, where we\u2019ve partnered with several pharma companies to \ndevelop and commercialize novel theranostics, and we\u2019re investing in our PET capabilities to support ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e97cdec905dd4af4fd2cfbd60e4cfc4554bc6f31465fc671b9f6889a50be096", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8eb1929-fa61-4ee7-9305-3b691eec2b84", "node_type": "1", "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion. ", "original_text": "For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n"}, "hash": "038f309002d7da389571df225e0965216b3b08b7455b108e7159c9958682fa52", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 13 \n \nrobust PET diagno stics. ", "start_char_idx": 0, "end_char_idx": 43, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8eb1929-fa61-4ee7-9305-3b691eec2b84": {"__data__": {"id_": "c8eb1929-fa61-4ee7-9305-3b691eec2b84", "embedding": null, "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion. ", "original_text": "For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f330ef66-a7ad-4e82-8b58-3d49b7458a5f", "node_type": "1", "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n", "original_text": " \nPage 7 of 13 \n \nrobust PET diagno stics. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2d8f8d1a09978030093a15c5d0d608ee806095abf817f950ba216e1c4408b58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bbcaa6c-59f6-41c7-b0c6-5770f82d0ab1", "node_type": "1", "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders. ", "original_text": "And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains. "}, "hash": "0dbb2e0e5b65277ee118be02e16855f1999bc19018b93aee5677569946a0bc0a", "class_name": "RelatedNodeInfo"}}, "text": "For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n", "start_char_idx": 43, "end_char_idx": 290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bbcaa6c-59f6-41c7-b0c6-5770f82d0ab1": {"__data__": {"id_": "7bbcaa6c-59f6-41c7-b0c6-5770f82d0ab1", "embedding": null, "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders. ", "original_text": "And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8eb1929-fa61-4ee7-9305-3b691eec2b84", "node_type": "1", "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion. ", "original_text": "For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "591dab222d91a66f034f53d25cecbdaceeabd79b412bfa17cf093db105281a29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54819cc6-55d2-4b3f-bb4f-12f9f34760f0", "node_type": "1", "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n", "original_text": "Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n"}, "hash": "b42dae3c8a334a24cbdee047f2d7b6f1393081db98898c31ff49fccfb9b45c30", "class_name": "RelatedNodeInfo"}}, "text": "And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains. ", "start_char_idx": 290, "end_char_idx": 426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54819cc6-55d2-4b3f-bb4f-12f9f34760f0": {"__data__": {"id_": "54819cc6-55d2-4b3f-bb4f-12f9f34760f0", "embedding": null, "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n", "original_text": "Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bbcaa6c-59f6-41c7-b0c6-5770f82d0ab1", "node_type": "1", "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders. ", "original_text": "And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fb8ff969a6160581db6a8a93461c9cd170cdfbfe457ed9fec904004b6de7a9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c461a42f-79ee-4eaa-99f9-9b91acaf70d8", "node_type": "1", "metadata": {"window": "For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n", "original_text": "With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion. "}, "hash": "3a239076581eaa09ad796d7f783f36e29a09979449f62dbefda52b72bbc5ba54", "class_name": "RelatedNodeInfo"}}, "text": "Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n", "start_char_idx": 426, "end_char_idx": 630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c461a42f-79ee-4eaa-99f9-9b91acaf70d8": {"__data__": {"id_": "c461a42f-79ee-4eaa-99f9-9b91acaf70d8", "embedding": null, "metadata": {"window": "For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n", "original_text": "With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54819cc6-55d2-4b3f-bb4f-12f9f34760f0", "node_type": "1", "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n", "original_text": "Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e905734dadafd63b3fe251734dea6a2ba02f03402e62864d49a622977d547371", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb948d6d-3d69-4a03-afe0-3d0071d4175e", "node_type": "1", "metadata": {"window": "And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n", "original_text": "We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders. "}, "hash": "c58f58cdd11a8e8afc4f699204ec4bc523a99bbb6741dcb180c70e56beef514b", "class_name": "RelatedNodeInfo"}}, "text": "With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion. ", "start_char_idx": 630, "end_char_idx": 823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb948d6d-3d69-4a03-afe0-3d0071d4175e": {"__data__": {"id_": "bb948d6d-3d69-4a03-afe0-3d0071d4175e", "embedding": null, "metadata": {"window": "And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n", "original_text": "We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c461a42f-79ee-4eaa-99f9-9b91acaf70d8", "node_type": "1", "metadata": {"window": "For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n", "original_text": "With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a1e7af9572ecca4c4b1537a362ea0be55a5e65489c0d4b75b494f34eda052a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93aa5f14-fb31-4392-9bbe-5395d8ae5a2c", "node_type": "1", "metadata": {"window": "Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n", "original_text": "Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n"}, "hash": "17f82552c19d45c8e983b2bd3e5d7c9998b406601997c6c234cf476a54766517", "class_name": "RelatedNodeInfo"}}, "text": "We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders. ", "start_char_idx": 823, "end_char_idx": 1050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93aa5f14-fb31-4392-9bbe-5395d8ae5a2c": {"__data__": {"id_": "93aa5f14-fb31-4392-9bbe-5395d8ae5a2c", "embedding": null, "metadata": {"window": "Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n", "original_text": "Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb948d6d-3d69-4a03-afe0-3d0071d4175e", "node_type": "1", "metadata": {"window": "And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n", "original_text": "We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40738cfbff7a54eb60fc253f94ee548b7f5682383702b8f530369b2c72b19bdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5534d9b8-05fd-4c68-952f-b02c50854cd1", "node_type": "1", "metadata": {"window": "With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n", "original_text": "These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n"}, "hash": "f91437a25d109b28ee98644091350c682033959f12b23f99a23a4b8547a6c46c", "class_name": "RelatedNodeInfo"}}, "text": "Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n", "start_char_idx": 1050, "end_char_idx": 1135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5534d9b8-05fd-4c68-952f-b02c50854cd1": {"__data__": {"id_": "5534d9b8-05fd-4c68-952f-b02c50854cd1", "embedding": null, "metadata": {"window": "With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n", "original_text": "These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93aa5f14-fb31-4392-9bbe-5395d8ae5a2c", "node_type": "1", "metadata": {"window": "Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n", "original_text": "Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe2ffc5022b8a83793b9dae571648dceae95672bf59e65e66779484ea84c873b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5329afb4-8175-4f2f-a029-1c12a434a977", "node_type": "1", "metadata": {"window": "We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed. ", "original_text": "Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n"}, "hash": "92d373496dd4a58bb37aca4ecb541fc6f2293fd32c4b67efc37bba5479f2ce8e", "class_name": "RelatedNodeInfo"}}, "text": "These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n", "start_char_idx": 1135, "end_char_idx": 1293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5329afb4-8175-4f2f-a029-1c12a434a977": {"__data__": {"id_": "5329afb4-8175-4f2f-a029-1c12a434a977", "embedding": null, "metadata": {"window": "We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed. ", "original_text": "Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5534d9b8-05fd-4c68-952f-b02c50854cd1", "node_type": "1", "metadata": {"window": "With respect to the Enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformat ion.  We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n", "original_text": "These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11ae4bbd4a3fa85ff7ffabff3ebd80807d9c492d285c7755150683854eb950e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa76cb72-27a7-4943-bf70-1f0c32959e82", "node_type": "1", "metadata": {"window": "Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n", "original_text": "As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n"}, "hash": "3fb53856f841bd32f4e219c520bb27dd545d76f42f2a513894cbbdc1d30922b6", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n", "start_char_idx": 1293, "end_char_idx": 1396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa76cb72-27a7-4943-bf70-1f0c32959e82": {"__data__": {"id_": "fa76cb72-27a7-4943-bf70-1f0c32959e82", "embedding": null, "metadata": {"window": "Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n", "original_text": "As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5329afb4-8175-4f2f-a029-1c12a434a977", "node_type": "1", "metadata": {"window": "We're \npairing cost reduction efforts with balanced, disciplined, and shareholder -friendly capital allocation \nwith a focus on investing in the business, maintaining a strong balance sheet and returning cash to \nshareholders.  Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed. ", "original_text": "Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9bacdb6e2cb355d0f8183478877dfff9d0d44d5f060f29c44938390048b4b57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40893f46-d54a-4780-adb0-a6bad706e396", "node_type": "1", "metadata": {"window": "These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities. ", "original_text": "The sign -on period for political subdivisions within participating states concluded on January 26th. \n"}, "hash": "e071d1c4e5c7401889956c1e796b06c31310ed406d30ee8ed0acadc575dc4dfd", "class_name": "RelatedNodeInfo"}}, "text": "As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n", "start_char_idx": 1396, "end_char_idx": 1492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40893f46-d54a-4780-adb0-a6bad706e396": {"__data__": {"id_": "40893f46-d54a-4780-adb0-a6bad706e396", "embedding": null, "metadata": {"window": "These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities. ", "original_text": "The sign -on period for political subdivisions within participating states concluded on January 26th. \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa76cb72-27a7-4943-bf70-1f0c32959e82", "node_type": "1", "metadata": {"window": "Long term, we're targeting a  double -digit combined EPS growth and dividend yield. \n These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n", "original_text": "As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a779bd0c54c3ee5888cdec96c2111997d0fa4b7e3db91454395d103971b7dc46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40555185-108b-4948-814e-03ade797ce5e", "node_type": "1", "metadata": {"window": "Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company. ", "original_text": "Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed. "}, "hash": "df66efa6869a369eac76b6923d47f8a7d419e732271bb78258b8be640c180b55", "class_name": "RelatedNodeInfo"}}, "text": "The sign -on period for political subdivisions within participating states concluded on January 26th. \n", "start_char_idx": 1492, "end_char_idx": 1595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40555185-108b-4948-814e-03ade797ce5e": {"__data__": {"id_": "40555185-108b-4948-814e-03ade797ce5e", "embedding": null, "metadata": {"window": "Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company. ", "original_text": "Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40893f46-d54a-4780-adb0-a6bad706e396", "node_type": "1", "metadata": {"window": "These expectations are driven by our growth targets for our segments, our commitment to our \ndividend, and our $3 billion share repurchase authorization.  \n \n Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities. ", "original_text": "The sign -on period for political subdivisions within participating states concluded on January 26th. \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30c5d7b2dd5e020a0798610d2b5ea06c79edd2ac808dfd944042fe6e1659de95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab752ea8-098d-4ce1-89c1-e8195d786a27", "node_type": "1", "metadata": {"window": "As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S. ", "original_text": "After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n"}, "hash": "e7a068836c28375b2ef3254e2daf366e72c7fbddc2d07ebc29e70fb4e6d86c7d", "class_name": "RelatedNodeInfo"}}, "text": "Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed. ", "start_char_idx": 1595, "end_char_idx": 1734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab752ea8-098d-4ce1-89c1-e8195d786a27": {"__data__": {"id_": "ab752ea8-098d-4ce1-89c1-e8195d786a27", "embedding": null, "metadata": {"window": "As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S. ", "original_text": "After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40555185-108b-4948-814e-03ade797ce5e", "node_type": "1", "metadata": {"window": "Now, let me provide an update on the proposed op ioid settlement agreement and settlement process.  \n \n As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company. ", "original_text": "Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eff7e2961ca8e049b08be6e3681be0ca71137f11dfbd0768dd805235cf461ff3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdaf5fd8-973f-4a8c-9cfc-e9d4ab385118", "node_type": "1", "metadata": {"window": "The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n", "original_text": "If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities. "}, "hash": "82e9e9fd95d79a658c1f3cd5e3eeb45e4d49091e77c997bcaa01d435e5be1c44", "class_name": "RelatedNodeInfo"}}, "text": "After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n", "start_char_idx": 1734, "end_char_idx": 1880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdaf5fd8-973f-4a8c-9cfc-e9d4ab385118": {"__data__": {"id_": "bdaf5fd8-973f-4a8c-9cfc-e9d4ab385118", "embedding": null, "metadata": {"window": "The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n", "original_text": "If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab752ea8-098d-4ce1-89c1-e8195d786a27", "node_type": "1", "metadata": {"window": "As of today, 46 out of 49 States have indicated their intent to join the global settlement.  \n \n The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S. ", "original_text": "After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5da47bde6036493d33ea72948f6363bdcc46c7b58508c45e516ad69961f41db6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ecca4db-1a58-471b-82b8-a10b2b17942d", "node_type": "1", "metadata": {"window": "Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n", "original_text": "This is an important step forward for \nour company. "}, "hash": "d8f0a9eac8ac7022c152d061bc74feb6ac0fe4b288c6097baa547db8b6cd4be1", "class_name": "RelatedNodeInfo"}}, "text": "If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities. ", "start_char_idx": 1880, "end_char_idx": 2057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ecca4db-1a58-471b-82b8-a10b2b17942d": {"__data__": {"id_": "9ecca4db-1a58-471b-82b8-a10b2b17942d", "embedding": null, "metadata": {"window": "Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n", "original_text": "This is an important step forward for \nour company. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdaf5fd8-973f-4a8c-9cfc-e9d4ab385118", "node_type": "1", "metadata": {"window": "The sign -on period for political subdivisions within participating states concluded on January 26th. \n Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n", "original_text": "If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a8785ec1d1ab3c76daa74c299726bdeff4648753d98ba319c6d53ea34f37f30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9c873ca-14e1-440a-bdf6-b2f69d554397", "node_type": "1", "metadata": {"window": "After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day. ", "original_text": "As we've consist ently said, we remain committed to being part of the solution to the \nU.S. "}, "hash": "8cf332c000b9d10b566c0723033124522b00aaa719c05679b27231dd23513803", "class_name": "RelatedNodeInfo"}}, "text": "This is an important step forward for \nour company. ", "start_char_idx": 2057, "end_char_idx": 2109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9c873ca-14e1-440a-bdf6-b2f69d554397": {"__data__": {"id_": "c9c873ca-14e1-440a-bdf6-b2f69d554397", "embedding": null, "metadata": {"window": "After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day. ", "original_text": "As we've consist ently said, we remain committed to being part of the solution to the \nU.S. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ecca4db-1a58-471b-82b8-a10b2b17942d", "node_type": "1", "metadata": {"window": "Now, each of the participating states are in the process of determining whether there is sufficient \nsubdivision participation to proceed.  After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n", "original_text": "This is an important step forward for \nour company. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2078e4ae8f8d47e10dec7799c7662b8c18ecc113953f4df68789ec5760155501", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2eddb6e-e022-4dc8-8b53-7a9e0ac9fdf7", "node_type": "1", "metadata": {"window": "If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n", "original_text": "opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n"}, "hash": "e666bc0076fc4c0e62ea89db5b2b2d3af2e221a7b0cd2402ad090005fe82c46c", "class_name": "RelatedNodeInfo"}}, "text": "As we've consist ently said, we remain committed to being part of the solution to the \nU.S. ", "start_char_idx": 2109, "end_char_idx": 2201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2eddb6e-e022-4dc8-8b53-7a9e0ac9fdf7": {"__data__": {"id_": "d2eddb6e-e022-4dc8-8b53-7a9e0ac9fdf7", "embedding": null, "metadata": {"window": "If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n", "original_text": "opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9c873ca-14e1-440a-bdf6-b2f69d554397", "node_type": "1", "metadata": {"window": "After we receive notice from the states regarding their decision, \neach of the distributors will make final determinations by Feb ruary 25th.  \n \n If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day. ", "original_text": "As we've consist ently said, we remain committed to being part of the solution to the \nU.S. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c10b720672299ea8d15fd376f522b3dd7b7da7e17394012e9c59364ac72335c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffbdb92c-3e13-42cb-8fe2-64856dcd6965", "node_type": "1", "metadata": {"window": "This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n", "original_text": "In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n"}, "hash": "25d018de513a33e547ec594ccf0dbd4b103ef4cdb39667acdf5b71768df18bc2", "class_name": "RelatedNodeInfo"}}, "text": "opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n", "start_char_idx": 2201, "end_char_idx": 2337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffbdb92c-3e13-42cb-8fe2-64856dcd6965": {"__data__": {"id_": "ffbdb92c-3e13-42cb-8fe2-64856dcd6965", "embedding": null, "metadata": {"window": "This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n", "original_text": "In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2eddb6e-e022-4dc8-8b53-7a9e0ac9fdf7", "node_type": "1", "metadata": {"window": "If all conditions are satisfied, this agreement would result in the settlement of a substantial majority of \nopioid lawsuits filed by the state and local governmental entities.  This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n", "original_text": "opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e383579a30ea38180d51b8110e9d1234a06448c7565cb4d176ed43a1b790bd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80eb4153-a141-4221-87cf-ba5d1bdb0fcd", "node_type": "1", "metadata": {"window": "As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters. ", "original_text": "We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day. "}, "hash": "7cc9e73b46071d5a7d4cb31a56b3a1230b2e068bf5ab638f97198d04d03b558d", "class_name": "RelatedNodeInfo"}}, "text": "In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n", "start_char_idx": 2337, "end_char_idx": 2441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80eb4153-a141-4221-87cf-ba5d1bdb0fcd": {"__data__": {"id_": "80eb4153-a141-4221-87cf-ba5d1bdb0fcd", "embedding": null, "metadata": {"window": "As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters. ", "original_text": "We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffbdb92c-3e13-42cb-8fe2-64856dcd6965", "node_type": "1", "metadata": {"window": "This is an important step forward for \nour company.  As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n", "original_text": "In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05fa7d24edac9292f87ad743d4725dcd70a0823b54c6a5a3a9b97547c2b5acab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b752b7f2-2695-4ec9-a9ff-55ec3fe08441", "node_type": "1", "metadata": {"window": "opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n", "original_text": "We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n"}, "hash": "9704dc28721ca2ffe07bb3534b09d04f22e3351dfa7e98d7c15b95b9c6d9b975", "class_name": "RelatedNodeInfo"}}, "text": "We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day. ", "start_char_idx": 2441, "end_char_idx": 2603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b752b7f2-2695-4ec9-a9ff-55ec3fe08441": {"__data__": {"id_": "b752b7f2-2695-4ec9-a9ff-55ec3fe08441", "embedding": null, "metadata": {"window": "opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n", "original_text": "We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80eb4153-a141-4221-87cf-ba5d1bdb0fcd", "node_type": "1", "metadata": {"window": "As we've consist ently said, we remain committed to being part of the solution to the \nU.S.  opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters. ", "original_text": "We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df4c6ffef29331e35c1a519e1b6e0669de4846b684d04c52b46834009cf62df7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4140fdc4-742c-4952-ae84-1ffff832137a", "node_type": "1", "metadata": {"window": "In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n", "original_text": "We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n"}, "hash": "b30a9db04c5b5159a1e72d63856e2419fc0528ac3069e6a757526f1f195c7f75", "class_name": "RelatedNodeInfo"}}, "text": "We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n", "start_char_idx": 2603, "end_char_idx": 2744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4140fdc4-742c-4952-ae84-1ffff832137a": {"__data__": {"id_": "4140fdc4-742c-4952-ae84-1ffff832137a", "embedding": null, "metadata": {"window": "In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n", "original_text": "We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b752b7f2-2695-4ec9-a9ff-55ec3fe08441", "node_type": "1", "metadata": {"window": "opioid epidemic and believe that settlement would provide relief for our communities and \nincreased certainty for our shareholders.  \n \n In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n", "original_text": "We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cd8b38dc4088736291e611a05163d12aa4efa9d5b4be07be1f948c7fbe8de1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a499d427-1b34-4173-9746-e843baf520b7", "node_type": "1", "metadata": {"window": "We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "What w e do matters. "}, "hash": "ba51b9ac7b35f447702b667ea8ce262e311c3e06cb4e9436a6c832fd76790d21", "class_name": "RelatedNodeInfo"}}, "text": "We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n", "start_char_idx": 2744, "end_char_idx": 2902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a499d427-1b34-4173-9746-e843baf520b7": {"__data__": {"id_": "a499d427-1b34-4173-9746-e843baf520b7", "embedding": null, "metadata": {"window": "We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "What w e do matters. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4140fdc4-742c-4952-ae84-1ffff832137a", "node_type": "1", "metadata": {"window": "In closing, our aspiration has been and continues to be that we are healthcare's most trusted partner. \n We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n", "original_text": "We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ac9606f6763a0ebaa7d24c1355a840444d68868d17bd49f63ea5411211e645a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a50eeeb-f988-4bbc-acf5-55820a3c58f6", "node_type": "1", "metadata": {"window": "We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n"}, "hash": "becc5ff6a68f351ddf3dea95e76838eb290c3e878dfca90f9f33d665f172192a", "class_name": "RelatedNodeInfo"}}, "text": "What w e do matters. ", "start_char_idx": 2902, "end_char_idx": 2923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a50eeeb-f988-4bbc-acf5-55820a3c58f6": {"__data__": {"id_": "6a50eeeb-f988-4bbc-acf5-55820a3c58f6", "embedding": null, "metadata": {"window": "We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a499d427-1b34-4173-9746-e843baf520b7", "node_type": "1", "metadata": {"window": "We will do this by focusing on our customer's needs and delivering the products and solutions that \nadvance healthcare and improve the lives of people every day.  We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "What w e do matters. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f9d3171b639e704df20afe7736893c8a694baf529554514cc90044aa9e2c608", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b90bc32d-e3ec-4931-91a6-22a61a5e5551", "node_type": "1", "metadata": {"window": "We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "And now, Jason and I will take your questions.  \n \n"}, "hash": "b24d63090023bdac86097774260d352dec34b3c1a24154fc1e3f7cbd47f7aa6f", "class_name": "RelatedNodeInfo"}}, "text": "A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n", "start_char_idx": 2923, "end_char_idx": 3062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b90bc32d-e3ec-4931-91a6-22a61a5e5551": {"__data__": {"id_": "b90bc32d-e3ec-4931-91a6-22a61a5e5551", "embedding": null, "metadata": {"window": "We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "And now, Jason and I will take your questions.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a50eeeb-f988-4bbc-acf5-55820a3c58f6", "node_type": "1", "metadata": {"window": "We bring life -changing healthcare \ninnovati on to market, harnessing the power of technology, data and insights to optimize care delivery. \n We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d948232a3b58329bf3bc49d0f82690ac9ec17d1b4ecbcdc081d6299c5339425", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "206b8b2c-107e-4ca3-99fb-dc18d2995378", "node_type": "1", "metadata": {"window": "What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "Operator:  Thank you.  "}, "hash": "ff4461d7a98e6b0bc657f53950b47a27baccb74a846d9b282fa77564d979b3e3", "class_name": "RelatedNodeInfo"}}, "text": "And now, Jason and I will take your questions.  \n \n", "start_char_idx": 3062, "end_char_idx": 3113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "206b8b2c-107e-4ca3-99fb-dc18d2995378": {"__data__": {"id_": "206b8b2c-107e-4ca3-99fb-dc18d2995378", "embedding": null, "metadata": {"window": "What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "Operator:  Thank you.  ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e21827db4eb432e7cd47e402dc4bef79dad1b22a7f87ea7eb4b5ff4783750f73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b90bc32d-e3ec-4931-91a6-22a61a5e5551", "node_type": "1", "metadata": {"window": "We're investing in technology and analytics to drive future growth in evolving areas of healthcare and \naddress healthcare's most complicated challenges.  \n \n What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "And now, Jason and I will take your questions.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "014ec1605efa93e3b16d63cd1ba3b87f1e8e5a825955a2822a320aee39983275", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09281493-57a8-4ae8-ae97-182af622c839", "node_type": "1", "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n", "original_text": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad. "}, "hash": "d075a5407c7371fe0359ff8f532cfa4e232751df611d7a4d60e50cda592b0a98", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 3113, "end_char_idx": 3136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09281493-57a8-4ae8-ae97-182af622c839": {"__data__": {"id_": "09281493-57a8-4ae8-ae97-182af622c839", "embedding": null, "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n", "original_text": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "206b8b2c-107e-4ca3-99fb-dc18d2995378", "node_type": "1", "metadata": {"window": "What w e do matters.  A nd we're focusing our resources on building solutions to meet the needs of our \ncustomers and their patients, now and in the future.  \n \n And now, Jason and I will take your questions.  \n \n Operator:  Thank you.  ", "original_text": "Operator:  Thank you.  ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c66151f6cff6a942a1644a39bb122f3fb38cf5f78d3b6b924a3a9298b7133fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf9f550c-7721-43cc-844f-322d3a9fb51e", "node_type": "1", "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah. ", "original_text": "If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n"}, "hash": "99d0c65428c283919c79571317050147a9709010f1eff0265405b7ccec6be9a4", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad. ", "start_char_idx": 0, "end_char_idx": 118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf9f550c-7721-43cc-844f-322d3a9fb51e": {"__data__": {"id_": "bf9f550c-7721-43cc-844f-322d3a9fb51e", "embedding": null, "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah. ", "original_text": "If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09281493-57a8-4ae8-ae97-182af622c839", "node_type": "1", "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n", "original_text": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f020d1e3abbadb0404d6f270c9b940fdf92b01d10abf32332ca4a16b050a9f17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aab3681d-8bcb-43f3-abd6-cec49141770e", "node_type": "1", "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys. ", "original_text": "And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n"}, "hash": "98745edbf653e70af7a5a68490355146746224801f4d7da249420190f3ba60cc", "class_name": "RelatedNodeInfo"}}, "text": "If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n", "start_char_idx": 118, "end_char_idx": 251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aab3681d-8bcb-43f3-abd6-cec49141770e": {"__data__": {"id_": "aab3681d-8bcb-43f3-abd6-cec49141770e", "embedding": null, "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys. ", "original_text": "And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf9f550c-7721-43cc-844f-322d3a9fb51e", "node_type": "1", "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah. ", "original_text": "If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "850353496e311173bb31ad3d142246107e2987dc1f72fc5f7bdf2cb44cc41f37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99e6b28e-9d8e-4359-922a-805b3668d3c1", "node_type": "1", "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off. ", "original_text": "Please, go ahead.  \n \n"}, "hash": "25b5cffaf642ac3f64dc5e6221566e6286b5a6c17829a66541bdf4b361e709a6", "class_name": "RelatedNodeInfo"}}, "text": "And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n", "start_char_idx": 251, "end_char_idx": 346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99e6b28e-9d8e-4359-922a-805b3668d3c1": {"__data__": {"id_": "99e6b28e-9d8e-4359-922a-805b3668d3c1", "embedding": null, "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off. ", "original_text": "Please, go ahead.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aab3681d-8bcb-43f3-abd6-cec49141770e", "node_type": "1", "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys. ", "original_text": "And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b6ee7da44c0d791a28c7657c6f441fe12000fc14d61220ed1a899631041548f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d9f6968-d4f0-461e-9a10-db22d21928a8", "node_type": "1", "metadata": {"window": "If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment. ", "original_text": "Charles Rhyee:  Yeah. "}, "hash": "c9dc5bdf7c8aa079732f128f739a67a98a9bd9eac0b28d0adfaa26aef6d0d6e7", "class_name": "RelatedNodeInfo"}}, "text": "Please, go ahead.  \n \n", "start_char_idx": 346, "end_char_idx": 368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d9f6968-d4f0-461e-9a10-db22d21928a8": {"__data__": {"id_": "9d9f6968-d4f0-461e-9a10-db22d21928a8", "embedding": null, "metadata": {"window": "If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment. ", "original_text": "Charles Rhyee:  Yeah. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99e6b28e-9d8e-4359-922a-805b3668d3c1", "node_type": "1", "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off. ", "original_text": "Please, go ahead.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9881476c132c8fbf360839ee0607c22d6cbdaf472649079ccd9d8df71d7dd35c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "438388f6-e34b-4a63-8e48-628bbb0cf952", "node_type": "1", "metadata": {"window": "And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n", "original_text": "Thanks, guys. "}, "hash": "bf81da9e5b89a0b9af91505f055bb9dd631a3504bd1be6b2ad1969817481629d", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  Yeah. ", "start_char_idx": 368, "end_char_idx": 390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "438388f6-e34b-4a63-8e48-628bbb0cf952": {"__data__": {"id_": "438388f6-e34b-4a63-8e48-628bbb0cf952", "embedding": null, "metadata": {"window": "And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n", "original_text": "Thanks, guys. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d9f6968-d4f0-461e-9a10-db22d21928a8", "node_type": "1", "metadata": {"window": "If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment. ", "original_text": "Charles Rhyee:  Yeah. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e1062bd5789a07ca56e6a0fd43f48d69ea8cb9bfde902efbc9bc12dd5a5e566", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af0499a9-39df-4b0d-9545-b8028f684e9f", "node_type": "1", "metadata": {"window": "Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?  ", "original_text": "Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off. "}, "hash": "59c565eb37e946c1714ff144a97ba41866fb7eb8ff2699f66b534a562b4ffbd7", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, guys. ", "start_char_idx": 390, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af0499a9-39df-4b0d-9545-b8028f684e9f": {"__data__": {"id_": "af0499a9-39df-4b0d-9545-b8028f684e9f", "embedding": null, "metadata": {"window": "Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?  ", "original_text": "Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "438388f6-e34b-4a63-8e48-628bbb0cf952", "node_type": "1", "metadata": {"window": "And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n", "original_text": "Thanks, guys. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f537f17340d5070abdeb2b747c70c0571b9671212bc1dd81eea1c34740b8a41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1aba7f59-3a3d-4405-87fb-b93d6160e79c", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful. ", "original_text": "Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment. "}, "hash": "f6ce5dfe4374ab261e504b5d9ac27cd031ebdf3b50107d8dfe9e7f00ee6ae2e1", "class_name": "RelatedNodeInfo"}}, "text": "Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off. ", "start_char_idx": 404, "end_char_idx": 727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1aba7f59-3a3d-4405-87fb-b93d6160e79c": {"__data__": {"id_": "1aba7f59-3a3d-4405-87fb-b93d6160e79c", "embedding": null, "metadata": {"window": "Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful. ", "original_text": "Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af0499a9-39df-4b0d-9545-b8028f684e9f", "node_type": "1", "metadata": {"window": "Please, go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?  ", "original_text": "Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fbc94d68418f1186a9adc23a12d812e7740391627dc4915d3ba4d9295b49c0b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34f63745-dcd7-418a-8b45-69eec821f3be", "node_type": "1", "metadata": {"window": "Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n", "original_text": "Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n"}, "hash": "7a7ff907371efc4802c50691129fe5a596dfee696b2f92b98247c579312efa58", "class_name": "RelatedNodeInfo"}}, "text": "Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment. ", "start_char_idx": 727, "end_char_idx": 881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34f63745-dcd7-418a-8b45-69eec821f3be": {"__data__": {"id_": "34f63745-dcd7-418a-8b45-69eec821f3be", "embedding": null, "metadata": {"window": "Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n", "original_text": "Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1aba7f59-3a3d-4405-87fb-b93d6160e79c", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yeah.  Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful. ", "original_text": "Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a01e4c2607dc37abd77beb3fda05adec95e6af803af5c9f9d4a29fdfbd531f41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "238b0dc2-2b41-4f46-9ee8-a0722b653a32", "node_type": "1", "metadata": {"window": "Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure. ", "original_text": "How long is that kind of follow -on effects before everything real ly would return to normal?  "}, "hash": "b697043d8463d6dfbd70c9ae3113ae1c7b8872bb53a126a977a78a3c9d30afc9", "class_name": "RelatedNodeInfo"}}, "text": "Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n", "start_char_idx": 881, "end_char_idx": 997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "238b0dc2-2b41-4f46-9ee8-a0722b653a32": {"__data__": {"id_": "238b0dc2-2b41-4f46-9ee8-a0722b653a32", "embedding": null, "metadata": {"window": "Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure. ", "original_text": "How long is that kind of follow -on effects before everything real ly would return to normal?  ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34f63745-dcd7-418a-8b45-69eec821f3be", "node_type": "1", "metadata": {"window": "Thanks, guys.  Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n", "original_text": "Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "812adef58e5519ec7459df0bb0a1435f8be4dd48e2abe4beb2e1073ddfec6401", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ce3089a-fac6-4997-a6a1-513f2d985d20", "node_type": "1", "metadata": {"window": "Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well . ", "original_text": "And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful. "}, "hash": "0f27ca035243853b340ed8abaa95512370d6b7905f0647a4654ccb74b0d11c22", "class_name": "RelatedNodeInfo"}}, "text": "How long is that kind of follow -on effects before everything real ly would return to normal?  ", "start_char_idx": 997, "end_char_idx": 1092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ce3089a-fac6-4997-a6a1-513f2d985d20": {"__data__": {"id_": "9ce3089a-fac6-4997-a6a1-513f2d985d20", "embedding": null, "metadata": {"window": "Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well . ", "original_text": "And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "238b0dc2-2b41-4f46-9ee8-a0722b653a32", "node_type": "1", "metadata": {"window": "Mike and Jason, I want to talk about the issues with supply \ncosts here and we're obviously challenged at the moment, but can you talk a little bit more about as \nlet's say these pressures ease , let's say hopefully later this year or whenever, can you talk about how \nthose expenses that you are incurring today roll off.  Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure. ", "original_text": "How long is that kind of follow -on effects before everything real ly would return to normal?  ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5288041b3d1ca1b9de9462da768e732ee18674d0a8a2839db4d006207e23c577", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0adb7022-0512-4741-a726-5e5c0c998522", "node_type": "1", "metadata": {"window": "Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare. ", "original_text": "Thank  you. \n \n"}, "hash": "38421f72cfc851f77602facdc8eece74c72f8f7f156ba6cc045e56c1e8c39e8e", "class_name": "RelatedNodeInfo"}}, "text": "And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful. ", "start_char_idx": 1092, "end_char_idx": 1293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0adb7022-0512-4741-a726-5e5c0c998522": {"__data__": {"id_": "0adb7022-0512-4741-a726-5e5c0c998522", "embedding": null, "metadata": {"window": "Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare. ", "original_text": "Thank  you. \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ce3089a-fac6-4997-a6a1-513f2d985d20", "node_type": "1", "metadata": {"window": "Do they kind of roll off fairly quickly , or is it that it \nthese kind of k nock on effects of delays and everything for all your supplies and equipment.  Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well . ", "original_text": "And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e225bfb71f9b0f32aa56da6d8da0fd5c79c8e6c15c9c52eb3e573c69d0706bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c3d53bf-2598-42f3-9966-abca7ed6b3b5", "node_type": "1", "metadata": {"window": "How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n", "original_text": "Jason Hollar:    Sure. "}, "hash": "84c9e14a75029302281744bf7ceb88c0760173df0dd428c75ad2acf2e4080d7a", "class_name": "RelatedNodeInfo"}}, "text": "Thank  you. \n \n", "start_char_idx": 1293, "end_char_idx": 1308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c3d53bf-2598-42f3-9966-abca7ed6b3b5": {"__data__": {"id_": "6c3d53bf-2598-42f3-9966-abca7ed6b3b5", "embedding": null, "metadata": {"window": "How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n", "original_text": "Jason Hollar:    Sure. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0adb7022-0512-4741-a726-5e5c0c998522", "node_type": "1", "metadata": {"window": "Just kind \nof just drag even further beyond if we were to see reports that, Hey, the ports are working as normal . \n How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare. ", "original_text": "Thank  you. \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be45b86d84a79798506b7d61398fc908641c60b84baaf4eceb69e5f86f5471f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a66e2fff-7e15-4fed-b528-36352331fb33", "node_type": "1", "metadata": {"window": "And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L. ", "original_text": "I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well . "}, "hash": "30b635ba35723fafb7673ceb1b41ed0122f6f4217b1d62808aef953779632e42", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:    Sure. ", "start_char_idx": 1308, "end_char_idx": 1331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a66e2fff-7e15-4fed-b528-36352331fb33": {"__data__": {"id_": "a66e2fff-7e15-4fed-b528-36352331fb33", "embedding": null, "metadata": {"window": "And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L. ", "original_text": "I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well . ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c3d53bf-2598-42f3-9966-abca7ed6b3b5", "node_type": "1", "metadata": {"window": "How long is that kind of follow -on effects before everything real ly would return to normal?   And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n", "original_text": "Jason Hollar:    Sure. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a3642f9319f66ffffed3d82e10268c92d2ed6d9342bac9c6b632148b65ac5de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "797aeb11-e70e-48fb-bc0d-6915e3c1d41c", "node_type": "1", "metadata": {"window": "Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n", "original_text": "But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare. "}, "hash": "114f74e0d46c4da5fc4b06feea91375d28b8ef03f0964e3db8c55453bb507e32", "class_name": "RelatedNodeInfo"}}, "text": "I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well . ", "start_char_idx": 1331, "end_char_idx": 1426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "797aeb11-e70e-48fb-bc0d-6915e3c1d41c": {"__data__": {"id_": "797aeb11-e70e-48fb-bc0d-6915e3c1d41c", "embedding": null, "metadata": {"window": "Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n", "original_text": "But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a66e2fff-7e15-4fed-b528-36352331fb33", "node_type": "1", "metadata": {"window": "And from a \nP&L perspective, do the - are these kind of expenses kind of overshadowing, let's say sort of the \nunderlying performance of the division or - a little more color on that would be helpful.  Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L. ", "original_text": "I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well . ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "486be80e00fb4d268ef029d391a633cffd59896573432bfcf3356c5b7af4ba6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d848bde-7171-4da8-bf27-80902e24f99f", "node_type": "1", "metadata": {"window": "Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint. ", "original_text": "And as such, most of those costs are included in inventory and then expensed as they're sold . \n"}, "hash": "ddbf53da6e662909be1859e42a0303afac6f6f5379595c2725a922f3f16be95f", "class_name": "RelatedNodeInfo"}}, "text": "But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare. ", "start_char_idx": 1426, "end_char_idx": 1626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d848bde-7171-4da8-bf27-80902e24f99f": {"__data__": {"id_": "8d848bde-7171-4da8-bf27-80902e24f99f", "embedding": null, "metadata": {"window": "Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint. ", "original_text": "And as such, most of those costs are included in inventory and then expensed as they're sold . \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "797aeb11-e70e-48fb-bc0d-6915e3c1d41c", "node_type": "1", "metadata": {"window": "Thank  you. \n \n Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n", "original_text": "But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "924f253c97804a406a804e939c64f1c36d54f39b3ce5aa75bac26c25b64908df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e69eaa6-0d75-4285-b6bf-663ecf99a029", "node_type": "1", "metadata": {"window": "I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up. ", "original_text": "So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L. "}, "hash": "49cf633d2d92f725afb73bf3112b00a35c0c2da406c65b2575e60ce11040211b", "class_name": "RelatedNodeInfo"}}, "text": "And as such, most of those costs are included in inventory and then expensed as they're sold . \n", "start_char_idx": 1626, "end_char_idx": 1722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e69eaa6-0d75-4285-b6bf-663ecf99a029": {"__data__": {"id_": "0e69eaa6-0d75-4285-b6bf-663ecf99a029", "embedding": null, "metadata": {"window": "I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up. ", "original_text": "So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d848bde-7171-4da8-bf27-80902e24f99f", "node_type": "1", "metadata": {"window": "Jason Hollar:    Sure.  I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint. ", "original_text": "And as such, most of those costs are included in inventory and then expensed as they're sold . \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37ba3a4efa9a1680017b575bf16634772fe5655210a7701caa538d0d34385560", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e715e99b-645c-4aa3-90e5-3ac4baab9128", "node_type": "1", "metadata": {"window": "But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant. ", "original_text": "And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n"}, "hash": "8790efd5ce6d93fc1e97a402025afb56ff66c7bac3be587f90581bb2837453ab", "class_name": "RelatedNodeInfo"}}, "text": "So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L. ", "start_char_idx": 1722, "end_char_idx": 1895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e715e99b-645c-4aa3-90e5-3ac4baab9128": {"__data__": {"id_": "e715e99b-645c-4aa3-90e5-3ac4baab9128", "embedding": null, "metadata": {"window": "But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant. ", "original_text": "And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e69eaa6-0d75-4285-b6bf-663ecf99a029", "node_type": "1", "metadata": {"window": "I'll definitely start here, Jason, and then I'm sure Mi ke will  have some thoughts \nas well .  But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up. ", "original_text": "So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7bcec943c1bc150f7a6d47ec3bb3cbb6098e13ca76ca64835f1d7f94b34b3a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f830f858-d9db-4727-8ae6-a260988726c2", "node_type": "1", "metadata": {"window": "And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described. ", "original_text": "Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint. "}, "hash": "a41a545d568d0917e358efee4a80b47f404a00c89038328813f8b087a48b53f4", "class_name": "RelatedNodeInfo"}}, "text": "And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n", "start_char_idx": 1895, "end_char_idx": 2018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f830f858-d9db-4727-8ae6-a260988726c2": {"__data__": {"id_": "f830f858-d9db-4727-8ae6-a260988726c2", "embedding": null, "metadata": {"window": "And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described. ", "original_text": "Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e715e99b-645c-4aa3-90e5-3ac4baab9128", "node_type": "1", "metadata": {"window": "But generally speaking, the vast majority of these costs that we've outlined are product -\nrelated costs or costs to get the products shipped to the United States  where our customers typically \nare.  And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant. ", "original_text": "And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da310619fe5fea3981689b960079d2703f0b6fd7df015df738dbe5489ad3cde3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "577d453d-e224-43b1-a74d-4c6d749b66b4", "node_type": "1", "metadata": {"window": "So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about . ", "original_text": "So that's obviously going to be at the time that volume frees up. "}, "hash": "7680435036cc021e9496640ed1b5e65f76a0f982e21afe58d5d7fde66e001b09", "class_name": "RelatedNodeInfo"}}, "text": "Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint. ", "start_char_idx": 2018, "end_char_idx": 2131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "577d453d-e224-43b1-a74d-4c6d749b66b4": {"__data__": {"id_": "577d453d-e224-43b1-a74d-4c6d749b66b4", "embedding": null, "metadata": {"window": "So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about . ", "original_text": "So that's obviously going to be at the time that volume frees up. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f830f858-d9db-4727-8ae6-a260988726c2", "node_type": "1", "metadata": {"window": "And as such, most of those costs are included in inventory and then expensed as they're sold . \n So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described. ", "original_text": "Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a217e718d157472b80eb3ab7bab52f1b4f497e8ed5dcab24dac1ab0849659ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9e5ceb1-6d54-48b8-9223-f89eaace0ea7", "node_type": "1", "metadata": {"window": "And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene. ", "original_text": "There's a small part that's \na period cost, but it's much less significant. "}, "hash": "a125b963b09c9b27194c5fd9a29a29aad6ed283668cfd6240f9ce0470fefd134", "class_name": "RelatedNodeInfo"}}, "text": "So that's obviously going to be at the time that volume frees up. ", "start_char_idx": 2131, "end_char_idx": 2197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9e5ceb1-6d54-48b8-9223-f89eaace0ea7": {"__data__": {"id_": "d9e5ceb1-6d54-48b8-9223-f89eaace0ea7", "embedding": null, "metadata": {"window": "And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene. ", "original_text": "There's a small part that's \na period cost, but it's much less significant. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "577d453d-e224-43b1-a74d-4c6d749b66b4", "node_type": "1", "metadata": {"window": "So that means that there would be a one to two quarter delay in terms of when those costs begin to \ncome down, and when you wou ld start to see that offset then in the P&L.  And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about . ", "original_text": "So that's obviously going to be at the time that volume frees up. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa67614627680c7248c34a96642e76136b81f79d0b3d6569aa421a916230480b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "671b660e-13d1-4608-a240-c2e0a2fb0b05", "node_type": "1", "metadata": {"window": "Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver. ", "original_text": "Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described. "}, "hash": "bde4d08014b8e8a4ade6b28ed65b7edd5de8851697d1853ffc2929055f541398", "class_name": "RelatedNodeInfo"}}, "text": "There's a small part that's \na period cost, but it's much less significant. ", "start_char_idx": 2197, "end_char_idx": 2273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "671b660e-13d1-4608-a240-c2e0a2fb0b05": {"__data__": {"id_": "671b660e-13d1-4608-a240-c2e0a2fb0b05", "embedding": null, "metadata": {"window": "Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver. ", "original_text": "Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9e5ceb1-6d54-48b8-9223-f89eaace0ea7", "node_type": "1", "metadata": {"window": "And that's I think, fairly \ntypical for the - what we saw with PPE as well last year in terms of that type of cadence.  \n \n Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene. ", "original_text": "There's a small part that's \na period cost, but it's much less significant. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d209de04b5b832803e0ddbb12046ee82c902cedba7af42292ce708ee02c2bdce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65ff7c9e-95b4-4a9f-a992-84a553d78c53", "node_type": "1", "metadata": {"window": "So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n", "original_text": "And then the second largest \nwould be the general commodities we've talked about . "}, "hash": "1ca72f0d17e6b911a3618bdd05570ed21335d729a3852dfe11c86a0e48840fec", "class_name": "RelatedNodeInfo"}}, "text": "Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described. ", "start_char_idx": 2273, "end_char_idx": 2512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65ff7c9e-95b4-4a9f-a992-84a553d78c53": {"__data__": {"id_": "65ff7c9e-95b4-4a9f-a992-84a553d78c53", "embedding": null, "metadata": {"window": "So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n", "original_text": "And then the second largest \nwould be the general commodities we've talked about . ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "671b660e-13d1-4608-a240-c2e0a2fb0b05", "node_type": "1", "metadata": {"window": "Now there's - some of this, a smaller portion is related to the volume impacts of the supply  chain \nconstraint.  So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver. ", "original_text": "Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "caeb807216867c06666c95f4a5a96e38b2b14ab13848a6d87cc7e4efea700243", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3b82c03-f600-415c-849c-13f0d3346367", "node_type": "1", "metadata": {"window": "There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction. ", "original_text": "Commodities like oil -based commodit ies like \npolypropylene. "}, "hash": "80ccd370e951555f0e0a2da490adb5037e6f66cf0ddc87181ab6955ee4cee8e7", "class_name": "RelatedNodeInfo"}}, "text": "And then the second largest \nwould be the general commodities we've talked about . ", "start_char_idx": 2512, "end_char_idx": 2595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3b82c03-f600-415c-849c-13f0d3346367": {"__data__": {"id_": "c3b82c03-f600-415c-849c-13f0d3346367", "embedding": null, "metadata": {"window": "There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction. ", "original_text": "Commodities like oil -based commodit ies like \npolypropylene. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65ff7c9e-95b4-4a9f-a992-84a553d78c53", "node_type": "1", "metadata": {"window": "So that's obviously going to be at the time that volume frees up.  There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n", "original_text": "And then the second largest \nwould be the general commodities we've talked about . ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba532eca0c7a2f0e0cb3cd4bda3a9e4e650fc11e2e0d48f7c9fde0f9cc2de69f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "655a81a8-64ea-407c-8542-2db8a9fb97e6", "node_type": "1", "metadata": {"window": "Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost. ", "original_text": "That is a big driver. "}, "hash": "23d3bed865ab22e34b658317587caef00dad207569074d955094cd8d71f41a5f", "class_name": "RelatedNodeInfo"}}, "text": "Commodities like oil -based commodit ies like \npolypropylene. ", "start_char_idx": 2595, "end_char_idx": 2657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "655a81a8-64ea-407c-8542-2db8a9fb97e6": {"__data__": {"id_": "655a81a8-64ea-407c-8542-2db8a9fb97e6", "embedding": null, "metadata": {"window": "Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost. ", "original_text": "That is a big driver. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3b82c03-f600-415c-849c-13f0d3346367", "node_type": "1", "metadata": {"window": "There's a small part that's \na period cost, but it's much less significant.  Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction. ", "original_text": "Commodities like oil -based commodit ies like \npolypropylene. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eccb81916e8a5a26d4f21a96aef9b922f4aa94e82b20213ce3ff53874678395b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d969bb9-be42-433e-9a42-84f338cd9292", "node_type": "1", "metadata": {"window": "And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year. ", "original_text": "That again, those would all the inventoried costs and then flowing \nthrough.  \n \n"}, "hash": "ad4981f97744fb2c35637e00fdfc634b2b366cba90b98e6a779d03fae61aac9d", "class_name": "RelatedNodeInfo"}}, "text": "That is a big driver. ", "start_char_idx": 2657, "end_char_idx": 2679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d969bb9-be42-433e-9a42-84f338cd9292": {"__data__": {"id_": "3d969bb9-be42-433e-9a42-84f338cd9292", "embedding": null, "metadata": {"window": "And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year. ", "original_text": "That again, those would all the inventoried costs and then flowing \nthrough.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "655a81a8-64ea-407c-8542-2db8a9fb97e6", "node_type": "1", "metadata": {"window": "Again, the biggest buckets when you step back and think \nabout the $250 to $300 million that's in  aggregate that we're talking about, it's that international freight \nis the biggest piece and is very much inventoried as I just described.  And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost. ", "original_text": "That is a big driver. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84d15ba8d405c8d2da24e6f53b8f3d8326373a9f13fb7ab56323c215fcc9d870", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47fa4d55-28ce-4f49-81b5-ef436f075391", "node_type": "1", "metadata": {"window": "Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact. ", "original_text": "As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction. "}, "hash": "26c7c254b4b75d0eb64a87475118657ef44fc45669075370cf4c77c241c5048c", "class_name": "RelatedNodeInfo"}}, "text": "That again, those would all the inventoried costs and then flowing \nthrough.  \n \n", "start_char_idx": 2679, "end_char_idx": 2760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47fa4d55-28ce-4f49-81b5-ef436f075391": {"__data__": {"id_": "47fa4d55-28ce-4f49-81b5-ef436f075391", "embedding": null, "metadata": {"window": "Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact. ", "original_text": "As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d969bb9-be42-433e-9a42-84f338cd9292", "node_type": "1", "metadata": {"window": "And then the second largest \nwould be the general commodities we've talked about .  Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year. ", "original_text": "That again, those would all the inventoried costs and then flowing \nthrough.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d1cd9aa6825146d90a7e36a4052bcf4cd854adc26a2b51a49e03ec7113b28d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7078a04e-887a-4026-8bd9-7d955d8cbc2b", "node_type": "1", "metadata": {"window": "That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter. ", "original_text": "We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost. "}, "hash": "3a06b1e64635a4c8b03dd529fc01919b40825980f09da619e8526aa4a03af972", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction. ", "start_char_idx": 2760, "end_char_idx": 3002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7078a04e-887a-4026-8bd9-7d955d8cbc2b": {"__data__": {"id_": "7078a04e-887a-4026-8bd9-7d955d8cbc2b", "embedding": null, "metadata": {"window": "That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter. ", "original_text": "We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47fa4d55-28ce-4f49-81b5-ef436f075391", "node_type": "1", "metadata": {"window": "Commodities like oil -based commodit ies like \npolypropylene.  That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact. ", "original_text": "As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94e59e7965790e9a5b1984f346b351f706392439c002a72169acf6f439de1ae1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5f94725-822b-4ed8-b136-f35f74495ffe", "node_type": "1", "metadata": {"window": "That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece. ", "original_text": "So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year. "}, "hash": "190acf25137b41bd7ca44cbe1b174680e4bd50c908f24c85bd1fccda59911a15", "class_name": "RelatedNodeInfo"}}, "text": "We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost. ", "start_char_idx": 3002, "end_char_idx": 3099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5f94725-822b-4ed8-b136-f35f74495ffe": {"__data__": {"id_": "a5f94725-822b-4ed8-b136-f35f74495ffe", "embedding": null, "metadata": {"window": "That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece. ", "original_text": "So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7078a04e-887a-4026-8bd9-7d955d8cbc2b", "node_type": "1", "metadata": {"window": "That is a big driver.  That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter. ", "original_text": "We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9e76263379c491d0dd5ca6bf6efbe5a637a834c756a5bfcaa515f56ddd0c31e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67c17ff9-aef0-4d92-83c4-9332d5e5b4a7", "node_type": "1", "metadata": {"window": "As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n", "original_text": "And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact. "}, "hash": "3193140a8a21c271654e5eaf6ee414e14cf41c36a61164d553b846cbbf83a9c2", "class_name": "RelatedNodeInfo"}}, "text": "So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year. ", "start_char_idx": 3099, "end_char_idx": 3249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67c17ff9-aef0-4d92-83c4-9332d5e5b4a7": {"__data__": {"id_": "67c17ff9-aef0-4d92-83c4-9332d5e5b4a7", "embedding": null, "metadata": {"window": "As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n", "original_text": "And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5f94725-822b-4ed8-b136-f35f74495ffe", "node_type": "1", "metadata": {"window": "That again, those would all the inventoried costs and then flowing \nthrough.  \n \n As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece. ", "original_text": "So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2be542ca5bf6ef920eef25ba5de6d24c25c6ebd309a5ebc0e6c20ec8a125199", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa31de79-a464-4987-8ecb-cf7f3b2bfcb0", "node_type": "1", "metadata": {"window": "We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.  ", "original_text": "And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter. "}, "hash": "798bf3eb766542e35d981527dc709d5e556c6965e2e84d8dd2fffae694a90d0b", "class_name": "RelatedNodeInfo"}}, "text": "And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact. ", "start_char_idx": 3249, "end_char_idx": 3355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa31de79-a464-4987-8ecb-cf7f3b2bfcb0": {"__data__": {"id_": "aa31de79-a464-4987-8ecb-cf7f3b2bfcb0", "embedding": null, "metadata": {"window": "We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.  ", "original_text": "And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67c17ff9-aef0-4d92-83c4-9332d5e5b4a7", "node_type": "1", "metadata": {"window": "As it relates to the overall impact to the business, just using Q2 as the example from a year -over-year \nperspective, this overall agg regate impact of the inflation and net of pricing is the greatest driver  that \nyear-over-year reduction.  We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n", "original_text": "And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b3cfd90ad4352ecf5f3e35087d7792c92853ced8660cdc16bd1eb4872ceee60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57bafc9e-4eff-47cf-80f1-c04e460139eb", "node_type": "1", "metadata": {"window": "So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "So the absence of that business as \nwas divested is that last piece. "}, "hash": "d0d8d5e7d93bc270850e91bd72f1e11402e8ee84d84e1c3a649c2ff962c0e461", "class_name": "RelatedNodeInfo"}}, "text": "And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter. ", "start_char_idx": 3355, "end_char_idx": 3470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57bafc9e-4eff-47cf-80f1-c04e460139eb": {"__data__": {"id_": "57bafc9e-4eff-47cf-80f1-c04e460139eb", "embedding": null, "metadata": {"window": "So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "So the absence of that business as \nwas divested is that last piece. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa31de79-a464-4987-8ecb-cf7f3b2bfcb0", "node_type": "1", "metadata": {"window": "We did as a reminder have favorability last Q2 as it relates to the timing of \nPPE pricing cost.  So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.  ", "original_text": "And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11a90c63d92898328f324356d2d58bd2efe1283360389d80dc12bec1a1eb845", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9c6c827-2fe0-4816-83a0-d99f82edbfe2", "node_type": "1", "metadata": {"window": "And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "So I think that gives you most of the key pieces.  \n \n"}, "hash": "cf681192d6cad6ceb86a59f1615002360b7b60ffa2d3b083e99f24ddb2806ddc", "class_name": "RelatedNodeInfo"}}, "text": "So the absence of that business as \nwas divested is that last piece. ", "start_char_idx": 3470, "end_char_idx": 3539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9c6c827-2fe0-4816-83a0-d99f82edbfe2": {"__data__": {"id_": "b9c6c827-2fe0-4816-83a0-d99f82edbfe2", "embedding": null, "metadata": {"window": "And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "So I think that gives you most of the key pieces.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57bafc9e-4eff-47cf-80f1-c04e460139eb", "node_type": "1", "metadata": {"window": "So there's a little bit of a headwind on an absolute bas is this quarter, but it's more \nsignificant the comparison to the favorability of last year.  And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "So the absence of that business as \nwas divested is that last piece. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59e8ba833ffda45654e1ee1c8d34358a3e539a9f28a7d6b64696a2fa890cb8c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1aa8f077-7243-49e4-a6b6-a6be18e9ea95", "node_type": "1", "metadata": {"window": "And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "Mike Kaufmann :  Yeah.  "}, "hash": "d12644586f496252fbb1aef7b298112a2ed4ff6cde5a6bccb70e37b43b8cb7a5", "class_name": "RelatedNodeInfo"}}, "text": "So I think that gives you most of the key pieces.  \n \n", "start_char_idx": 3539, "end_char_idx": 3593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1aa8f077-7243-49e4-a6b6-a6be18e9ea95": {"__data__": {"id_": "1aa8f077-7243-49e4-a6b6-a6be18e9ea95", "embedding": null, "metadata": {"window": "And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "Mike Kaufmann :  Yeah.  ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9c6c827-2fe0-4816-83a0-d99f82edbfe2", "node_type": "1", "metadata": {"window": "And that's about $60 million in this quarter , \nso that's a relevant piece to the year -over-year impact.  And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "So I think that gives you most of the key pieces.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec92df2ffe16e2c6f01fe259877247d765d4bf7f0c38664a3e0a4713ff039acd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "265632a6-5754-4549-a46d-06e44b6db58c", "node_type": "1", "metadata": {"window": "So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're "}, "hash": "16eb41d0cd35785a03137e21b38279d9837a0ef5c70f056ec9f7dfe568208001", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yeah.  ", "start_char_idx": 3593, "end_char_idx": 3617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "265632a6-5754-4549-a46d-06e44b6db58c": {"__data__": {"id_": "265632a6-5754-4549-a46d-06e44b6db58c", "embedding": null, "metadata": {"window": "So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84da6a9c6b743076ea7cd710c83f0ccccd737ff666e54131c74aad711e66b9d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1aa8f077-7243-49e4-a6b6-a6be18e9ea95", "node_type": "1", "metadata": {"window": "And then the final piece, as you know, Cordis \nis running at r oughly last year was roughly $20 million a quarter.  So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "Mike Kaufmann :  Yeah.  ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82ac50f6110822ebbdbcbb91150e118c239644fda4533d240dc361ec0d213c5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c7c1836-652c-4005-99c3-6dcd068e6c44", "node_type": "1", "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing. ", "original_text": " \nPage 9 of 13 \n \nactively getting after this now . "}, "hash": "75c2a7e21546275c5eeea6c110226956cd1436374f5d73e64a9208a792cc2e3a", "class_name": "RelatedNodeInfo"}}, "text": "The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "start_char_idx": 3617, "end_char_idx": 3799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c7c1836-652c-4005-99c3-6dcd068e6c44": {"__data__": {"id_": "6c7c1836-652c-4005-99c3-6dcd068e6c44", "embedding": null, "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing. ", "original_text": " \nPage 9 of 13 \n \nactively getting after this now . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "265632a6-5754-4549-a46d-06e44b6db58c", "node_type": "1", "metadata": {"window": "So the absence of that business as \nwas divested is that last piece.  So I think that gives you most of the key pieces.  \n \n Mike Kaufmann :  Yeah.   The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "original_text": "The only thing I would add, Charles, is that, while everything Jason said is \ntrue, the one, the two quarters and all that, one thing I want to make sure people understand is, we're ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b85d1ff05a8cbcff5cd432cbb75f0678e306aded3cb4472d1f0eca27db99536", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c8108aa-4e96-44a7-8a55-cd8c8c85a3db", "node_type": "1", "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses. ", "original_text": "So we're not going to have a strategy of just waiting for these to come \ndown . "}, "hash": "1c686b6b370e55e1c36f368cfae3b4750116e7c9add1602f6236b149f76c8395", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 13 \n \nactively getting after this now . ", "start_char_idx": 0, "end_char_idx": 52, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c8108aa-4e96-44a7-8a55-cd8c8c85a3db": {"__data__": {"id_": "4c8108aa-4e96-44a7-8a55-cd8c8c85a3db", "embedding": null, "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses. ", "original_text": "So we're not going to have a strategy of just waiting for these to come \ndown . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c7c1836-652c-4005-99c3-6dcd068e6c44", "node_type": "1", "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing. ", "original_text": " \nPage 9 of 13 \n \nactively getting after this now . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0019045b1380897f099fcb8f604bee6ccaad9fa1ceaf9872e7e1060625fa30f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "320cd030-07e3-4c2a-b121-cb5e342017e2", "node_type": "1", "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively . ", "original_text": "So we are evolving our comm ercial and contracting strategies. "}, "hash": "be9e2c5e4b113a79814b07d94f3a2b524695546f9ebcbb78cac8100c234794bd", "class_name": "RelatedNodeInfo"}}, "text": "So we're not going to have a strategy of just waiting for these to come \ndown . ", "start_char_idx": 52, "end_char_idx": 132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "320cd030-07e3-4c2a-b121-cb5e342017e2": {"__data__": {"id_": "320cd030-07e3-4c2a-b121-cb5e342017e2", "embedding": null, "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively . ", "original_text": "So we are evolving our comm ercial and contracting strategies. ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c8108aa-4e96-44a7-8a55-cd8c8c85a3db", "node_type": "1", "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses. ", "original_text": "So we're not going to have a strategy of just waiting for these to come \ndown . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef249afc9eff423ea97e07fce6bb73a74b561bdab4e9f127e45a129d0b331071", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "524d9df3-9fe3-4388-91cc-cd25e2b9e608", "node_type": "1", "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n", "original_text": "That is something we're actively \ndoing. "}, "hash": "1cfa1d50800eb76c04814141f20cbf934097d3697265a1195354090af5476473", "class_name": "RelatedNodeInfo"}}, "text": "So we are evolving our comm ercial and contracting strategies. ", "start_char_idx": 132, "end_char_idx": 195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "524d9df3-9fe3-4388-91cc-cd25e2b9e608": {"__data__": {"id_": "524d9df3-9fe3-4388-91cc-cd25e2b9e608", "embedding": null, "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n", "original_text": "That is something we're actively \ndoing. ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "320cd030-07e3-4c2a-b121-cb5e342017e2", "node_type": "1", "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively . ", "original_text": "So we are evolving our comm ercial and contracting strategies. ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e13dce7aa89f11713a1869a1074a56499799e8c566135b8f013e21093b961810", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da8c6b86-07f4-4d8d-a23c-bcee2181bdea", "node_type": "1", "metadata": {"window": "So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P. ", "original_text": "Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses. "}, "hash": "70984d97475e2994d779d5d52c96c6168b8219fe08c88f3c0429c7c65060fa24", "class_name": "RelatedNodeInfo"}}, "text": "That is something we're actively \ndoing. ", "start_char_idx": 195, "end_char_idx": 236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da8c6b86-07f4-4d8d-a23c-bcee2181bdea": {"__data__": {"id_": "da8c6b86-07f4-4d8d-a23c-bcee2181bdea", "embedding": null, "metadata": {"window": "So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P. ", "original_text": "Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses. ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "524d9df3-9fe3-4388-91cc-cd25e2b9e608", "node_type": "1", "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n", "original_text": "That is something we're actively \ndoing. ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9883134739d498b4f53fab6781adfde9a9eddb2899112182a491998d12e0774d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbb4c677-2f32-4eea-b18a-771fbefa94c0", "node_type": "1", "metadata": {"window": "So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n", "original_text": "So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively . "}, "hash": "199b4971c6f5f0762cdf74fe2f431a1d4601f7fb697cfa340fa0ba158f560684", "class_name": "RelatedNodeInfo"}}, "text": "Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses. ", "start_char_idx": 236, "end_char_idx": 462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbb4c677-2f32-4eea-b18a-771fbefa94c0": {"__data__": {"id_": "cbb4c677-2f32-4eea-b18a-771fbefa94c0", "embedding": null, "metadata": {"window": "So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n", "original_text": "So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da8c6b86-07f4-4d8d-a23c-bcee2181bdea", "node_type": "1", "metadata": {"window": "So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P. ", "original_text": "Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses. ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "079ad7be0a4049a6eb38a3d2fbd5dc4c5398d9b2991bf4ebd8968ee9b78213d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0fee498-497f-43b5-9f3c-44a1f288c7ef", "node_type": "1", "metadata": {"window": "That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n", "original_text": "Next question.  \n \n"}, "hash": "f1e775270f17ff087d0ccd10458e701f5dd24c8407bbde2ee24446096a9744fa", "class_name": "RelatedNodeInfo"}}, "text": "So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively . ", "start_char_idx": 462, "end_char_idx": 674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0fee498-497f-43b5-9f3c-44a1f288c7ef": {"__data__": {"id_": "d0fee498-497f-43b5-9f3c-44a1f288c7ef", "embedding": null, "metadata": {"window": "That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n", "original_text": "Next question.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbb4c677-2f32-4eea-b18a-771fbefa94c0", "node_type": "1", "metadata": {"window": "So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n", "original_text": "So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f8de898af226331cd462810c2345528673fe77fdb6dee88a1a200a189d80095", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "406685f8-de1f-486f-986f-0227c7831861", "node_type": "1", "metadata": {"window": "Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much. ", "original_text": "Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P. "}, "hash": "8d49a6fb10bda64d1a1217bd95365166fd3f08b844d2c0c1dc9ec02e2d56d5d2", "class_name": "RelatedNodeInfo"}}, "text": "Next question.  \n \n", "start_char_idx": 674, "end_char_idx": 693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "406685f8-de1f-486f-986f-0227c7831861": {"__data__": {"id_": "406685f8-de1f-486f-986f-0227c7831861", "embedding": null, "metadata": {"window": "Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much. ", "original_text": "Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P. ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0fee498-497f-43b5-9f3c-44a1f288c7ef", "node_type": "1", "metadata": {"window": "That is something we're actively \ndoing.  Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n", "original_text": "Next question.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9109c2fa40fd4633b538a12a25af8cd4aaad913d67a3237742131ca34d356ada", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b6b11c0-6230-4bf3-9d37-4ee9549ba7f8", "node_type": "1", "metadata": {"window": "So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n", "original_text": "Morgan . \n"}, "hash": "fbe2e82ba1a3283517a005631455f079e4e85f7c2bd0a4c3f79b4ed74df82380", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P. ", "start_char_idx": 693, "end_char_idx": 786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b6b11c0-6230-4bf3-9d37-4ee9549ba7f8": {"__data__": {"id_": "4b6b11c0-6230-4bf3-9d37-4ee9549ba7f8", "embedding": null, "metadata": {"window": "So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n", "original_text": "Morgan . \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "406685f8-de1f-486f-986f-0227c7831861", "node_type": "1", "metadata": {"window": "Working with customers to be able to either pass on some of these prices, change our \ncontracting , driving our mix as we talked about , and continuing to aggressively get after our co st and \ninvest in our growth businesses.  So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much. ", "original_text": "Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P. ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b15511cb088a4f18ea4838c2f9cb401af6228d5f39be3e544a8bb45d088a340e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55e0bf01-9bf0-4d0b-a441-c2355e3b570b", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge . ", "original_text": "Please go ahead.  \n \n"}, "hash": "25f1020d9cdfeee474b41439c048805d7c888c3a479d27aa50d33b92ef787354", "class_name": "RelatedNodeInfo"}}, "text": "Morgan . \n", "start_char_idx": 786, "end_char_idx": 796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55e0bf01-9bf0-4d0b-a441-c2355e3b570b": {"__data__": {"id_": "55e0bf01-9bf0-4d0b-a441-c2355e3b570b", "embedding": null, "metadata": {"window": "Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge . ", "original_text": "Please go ahead.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b6b11c0-6230-4bf3-9d37-4ee9549ba7f8", "node_type": "1", "metadata": {"window": "So , while we will hopefully see these come down because we do \nbelieve these are temporary , we're also at the same time getting after things that we need to do to \nmanage to operate the business aggressively .  Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n", "original_text": "Morgan . \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d13b1784741058e345a59e65162c8efda76c93bf84894f1b947c4de7c0e01bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb2ae605-5318-48e0-8c5a-5847d1df53cd", "node_type": "1", "metadata": {"window": "Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n", "original_text": "Lisa:  Thanks very much. "}, "hash": "63a083481f2cf389d0b1ff6096a41635c2a1f3176aaf65c9f7cab72eaa306865", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 796, "end_char_idx": 817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb2ae605-5318-48e0-8c5a-5847d1df53cd": {"__data__": {"id_": "eb2ae605-5318-48e0-8c5a-5847d1df53cd", "embedding": null, "metadata": {"window": "Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n", "original_text": "Lisa:  Thanks very much. ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55e0bf01-9bf0-4d0b-a441-c2355e3b570b", "node_type": "1", "metadata": {"window": "Next question.  \n \n Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge . ", "original_text": "Please go ahead.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24359f424f6c6d8fd393dd81ff8d2b081be141c46105746eb9f4150b8b56eaa5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8962395-8001-4b5e-909b-4865de0de7c1", "node_type": "1", "metadata": {"window": "Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah . ", "original_text": "Mike, can I just first start with just a follow -up to what you just talked about . \n"}, "hash": "cab3ea76780735a535718eee1c1b8e0371e34744e538e5c6cc6e6bd0d5a1d7af", "class_name": "RelatedNodeInfo"}}, "text": "Lisa:  Thanks very much. ", "start_char_idx": 817, "end_char_idx": 842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8962395-8001-4b5e-909b-4865de0de7c1": {"__data__": {"id_": "b8962395-8001-4b5e-909b-4865de0de7c1", "embedding": null, "metadata": {"window": "Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah . ", "original_text": "Mike, can I just first start with just a follow -up to what you just talked about . \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb2ae605-5318-48e0-8c5a-5847d1df53cd", "node_type": "1", "metadata": {"window": "Operator:   And we'll go ahead and move on to our next question now from Lisa Gill with J.P.  Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n", "original_text": "Lisa:  Thanks very much. ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5764322a817d0422ead02c8110c31cc7c658eb39c029bd416622ce27e31b0a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0595ad51-ba69-4418-bb83-5808c84b98aa", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question . ", "original_text": "When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge . "}, "hash": "29c0b75cca39eced7cad28e2124dc0e45b2989c28fe7419761af5418ed1ef968", "class_name": "RelatedNodeInfo"}}, "text": "Mike, can I just first start with just a follow -up to what you just talked about . \n", "start_char_idx": 842, "end_char_idx": 927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0595ad51-ba69-4418-bb83-5808c84b98aa": {"__data__": {"id_": "0595ad51-ba69-4418-bb83-5808c84b98aa", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question . ", "original_text": "When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8962395-8001-4b5e-909b-4865de0de7c1", "node_type": "1", "metadata": {"window": "Morgan . \n Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah . ", "original_text": "Mike, can I just first start with just a follow -up to what you just talked about . \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b7abf1abbb1a3efc0120b40843bf19dd979536ff7215c43e4a810f85b605ec7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9078317-8511-416d-a6a5-9391dd35ade7", "node_type": "1", "metadata": {"window": "Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there . ", "original_text": "I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n"}, "hash": "620c9f3b424e2a17c80f53caa34edda0ea89c1201102dc3d8c292bc767181c27", "class_name": "RelatedNodeInfo"}}, "text": "When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge . ", "start_char_idx": 927, "end_char_idx": 1065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9078317-8511-416d-a6a5-9391dd35ade7": {"__data__": {"id_": "d9078317-8511-416d-a6a5-9391dd35ade7", "embedding": null, "metadata": {"window": "Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there . ", "original_text": "I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0595ad51-ba69-4418-bb83-5808c84b98aa", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question . ", "original_text": "When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50592948531004e39c8d88ef857d07ed092bcfd3517095a77026b0f3e19aff03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40ba7804-74eb-46ab-8d35-19ea7b48b48f", "node_type": "1", "metadata": {"window": "Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things . ", "original_text": "Mike Kaufmann :  Yeah . "}, "hash": "2118b78e6a5a4984683ba2f491b301f7061c221515d3d8190eb84f57e7abb092", "class_name": "RelatedNodeInfo"}}, "text": "I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n", "start_char_idx": 1065, "end_char_idx": 1255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40ba7804-74eb-46ab-8d35-19ea7b48b48f": {"__data__": {"id_": "40ba7804-74eb-46ab-8d35-19ea7b48b48f", "embedding": null, "metadata": {"window": "Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things . ", "original_text": "Mike Kaufmann :  Yeah . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9078317-8511-416d-a6a5-9391dd35ade7", "node_type": "1", "metadata": {"window": "Lisa:  Thanks very much.  Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there . ", "original_text": "I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf9365a27ccd4f87730ddd0f8b5aee022b843c6beddeb748b446711b4c01479d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8accf6c-a9a8-49c6-a438-43d63d4a5360", "node_type": "1", "metadata": {"window": "When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver . ", "original_text": "You know, it's a great question . "}, "hash": "a7c24cef55d118c6b3f056b3d1e6ce5142161b1c9a763b117b323cbcdb09b790", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Yeah . ", "start_char_idx": 1255, "end_char_idx": 1279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8accf6c-a9a8-49c6-a438-43d63d4a5360": {"__data__": {"id_": "e8accf6c-a9a8-49c6-a438-43d63d4a5360", "embedding": null, "metadata": {"window": "When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver . ", "original_text": "You know, it's a great question . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40ba7804-74eb-46ab-8d35-19ea7b48b48f", "node_type": "1", "metadata": {"window": "Mike, can I just first start with just a follow -up to what you just talked about . \n When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things . ", "original_text": "Mike Kaufmann :  Yeah . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3141248befebaaf48030c434c6769f35ce4b155d9bf7ebe18882b95ba3c85f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18de2489-bfd3-4d33-aafd-30623a95cbe7", "node_type": "1", "metadata": {"window": "I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix . ", "original_text": "We've not put that out there . "}, "hash": "6ba6f29437d59054bc1d446ce610241f89f3068bb2b728c2b8c705411ec0d7ef", "class_name": "RelatedNodeInfo"}}, "text": "You know, it's a great question . ", "start_char_idx": 1279, "end_char_idx": 1313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18de2489-bfd3-4d33-aafd-30623a95cbe7": {"__data__": {"id_": "18de2489-bfd3-4d33-aafd-30623a95cbe7", "embedding": null, "metadata": {"window": "I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix . ", "original_text": "We've not put that out there . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8accf6c-a9a8-49c6-a438-43d63d4a5360", "node_type": "1", "metadata": {"window": "When we think about your Medical business longer -term, I know you previously had a goal of north of \n5% operating margin for med surge .  I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver . ", "original_text": "You know, it's a great question . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b91471d15fd3038476da65a6632d473ab40c4dd6a1822395761211516a61779a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fcd8fcb-2c9f-4765-8af7-6d4752a76f27", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand . ", "original_text": "I will give you a \ncouple things . "}, "hash": "cfc596145ed21b60c18480d3ee8e01e9fbbbe6504a7d455997177a5cf37a0180", "class_name": "RelatedNodeInfo"}}, "text": "We've not put that out there . ", "start_char_idx": 1313, "end_char_idx": 1344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fcd8fcb-2c9f-4765-8af7-6d4752a76f27": {"__data__": {"id_": "0fcd8fcb-2c9f-4765-8af7-6d4752a76f27", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand . ", "original_text": "I will give you a \ncouple things . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18de2489-bfd3-4d33-aafd-30623a95cbe7", "node_type": "1", "metadata": {"window": "I know they - part of that was the higher margin of Cordis , but \nwhen we get back to a more normalized basis, how do we thi nk about what the margin should look \nlike in that business?  \n \n Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix . ", "original_text": "We've not put that out there . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbb1da1374d5ff68f1f6d8a4600e2af4a20a8337b37307dcea0d5a47a3af20bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfa84433-8a1b-47c1-bab4-406391bc3fe8", "node_type": "1", "metadata": {"window": "You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way . ", "original_text": "Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver . "}, "hash": "d3137963e652d14d8327803761e23c988cef798b0826f24cf8b2e54fba4e2a52", "class_name": "RelatedNodeInfo"}}, "text": "I will give you a \ncouple things . ", "start_char_idx": 1344, "end_char_idx": 1379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfa84433-8a1b-47c1-bab4-406391bc3fe8": {"__data__": {"id_": "bfa84433-8a1b-47c1-bab4-406391bc3fe8", "embedding": null, "metadata": {"window": "You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way . ", "original_text": "Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fcd8fcb-2c9f-4765-8af7-6d4752a76f27", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Yeah .  You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand . ", "original_text": "I will give you a \ncouple things . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc9acd4fecd5d307c0fce8ae77ca29505e98e743d0d63c3b245da5d52e90574f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2364330-3920-4172-a225-d1b660d04022", "node_type": "1", "metadata": {"window": "We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses . ", "original_text": "Second of all, the second thing I would add , is we said we want to drive mix . "}, "hash": "f9ca41baeda2e131b9e5b6f4f8bd516e11d84f792bb55d0eea05f087910f7e5b", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver . ", "start_char_idx": 1379, "end_char_idx": 1577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2364330-3920-4172-a225-d1b660d04022": {"__data__": {"id_": "e2364330-3920-4172-a225-d1b660d04022", "embedding": null, "metadata": {"window": "We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses . ", "original_text": "Second of all, the second thing I would add , is we said we want to drive mix . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfa84433-8a1b-47c1-bab4-406391bc3fe8", "node_type": "1", "metadata": {"window": "You know, it's a great question .  We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way . ", "original_text": "Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9474c8b7975ea8f8e77f5b29272443ce24e4663c61a9ccbac05a1e1a1ecfeee4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec84a815-65c9-4fa5-b150-ca98152e7e4a", "node_type": "1", "metadata": {"window": "I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment . ", "original_text": "And what we \nmean by that is selling more of Cardinal Health branded products versus national brand . "}, "hash": "e7ec13363b64c9426def63bf0215cd420c15140b7e33dfde9cc00758f72ce79d", "class_name": "RelatedNodeInfo"}}, "text": "Second of all, the second thing I would add , is we said we want to drive mix . ", "start_char_idx": 1577, "end_char_idx": 1657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec84a815-65c9-4fa5-b150-ca98152e7e4a": {"__data__": {"id_": "ec84a815-65c9-4fa5-b150-ca98152e7e4a", "embedding": null, "metadata": {"window": "I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment . ", "original_text": "And what we \nmean by that is selling more of Cardinal Health branded products versus national brand . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2364330-3920-4172-a225-d1b660d04022", "node_type": "1", "metadata": {"window": "We've not put that out there .  I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses . ", "original_text": "Second of all, the second thing I would add , is we said we want to drive mix . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1dfc046c6e5903e2302b46953190c364e77f19bb88ffa10a59cba1a60f53a27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12deb404-bb80-4c62-9633-57cd790f7a34", "node_type": "1", "metadata": {"window": "Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins . ", "original_text": "That's going \nto also drive our mix in a positive way . "}, "hash": "cd14de9902ace3e3129ff0a1f66a977d77bbc674713b60f5c98e1e2a4381157d", "class_name": "RelatedNodeInfo"}}, "text": "And what we \nmean by that is selling more of Cardinal Health branded products versus national brand . ", "start_char_idx": 1657, "end_char_idx": 1759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12deb404-bb80-4c62-9633-57cd790f7a34": {"__data__": {"id_": "12deb404-bb80-4c62-9633-57cd790f7a34", "embedding": null, "metadata": {"window": "Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins . ", "original_text": "That's going \nto also drive our mix in a positive way . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec84a815-65c9-4fa5-b150-ca98152e7e4a", "node_type": "1", "metadata": {"window": "I will give you a \ncouple things .  Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment . ", "original_text": "And what we \nmean by that is selling more of Cardinal Health branded products versus national brand . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f19f5422b29e7f98baeb8087b765a1ad52a4c76bef171983c68aec3913547880", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcbdc5d8-3d5f-4203-bba1-bf6b0402e1f1", "node_type": "1", "metadata": {"window": "Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly . ", "original_text": "We're getting after expenses . "}, "hash": "45be0b0e1d52b85c87f13a2db4016440682411744429fe678b7da5fdad1b8126", "class_name": "RelatedNodeInfo"}}, "text": "That's going \nto also drive our mix in a positive way . ", "start_char_idx": 1759, "end_char_idx": 1815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcbdc5d8-3d5f-4203-bba1-bf6b0402e1f1": {"__data__": {"id_": "fcbdc5d8-3d5f-4203-bba1-bf6b0402e1f1", "embedding": null, "metadata": {"window": "Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly . ", "original_text": "We're getting after expenses . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12deb404-bb80-4c62-9633-57cd790f7a34", "node_type": "1", "metadata": {"window": "Obviously, as the inflation goes away, and as we said  we believe this $250 t o $300, \nthe vast majority of that is temporary , so you can add that back to our margin rates as the biggest \ndriver .  Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins . ", "original_text": "That's going \nto also drive our mix in a positive way . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77f80ef7f46fa8555b363ba5c96afe761c7e74977f5f8f482f7644d3899391c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97588fc8-1492-4a80-b928-9042c440e571", "node_type": "1", "metadata": {"window": "And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n", "original_text": "That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment . "}, "hash": "1c583ebf924a2015adf1d04e879be9abd087a86a99e4b0dde88a4090567c203b", "class_name": "RelatedNodeInfo"}}, "text": "We're getting after expenses . ", "start_char_idx": 1815, "end_char_idx": 1846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97588fc8-1492-4a80-b928-9042c440e571": {"__data__": {"id_": "97588fc8-1492-4a80-b928-9042c440e571", "embedding": null, "metadata": {"window": "And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n", "original_text": "That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcbdc5d8-3d5f-4203-bba1-bf6b0402e1f1", "node_type": "1", "metadata": {"window": "Second of all, the second thing I would add , is we said we want to drive mix .  And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly . ", "original_text": "We're getting after expenses . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4cf9d6dc9a6651958104c4b8c8f72becb81210c59c7e6d76cc65f8576d3f9d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3248ffed-7540-4144-b784-9899015eca46", "node_type": "1", "metadata": {"window": "That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch . ", "original_text": "And we're growing our growth business, w hich do \nhave higher margins . "}, "hash": "7c9ca01cf782d4938f6ae08194f814825b79c5141d38a4b3ff2722c5b71324bb", "class_name": "RelatedNodeInfo"}}, "text": "That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment . ", "start_char_idx": 1846, "end_char_idx": 1935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3248ffed-7540-4144-b784-9899015eca46": {"__data__": {"id_": "3248ffed-7540-4144-b784-9899015eca46", "embedding": null, "metadata": {"window": "That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch . ", "original_text": "And we're growing our growth business, w hich do \nhave higher margins . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97588fc8-1492-4a80-b928-9042c440e571", "node_type": "1", "metadata": {"window": "And what we \nmean by that is selling more of Cardinal Health branded products versus national brand .  That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n", "original_text": "That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea4692ee07661a215fa376293a3f39fec1fa4715c821c9ceee6710896b524b66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "844450bf-54b0-48cd-b312-14d976083a99", "node_type": "1", "metadata": {"window": "We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n", "original_text": "So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly . "}, "hash": "9da8a9fc48a924941de9fd2477d8ef1e73aa02dcc7a0012ed5dac6dea20e8ea6", "class_name": "RelatedNodeInfo"}}, "text": "And we're growing our growth business, w hich do \nhave higher margins . ", "start_char_idx": 1935, "end_char_idx": 2007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "844450bf-54b0-48cd-b312-14d976083a99": {"__data__": {"id_": "844450bf-54b0-48cd-b312-14d976083a99", "embedding": null, "metadata": {"window": "We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n", "original_text": "So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3248ffed-7540-4144-b784-9899015eca46", "node_type": "1", "metadata": {"window": "That's going \nto also drive our mix in a positive way .  We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch . ", "original_text": "And we're growing our growth business, w hich do \nhave higher margins . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f1905a7413f4900d4ccc9128aa6f0420351bd7c5758015e4be45f8cd533c02a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c59148e-ad22-4276-8ca4-14a507ae6250", "node_type": "1", "metadata": {"window": "That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you . ", "original_text": "But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n"}, "hash": "ae88914415e4f0f6e709d536e277304e38e6b0e04bc4fb2abfcbe62ba7e3cb9b", "class_name": "RelatedNodeInfo"}}, "text": "So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly . ", "start_char_idx": 2007, "end_char_idx": 2129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c59148e-ad22-4276-8ca4-14a507ae6250": {"__data__": {"id_": "5c59148e-ad22-4276-8ca4-14a507ae6250", "embedding": null, "metadata": {"window": "That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you . ", "original_text": "But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "844450bf-54b0-48cd-b312-14d976083a99", "node_type": "1", "metadata": {"window": "We're getting after expenses .  That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n", "original_text": "So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6bbf8ab0a1b6095142e40ae4b74ed239708d88f30f44a29f7ec122f1601d50d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fbd0858-40f8-4517-aa66-61b5be12a91f", "node_type": "1", "metadata": {"window": "And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic . ", "original_text": "Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch . "}, "hash": "58b50e69d7d26927abc376adadefe0da17f99b6cdbf8065bbb8151be4f10f7fc", "class_name": "RelatedNodeInfo"}}, "text": "But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n", "start_char_idx": 2129, "end_char_idx": 2230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fbd0858-40f8-4517-aa66-61b5be12a91f": {"__data__": {"id_": "2fbd0858-40f8-4517-aa66-61b5be12a91f", "embedding": null, "metadata": {"window": "And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic . ", "original_text": "Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c59148e-ad22-4276-8ca4-14a507ae6250", "node_type": "1", "metadata": {"window": "That's going to  - I'm sorry  - that's \ngoing to drive our margins too for the segment .  And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you . ", "original_text": "But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c734a2a6dd084c4df2677710af4623521bb54843e21c88f793375c573374fec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53ca9fc8-ece1-40bf-8c56-50475386b1b2", "node_type": "1", "metadata": {"window": "So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n", "original_text": "Please go ahead.  \n \n"}, "hash": "c94c4d91400aacf261d15a66236696c4996eed5c31c07390279e81ad35bf5dfc", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch . ", "start_char_idx": 2230, "end_char_idx": 2334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53ca9fc8-ece1-40bf-8c56-50475386b1b2": {"__data__": {"id_": "53ca9fc8-ece1-40bf-8c56-50475386b1b2", "embedding": null, "metadata": {"window": "So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n", "original_text": "Please go ahead.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fbd0858-40f8-4517-aa66-61b5be12a91f", "node_type": "1", "metadata": {"window": "And we're growing our growth business, w hich do \nhave higher margins .  So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic . ", "original_text": "Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90fd8bc4839dfacbf1604ef26dde88e91dd4d8ce7ac5af55154a5298e1aa9eae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea32f2c0-529a-41e9-a5cb-e7b67cc23856", "node_type": "1", "metadata": {"window": "But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology . ", "original_text": "Eric Percher:   Thank you . "}, "hash": "e0a80a4f8089de257cb68224eda07637203b206df145c31e236298aefd62d96d", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 796, "end_char_idx": 817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea32f2c0-529a-41e9-a5cb-e7b67cc23856": {"__data__": {"id_": "ea32f2c0-529a-41e9-a5cb-e7b67cc23856", "embedding": null, "metadata": {"window": "But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology . ", "original_text": "Eric Percher:   Thank you . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53ca9fc8-ece1-40bf-8c56-50475386b1b2", "node_type": "1", "metadata": {"window": "So all of our key initiatives not only will drive bottom line, but they all should \ndrive margin rates up significantly .  But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n", "original_text": "Please go ahead.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60c02612c1d1c1440813023038183321226ed3cf8b7a7964b475a0ff910855bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dad0968d-eec6-4aff-bd22-6735edf5c67a", "node_type": "1", "metadata": {"window": "Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n", "original_text": "I want to stay on this topic . "}, "hash": "0648dd805ddf5d3e7652b6c8eaf9bff55893f0771cea3a0e4d7e0634f141d074", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:   Thank you . ", "start_char_idx": 2355, "end_char_idx": 2383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dad0968d-eec6-4aff-bd22-6735edf5c67a": {"__data__": {"id_": "dad0968d-eec6-4aff-bd22-6735edf5c67a", "embedding": null, "metadata": {"window": "Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n", "original_text": "I want to stay on this topic . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea32f2c0-529a-41e9-a5cb-e7b67cc23856", "node_type": "1", "metadata": {"window": "But at this point in time, we've not put a target margin rate out \nthere that we're going after.  \n \n Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology . ", "original_text": "Eric Percher:   Thank you . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f26ae79ef79a97106528f256c17ddd818ca46c1564fdbc30c92df898cb5dbb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fefff314-e519-4049-8cac-d5b43c562e7b", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah . ", "original_text": "And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n"}, "hash": "74f433d67bd6b83940793300dced72425ccc42dd30327a811947200e891dc12a", "class_name": "RelatedNodeInfo"}}, "text": "I want to stay on this topic . ", "start_char_idx": 2383, "end_char_idx": 2414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fefff314-e519-4049-8cac-d5b43c562e7b": {"__data__": {"id_": "fefff314-e519-4049-8cac-d5b43c562e7b", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah . ", "original_text": "And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dad0968d-eec6-4aff-bd22-6735edf5c67a", "node_type": "1", "metadata": {"window": "Operator:   And we'll go ahead and move on our next question from Eric Percher with Nephron \nResearch .  Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n", "original_text": "I want to stay on this topic . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8404ee5bc2c7ed82f052ff04c84a44184c03c305e1573486c01dd9ada2af62ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "624433a9-d947-4ca6-bb08-6ea8f79f7810", "node_type": "1", "metadata": {"window": "Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason . ", "original_text": "And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology . "}, "hash": "80bd94dd140823e8ceeb171c4399934d5383b89279792a1818a7f8056d270592", "class_name": "RelatedNodeInfo"}}, "text": "And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n", "start_char_idx": 2414, "end_char_idx": 2572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "624433a9-d947-4ca6-bb08-6ea8f79f7810": {"__data__": {"id_": "624433a9-d947-4ca6-bb08-6ea8f79f7810", "embedding": null, "metadata": {"window": "Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason . ", "original_text": "And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fefff314-e519-4049-8cac-d5b43c562e7b", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah . ", "original_text": "And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72a75c9cc0931eef537599c930057e4f3921f0b81082bd8c3c83c5c8323a2472", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e30fa7cc-88ee-49d5-9ed2-778dc13e31f8", "node_type": "1", "metadata": {"window": "I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start . ", "original_text": "Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n"}, "hash": "f341a45348461adfc029ffc860bca542f2ec5d2825d46bdd065b60ed5f650cc4", "class_name": "RelatedNodeInfo"}}, "text": "And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology . ", "start_char_idx": 2572, "end_char_idx": 2714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e30fa7cc-88ee-49d5-9ed2-778dc13e31f8": {"__data__": {"id_": "e30fa7cc-88ee-49d5-9ed2-778dc13e31f8", "embedding": null, "metadata": {"window": "I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start . ", "original_text": "Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "624433a9-d947-4ca6-bb08-6ea8f79f7810", "node_type": "1", "metadata": {"window": "Eric Percher:   Thank you .  I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason . ", "original_text": "And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "988e366f782f44bef70b553d6bdf0ae00546d0ce83de81bb8aaf613fd9b33732", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e245a7-39be-4199-9cdd-f7ae86d549ab", "node_type": "1", "metadata": {"window": "And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about . ", "original_text": "Jason Hollar:   Yeah . "}, "hash": "4c093b15b16a09482f1752224e52f3c5925f356f565c8508a367f6b9f4df32d0", "class_name": "RelatedNodeInfo"}}, "text": "Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n", "start_char_idx": 2714, "end_char_idx": 2866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4e245a7-39be-4199-9cdd-f7ae86d549ab": {"__data__": {"id_": "a4e245a7-39be-4199-9cdd-f7ae86d549ab", "embedding": null, "metadata": {"window": "And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about . ", "original_text": "Jason Hollar:   Yeah . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e30fa7cc-88ee-49d5-9ed2-778dc13e31f8", "node_type": "1", "metadata": {"window": "I want to stay on this topic .  And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start . ", "original_text": "Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d28ad0f346a1728559b81fa43b41204f1f36265ff232ecaf8d0b9ecd92c5a33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a993d9b-4140-43ef-bc71-b3d09eebdb0d", "node_type": "1", "metadata": {"window": "And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels . ", "original_text": "Again, this is Jason . "}, "hash": "481789bd2572e7c123a82e2e0b99b765cbbf9f0a0e66abbd753475ec4e7ae6b7", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:   Yeah . ", "start_char_idx": 2866, "end_char_idx": 2889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a993d9b-4140-43ef-bc71-b3d09eebdb0d": {"__data__": {"id_": "4a993d9b-4140-43ef-bc71-b3d09eebdb0d", "embedding": null, "metadata": {"window": "And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels . ", "original_text": "Again, this is Jason . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4e245a7-39be-4199-9cdd-f7ae86d549ab", "node_type": "1", "metadata": {"window": "And my question is, can we talk a little bit about \nyour expectations for some of these spec ific items maybe built into the year or your view on duration . \n And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about . ", "original_text": "Jason Hollar:   Yeah . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cca6fc8fe5ce55df32d515dbb222c5024f16163b56957be6ad67eb3eb1e1f60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3661884-d59b-4b17-a41b-db31fe20b462", "node_type": "1", "metadata": {"window": "Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been . ", "original_text": "I'll start . "}, "hash": "740fc7c9537a751c52d33e7eb7f8a8bee63f4da5fc58e22483da89a80ac925e7", "class_name": "RelatedNodeInfo"}}, "text": "Again, this is Jason . ", "start_char_idx": 2889, "end_char_idx": 2912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3661884-d59b-4b17-a41b-db31fe20b462": {"__data__": {"id_": "e3661884-d59b-4b17-a41b-db31fe20b462", "embedding": null, "metadata": {"window": "Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been . ", "original_text": "I'll start . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a993d9b-4140-43ef-bc71-b3d09eebdb0d", "node_type": "1", "metadata": {"window": "And I separate freight commodity and then the sales volume and duration on how long you pass this \non given the new contracting methodology .  Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels . ", "original_text": "Again, this is Jason . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f7c3f75134619f7df1b87b837c6365c9c74bd03d80608f67738bd66d406608b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bd6de5c-5e10-4a83-b7fc-66aef2f40476", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered . ", "original_text": "So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about . "}, "hash": "63ec8848ddcaaedc279076d9d57805a1de56b8042f32db09f10dbe1494b5bd61", "class_name": "RelatedNodeInfo"}}, "text": "I'll start . ", "start_char_idx": 2912, "end_char_idx": 2925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bd6de5c-5e10-4a83-b7fc-66aef2f40476": {"__data__": {"id_": "2bd6de5c-5e10-4a83-b7fc-66aef2f40476", "embedding": null, "metadata": {"window": "Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered . ", "original_text": "So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3661884-d59b-4b17-a41b-db31fe20b462", "node_type": "1", "metadata": {"window": "Can you just give us your take on either expectations  \ntoday or based on prior experience in what you know today, the duration of those pressures.  \n \n Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been . ", "original_text": "I'll start . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8444cc2fc8a002d6a47956db366e40ee28acfcb499971e429663ebbb1a2e37c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc2f3f35-00df-4665-8fa0-5912a19591c6", "node_type": "1", "metadata": {"window": "Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile . ", "original_text": "So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels . "}, "hash": "5a6f1fd595de3316d4b47029a18c3f8fe77f18dd8463d64fda33a5899ca4aaf9", "class_name": "RelatedNodeInfo"}}, "text": "So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about . ", "start_char_idx": 2925, "end_char_idx": 3052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc2f3f35-00df-4665-8fa0-5912a19591c6": {"__data__": {"id_": "cc2f3f35-00df-4665-8fa0-5912a19591c6", "embedding": null, "metadata": {"window": "Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile . ", "original_text": "So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bd6de5c-5e10-4a83-b7fc-66aef2f40476", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah .  Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered . ", "original_text": "So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a8a7ed1001f31497557dcef31f009dfc7362902ba288f39fc5aa463893612b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f791413-b78d-4c38-8ee6-90d9f7014a7a", "node_type": "1", "metadata": {"window": "I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of . ", "original_text": "So at this point, we're not seeing much of a change from where we have been . "}, "hash": "5c954e721ab3c827e651b764af623a751da03cbd525cc4a44eaf34c59624efc9", "class_name": "RelatedNodeInfo"}}, "text": "So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels . ", "start_char_idx": 3052, "end_char_idx": 3214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f791413-b78d-4c38-8ee6-90d9f7014a7a": {"__data__": {"id_": "9f791413-b78d-4c38-8ee6-90d9f7014a7a", "embedding": null, "metadata": {"window": "I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of . ", "original_text": "So at this point, we're not seeing much of a change from where we have been . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc2f3f35-00df-4665-8fa0-5912a19591c6", "node_type": "1", "metadata": {"window": "Again, this is Jason .  I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile . ", "original_text": "So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2dc289bb4bf59b9072ad9071580a015c257684a80144e09f4f1b1889eec7d461", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56d3608a-eaff-4c28-b6d5-80b8882b7add", "node_type": "1", "metadata": {"window": "So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier . ", "original_text": "And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered . "}, "hash": "0ba2c5861bd2c1f8f5fbf717d8bc4a797b6d72f25d12d2d8076041ccdeb41279", "class_name": "RelatedNodeInfo"}}, "text": "So at this point, we're not seeing much of a change from where we have been . ", "start_char_idx": 3214, "end_char_idx": 3292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56d3608a-eaff-4c28-b6d5-80b8882b7add": {"__data__": {"id_": "56d3608a-eaff-4c28-b6d5-80b8882b7add", "embedding": null, "metadata": {"window": "So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier . ", "original_text": "And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f791413-b78d-4c38-8ee6-90d9f7014a7a", "node_type": "1", "metadata": {"window": "I'll start .  So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of . ", "original_text": "So at this point, we're not seeing much of a change from where we have been . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adc61c032b978deec995cbf09237297195862b5156e086f373a176218b178a53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3bd42d0-4188-4b3b-a995-6ad754856081", "node_type": "1", "metadata": {"window": "So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "As it relates to some of the other commodities, they've been more volatile . "}, "hash": "34b1575b1d5a8876a0adf904eeabdd5f089ac9ea6ef78381b46edbcae3b4bc4f", "class_name": "RelatedNodeInfo"}}, "text": "And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered . ", "start_char_idx": 3292, "end_char_idx": 3430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3bd42d0-4188-4b3b-a995-6ad754856081": {"__data__": {"id_": "a3bd42d0-4188-4b3b-a995-6ad754856081", "embedding": null, "metadata": {"window": "So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "As it relates to some of the other commodities, they've been more volatile . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56d3608a-eaff-4c28-b6d5-80b8882b7add", "node_type": "1", "metadata": {"window": "So to your point, it will potentially differ, not only by \ntype of cost, but also the magnitude of what we'r e talking about .  So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier . ", "original_text": "And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcfcda75ecab9eb76fe62546987c5bfd4da0f8792087ff176852ffa823df1572", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a44d87d-703d-42bc-9d77-8b1291bd70c1", "node_type": "1", "metadata": {"window": "So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "We have \nseen some that have started to appear to  come down that cost of . "}, "hash": "22aebc33d4a2ec90e563ce375fb56b640a4e530197247dcf4de5f393fc728318", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to some of the other commodities, they've been more volatile . ", "start_char_idx": 3430, "end_char_idx": 3507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a44d87d-703d-42bc-9d77-8b1291bd70c1": {"__data__": {"id_": "5a44d87d-703d-42bc-9d77-8b1291bd70c1", "embedding": null, "metadata": {"window": "So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "We have \nseen some that have started to appear to  come down that cost of . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3bd42d0-4188-4b3b-a995-6ad754856081", "node_type": "1", "metadata": {"window": "So as it relates to first of all, just the \ninternational freight, one thing to highlight is that particular area of cost has remained at very elevated \nlevels .  So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "As it relates to some of the other commodities, they've been more volatile . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def5659a260011a41caaee87a74b3aedcf046c81b3a95e3a0a2a8a228ba3ea95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ce3d17c-3c1a-4091-84ab-66ac074e4371", "node_type": "1", "metadata": {"window": "And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "It looks like they may have \nplateaued and started to reduce others that have been choppier . "}, "hash": "820519f11f85afa523c071e16535cef4fd0b9353669c4eb36b5ae7e5524eaac9", "class_name": "RelatedNodeInfo"}}, "text": "We have \nseen some that have started to appear to  come down that cost of . ", "start_char_idx": 3507, "end_char_idx": 3583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ce3d17c-3c1a-4091-84ab-66ac074e4371": {"__data__": {"id_": "2ce3d17c-3c1a-4091-84ab-66ac074e4371", "embedding": null, "metadata": {"window": "And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "It looks like they may have \nplateaued and started to reduce others that have been choppier . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a44d87d-703d-42bc-9d77-8b1291bd70c1", "node_type": "1", "metadata": {"window": "So at this point, we're not seeing much of a change from where we have been .  And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "We have \nseen some that have started to appear to  come down that cost of . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81e2eb4942727d2192dd40150a0007e2e27984aaab0c60039697047971966bc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3e35f35-1ab2-4473-b500-30cd734331ac", "node_type": "1", "metadata": {"window": "As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "And so in that environment where "}, "hash": "83622241f1b46214fcd2e99003db9b9024c7b1bee84b950fc7fa2e6dae0b250b", "class_name": "RelatedNodeInfo"}}, "text": "It looks like they may have \nplateaued and started to reduce others that have been choppier . ", "start_char_idx": 3583, "end_char_idx": 3677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3e35f35-1ab2-4473-b500-30cd734331ac": {"__data__": {"id_": "a3e35f35-1ab2-4473-b500-30cd734331ac", "embedding": null, "metadata": {"window": "As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "And so in that environment where ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d70fb666154e41d3a8c97732682625ae45ba1d69091ec77cb6a46a6a195688", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ce3d17c-3c1a-4091-84ab-66ac074e4371", "node_type": "1", "metadata": {"window": "And so that's \nsomething that is a clear part of our pricing focuses to make sure we can get at least a good portion \nof that recovered .  As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "It looks like they may have \nplateaued and started to reduce others that have been choppier . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "915c500967617126feff36accecdda66722b7ff608cb12f2840cab601b36a408", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d07168f-344c-4e91-8a23-ae87b7710090", "node_type": "1", "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year . ", "original_text": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n"}, "hash": "bdf4f06d60394dc0cf1e3a06eefc2d404a084e0e92d144145b0dd00c24b459f9", "class_name": "RelatedNodeInfo"}}, "text": "And so in that environment where ", "start_char_idx": 3677, "end_char_idx": 3710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d07168f-344c-4e91-8a23-ae87b7710090": {"__data__": {"id_": "0d07168f-344c-4e91-8a23-ae87b7710090", "embedding": null, "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year . ", "original_text": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3e35f35-1ab2-4473-b500-30cd734331ac", "node_type": "1", "metadata": {"window": "As it relates to some of the other commodities, they've been more volatile .  We have \nseen some that have started to appear to  come down that cost of .  It looks like they may have \nplateaued and started to reduce others that have been choppier .  And so in that environment where ", "original_text": "And so in that environment where ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "014342b768fb017fec44856826410403eed965f9eb2f1924a04a3f7c99e1e110", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51b25754-891d-4a33-bde9-dbbe0349e5a9", "node_type": "1", "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n", "original_text": "I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date. "}, "hash": "b968e975f7d4dd503a7e0a9ed6a9363e090eb4f010a03a7eb8f2105d6a61b4eb", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n", "start_char_idx": 0, "end_char_idx": 147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51b25754-891d-4a33-bde9-dbbe0349e5a9": {"__data__": {"id_": "51b25754-891d-4a33-bde9-dbbe0349e5a9", "embedding": null, "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n", "original_text": "I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date. ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d07168f-344c-4e91-8a23-ae87b7710090", "node_type": "1", "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year . ", "original_text": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53b5c048579620132c76c49add309af90d079d1874ae404d5a4372fce78b8cec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c3dfcfb-61c7-49c6-83cb-af270bdb99a1", "node_type": "1", "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning . ", "original_text": "That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest . "}, "hash": "5cb3e8c579013209f497b51b0bb8e4a458cf338e0d2dfd752db670df6fe3586e", "class_name": "RelatedNodeInfo"}}, "text": "I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date. ", "start_char_idx": 147, "end_char_idx": 331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c3dfcfb-61c7-49c6-83cb-af270bdb99a1": {"__data__": {"id_": "0c3dfcfb-61c7-49c6-83cb-af270bdb99a1", "embedding": null, "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning . ", "original_text": "That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51b25754-891d-4a33-bde9-dbbe0349e5a9", "node_type": "1", "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n", "original_text": "I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date. ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3705c5d2659f5f006afb7420e7d52517fe01db9b51e0846b9f94d33ba141ea30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "deb05d14-b06d-410c-9b43-4e5eed5ed1e0", "node_type": "1", "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost . ", "original_text": "And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year . "}, "hash": "453c708313d569bbe6f29f3ef4c6faceed8a7c745f67b5e16d2cbd207b122642", "class_name": "RelatedNodeInfo"}}, "text": "That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest . ", "start_char_idx": 331, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "deb05d14-b06d-410c-9b43-4e5eed5ed1e0": {"__data__": {"id_": "deb05d14-b06d-410c-9b43-4e5eed5ed1e0", "embedding": null, "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost . ", "original_text": "And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c3dfcfb-61c7-49c6-83cb-af270bdb99a1", "node_type": "1", "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning . ", "original_text": "That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "246cd153dbd5ac3b65dafd10846fcf536794510a517e4a2cb767d2df21bd1bb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dc1ef36-7bef-4ea5-97c1-4c6e34fce277", "node_type": "1", "metadata": {"window": "I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear. ", "original_text": "But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n"}, "hash": "5a5c2d471c8758d0ff76be5f97fec1dd9c4d8fadd5857121b29de499ba1a73dc", "class_name": "RelatedNodeInfo"}}, "text": "And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year . ", "start_char_idx": 520, "end_char_idx": 700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dc1ef36-7bef-4ea5-97c1-4c6e34fce277": {"__data__": {"id_": "1dc1ef36-7bef-4ea5-97c1-4c6e34fce277", "embedding": null, "metadata": {"window": "I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear. ", "original_text": "But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "deb05d14-b06d-410c-9b43-4e5eed5ed1e0", "node_type": "1", "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost . ", "original_text": "And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91c546c8a782257bf87424c9e9554d87fbf67c8a3d93d5373286f46b58c7c86c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd24591d-565e-46db-aed8-c77f2bd4598c", "node_type": "1", "metadata": {"window": "That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823. ", "original_text": "It is just the beginning . "}, "hash": "e3de787a91db6faede460fcd110e7d9b898e2fe3bea0bf5081e3448c96486a32", "class_name": "RelatedNodeInfo"}}, "text": "But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n", "start_char_idx": 700, "end_char_idx": 849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd24591d-565e-46db-aed8-c77f2bd4598c": {"__data__": {"id_": "cd24591d-565e-46db-aed8-c77f2bd4598c", "embedding": null, "metadata": {"window": "That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823. ", "original_text": "It is just the beginning . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dc1ef36-7bef-4ea5-97c1-4c6e34fce277", "node_type": "1", "metadata": {"window": "I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear. ", "original_text": "But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a512640f96910e589895801fb3edeafc23171bc1aa43eb0142dc680e07753103", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "409572ba-d848-4c0d-9966-f6a445aec269", "node_type": "1", "metadata": {"window": "And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n", "original_text": "It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost . "}, "hash": "a1df03e5685c263806d9cb7c18c60396e69ea0a40d59aa1f5ca8542d9c753f71", "class_name": "RelatedNodeInfo"}}, "text": "It is just the beginning . ", "start_char_idx": 849, "end_char_idx": 876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "409572ba-d848-4c0d-9966-f6a445aec269": {"__data__": {"id_": "409572ba-d848-4c0d-9966-f6a445aec269", "embedding": null, "metadata": {"window": "And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n", "original_text": "It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd24591d-565e-46db-aed8-c77f2bd4598c", "node_type": "1", "metadata": {"window": "That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823. ", "original_text": "It is just the beginning . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06bb78e62c56ac65d3043d65d3ba8e228e1ff2ea10f4b55affe3393f4d4840de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b88f1aa-f736-42b0-b514-f1e009cff485", "node_type": "1", "metadata": {"window": "But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley . ", "original_text": "And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear. "}, "hash": "0c6d0bfa8fe0d3488621d759fd259b6be54266d7e19a43d50588cbb895f00349", "class_name": "RelatedNodeInfo"}}, "text": "It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost . ", "start_char_idx": 876, "end_char_idx": 1032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b88f1aa-f736-42b0-b514-f1e009cff485": {"__data__": {"id_": "2b88f1aa-f736-42b0-b514-f1e009cff485", "embedding": null, "metadata": {"window": "But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley . ", "original_text": "And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear. ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "409572ba-d848-4c0d-9966-f6a445aec269", "node_type": "1", "metadata": {"window": "And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year .  But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n", "original_text": "It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed1a22f0fa98e12759c726ced83f8f3e501225d73e13472bca44909e0c90760b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d45cc359-3228-4de6-a018-b2deadd9f2ea", "node_type": "1", "metadata": {"window": "It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n", "original_text": "With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823. "}, "hash": "1a40561d7cc12c80f83d950e18b551c4e5f3e06624d8b8e797c267f412d6795d", "class_name": "RelatedNodeInfo"}}, "text": "And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear. ", "start_char_idx": 1032, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d45cc359-3228-4de6-a018-b2deadd9f2ea": {"__data__": {"id_": "d45cc359-3228-4de6-a018-b2deadd9f2ea", "embedding": null, "metadata": {"window": "It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n", "original_text": "With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823. ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b88f1aa-f736-42b0-b514-f1e009cff485", "node_type": "1", "metadata": {"window": "But also, that's also the timing of when we would start to see some of \nthe pricing actions that we have already begun to start to come through.  \n \n It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley . ", "original_text": "And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear. ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00fea60d9c613a1bb0ea929323d6602b069f9d6bd23179d6bbf88c204700bdc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0beafb5b-c328-4d79-b87b-f1f5d16db3b8", "node_type": "1", "metadata": {"window": "It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning . ", "original_text": "There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n"}, "hash": "12ef61adf5408fc39e346acce4cc861ba64b9ac9d743d96e8fbd00ed9d87d285", "class_name": "RelatedNodeInfo"}}, "text": "With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823. ", "start_char_idx": 1271, "end_char_idx": 1462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0beafb5b-c328-4d79-b87b-f1f5d16db3b8": {"__data__": {"id_": "0beafb5b-c328-4d79-b87b-f1f5d16db3b8", "embedding": null, "metadata": {"window": "It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning . ", "original_text": "There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d45cc359-3228-4de6-a018-b2deadd9f2ea", "node_type": "1", "metadata": {"window": "It is just the beginning .  It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n", "original_text": "With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823. ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e50175a6069cb8b3bc7f49ef14c73bd498083db53d360ac6d0505805a038531", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a1096b5-e3be-4eb2-acd5-b947525f519b", "node_type": "1", "metadata": {"window": "And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky . ", "original_text": "Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley . "}, "hash": "363bf2d28c10e9406b28e7c23879ecb390acee0f1aa3eb270af283915247fe85", "class_name": "RelatedNodeInfo"}}, "text": "There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n", "start_char_idx": 1462, "end_char_idx": 1635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a1096b5-e3be-4eb2-acd5-b947525f519b": {"__data__": {"id_": "4a1096b5-e3be-4eb2-acd5-b947525f519b", "embedding": null, "metadata": {"window": "And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky . ", "original_text": "Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0beafb5b-c328-4d79-b87b-f1f5d16db3b8", "node_type": "1", "metadata": {"window": "It's not offsetting enough of tha t. And there's more activity that will need to still \noccur, but it all depends on exactly what that cadence is of cost .  And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning . ", "original_text": "There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b291f375707c618d310656833913a59965aab669731d72b34a208b7548631de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4798d375-f06f-4d2d-b422-41e3bae67f66", "node_type": "1", "metadata": {"window": "With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us . ", "original_text": "Please go ahead.  \n \n"}, "hash": "66e374d8deb43a9345ec0f6639e2942e08e4155e7ee2239b5b5f936be1c762e3", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley . ", "start_char_idx": 1635, "end_char_idx": 1740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4798d375-f06f-4d2d-b422-41e3bae67f66": {"__data__": {"id_": "4798d375-f06f-4d2d-b422-41e3bae67f66", "embedding": null, "metadata": {"window": "With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us . ", "original_text": "Please go ahead.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a1096b5-e3be-4eb2-acd5-b947525f519b", "node_type": "1", "metadata": {"window": "And the key is that we remain very \nclose to both the GPOs, as well as our customers , to manage through that on an item -by-item, \ncustomer -customer basis to get to an answer  then that would give us the right cadence exiting the \nyear.  With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky . ", "original_text": "Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76ff31897ba1aeefa51c8117b4c21607beddb2b34fe2a20b6a5436d270213443", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccb817c2-cbfa-45e4-9683-da7433fc6a04", "node_type": "1", "metadata": {"window": "There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters . ", "original_text": "Dan:  Hi, good morning . "}, "hash": "f42c26fc3ce163e0f461faae92b15afd534bf0331d0333cc49438f8a874c64ec", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1740, "end_char_idx": 1761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccb817c2-cbfa-45e4-9683-da7433fc6a04": {"__data__": {"id_": "ccb817c2-cbfa-45e4-9683-da7433fc6a04", "embedding": null, "metadata": {"window": "There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters . ", "original_text": "Dan:  Hi, good morning . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4798d375-f06f-4d2d-b422-41e3bae67f66", "node_type": "1", "metadata": {"window": "With all that said , given the one to two quarter lag even if costs do come down and even if we \nhave more success with the pricing, we would expect there to be a  carryover into fiscal \u201823.  There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us . ", "original_text": "Please go ahead.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4f498a7c391faff135195ab34e7a90c63c7910645c89e9c87adc0cd2e88e86f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ec6b0d8-7f53-4d19-8f79-4d5c12a3e115", "node_type": "1", "metadata": {"window": "Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?  ", "original_text": "This is Dan on for Ricky . "}, "hash": "dd75d58cda5a1c7e232f3e959d396067fe0c8d58e4a721bc6872f5ed8c5eb786", "class_name": "RelatedNodeInfo"}}, "text": "Dan:  Hi, good morning . ", "start_char_idx": 1761, "end_char_idx": 1786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ec6b0d8-7f53-4d19-8f79-4d5c12a3e115": {"__data__": {"id_": "8ec6b0d8-7f53-4d19-8f79-4d5c12a3e115", "embedding": null, "metadata": {"window": "Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?  ", "original_text": "This is Dan on for Ricky . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccb817c2-cbfa-45e4-9683-da7433fc6a04", "node_type": "1", "metadata": {"window": "There will \nbe some impact that carries over into that year, but we need to see the cadence of both the cost and \nthe pricing before we can establish that more clearly.  \n \n Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters . ", "original_text": "Dan:  Hi, good morning . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f07fd79c225f87949b9948ea14201b87eb38b6351dc4aac0c4ff5699fc0f68b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94a55e53-fa85-4357-95cd-c6943a29f52e", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n", "original_text": "Two questions from us . "}, "hash": "6fd58880c7254639b49c9c524b975e0459733899a0dd75b2b8595b881a6d494a", "class_name": "RelatedNodeInfo"}}, "text": "This is Dan on for Ricky . ", "start_char_idx": 1786, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94a55e53-fa85-4357-95cd-c6943a29f52e": {"__data__": {"id_": "94a55e53-fa85-4357-95cd-c6943a29f52e", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n", "original_text": "Two questions from us . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ec6b0d8-7f53-4d19-8f79-4d5c12a3e115", "node_type": "1", "metadata": {"window": "Operator:   I'll go ahead and move on to our next question fr om Ricky Goldwasser with Morgan \nStanley .  Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?  ", "original_text": "This is Dan on for Ricky . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "decd6018e656465225122e74ab35e3aa493b5d0ddb7f01f2b7ed10bc654182ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e6cb8d0-42ee-4084-9edb-081e60b92be5", "node_type": "1", "metadata": {"window": "Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n", "original_text": "One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters . "}, "hash": "a9595cbf6571ea52d81b53d239bf6f9099d06db78ddaa87599a0f31004f5c050", "class_name": "RelatedNodeInfo"}}, "text": "Two questions from us . ", "start_char_idx": 1813, "end_char_idx": 1837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e6cb8d0-42ee-4084-9edb-081e60b92be5": {"__data__": {"id_": "6e6cb8d0-42ee-4084-9edb-081e60b92be5", "embedding": null, "metadata": {"window": "Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n", "original_text": "One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94a55e53-fa85-4357-95cd-c6943a29f52e", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n", "original_text": "Two questions from us . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c5fb9d095a7347705b4a3d06a2b21dfa08575febc53723a09ef8e597b17d94c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daf989b2-00f4-4ced-a5be-a77dc5d6d981", "node_type": "1", "metadata": {"window": "This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah . ", "original_text": "And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?  "}, "hash": "9eb56b1314abc344f3b159c3a527636859e69329b58f15535d148c4fe7c1618c", "class_name": "RelatedNodeInfo"}}, "text": "One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters . ", "start_char_idx": 1837, "end_char_idx": 2110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daf989b2-00f4-4ced-a5be-a77dc5d6d981": {"__data__": {"id_": "daf989b2-00f4-4ced-a5be-a77dc5d6d981", "embedding": null, "metadata": {"window": "This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah . ", "original_text": "And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?  ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e6cb8d0-42ee-4084-9edb-081e60b92be5", "node_type": "1", "metadata": {"window": "Dan:  Hi, good morning .  This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n", "original_text": "One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0843814bf0fe9a757a9b930e245261bc2a908640fafbc1b3d5a0affda7fe04e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cc5bd73-39ec-4b59-ae9a-9d625c7fd052", "node_type": "1", "metadata": {"window": "Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update . ", "original_text": "Thank you.  \n \n"}, "hash": "6540bb3cc3e8b3be8f1f9a162526d6185064a12bf98dee05f75283afb130359a", "class_name": "RelatedNodeInfo"}}, "text": "And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?  ", "start_char_idx": 2110, "end_char_idx": 2305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cc5bd73-39ec-4b59-ae9a-9d625c7fd052": {"__data__": {"id_": "4cc5bd73-39ec-4b59-ae9a-9d625c7fd052", "embedding": null, "metadata": {"window": "Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update . ", "original_text": "Thank you.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daf989b2-00f4-4ced-a5be-a77dc5d6d981", "node_type": "1", "metadata": {"window": "This is Dan on for Ricky .  Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah . ", "original_text": "And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?  ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c5c2ad39fd8605107aa35ff9a3c56ed91d93e4f886e375205e6140177727bc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c4d2cd4-831d-453c-9291-b291c10b0e65", "node_type": "1", "metadata": {"window": "One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there . ", "original_text": "Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n"}, "hash": "7507921f208c8152873bfe097afbf9ac9251242ffb12e8122d8c0a5c1a0f15ad", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 2305, "end_char_idx": 2320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c4d2cd4-831d-453c-9291-b291c10b0e65": {"__data__": {"id_": "3c4d2cd4-831d-453c-9291-b291c10b0e65", "embedding": null, "metadata": {"window": "One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there . ", "original_text": "Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cc5bd73-39ec-4b59-ae9a-9d625c7fd052", "node_type": "1", "metadata": {"window": "Two questions from us .  One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update . ", "original_text": "Thank you.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47a1b64a87c5426cbdeb2240f54d6a939cd0f9211704098d536ae7331d3e46f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3657af96-808a-443f-af9c-860f61d072f3", "node_type": "1", "metadata": {"window": "And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n", "original_text": "Jason Hollar:   Yeah . "}, "hash": "33fd720bd2966556ac88d859d0c84cd366395eb932fe36328ecec9853a7846d7", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n", "start_char_idx": 2320, "end_char_idx": 2419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3657af96-808a-443f-af9c-860f61d072f3": {"__data__": {"id_": "3657af96-808a-443f-af9c-860f61d072f3", "embedding": null, "metadata": {"window": "And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n", "original_text": "Jason Hollar:   Yeah . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c4d2cd4-831d-453c-9291-b291c10b0e65", "node_type": "1", "metadata": {"window": "One, as we think about \nyour move to move more finished goods production back to North America, how should we think \nabout that  in terms of margin, both sort of in a pre -COVID environment and then the impact to margin \nas we think about your margins in recent quarters .  And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there . ", "original_text": "Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4cd592b8177fce1f4c0a1e040bb400ab30fc8b30afb4d9c3226f234c1e2a791", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62840c34-b24b-4f44-b199-6185a492358b", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A . ", "original_text": "And so the - there were some small differences in t his latest update . "}, "hash": "319a54ae22a04912c0558ee6d52807d32636cc6cc223918b8c5e1370ae9d2c5d", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:   Yeah . ", "start_char_idx": 2419, "end_char_idx": 2442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62840c34-b24b-4f44-b199-6185a492358b": {"__data__": {"id_": "62840c34-b24b-4f44-b199-6185a492358b", "embedding": null, "metadata": {"window": "Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A . ", "original_text": "And so the - there were some small differences in t his latest update . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3657af96-808a-443f-af9c-860f61d072f3", "node_type": "1", "metadata": {"window": "And then as a follow -up just wanted to confirm, \nwas the updated tax rate interest expense guidance that came out t oday, was that included in the \nearly January update or is that incremental?   Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n", "original_text": "Jason Hollar:   Yeah . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4d36a8e4a141b1b50c91834130571895d58ff0dc4e44c3395947a82e34aca04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3a802b9-fb04-4236-bee9-59a59a81a386", "node_type": "1", "metadata": {"window": "Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n", "original_text": "The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there . "}, "hash": "d17b7c0e6551fa13b6725685dc75d50129231821f6a936cf23ee482bcf65815d", "class_name": "RelatedNodeInfo"}}, "text": "And so the - there were some small differences in t his latest update . ", "start_char_idx": 2442, "end_char_idx": 2514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3a802b9-fb04-4236-bee9-59a59a81a386": {"__data__": {"id_": "f3a802b9-fb04-4236-bee9-59a59a81a386", "embedding": null, "metadata": {"window": "Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n", "original_text": "The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62840c34-b24b-4f44-b199-6185a492358b", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A . ", "original_text": "And so the - there were some small differences in t his latest update . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13519ae55317945864b97ff1d9a7d580b28399cc54f3dbb6176354916fa2c90e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed23a65b-70b4-467d-b76e-f25c12a5f7e0", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things . ", "original_text": "The Interest  and O ther change I highlighted was in part related to deferred comp . \n"}, "hash": "70054a28d463eb1e6f84990e0e18386fd23c0b291f540ea1c3f551cb0608bbee", "class_name": "RelatedNodeInfo"}}, "text": "The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there . ", "start_char_idx": 2514, "end_char_idx": 2646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed23a65b-70b4-467d-b76e-f25c12a5f7e0": {"__data__": {"id_": "ed23a65b-70b4-467d-b76e-f25c12a5f7e0", "embedding": null, "metadata": {"window": "Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things . ", "original_text": "The Interest  and O ther change I highlighted was in part related to deferred comp . \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3a802b9-fb04-4236-bee9-59a59a81a386", "node_type": "1", "metadata": {"window": "Mike Kaufmann:   I'll have Jason talk about the tax rate and then I can talk about the margin.  \n \n Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n", "original_text": "The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "699c7773c88fda033b6cd9c53b4e051caf3dc8ff0eba2a893dbac7d5b5ddffeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edeac990-d822-4018-8c55-3202ce5489dd", "node_type": "1", "metadata": {"window": "And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here . ", "original_text": "And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A . "}, "hash": "7e4075afece60cd77a1c72282c9a7babff55e597808a5fe89bf2ecc87e5898fb", "class_name": "RelatedNodeInfo"}}, "text": "The Interest  and O ther change I highlighted was in part related to deferred comp . \n", "start_char_idx": 2646, "end_char_idx": 2732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edeac990-d822-4018-8c55-3202ce5489dd": {"__data__": {"id_": "edeac990-d822-4018-8c55-3202ce5489dd", "embedding": null, "metadata": {"window": "And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here . ", "original_text": "And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed23a65b-70b4-467d-b76e-f25c12a5f7e0", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah .  And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things . ", "original_text": "The Interest  and O ther change I highlighted was in part related to deferred comp . \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a52b2d76b5fae2f8d6b404ce44192e1ed59bd1d0a5bdb99bfdb8da6952282477", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b714f97f-f512-4311-b4ad-b10013bf6320", "node_type": "1", "metadata": {"window": "The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver . ", "original_text": "So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n"}, "hash": "3f20b82c90ee55b2abbfa704fd6c57651f2209ec27858585fe5bb272321cfe2d", "class_name": "RelatedNodeInfo"}}, "text": "And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A . ", "start_char_idx": 2732, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b714f97f-f512-4311-b4ad-b10013bf6320": {"__data__": {"id_": "b714f97f-f512-4311-b4ad-b10013bf6320", "embedding": null, "metadata": {"window": "The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver . ", "original_text": "So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edeac990-d822-4018-8c55-3202ce5489dd", "node_type": "1", "metadata": {"window": "And so the - there were some small differences in t his latest update .  The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here . ", "original_text": "And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e8eb9aa48a3c6883215f79fc90c14d893715b8ed5f4c5bb7207a8af05035d5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5872d0d5-f6d0-49f6-915e-36204fe0eb68", "node_type": "1", "metadata": {"window": "The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there . ", "original_text": "Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things . "}, "hash": "04f41ead84b9ca0247d2dad76422c9b9443877f554d2a74f36affefba4163bbd", "class_name": "RelatedNodeInfo"}}, "text": "So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n", "start_char_idx": 2829, "end_char_idx": 3000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5872d0d5-f6d0-49f6-915e-36204fe0eb68": {"__data__": {"id_": "5872d0d5-f6d0-49f6-915e-36204fe0eb68", "embedding": null, "metadata": {"window": "The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there . ", "original_text": "Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b714f97f-f512-4311-b4ad-b10013bf6320", "node_type": "1", "metadata": {"window": "The tax rate \nwas just bringing down the top end a little bit , the low end was the same, so it's not much of a \ndifference there .  The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver . ", "original_text": "So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bce95cc3020f77a5c6c46cdea8b1f8670d703e32f80072cb5082634c465d05d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f872346-ea36-4cf0-acb2-caeb3e46e20f", "node_type": "1", "metadata": {"window": "And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here . ", "original_text": "Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here . "}, "hash": "00bc9d93b4ee0c87350cf657a5c8e62c9865625de8261b6728ba781fc693bddb", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things . ", "start_char_idx": 3000, "end_char_idx": 3132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f872346-ea36-4cf0-acb2-caeb3e46e20f": {"__data__": {"id_": "5f872346-ea36-4cf0-acb2-caeb3e46e20f", "embedding": null, "metadata": {"window": "And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here . ", "original_text": "Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5872d0d5-f6d0-49f6-915e-36204fe0eb68", "node_type": "1", "metadata": {"window": "The Interest  and O ther change I highlighted was in part related to deferred comp . \n And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there . ", "original_text": "Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "239df5495c6f0cc8398b184bdb2c9a51407c311308ef8a4aa1565665a09e6f10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca96655c-64eb-42df-a28a-569772ee17db", "node_type": "1", "metadata": {"window": "So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "That is \nnot something I would say would be a margin driver . "}, "hash": "060b0299a61e133fc03aef7a9d4c944be92d59d86857b996796e9f667a5d66ff", "class_name": "RelatedNodeInfo"}}, "text": "Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here . ", "start_char_idx": 3132, "end_char_idx": 3284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca96655c-64eb-42df-a28a-569772ee17db": {"__data__": {"id_": "ca96655c-64eb-42df-a28a-569772ee17db", "embedding": null, "metadata": {"window": "So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "That is \nnot something I would say would be a margin driver . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f872346-ea36-4cf0-acb2-caeb3e46e20f", "node_type": "1", "metadata": {"window": "And as a reminder, that's j ust geography between Interest and Other as well as corporate SG&A .  So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here . ", "original_text": "Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2862edbc5d91b4cd600c0d6ae21291436166e6f39a0594dfbc4df776373f916b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c26a927-62ca-4065-ac80-6f390332956b", "node_type": "1", "metadata": {"window": "Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "It's more about supply chain integrity, which is \nwhy we've moved them there . "}, "hash": "e99faafa5369a3fa7762af45910a0ff2054cbba1e3fd286f0cf2f8a189e35636", "class_name": "RelatedNodeInfo"}}, "text": "That is \nnot something I would say would be a margin driver . ", "start_char_idx": 3284, "end_char_idx": 3346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c26a927-62ca-4065-ac80-6f390332956b": {"__data__": {"id_": "3c26a927-62ca-4065-ac80-6f390332956b", "embedding": null, "metadata": {"window": "Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "It's more about supply chain integrity, which is \nwhy we've moved them there . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca96655c-64eb-42df-a28a-569772ee17db", "node_type": "1", "metadata": {"window": "So \nyes, it was largely considered in our prior assumptions, but as a lot of it was just geography, anyway, \nso there's no material difference in those other updates.  \n \n Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "That is \nnot something I would say would be a margin driver . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18851a1fc80384bf1cde0a6e8091e97b492f9e5f52153dbbd7cb1900690282d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "def9b295-91bd-4d4b-8278-0cfda143a631", "node_type": "1", "metadata": {"window": "Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "So if there are disruptions in the future, we obviously then have certain \nkey items closer here . "}, "hash": "0a813aa4d7a90d6b5cf239d8f8de225f05ee0e486cb042413668fc30e34e16b1", "class_name": "RelatedNodeInfo"}}, "text": "It's more about supply chain integrity, which is \nwhy we've moved them there . ", "start_char_idx": 3346, "end_char_idx": 3425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "def9b295-91bd-4d4b-8278-0cfda143a631": {"__data__": {"id_": "def9b295-91bd-4d4b-8278-0cfda143a631", "embedding": null, "metadata": {"window": "Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "So if there are disruptions in the future, we obviously then have certain \nkey items closer here . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c26a927-62ca-4065-ac80-6f390332956b", "node_type": "1", "metadata": {"window": "Mike Kaufmann:   And as far as moving capacity to North, you know, to our North American \noperations, I would say a couple things .  Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "It's more about supply chain integrity, which is \nwhy we've moved them there . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b07f6a4ed220ac4c26cd0f96a01e14f213092484b074bba3ec59bd155e2e87a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d9a2c8a-217a-4ad4-aec3-3561555200e8", "node_type": "1", "metadata": {"window": "That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "So we 've chosen these items that can be highly automated, make a lot of "}, "hash": "558117778c96bce45c67c748c826d2e157de87421ed37f2b4c130c353490b83a", "class_name": "RelatedNodeInfo"}}, "text": "So if there are disruptions in the future, we obviously then have certain \nkey items closer here . ", "start_char_idx": 3425, "end_char_idx": 3524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d9a2c8a-217a-4ad4-aec3-3561555200e8": {"__data__": {"id_": "8d9a2c8a-217a-4ad4-aec3-3561555200e8", "embedding": null, "metadata": {"window": "That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "So we 've chosen these items that can be highly automated, make a lot of ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c4b1766-ca74-421e-9272-c22eb00993aa", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b231dabe466748b2144f5813936fe0a53e601f0897442832b47f548eada0c5f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "def9b295-91bd-4d4b-8278-0cfda143a631", "node_type": "1", "metadata": {"window": "Generally, I wouldn't say that we would expect much of a \nmargin difference if it was manufactured outside of North America versus ma nufactured here .  That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "So if there are disruptions in the future, we obviously then have certain \nkey items closer here . ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1bd8d82c27ccb2447948595c2e8bf8f07de534b87200e237865db4163b009855", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bd3373b-c980-46be-892e-969dac8febe1", "node_type": "1", "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse . ", "original_text": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive . "}, "hash": "50f579683aca2fc1e95431075c12f38c9575c7a80408cdc88051f095e7d2ab17", "class_name": "RelatedNodeInfo"}}, "text": "So we 've chosen these items that can be highly automated, make a lot of ", "start_char_idx": 3524, "end_char_idx": 3597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bd3373b-c980-46be-892e-969dac8febe1": {"__data__": {"id_": "8bd3373b-c980-46be-892e-969dac8febe1", "embedding": null, "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse . ", "original_text": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d9a2c8a-217a-4ad4-aec3-3561555200e8", "node_type": "1", "metadata": {"window": "That is \nnot something I would say would be a margin driver .  It's more about supply chain integrity, which is \nwhy we've moved them there .  So if there are disruptions in the future, we obviously then have certain \nkey items closer here .  So we 've chosen these items that can be highly automated, make a lot of ", "original_text": "So we 've chosen these items that can be highly automated, make a lot of ", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f169aaee81f49bd19772a6dc43b8e9d0bd6d7b23ec45283dfa926ea4e69d7c7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4819d2ee-6ff1-4228-9e0e-e6de41f085a7", "node_type": "1", "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n", "original_text": "So again, wouldn't say \nit's margin generating in and of itself . "}, "hash": "c53108c41e89ade95c05f0e4bcea8b4f03b4b69d7db8436f8169b6c49f70d20e", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive . ", "start_char_idx": 0, "end_char_idx": 104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4819d2ee-6ff1-4228-9e0e-e6de41f085a7": {"__data__": {"id_": "4819d2ee-6ff1-4228-9e0e-e6de41f085a7", "embedding": null, "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n", "original_text": "So again, wouldn't say \nit's margin generating in and of itself . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bd3373b-c980-46be-892e-969dac8febe1", "node_type": "1", "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse . ", "original_text": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41515baff7d28bc2f6531f533d12349fd3b93a8eb679a27acd14b56ee276f46a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3725c1e6-dd8d-419e-806a-13e26c7c302c", "node_type": "1", "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone . ", "original_text": "However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n"}, "hash": "0af2172c035af7876c3b6b5fcbfcf8e7fc1514f106e89cf3c34f92ca31d6d93e", "class_name": "RelatedNodeInfo"}}, "text": "So again, wouldn't say \nit's margin generating in and of itself . ", "start_char_idx": 104, "end_char_idx": 170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3725c1e6-dd8d-419e-806a-13e26c7c302c": {"__data__": {"id_": "3725c1e6-dd8d-419e-806a-13e26c7c302c", "embedding": null, "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone . ", "original_text": "However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4819d2ee-6ff1-4228-9e0e-e6de41f085a7", "node_type": "1", "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n", "original_text": "So again, wouldn't say \nit's margin generating in and of itself . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88b2fdb7b8ebaecc62f9f3d38d977ffadc699db6922f4123e8f7a17b5108cde0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66c00aba-19d9-4a28-84e6-09919f0b5b33", "node_type": "1", "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half . ", "original_text": "Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse . "}, "hash": "6748b0d940497bac72cd62f174fc8ad93b5a5ab0541e729ff660c9ec880542c9", "class_name": "RelatedNodeInfo"}}, "text": "However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n", "start_char_idx": 170, "end_char_idx": 431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66c00aba-19d9-4a28-84e6-09919f0b5b33": {"__data__": {"id_": "66c00aba-19d9-4a28-84e6-09919f0b5b33", "embedding": null, "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half . ", "original_text": "Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3725c1e6-dd8d-419e-806a-13e26c7c302c", "node_type": "1", "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone . ", "original_text": "However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cadfca9b0cbaae14398745fef35b0550445e28234079c796d1c2b50eab36dcea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5512574d-dadf-4988-a287-628397c55fd6", "node_type": "1", "metadata": {"window": "So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact . ", "original_text": "Please go \nahead.  \n \n"}, "hash": "750345a09d438b4df0fe5cee4b9a7b8e24dcb38baa22a47082fb5d258fb5c881", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse . ", "start_char_idx": 431, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5512574d-dadf-4988-a287-628397c55fd6": {"__data__": {"id_": "5512574d-dadf-4988-a287-628397c55fd6", "embedding": null, "metadata": {"window": "So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact . ", "original_text": "Please go \nahead.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66c00aba-19d9-4a28-84e6-09919f0b5b33", "node_type": "1", "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half . ", "original_text": "Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "606f5f09f07fb9f2b10a8666574f2d5d053a43c146f6cdbf6a1bd47b12fed029", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57e6518d-e97b-4acb-b7f4-f56a74792df8", "node_type": "1", "metadata": {"window": "However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n", "original_text": "Jailendra Singh:   Thank you, and good morning, everyone . "}, "hash": "3e637b8e1b2ecac62c708a99f6c74117fdf844b1a023765896d0e742c17e9003", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 525, "end_char_idx": 547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57e6518d-e97b-4acb-b7f4-f56a74792df8": {"__data__": {"id_": "57e6518d-e97b-4acb-b7f4-f56a74792df8", "embedding": null, "metadata": {"window": "However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n", "original_text": "Jailendra Singh:   Thank you, and good morning, everyone . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5512574d-dadf-4988-a287-628397c55fd6", "node_type": "1", "metadata": {"window": "So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact . ", "original_text": "Please go \nahead.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9d61f32ed0a029191cd21a6f1d3e0ce07a434e915af50c3410e73c22e6dde13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe2a32e6-dd1d-4731-8f87-64941a19a60a", "node_type": "1", "metadata": {"window": "Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that . ", "original_text": "With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half . "}, "hash": "007c6b1b956f1b9d6c68c8137b8ea53006e166e89a157227fbec3e8ccf1b305d", "class_name": "RelatedNodeInfo"}}, "text": "Jailendra Singh:   Thank you, and good morning, everyone . ", "start_char_idx": 547, "end_char_idx": 606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe2a32e6-dd1d-4731-8f87-64941a19a60a": {"__data__": {"id_": "fe2a32e6-dd1d-4731-8f87-64941a19a60a", "embedding": null, "metadata": {"window": "Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that . ", "original_text": "With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57e6518d-e97b-4acb-b7f4-f56a74792df8", "node_type": "1", "metadata": {"window": "However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n", "original_text": "Jailendra Singh:   Thank you, and good morning, everyone . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d366cfe93b9b9ae610b4e074da15a36abed0c1e19b40034a487062319f66950", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ddb5c50-f827-4035-9b1b-d704ecfccb85", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf. ", "original_text": "And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact . "}, "hash": "dd0ef538bd90fd96f0c6d5d6f995fb36a629321139800ab04d238f50ba7f38fb", "class_name": "RelatedNodeInfo"}}, "text": "With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half . ", "start_char_idx": 606, "end_char_idx": 807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ddb5c50-f827-4035-9b1b-d704ecfccb85": {"__data__": {"id_": "6ddb5c50-f827-4035-9b1b-d704ecfccb85", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf. ", "original_text": "And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe2a32e6-dd1d-4731-8f87-64941a19a60a", "node_type": "1", "metadata": {"window": "Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse .  Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that . ", "original_text": "With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d57b064e7370f28f9e5d29d728d3fc7308d62631ebd0804e98259f19424be976", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f513455-9f31-495a-8383-243cf8aac3ab", "node_type": "1", "metadata": {"window": "Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up . ", "original_text": "Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n"}, "hash": "0cd3e0f5ce33fe6499c6618e2d524747166fe056961dd96b34bbdfe4e8313a65", "class_name": "RelatedNodeInfo"}}, "text": "And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact . ", "start_char_idx": 807, "end_char_idx": 923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f513455-9f31-495a-8383-243cf8aac3ab": {"__data__": {"id_": "8f513455-9f31-495a-8383-243cf8aac3ab", "embedding": null, "metadata": {"window": "Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up . ", "original_text": "Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ddb5c50-f827-4035-9b1b-d704ecfccb85", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf. ", "original_text": "And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea3be38803484bf27beae379b109135548a0ff1c540fb44b555b82944f73c6ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2b371e4-ede5-42ab-b80f-91da42417016", "node_type": "1", "metadata": {"window": "With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down . ", "original_text": "Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that . "}, "hash": "8d73327f9273c2e8c075cf080daacf7402c93c32635d936d0341e38b2e220563", "class_name": "RelatedNodeInfo"}}, "text": "Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n", "start_char_idx": 923, "end_char_idx": 1230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2b371e4-ede5-42ab-b80f-91da42417016": {"__data__": {"id_": "c2b371e4-ede5-42ab-b80f-91da42417016", "embedding": null, "metadata": {"window": "With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down . ", "original_text": "Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f513455-9f31-495a-8383-243cf8aac3ab", "node_type": "1", "metadata": {"window": "Jailendra Singh:   Thank you, and good morning, everyone .  With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up . ", "original_text": "Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b6d7b83c7a1e9ab57c4e500def51f6cbed79f51f5aaabac1a0ae28ea7c2821", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "985ba636-0675-4304-9a25-195671318bc7", "node_type": "1", "metadata": {"window": "And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.  ", "original_text": "So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf. "}, "hash": "ba5d31cf74203fa989206236d9a1cbe52ea816dbc2f3de12ff42b48f1893f57a", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that . ", "start_char_idx": 1230, "end_char_idx": 1366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "985ba636-0675-4304-9a25-195671318bc7": {"__data__": {"id_": "985ba636-0675-4304-9a25-195671318bc7", "embedding": null, "metadata": {"window": "And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.  ", "original_text": "So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf. ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2b371e4-ede5-42ab-b80f-91da42417016", "node_type": "1", "metadata": {"window": "With respect to this 250 to 300 million \nimpact in Medical segment, can you be a little bit more specific on how much impact did you see in \nfiscal first half and how much is expected in second half .  And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down . ", "original_text": "Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2cf4c7a50b4dcd9b71340e662691dcde1f304c1f101854d9f364d55da4b58f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "444b601d-c56a-4d54-9599-ab73775f7f6c", "node_type": "1", "metadata": {"window": "Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue . ", "original_text": "Think about it as kind of a sequential step up . "}, "hash": "0c98d5df84e99c659378b139942b313b033286ff0fa6e60b5ebf29e2423d497b", "class_name": "RelatedNodeInfo"}}, "text": "So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf. ", "start_char_idx": 1366, "end_char_idx": 1453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "444b601d-c56a-4d54-9599-ab73775f7f6c": {"__data__": {"id_": "444b601d-c56a-4d54-9599-ab73775f7f6c", "embedding": null, "metadata": {"window": "Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue . ", "original_text": "Think about it as kind of a sequential step up . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "985ba636-0675-4304-9a25-195671318bc7", "node_type": "1", "metadata": {"window": "And a follow -up to an earlier question, how \nshould we model the split between 3Q and 4Q on the remaining impact .  Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.  ", "original_text": "So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf. ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3692eccfcd463796235b88c3f009e85d60933268c3a7b8b74ef7bf98ea60b9c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fc1dd9f-8a58-471a-aef0-75cf2afaabdf", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there . ", "original_text": "So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down . "}, "hash": "1f7e8818bc3922590190354a8b8bed5a30e75c48b31afa73a639d241afc58823", "class_name": "RelatedNodeInfo"}}, "text": "Think about it as kind of a sequential step up . ", "start_char_idx": 1453, "end_char_idx": 1502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fc1dd9f-8a58-471a-aef0-75cf2afaabdf": {"__data__": {"id_": "0fc1dd9f-8a58-471a-aef0-75cf2afaabdf", "embedding": null, "metadata": {"window": "Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there . ", "original_text": "So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "444b601d-c56a-4d54-9599-ab73775f7f6c", "node_type": "1", "metadata": {"window": "Trying to better understand if \nall these initiatives you're put in place are more focused on p olicing  the company better next time you \nsee these kind of pressure, or do you think there's a possibility these initiatives result in some near -\nterm offset, and are you capturing those in your outlook?  \n \n Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue . ", "original_text": "Think about it as kind of a sequential step up . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f19c00a86c49d832dc9e23e0f72af6fbfd0a979e60e2094625f4f8ae584a8e2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ebee5d1-ac00-455b-ad3e-58a8ec7b6f46", "node_type": "1", "metadata": {"window": "So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind . ", "original_text": "So \nthere's - depends on if we're talking sequential or year -over-year.  "}, "hash": "88a23fde383677ed409bccc00fe67b54ff33201d85f2e3db397bb296f4b484aa", "class_name": "RelatedNodeInfo"}}, "text": "So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down . ", "start_char_idx": 1502, "end_char_idx": 1652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ebee5d1-ac00-455b-ad3e-58a8ec7b6f46": {"__data__": {"id_": "0ebee5d1-ac00-455b-ad3e-58a8ec7b6f46", "embedding": null, "metadata": {"window": "So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind . ", "original_text": "So \nthere's - depends on if we're talking sequential or year -over-year.  ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fc1dd9f-8a58-471a-aef0-75cf2afaabdf", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah, if I understo od the question right, Jailendra, the - I think I'd answered before, but \nI'll go and repeat that .  So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there . ", "original_text": "So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "162db3d45166a8cf12d4225f839aab6135e77ab397c4b6f375e985d4910f99d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29be5e65-ab08-4ad6-80b3-817174ca9e68", "node_type": "1", "metadata": {"window": "Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant . ", "original_text": "From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue . "}, "hash": "8917aa58de6c460c835f229a9698ec88414a31e1642f20d2f8d5b278f7571ee2", "class_name": "RelatedNodeInfo"}}, "text": "So \nthere's - depends on if we're talking sequential or year -over-year.  ", "start_char_idx": 1652, "end_char_idx": 1726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29be5e65-ab08-4ad6-80b3-817174ca9e68": {"__data__": {"id_": "29be5e65-ab08-4ad6-80b3-817174ca9e68", "embedding": null, "metadata": {"window": "Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant . ", "original_text": "From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ebee5d1-ac00-455b-ad3e-58a8ec7b6f46", "node_type": "1", "metadata": {"window": "So the $250 to $300 , $100 million was - has already been incurred in the first \nhalf.  Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind . ", "original_text": "So \nthere's - depends on if we're talking sequential or year -over-year.  ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffc919f2c30d835f0e9a32cd1766425e4b5d33b5070d4ad8fdcf0aff280cd0e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c83568f4-0774-45d0-9a07-fdd629e0f2c4", "node_type": "1", "metadata": {"window": "So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact . ", "original_text": "Those initiatives we've talked fairly consistently about are there . "}, "hash": "a702223e3fab2dc677554a97cb509f0faf9c0a5e83cda5edae7fe205d157ff05", "class_name": "RelatedNodeInfo"}}, "text": "From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue . ", "start_char_idx": 1726, "end_char_idx": 1893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c83568f4-0774-45d0-9a07-fdd629e0f2c4": {"__data__": {"id_": "c83568f4-0774-45d0-9a07-fdd629e0f2c4", "embedding": null, "metadata": {"window": "So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact . ", "original_text": "Those initiatives we've talked fairly consistently about are there . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29be5e65-ab08-4ad6-80b3-817174ca9e68", "node_type": "1", "metadata": {"window": "Think about it as kind of a sequential step up .  So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant . ", "original_text": "From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6817b70e743f0f023ab1ca1fbc7e86c4f5f1dc36582d60cfeccd73237f98f076", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48393774-05b1-4a04-b804-6baace95b30c", "node_type": "1", "metadata": {"window": "So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n", "original_text": "Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind . "}, "hash": "f928912f974bf47b3ab4bb292a0b6f769ad9c15f509465849c5ca57304f5f1f3", "class_name": "RelatedNodeInfo"}}, "text": "Those initiatives we've talked fairly consistently about are there . ", "start_char_idx": 1893, "end_char_idx": 1962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48393774-05b1-4a04-b804-6baace95b30c": {"__data__": {"id_": "48393774-05b1-4a04-b804-6baace95b30c", "embedding": null, "metadata": {"window": "So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n", "original_text": "Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c83568f4-0774-45d0-9a07-fdd629e0f2c4", "node_type": "1", "metadata": {"window": "So Q2 is higher than Q1 a nd Q3 is expected to be \nhigher than Q2, and then it - then that's the period it peaks before it starts to come back down .  So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact . ", "original_text": "Those initiatives we've talked fairly consistently about are there . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67659f2be39e5b1c1139087f6ad12430eccb1c964ca7a382d8ff52a69f5d8e4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35525356-dc0d-48c8-b6a3-5eccec355b75", "node_type": "1", "metadata": {"window": "From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 . ", "original_text": "There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant . "}, "hash": "4435e91035db2064897040ac53c0ab9d08459144ae3a45655b6f4dda601ca00e", "class_name": "RelatedNodeInfo"}}, "text": "Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind . ", "start_char_idx": 1962, "end_char_idx": 2101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35525356-dc0d-48c8-b6a3-5eccec355b75": {"__data__": {"id_": "35525356-dc0d-48c8-b6a3-5eccec355b75", "embedding": null, "metadata": {"window": "From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 . ", "original_text": "There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48393774-05b1-4a04-b804-6baace95b30c", "node_type": "1", "metadata": {"window": "So \nthere's - depends on if we're talking sequential or year -over-year.   From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n", "original_text": "Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bca754988c6522216aad3c3108e30d55e6e98f0ad135ea5a2ecd3c5c815988c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7fee178-262f-412e-afac-cce1615417b1", "node_type": "1", "metadata": {"window": "Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions . ", "original_text": "But generally speaking, \nit's the inflationary impact . "}, "hash": "a75025af2d5e29e416ae001ef53d0389e4feaff0c8cde3f4343e7d6022a69be5", "class_name": "RelatedNodeInfo"}}, "text": "There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant . ", "start_char_idx": 2101, "end_char_idx": 2270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7fee178-262f-412e-afac-cce1615417b1": {"__data__": {"id_": "e7fee178-262f-412e-afac-cce1615417b1", "embedding": null, "metadata": {"window": "Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions . ", "original_text": "But generally speaking, \nit's the inflationary impact . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35525356-dc0d-48c8-b6a3-5eccec355b75", "node_type": "1", "metadata": {"window": "From a sequential perspective from \nQ2 to Q3 , within the Medical  business there's just the ongoing cost that we would expect to be always \nin place, that continue .  Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 . ", "original_text": "There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94eb777198b923d73fa473dff1461ffed6731cc9f41d88ab0087c870c2cb1ebb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccbf56b9-a0b8-43a0-a513-f4ce6215f4bf", "node_type": "1", "metadata": {"window": "Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those . ", "original_text": "So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n"}, "hash": "23e6253271d82257c9fd3e67437ecace6952ca87994e044d14b00a38d18b393f", "class_name": "RelatedNodeInfo"}}, "text": "But generally speaking, \nit's the inflationary impact . ", "start_char_idx": 2270, "end_char_idx": 2326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccbf56b9-a0b8-43a0-a513-f4ce6215f4bf": {"__data__": {"id_": "ccbf56b9-a0b8-43a0-a513-f4ce6215f4bf", "embedding": null, "metadata": {"window": "Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those . ", "original_text": "So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7fee178-262f-412e-afac-cce1615417b1", "node_type": "1", "metadata": {"window": "Those initiatives we've talked fairly consistently about are there .  Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions . ", "original_text": "But generally speaking, \nit's the inflationary impact . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "748f96c9e35a9a077c518de9326eb43eaa9095aaf2a5f551c16528227d1e995e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdddc7b8-c3ab-4a60-a866-db9e6e3bf135", "node_type": "1", "metadata": {"window": "There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.  ", "original_text": "Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 . "}, "hash": "86624a9147689050b9897af14e354ee43f8f4b3ebfe56a458216e0600585d699", "class_name": "RelatedNodeInfo"}}, "text": "So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n", "start_char_idx": 2326, "end_char_idx": 2450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdddc7b8-c3ab-4a60-a866-db9e6e3bf135": {"__data__": {"id_": "fdddc7b8-c3ab-4a60-a866-db9e6e3bf135", "embedding": null, "metadata": {"window": "There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.  ", "original_text": "Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccbf56b9-a0b8-43a0-a513-f4ce6215f4bf", "node_type": "1", "metadata": {"window": "Within the \nother type of PPE impacts, like I said from a year -to-year perspective in the second quarter , it was \n$60 million headwind .  There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those . ", "original_text": "So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7a156e85d06cef08e355d38cab64bf57c0694bfa203bf78274e285ca1c8e4a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3280658-e1a3-4022-a8c7-34e09e865af0", "node_type": "1", "metadata": {"window": "But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n", "original_text": "We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions . "}, "hash": "41a3db35cc345bfcbf52a5fe3a2524fe58bb863def00b5e7310dd3bed1c72c83", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 . ", "start_char_idx": 2450, "end_char_idx": 2669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3280658-e1a3-4022-a8c7-34e09e865af0": {"__data__": {"id_": "c3280658-e1a3-4022-a8c7-34e09e865af0", "embedding": null, "metadata": {"window": "But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n", "original_text": "We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdddc7b8-c3ab-4a60-a866-db9e6e3bf135", "node_type": "1", "metadata": {"window": "There was a small headwind in an absolute basis in the second quarter that we \nthink will be less in the third quarter , so that's a bit of an offset, not significant .  But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.  ", "original_text": "Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d62615ac21bc70e47dc8da269c2cf5e66047951566374024113ce0196970141", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de68868f-8c8a-46c6-9a35-08fb243dea44", "node_type": "1", "metadata": {"window": "So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way . ", "original_text": "We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those . "}, "hash": "d175d551f4675fdc324fd5928e0faef47669d95f36786fba0347cc97f3d1734e", "class_name": "RelatedNodeInfo"}}, "text": "We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions . ", "start_char_idx": 2669, "end_char_idx": 2798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de68868f-8c8a-46c6-9a35-08fb243dea44": {"__data__": {"id_": "de68868f-8c8a-46c6-9a35-08fb243dea44", "embedding": null, "metadata": {"window": "So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way . ", "original_text": "We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3280658-e1a3-4022-a8c7-34e09e865af0", "node_type": "1", "metadata": {"window": "But generally speaking, \nit's the inflationary impact .  So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n", "original_text": "We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f49c759324331f16c7d48734b7f8f53ce9efd06c5a528a5bdabd9447ed51fb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2be6c45-5c6f-4390-9637-72cedf94b162", "node_type": "1", "metadata": {"window": "Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind . ", "original_text": "So I would say that that would be a positive item \ngoing forward for us.  "}, "hash": "527b5a92ffad17cf0f47193c7f45a2e92ef2aa6304072db4d46e2ae9e0980f42", "class_name": "RelatedNodeInfo"}}, "text": "We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those . ", "start_char_idx": 2798, "end_char_idx": 2908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2be6c45-5c6f-4390-9637-72cedf94b162": {"__data__": {"id_": "e2be6c45-5c6f-4390-9637-72cedf94b162", "embedding": null, "metadata": {"window": "Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind . ", "original_text": "So I would say that that would be a positive item \ngoing forward for us.  ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de68868f-8c8a-46c6-9a35-08fb243dea44", "node_type": "1", "metadata": {"window": "So the most pronounced from a year -to-year, as well as expected to be a \nlittle bit greater than in the third quarter.  \n \n Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way . ", "original_text": "We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc0ce72db34a049acba3245e727e8367fb130d9d88b4b99a3fe6030f9c7d9429", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4ebb2a2-e3dd-4c1b-94a8-acac6682bf5b", "node_type": "1", "metadata": {"window": "We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n", "original_text": "Also, as we mentioned, are working on our commercial contracting strategies . \n"}, "hash": "ee97bce83f7b7c1b67f39fcbc651cd2416a09533e21b3ea4b328f2c254a1a0b0", "class_name": "RelatedNodeInfo"}}, "text": "So I would say that that would be a positive item \ngoing forward for us.  ", "start_char_idx": 2908, "end_char_idx": 2982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4ebb2a2-e3dd-4c1b-94a8-acac6682bf5b": {"__data__": {"id_": "f4ebb2a2-e3dd-4c1b-94a8-acac6682bf5b", "embedding": null, "metadata": {"window": "We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n", "original_text": "Also, as we mentioned, are working on our commercial contracting strategies . \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2be6c45-5c6f-4390-9637-72cedf94b162", "node_type": "1", "metadata": {"window": "Mike Kaufmann:   The things I would add to be helpful here is, as Jason mentioned, as we expect \nsome of the inflation  impacts to start to hopefully come down some, and that'll give us a little bit of \nbenefit in Q4 .  We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind . ", "original_text": "So I would say that that would be a positive item \ngoing forward for us.  ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d3e68f59532cc07c318b8ae414965c68b6834fdc9bbbb2c16d1af4ec29cf0fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8440062c-68ff-47cc-83c9-bdcfc30835f1", "node_type": "1", "metadata": {"window": "We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way . "}, "hash": "cdb0faa8b419354c5179211f475743f837a287ddab5d6dfe9e5736f6f0bb5793", "class_name": "RelatedNodeInfo"}}, "text": "Also, as we mentioned, are working on our commercial contracting strategies . \n", "start_char_idx": 2982, "end_char_idx": 3061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8440062c-68ff-47cc-83c9-bdcfc30835f1": {"__data__": {"id_": "8440062c-68ff-47cc-83c9-bdcfc30835f1", "embedding": null, "metadata": {"window": "We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4ebb2a2-e3dd-4c1b-94a8-acac6682bf5b", "node_type": "1", "metadata": {"window": "We also see our pricing actions ramping up some in Q4 too , because we are continuing \nto implement additional pricing actions .  We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n", "original_text": "Also, as we mentioned, are working on our commercial contracting strategies . \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb76bf7ab272eaa3fc990e4044c1faa4704b98d1a040553bb209af0ac6f5a3c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2ce6169-6ace-432a-bf70-eb135c71e5da", "node_type": "1", "metadata": {"window": "So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "Because our customers are obviously \nsome thing  that we have to always have in the front of our mind . "}, "hash": "1ab506668ea8c2ff675f90685865dcc6eb89d0ab60c39a9302de6e374d6f2290", "class_name": "RelatedNodeInfo"}}, "text": "And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way . ", "start_char_idx": 3061, "end_char_idx": 3333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2ce6169-6ace-432a-bf70-eb135c71e5da": {"__data__": {"id_": "d2ce6169-6ace-432a-bf70-eb135c71e5da", "embedding": null, "metadata": {"window": "So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "Because our customers are obviously \nsome thing  that we have to always have in the front of our mind . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8440062c-68ff-47cc-83c9-bdcfc30835f1", "node_type": "1", "metadata": {"window": "We have some going into effect h ere very soon , that have \nbeen agreed to , so we're working through those .  So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "090493d4a31bfb953f935487466ab05c9d9967b6c011674d84a5e696fb5dd160", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96337448-f128-4180-9bd9-69050e746959", "node_type": "1", "metadata": {"window": "Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n"}, "hash": "a478a394b984fff1c7d6fdb0f69ccbbe2e8b3d3b942533dffd4a4602b0f36212", "class_name": "RelatedNodeInfo"}}, "text": "Because our customers are obviously \nsome thing  that we have to always have in the front of our mind . ", "start_char_idx": 3333, "end_char_idx": 3437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96337448-f128-4180-9bd9-69050e746959": {"__data__": {"id_": "96337448-f128-4180-9bd9-69050e746959", "embedding": null, "metadata": {"window": "Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2ce6169-6ace-432a-bf70-eb135c71e5da", "node_type": "1", "metadata": {"window": "So I would say that that would be a positive item \ngoing forward for us.   Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "Because our customers are obviously \nsome thing  that we have to always have in the front of our mind . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0db8d1cfec7e95e60abbfdd5d8459045e42904e27b524e82b522190ecb09b15e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e7a0334-cc8f-4da8-82ae-a4e121beebce", "node_type": "1", "metadata": {"window": "And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  "}, "hash": "e47b3bfb634ec0ebb42072e4876bb2b494f59c83f50a3411ac54c86c56bf4081", "class_name": "RelatedNodeInfo"}}, "text": "But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n", "start_char_idx": 3437, "end_char_idx": 3580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e7a0334-cc8f-4da8-82ae-a4e121beebce": {"__data__": {"id_": "7e7a0334-cc8f-4da8-82ae-a4e121beebce", "embedding": null, "metadata": {"window": "And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af6def2d21b439a3419ba5a48d58d58330aa40b0ebcc88841def0d2769686598", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96337448-f128-4180-9bd9-69050e746959", "node_type": "1", "metadata": {"window": "Also, as we mentioned, are working on our commercial contracting strategies . \n And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ed7f7d3af92bb68654896f6e062ebda7eb1837894904412a65b7a6d23be05fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b3584d3-9b8b-4adc-b92a-fde80a16190d", "node_type": "1", "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details . ", "original_text": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica . "}, "hash": "dac2eebbee83ba55af6fef4fa598fd47e6a23cbcd3a82e1bad964a5863424d87", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "start_char_idx": 3580, "end_char_idx": 3806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b3584d3-9b8b-4adc-b92a-fde80a16190d": {"__data__": {"id_": "5b3584d3-9b8b-4adc-b92a-fde80a16190d", "embedding": null, "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details . ", "original_text": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e7a0334-cc8f-4da8-82ae-a4e121beebce", "node_type": "1", "metadata": {"window": "And so as we work through those co ntracts, our goal is to give us more flexibility so that in the future, \nif there is another instance like this, we are able to react quicker and address our pricing and work \nwith our partners in a very transparent and productive way .  Because our customers are obviously \nsome thing  that we have to always have in the front of our mind .  But we do need some more flexibility \nin the business, and we are working aggressively to work with the GPOs and our customers to do \nthat. \n \n Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "original_text": "Jason Hollar:    And Jailendra as you do  your modeling for the balance year, just remember in the prior \nyear, we had a significant inventory charge in Q4 that would, of course, not be expected to replicate \nhere this year.  ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af18cdcdafe3eea76969caea20dbe0cc9fbf11184d085a903ee6b5c04dfb1f18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "477ef5d9-fd5f-413c-b33e-6fd8d48b6438", "node_type": "1", "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side . ", "original_text": "Please go ahead.  \n \n"}, "hash": "eccbd131bc1db4741a0667aca6cf017a354ef49decb642a3fc1c99e3d9b056e6", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica . ", "start_char_idx": 0, "end_char_idx": 132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "477ef5d9-fd5f-413c-b33e-6fd8d48b6438": {"__data__": {"id_": "477ef5d9-fd5f-413c-b33e-6fd8d48b6438", "embedding": null, "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side . ", "original_text": "Please go ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b3584d3-9b8b-4adc-b92a-fde80a16190d", "node_type": "1", "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details . ", "original_text": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e872544d51f40b2ae3efaee4f5f09ce13eca7027800cff8c996cc5b4440de1af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a663665-f06b-41f9-ae17-3436c447a0fb", "node_type": "1", "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?  ", "original_text": "Michael  Cherny :  Good morning . "}, "hash": "cfe414273d43eeb5a13c5df13ecb707091868c16219b13381a49c1e7051c4b8e", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 132, "end_char_idx": 153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a663665-f06b-41f9-ae17-3436c447a0fb": {"__data__": {"id_": "8a663665-f06b-41f9-ae17-3436c447a0fb", "embedding": null, "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?  ", "original_text": "Michael  Cherny :  Good morning . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "477ef5d9-fd5f-413c-b33e-6fd8d48b6438", "node_type": "1", "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side . ", "original_text": "Please go ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea5f81226de4b2ed3c14df61a92cc70ad805fd40d95bdb797ebc624ef7bf9fb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9efd74a8-dcd4-4063-a7f7-114eaa925a9e", "node_type": "1", "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n", "original_text": "Thanks for the details . "}, "hash": "0403524f688c38d78a33a80139b3dea514ff3c050231fdf1754c0b77d4e2eff4", "class_name": "RelatedNodeInfo"}}, "text": "Michael  Cherny :  Good morning . ", "start_char_idx": 153, "end_char_idx": 187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9efd74a8-dcd4-4063-a7f7-114eaa925a9e": {"__data__": {"id_": "9efd74a8-dcd4-4063-a7f7-114eaa925a9e", "embedding": null, "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n", "original_text": "Thanks for the details . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a663665-f06b-41f9-ae17-3436c447a0fb", "node_type": "1", "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?  ", "original_text": "Michael  Cherny :  Good morning . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3280ec50d0a78f3f625724b666bd8c13398f53a84e8dc16234d867fcbc67c0b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d55238ee-4d9f-4e10-9c8b-d7c1c71a11e2", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question . ", "original_text": "Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side . "}, "hash": "5e3944d7c717a3e755fbbf48f695435e9daa0b9fdd0ff16bd7ef715718803880", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the details . ", "start_char_idx": 187, "end_char_idx": 212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d55238ee-4d9f-4e10-9c8b-d7c1c71a11e2": {"__data__": {"id_": "d55238ee-4d9f-4e10-9c8b-d7c1c71a11e2", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question . ", "original_text": "Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9efd74a8-dcd4-4063-a7f7-114eaa925a9e", "node_type": "1", "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n", "original_text": "Thanks for the details . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77eb5ef89011403e4755148758f9210b1550506c0b0792176c98778b68668648", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64cfbdbd-7fa7-454d-947e-d0cabb098a54", "node_type": "1", "metadata": {"window": "Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that . ", "original_text": "Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?  "}, "hash": "6630792be1e364248dd54d277c7e00e8721e927363bd0bc8f7f6373d26235c5b", "class_name": "RelatedNodeInfo"}}, "text": "Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side . ", "start_char_idx": 212, "end_char_idx": 338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64cfbdbd-7fa7-454d-947e-d0cabb098a54": {"__data__": {"id_": "64cfbdbd-7fa7-454d-947e-d0cabb098a54", "embedding": null, "metadata": {"window": "Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that . ", "original_text": "Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?  ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d55238ee-4d9f-4e10-9c8b-d7c1c71a11e2", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question . ", "original_text": "Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "147b596c873b5e01c6b7e2538df8556f69c8428c2544431580eb83241ec9b0d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0a70d93-a4bd-47cd-8255-01c1a42d2c47", "node_type": "1", "metadata": {"window": "Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers . ", "original_text": "What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n"}, "hash": "45f17ff65949aaca7b42ea3cac10edc3718e254818574c1e08453a298b19ce59", "class_name": "RelatedNodeInfo"}}, "text": "Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?  ", "start_char_idx": 338, "end_char_idx": 576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0a70d93-a4bd-47cd-8255-01c1a42d2c47": {"__data__": {"id_": "f0a70d93-a4bd-47cd-8255-01c1a42d2c47", "embedding": null, "metadata": {"window": "Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers . ", "original_text": "What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64cfbdbd-7fa7-454d-947e-d0cabb098a54", "node_type": "1", "metadata": {"window": "Michael  Cherny :  Good morning .  Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that . ", "original_text": "Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?  ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2ff498975d0461f931ccfd7395184335618f8af214d9aec33c999a294924654", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d1882ed-e5c3-49d6-af7c-3513d0217ba8", "node_type": "1", "metadata": {"window": "Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them . ", "original_text": "Mike Kaufmann:   That's a great question . "}, "hash": "d8d0c294fed8220c6a9242c3478cc129d2dd40b456baed78eea9bb5717a0c434", "class_name": "RelatedNodeInfo"}}, "text": "What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n", "start_char_idx": 576, "end_char_idx": 854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d1882ed-e5c3-49d6-af7c-3513d0217ba8": {"__data__": {"id_": "3d1882ed-e5c3-49d6-af7c-3513d0217ba8", "embedding": null, "metadata": {"window": "Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them . ", "original_text": "Mike Kaufmann:   That's a great question . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0a70d93-a4bd-47cd-8255-01c1a42d2c47", "node_type": "1", "metadata": {"window": "Thanks for the details .  Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers . ", "original_text": "What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66c19726453283a673f69c1e5ac458a5eca7fdc2c31522773c062704e455ed2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c880aab-49a5-4079-a799-43e8078dd9a9", "node_type": "1", "metadata": {"window": "Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.  ", "original_text": "Yeah, we  are working aggressively on that . "}, "hash": "f03acda113440393d25c11f9f71ecc56372e273f967d7bca0a0fdde2d26c038f", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:   That's a great question . ", "start_char_idx": 854, "end_char_idx": 897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c880aab-49a5-4079-a799-43e8078dd9a9": {"__data__": {"id_": "3c880aab-49a5-4079-a799-43e8078dd9a9", "embedding": null, "metadata": {"window": "Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.  ", "original_text": "Yeah, we  are working aggressively on that . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d1882ed-e5c3-49d6-af7c-3513d0217ba8", "node_type": "1", "metadata": {"window": "Mike, you mentioned your remarks how you \nhad a few customer extensions with some of your key customers on the Medical side .  Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them . ", "original_text": "Mike Kaufmann:   That's a great question . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77f7e1c94a59b0acce12ced0148a69a1f7c202faa0856b2ab281375a772d70a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "817ecabd-73bf-4a33-8a03-f1a08847ef9a", "node_type": "1", "metadata": {"window": "What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?  ", "original_text": "It's not just the \nindividual customers . "}, "hash": "bb6508ccffab7fbf6c952e0dff6e0fe721bf8206d8b091f36f7b8cf3bbe5337c", "class_name": "RelatedNodeInfo"}}, "text": "Yeah, we  are working aggressively on that . ", "start_char_idx": 897, "end_char_idx": 942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "817ecabd-73bf-4a33-8a03-f1a08847ef9a": {"__data__": {"id_": "817ecabd-73bf-4a33-8a03-f1a08847ef9a", "embedding": null, "metadata": {"window": "What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?  ", "original_text": "It's not just the \nindividual customers . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c880aab-49a5-4079-a799-43e8078dd9a9", "node_type": "1", "metadata": {"window": "Especially \nagainst this bac kdrop of your focus on recontracting, would love to know a little more detail about how \nqualitatively those discussions went in terms of your thought presses about recontracting, were you \nable to test out?   What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.  ", "original_text": "Yeah, we  are working aggressively on that . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d47a4e39427642163f61ae5db924d56eeb65467085fe9a69743a7035509755", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c7cbd7e-d1d2-4103-bf95-9f35253d6f55", "node_type": "1", "metadata": {"window": "Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n", "original_text": "In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them . "}, "hash": "48e005bef20cf7cad2b677a5f22c0156004455ca887bfa6a3fb9bfaf80e916f6", "class_name": "RelatedNodeInfo"}}, "text": "It's not just the \nindividual customers . ", "start_char_idx": 942, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c7cbd7e-d1d2-4103-bf95-9f35253d6f55": {"__data__": {"id_": "5c7cbd7e-d1d2-4103-bf95-9f35253d6f55", "embedding": null, "metadata": {"window": "Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n", "original_text": "In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "817ecabd-73bf-4a33-8a03-f1a08847ef9a", "node_type": "1", "metadata": {"window": "What you were able to get through and not get thr ough, and what customers were \nwilling to accept relative to that change contracting dynamic, especially given that these are obviously \nextensions on customers that have worked with you, I assume, for at least a long time.  \n \n Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?  ", "original_text": "It's not just the \nindividual customers . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c41574eba9d4379d9cbc7b79b65cf23b399ecb52046196739ace6d4aa8e089b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09f30da6-22df-4319-abcc-b15efc440203", "node_type": "1", "metadata": {"window": "Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint . ", "original_text": "So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.  "}, "hash": "c201179471a15ebdd5d5ff04e51fda81377f222be696022c6036130646c66111", "class_name": "RelatedNodeInfo"}}, "text": "In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them . ", "start_char_idx": 984, "end_char_idx": 1137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09f30da6-22df-4319-abcc-b15efc440203": {"__data__": {"id_": "09f30da6-22df-4319-abcc-b15efc440203", "embedding": null, "metadata": {"window": "Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint . ", "original_text": "So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.  ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c7cbd7e-d1d2-4103-bf95-9f35253d6f55", "node_type": "1", "metadata": {"window": "Mike Kaufmann:   That's a great question .  Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n", "original_text": "In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16075495f27bf3461164c730de2ed54512731371751891c9b3f94ba0dc726fd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed0de57d-b1fa-4823-b259-473492f54da8", "node_type": "1", "metadata": {"window": "It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n", "original_text": "Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?  "}, "hash": "729c2be2a51bc11bf36400ed2a230d696c7506454e8d47b6eefe24b7a9d2da46", "class_name": "RelatedNodeInfo"}}, "text": "So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.  ", "start_char_idx": 1137, "end_char_idx": 1452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed0de57d-b1fa-4823-b259-473492f54da8": {"__data__": {"id_": "ed0de57d-b1fa-4823-b259-473492f54da8", "embedding": null, "metadata": {"window": "It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n", "original_text": "Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?  ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09f30da6-22df-4319-abcc-b15efc440203", "node_type": "1", "metadata": {"window": "Yeah, we  are working aggressively on that .  It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint . ", "original_text": "So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.  ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "499f5b4875550afd8398a68bbb07f0b74d298d304a9533b327df6a5b9c88b1d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c662fd7-7996-4f63-869f-6f3f4ef79322", "node_type": "1", "metadata": {"window": "In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore . ", "original_text": "But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n"}, "hash": "a68987c19e0ee6957f19cd60e8449bbacef2d6070486f206e0b62f62746f68c4", "class_name": "RelatedNodeInfo"}}, "text": "Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?  ", "start_char_idx": 1452, "end_char_idx": 1648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c662fd7-7996-4f63-869f-6f3f4ef79322": {"__data__": {"id_": "0c662fd7-7996-4f63-869f-6f3f4ef79322", "embedding": null, "metadata": {"window": "In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore . ", "original_text": "But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed0de57d-b1fa-4823-b259-473492f54da8", "node_type": "1", "metadata": {"window": "It's not just the \nindividual customers .  In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n", "original_text": "Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?  ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89ad68037f0b98f9b01e200e69f39a050c19b8890109534ae2fc09c0abf437a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67319be8-de99-4f08-a884-4ffae21c90c9", "node_type": "1", "metadata": {"window": "So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n", "original_text": "And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint . "}, "hash": "9b4b1d4c596aebb6c8bff1eef5a2ab19ca92ca8cfd4d72d749cdf6819d9b5aea", "class_name": "RelatedNodeInfo"}}, "text": "But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n", "start_char_idx": 1648, "end_char_idx": 1779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67319be8-de99-4f08-a884-4ffae21c90c9": {"__data__": {"id_": "67319be8-de99-4f08-a884-4ffae21c90c9", "embedding": null, "metadata": {"window": "So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n", "original_text": "And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c662fd7-7996-4f63-869f-6f3f4ef79322", "node_type": "1", "metadata": {"window": "In fact, it's just as important to be able to work with our GPO partners to allow \nus, because you really have to coordinate between all three of them .  So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore . ", "original_text": "But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e632d2a9bbd57d0de2258c92e79dd479a0029451b21810a5a48d9b94c463897b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da4756d7-8c0d-4b1c-9795-1a02404eb7ed", "node_type": "1", "metadata": {"window": "Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys . ", "original_text": "So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n"}, "hash": "be2741cc46e24ec39811729df5835ae092e2500c7643ab034e8104c24c5b97f5", "class_name": "RelatedNodeInfo"}}, "text": "And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint . ", "start_char_idx": 1779, "end_char_idx": 1968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da4756d7-8c0d-4b1c-9795-1a02404eb7ed": {"__data__": {"id_": "da4756d7-8c0d-4b1c-9795-1a02404eb7ed", "embedding": null, "metadata": {"window": "Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys . ", "original_text": "So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67319be8-de99-4f08-a884-4ffae21c90c9", "node_type": "1", "metadata": {"window": "So the re's still absolutely work to \ndo, but we're seeing some positive signs from both the GPOs and the customers that understand the \nimportance of having a strong supply chain and strong supply chain partners in the - in Medical \ndistribution, that these are thi ngs that we're going to have to work together.   Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n", "original_text": "And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e36d0391040e467fde06ae71f0aa5d6ec14946ad35c43f5687fbf47dd414351", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5a66642-d5b2-4c03-891d-de07dd0fbe9f", "node_type": "1", "metadata": {"window": "But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question . ", "original_text": "Operator:   And our last question comes from Elizabeth Anderson with Evercore . "}, "hash": "5d2703c17fcd59240e9c1e973d9acec80c9785b873b69430810e0c5935a0d405", "class_name": "RelatedNodeInfo"}}, "text": "So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n", "start_char_idx": 1968, "end_char_idx": 2107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5a66642-d5b2-4c03-891d-de07dd0fbe9f": {"__data__": {"id_": "f5a66642-d5b2-4c03-891d-de07dd0fbe9f", "embedding": null, "metadata": {"window": "But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question . ", "original_text": "Operator:   And our last question comes from Elizabeth Anderson with Evercore . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da4756d7-8c0d-4b1c-9795-1a02404eb7ed", "node_type": "1", "metadata": {"window": "Key things that we've \nlearned through those discussions that will be helpful is, one, a willingness to be transparent with \nthem so that they understand as costs come up, why are they going up?   But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys . ", "original_text": "So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7070c65ba3163321a50320534c14ad0af916a73770909cb46ddb12d8f83fd2cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e7e4520-e385-4509-b7d2-7918517d1ad8", "node_type": "1", "metadata": {"window": "And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back . ", "original_text": "Please go ahead.  \n \n"}, "hash": "c6db0c7f53c29a5a436766c59768aef1c44d82a67b97286d3515962c009a298a", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   And our last question comes from Elizabeth Anderson with Evercore . ", "start_char_idx": 2107, "end_char_idx": 2187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e7e4520-e385-4509-b7d2-7918517d1ad8": {"__data__": {"id_": "9e7e4520-e385-4509-b7d2-7918517d1ad8", "embedding": null, "metadata": {"window": "And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back . ", "original_text": "Please go ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5a66642-d5b2-4c03-891d-de07dd0fbe9f", "node_type": "1", "metadata": {"window": "But also when c osts come \ndown so that they know that you're not continuing to charge a high price when things have got better . \n And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question . ", "original_text": "Operator:   And our last question comes from Elizabeth Anderson with Evercore . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bff930118e8d090f4e528b0088cfe5c5728edaabbd215ed89245d2fbe6fa4a1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af88e9ec-f419-481f-9cb8-fd91f7d83952", "node_type": "1", "metadata": {"window": "So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n", "original_text": "Elizabeth Anderson:    Hi guys . "}, "hash": "59feee79ce8cb791bd4ab5b56db1a9bca2d54ed4830729e1f88f2013e0be95d0", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 132, "end_char_idx": 153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af88e9ec-f419-481f-9cb8-fd91f7d83952": {"__data__": {"id_": "af88e9ec-f419-481f-9cb8-fd91f7d83952", "embedding": null, "metadata": {"window": "So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n", "original_text": "Elizabeth Anderson:    Hi guys . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e7e4520-e385-4509-b7d2-7918517d1ad8", "node_type": "1", "metadata": {"window": "And we're very willing to work with them on this transparency piece, which I think will help both parties \nunderstand the importance of what we n eed to do here from a pricing standpoint .  So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back . ", "original_text": "Please go ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2a0a5fe473a3603d5823ab5b82901f4ce2d442a7da380718f4a7bf305a519c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bcc3176-d3c7-4bae-a302-9ce001a97e42", "node_type": "1", "metadata": {"window": "Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah . ", "original_text": "Thanks so much for the question . "}, "hash": "f94fe988c937d647b89884775f490214e6097c84858423826a40a73fb8dc87f2", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson:    Hi guys . ", "start_char_idx": 2208, "end_char_idx": 2241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bcc3176-d3c7-4bae-a302-9ce001a97e42": {"__data__": {"id_": "1bcc3176-d3c7-4bae-a302-9ce001a97e42", "embedding": null, "metadata": {"window": "Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah . ", "original_text": "Thanks so much for the question . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af88e9ec-f419-481f-9cb8-fd91f7d83952", "node_type": "1", "metadata": {"window": "So I would say early \nindications have been positive, but still a lot of work to do as we work on changing our commercial \nstrategies.  \n \n Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n", "original_text": "Elizabeth Anderson:    Hi guys . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62dce944527dba70f60ebeeb5248c99ebf9a53e395413472efdebf80ee450c7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6353a08-304a-4382-95df-6ad18c311f4a", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same . ", "original_text": "I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back . "}, "hash": "02e76c0d9c9dc7aac463fce4de73dc4413ccec2815f2b0cfccb46e9e606d2563", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question . ", "start_char_idx": 2241, "end_char_idx": 2275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6353a08-304a-4382-95df-6ad18c311f4a": {"__data__": {"id_": "c6353a08-304a-4382-95df-6ad18c311f4a", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same . ", "original_text": "I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bcc3176-d3c7-4bae-a302-9ce001a97e42", "node_type": "1", "metadata": {"window": "Operator:   And our last question comes from Elizabeth Anderson with Evercore .  Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah . ", "original_text": "Thanks so much for the question . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "041589447aefc680787807d1b394956ca687bfa5d3269eacfdc3359c1adb6bf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a95b8af-cec1-49a8-b63e-c54eb0de905f", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations . ", "original_text": "Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n"}, "hash": "fd2e119646c8af73a40f92e6f10468afe754f7b74545482a0d84b4b8e7479989", "class_name": "RelatedNodeInfo"}}, "text": "I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back . ", "start_char_idx": 2275, "end_char_idx": 2429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a95b8af-cec1-49a8-b63e-c54eb0de905f": {"__data__": {"id_": "9a95b8af-cec1-49a8-b63e-c54eb0de905f", "embedding": null, "metadata": {"window": "Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations . ", "original_text": "Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6353a08-304a-4382-95df-6ad18c311f4a", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same . ", "original_text": "I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3dc036a4f336d798d89fbfa286b12d4621a81c68f858425e0ddb45094c49823a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0ca695a-ed8a-4795-9bec-c635a37d9540", "node_type": "1", "metadata": {"window": "Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels . ", "original_text": "Jason Hollar:   Yeah . "}, "hash": "190ec1771798c80dcdeb69f4fab3697536f7c6c816bba221a8211700bded6674", "class_name": "RelatedNodeInfo"}}, "text": "Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n", "start_char_idx": 2429, "end_char_idx": 2593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0ca695a-ed8a-4795-9bec-c635a37d9540": {"__data__": {"id_": "c0ca695a-ed8a-4795-9bec-c635a37d9540", "embedding": null, "metadata": {"window": "Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels . ", "original_text": "Jason Hollar:   Yeah . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a95b8af-cec1-49a8-b63e-c54eb0de905f", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:    Hi guys .  Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations . ", "original_text": "Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04c8add939c970e93d68ff8482b8784ef1fda0f2d7ef264e7e90bd83499d2b31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3ed4f66-a831-4a1a-b523-85daa49d2afd", "node_type": "1", "metadata": {"window": "I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences . ", "original_text": "And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same . "}, "hash": "360350e39f3ced4e5d9207a59be5a6c510305e5587630c5980fa61557c4efad4", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:   Yeah . ", "start_char_idx": 2593, "end_char_idx": 2616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3ed4f66-a831-4a1a-b523-85daa49d2afd": {"__data__": {"id_": "e3ed4f66-a831-4a1a-b523-85daa49d2afd", "embedding": null, "metadata": {"window": "I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences . ", "original_text": "And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0ca695a-ed8a-4795-9bec-c635a37d9540", "node_type": "1", "metadata": {"window": "Thanks so much for the question .  I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels . ", "original_text": "Jason Hollar:   Yeah . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75753925fe363f2573a4530276f271a52ce18b48ef7593db9f39a58e28bc4d69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2871197d-f858-450a-94b3-156f785288e4", "node_type": "1", "metadata": {"window": "Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts . ", "original_text": "Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations . "}, "hash": "048a66f64f8275663627e5d24084da5365ea43f0550212503253ffb5136c398d", "class_name": "RelatedNodeInfo"}}, "text": "And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same . ", "start_char_idx": 2616, "end_char_idx": 2786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2871197d-f858-450a-94b3-156f785288e4": {"__data__": {"id_": "2871197d-f858-450a-94b3-156f785288e4", "embedding": null, "metadata": {"window": "Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts . ", "original_text": "Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3ed4f66-a831-4a1a-b523-85daa49d2afd", "node_type": "1", "metadata": {"window": "I was wondering if you could \ncomment on, as we sort of have gone through a month of the new quarter, just how you're seeing sort \nof volumes come back .  Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences . ", "original_text": "And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e87f9426e48962f34424ceddbc366a0ae1f85540649b7378803e43277d8cf30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bca25f42-2f6b-477d-8451-f8a9dfa833a7", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients . ", "original_text": "We indicated before we are back to ne ar pre -COVID levels . "}, "hash": "866cbd466e22a27d59812e2b9471a88b8c6b6af6a2f6c4f982c304fd928040d6", "class_name": "RelatedNodeInfo"}}, "text": "Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations . ", "start_char_idx": 2786, "end_char_idx": 2942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bca25f42-2f6b-477d-8451-f8a9dfa833a7": {"__data__": {"id_": "bca25f42-2f6b-477d-8451-f8a9dfa833a7", "embedding": null, "metadata": {"window": "Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients . ", "original_text": "We indicated before we are back to ne ar pre -COVID levels . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2871197d-f858-450a-94b3-156f785288e4", "node_type": "1", "metadata": {"window": "Particularly on the surgi cal side and also on sort of home care, just to sort of \nwe think about the cadence for that going through the back half of the year.  \n \n Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts . ", "original_text": "Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "253c97b9635a05ea6650e16b03208ef497820cefbd12d3e5fa82e45b290c48d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ddb4a68-7280-4ebd-81dc-b54f91235fa1", "node_type": "1", "metadata": {"window": "And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences . "}, "hash": "49df26f55b67e9bec1dc05c2191b1057490b844591de3120c41845aff77380ba", "class_name": "RelatedNodeInfo"}}, "text": "We indicated before we are back to ne ar pre -COVID levels . ", "start_char_idx": 2942, "end_char_idx": 3003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ddb4a68-7280-4ebd-81dc-b54f91235fa1": {"__data__": {"id_": "3ddb4a68-7280-4ebd-81dc-b54f91235fa1", "embedding": null, "metadata": {"window": "And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bca25f42-2f6b-477d-8451-f8a9dfa833a7", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah .  And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients . ", "original_text": "We indicated before we are back to ne ar pre -COVID levels . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc6d4060401ac5309bef65a06fdb45dd9d96345cd348a751f29f3ea11271801b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa35469a-7253-44d1-85b3-73ff8b40b759", "node_type": "1", "metadata": {"window": "Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts . "}, "hash": "8e86499980bb89481cfbd0a2746f4b5f4c2c0e7c0b4fbb4e6e070c6637883588", "class_name": "RelatedNodeInfo"}}, "text": "And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences . ", "start_char_idx": 3003, "end_char_idx": 3169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa35469a-7253-44d1-85b3-73ff8b40b759": {"__data__": {"id_": "aa35469a-7253-44d1-85b3-73ff8b40b759", "embedding": null, "metadata": {"window": "Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ddb4a68-7280-4ebd-81dc-b54f91235fa1", "node_type": "1", "metadata": {"window": "And maybe I'll just take the opportunity to talk about volumes in general because \nit - I think whethe r it's Pharma or Medical, the general response is about the same .  Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40460fc79aa89b4b6c75900ac9b59134932e50bbfee445e2cf3fe7512459e941", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9951aee1-1a45-4a3b-967f-dc83d9a556cc", "node_type": "1", "metadata": {"window": "We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And that's because our customers continue to do a wonderful \njob of providing great service to their patients . "}, "hash": "84ee4c1f4c4e62a04063d616617bfe8033fbb770c2556818ec5e995dbf6aeaa4", "class_name": "RelatedNodeInfo"}}, "text": "And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts . ", "start_char_idx": 3169, "end_char_idx": 3365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9951aee1-1a45-4a3b-967f-dc83d9a556cc": {"__data__": {"id_": "9951aee1-1a45-4a3b-967f-dc83d9a556cc", "embedding": null, "metadata": {"window": "We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And that's because our customers continue to do a wonderful \njob of providing great service to their patients . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa35469a-7253-44d1-85b3-73ff8b40b759", "node_type": "1", "metadata": {"window": "Within Medical, \nwhile there's been certain level of choppiness over the last three, six months, largely it's been very \nconsistent with our expectations .  We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f75b158c3fa000ef0219f1575539bf3177380a68127ddd22db4a06a1a19dc234", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08b0c490-fd3c-4fe6-8b2e-b92e8ce6f54b", "node_type": "1", "metadata": {"window": "And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n "}, "hash": "758e0e32f0e95982120f96e2e70e9bd7330d82eab20add0878a5c8b60126a31d", "class_name": "RelatedNodeInfo"}}, "text": "And that's because our customers continue to do a wonderful \njob of providing great service to their patients . ", "start_char_idx": 3365, "end_char_idx": 3477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08b0c490-fd3c-4fe6-8b2e-b92e8ce6f54b": {"__data__": {"id_": "08b0c490-fd3c-4fe6-8b2e-b92e8ce6f54b", "embedding": null, "metadata": {"window": "And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "545701e08a8e8802cf2d65f13393c0f07b96dd27fdae0d71257705a7fdad5465", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9951aee1-1a45-4a3b-967f-dc83d9a556cc", "node_type": "1", "metadata": {"window": "We indicated before we are back to ne ar pre -COVID levels .  And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And that's because our customers continue to do a wonderful \njob of providing great service to their patients . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e565190e24731c6456ed7966bb58e11cec076cd2a0446ba19c52a8ee84eae36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb45d58e-8a9d-44e8-8207-5eee18ebeb2b", "node_type": "1", "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today . ", "original_text": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels . "}, "hash": "e05ba39969b4bd7851e8c8f461ccab2385a5359bcee41aac8c5d20499fbc9ea2", "class_name": "RelatedNodeInfo"}}, "text": "And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "start_char_idx": 3477, "end_char_idx": 3587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb45d58e-8a9d-44e8-8207-5eee18ebeb2b": {"__data__": {"id_": "bb45d58e-8a9d-44e8-8207-5eee18ebeb2b", "embedding": null, "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today . ", "original_text": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08b0c490-fd3c-4fe6-8b2e-b92e8ce6f54b", "node_type": "1", "metadata": {"window": "And this \nquarter was pretty consistent with our expectations, and sequentially, from the first quarter as well as \nyear-over-year, there were not many differences .  And so there's noise, but the key is that state -by-\nstate, geography -by-geography different regions are impacted at different times to different extent, \nbut we're just not seeing big impacts .  And that's because our customers continue to do a wonderful \njob of providing great service to their patients .  And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "original_text": "And that's providing a bett er balance underneath the \nvolume than what we saw earlier on in the pandemic.  \n ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb573b61efc44bd45eba51a726376ac261e99be924de23cbd812d0d9bca95fd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11d5b1c0-f007-4974-a6bd-b65078219561", "node_type": "1", "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n", "original_text": "And we \nhave largely gotten back to that point at the end of the second quarter . "}, "hash": "5feb95fe5a8e07de9d794ef674f23d5d165a1b462f11f677e57d0c8b2d8f58bb", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels . ", "start_char_idx": 0, "end_char_idx": 207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11d5b1c0-f007-4974-a6bd-b65078219561": {"__data__": {"id_": "11d5b1c0-f007-4974-a6bd-b65078219561", "embedding": null, "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n", "original_text": "And we \nhave largely gotten back to that point at the end of the second quarter . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb45d58e-8a9d-44e8-8207-5eee18ebeb2b", "node_type": "1", "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today . ", "original_text": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6e7b89ae6e6339c1545653d518c0703c7f58518c726140078f7b02ecb72dc50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71a36ced-3a8a-4db7-b7fd-739e60f3f32b", "node_type": "1", "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie . ", "original_text": "And so we're just not seeing a \nlot of variability there as well.  \n \n"}, "hash": "33fb7760354819cce5ec341f52e255edccf1cbfadf62267ff858630b56755048", "class_name": "RelatedNodeInfo"}}, "text": "And we \nhave largely gotten back to that point at the end of the second quarter . ", "start_char_idx": 207, "end_char_idx": 289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71a36ced-3a8a-4db7-b7fd-739e60f3f32b": {"__data__": {"id_": "71a36ced-3a8a-4db7-b7fd-739e60f3f32b", "embedding": null, "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie . ", "original_text": "And so we're just not seeing a \nlot of variability there as well.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11d5b1c0-f007-4974-a6bd-b65078219561", "node_type": "1", "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n", "original_text": "And we \nhave largely gotten back to that point at the end of the second quarter . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "852bb644234dac15c4c2fc63652800901451d0c60e84a7f4eea501ce168cccd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afdaebe8-46b8-49a7-8991-e3afb1ecdb1a", "node_type": "1", "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.  ", "original_text": "Operator:   And with that, that does conclude our question -and-answer session  for today . "}, "hash": "b3b0724bcb9fc0ed79a19f470850d3a8bb0f1afe128921ca9420601323817e48", "class_name": "RelatedNodeInfo"}}, "text": "And so we're just not seeing a \nlot of variability there as well.  \n \n", "start_char_idx": 289, "end_char_idx": 359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afdaebe8-46b8-49a7-8991-e3afb1ecdb1a": {"__data__": {"id_": "afdaebe8-46b8-49a7-8991-e3afb1ecdb1a", "embedding": null, "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.  ", "original_text": "Operator:   And with that, that does conclude our question -and-answer session  for today . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71a36ced-3a8a-4db7-b7fd-739e60f3f32b", "node_type": "1", "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie . ", "original_text": "And so we're just not seeing a \nlot of variability there as well.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16a46dc0a4b7b3ea4a4e96ab9a6bdde3a1fdd9b9180e9b58cabe139b825a0649", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "589c5760-87c3-4ec6-b2d2-b8e448f83196", "node_type": "1", "metadata": {"window": "And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses . ", "original_text": "I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n"}, "hash": "1c31658f678c7743ada09ab36a43b96d7cb3f515a1a14d531d1e096584e720da", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   And with that, that does conclude our question -and-answer session  for today . ", "start_char_idx": 359, "end_char_idx": 451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "589c5760-87c3-4ec6-b2d2-b8e448f83196": {"__data__": {"id_": "589c5760-87c3-4ec6-b2d2-b8e448f83196", "embedding": null, "metadata": {"window": "And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses . ", "original_text": "I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afdaebe8-46b8-49a7-8991-e3afb1ecdb1a", "node_type": "1", "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.  ", "original_text": "Operator:   And with that, that does conclude our question -and-answer session  for today . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6745d92e8c222d1c91365d331dbc3815b831904c8263356438710898f615b88d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09933c53-3eba-42c1-816e-cd993e9c8a4d", "node_type": "1", "metadata": {"window": "And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n", "original_text": "Mike  Kaufmann:   Thanks, Allie . "}, "hash": "fe6760c589b04cf1b16e83d513bf7110849b3e35f48e17e7cf98717e6769ab28", "class_name": "RelatedNodeInfo"}}, "text": "I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n", "start_char_idx": 451, "end_char_idx": 539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09933c53-3eba-42c1-816e-cd993e9c8a4d": {"__data__": {"id_": "09933c53-3eba-42c1-816e-cd993e9c8a4d", "embedding": null, "metadata": {"window": "And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n", "original_text": "Mike  Kaufmann:   Thanks, Allie . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "589c5760-87c3-4ec6-b2d2-b8e448f83196", "node_type": "1", "metadata": {"window": "And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses . ", "original_text": "I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12470928446b41777bbc2ea15318e6effdd60bb1e742e5f18241f39d088fd420", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4e40dfc-d41c-4004-8f1f-f27b879f817d", "node_type": "1", "metadata": {"window": "Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n", "original_text": "I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.  "}, "hash": "c666646339db53f5a47566caafbf4120a3c45b942b079d733d405f5591da4c5a", "class_name": "RelatedNodeInfo"}}, "text": "Mike  Kaufmann:   Thanks, Allie . ", "start_char_idx": 539, "end_char_idx": 573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4e40dfc-d41c-4004-8f1f-f27b879f817d": {"__data__": {"id_": "c4e40dfc-d41c-4004-8f1f-f27b879f817d", "embedding": null, "metadata": {"window": "Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n", "original_text": "I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.  ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09933c53-3eba-42c1-816e-cd993e9c8a4d", "node_type": "1", "metadata": {"window": "And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n", "original_text": "Mike  Kaufmann:   Thanks, Allie . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b74b928c9015be79a6ff31844549c1bd8ecfa44c8dca5fdae4d405cf923df0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c2061d0-c3e2-4215-bc7c-cb0fdc47cc28", "node_type": "1", "metadata": {"window": "I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call . ", "original_text": "I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses . "}, "hash": "83271cd7993e72479347cd1df09abbcfa940ed419fea556ebf33579767c44a0d", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.  ", "start_char_idx": 573, "end_char_idx": 678, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c2061d0-c3e2-4215-bc7c-cb0fdc47cc28": {"__data__": {"id_": "2c2061d0-c3e2-4215-bc7c-cb0fdc47cc28", "embedding": null, "metadata": {"window": "I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call . ", "original_text": "I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4e40dfc-d41c-4004-8f1f-f27b879f817d", "node_type": "1", "metadata": {"window": "Operator:   And with that, that does conclude our question -and-answer session  for today .  I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n", "original_text": "I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.  ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63b240c4a8127fee5230a70509e786a7da321a95f06c63598101ebfecb52afc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53cc5cfb-36af-41f9-a871-eb50239fe5d4", "node_type": "1", "metadata": {"window": "Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation . ", "original_text": "So please stay safe , and we'll speak with you again soon . \n"}, "hash": "519d691c11e180744be3920bb395f1029b54f76286d82e7c6fda6ec1365349e9", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses . ", "start_char_idx": 678, "end_char_idx": 900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53cc5cfb-36af-41f9-a871-eb50239fe5d4": {"__data__": {"id_": "53cc5cfb-36af-41f9-a871-eb50239fe5d4", "embedding": null, "metadata": {"window": "Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation . ", "original_text": "So please stay safe , and we'll speak with you again soon . \n", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c2061d0-c3e2-4215-bc7c-cb0fdc47cc28", "node_type": "1", "metadata": {"window": "I would now \nlike to turn the call back over to Mike Kaufmann  for closing remarks.  \n \n Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call . ", "original_text": "I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e44bc8bd0647bcbb6f57a59627c6b05031862cecf0929908950f1b1453f607c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "463fcd49-d2aa-49eb-afff-0a81e523730a", "node_type": "1", "metadata": {"window": "I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation .  You may now \ndisconnect.  \n \n \n \n \n ", "original_text": "Take care everybody.  \n \n"}, "hash": "1bd2c1dcd9c1068ef70dc1a34d696af08ccf237c9267c86e9a16fb65a980b0ba", "class_name": "RelatedNodeInfo"}}, "text": "So please stay safe , and we'll speak with you again soon . \n", "start_char_idx": 900, "end_char_idx": 961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "463fcd49-d2aa-49eb-afff-0a81e523730a": {"__data__": {"id_": "463fcd49-d2aa-49eb-afff-0a81e523730a", "embedding": null, "metadata": {"window": "I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation .  You may now \ndisconnect.  \n \n \n \n \n ", "original_text": "Take care everybody.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53cc5cfb-36af-41f9-a871-eb50239fe5d4", "node_type": "1", "metadata": {"window": "Mike  Kaufmann:   Thanks, Allie .  I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation . ", "original_text": "So please stay safe , and we'll speak with you again soon . \n", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a347c2cf233d630f292406e9521314d6b405b1209701260f4dacf17cf690583", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75292374-cc01-4414-8d31-bd1b882b6033", "node_type": "1", "metadata": {"window": "I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation .  You may now \ndisconnect.  \n \n \n \n \n ", "original_text": "Operator:   And with that, that does conclude today's call . "}, "hash": "03377a945fc80ec741fd525146b5930437148c26237d560691e0c799c3fd7260", "class_name": "RelatedNodeInfo"}}, "text": "Take care everybody.  \n \n", "start_char_idx": 961, "end_char_idx": 986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75292374-cc01-4414-8d31-bd1b882b6033": {"__data__": {"id_": "75292374-cc01-4414-8d31-bd1b882b6033", "embedding": null, "metadata": {"window": "I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation .  You may now \ndisconnect.  \n \n \n \n \n ", "original_text": "Operator:   And with that, that does conclude today's call . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "463fcd49-d2aa-49eb-afff-0a81e523730a", "node_type": "1", "metadata": {"window": "I want to thank everybody for taking the time to be on the call today , \nand for all of your questions.   I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation .  You may now \ndisconnect.  \n \n \n \n \n ", "original_text": "Take care everybody.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a33223ee245e5b51ea3fdc19b9dd373e8f95b49d3a6b98dbe4bd18fb0e81d470", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bc690af-e017-4c37-b145-d483c4e180e9", "node_type": "1", "metadata": {"window": "So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation .  You may now \ndisconnect.  \n \n \n \n \n ", "original_text": "Thank you for participation . "}, "hash": "4689a043e02fd35642540b89a18a4f501bccc57481adff0fa39f32557aae7350", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   And with that, that does conclude today's call . ", "start_char_idx": 986, "end_char_idx": 1047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bc690af-e017-4c37-b145-d483c4e180e9": {"__data__": {"id_": "8bc690af-e017-4c37-b145-d483c4e180e9", "embedding": null, "metadata": {"window": "So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation .  You may now \ndisconnect.  \n \n \n \n \n ", "original_text": "Thank you for participation . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75292374-cc01-4414-8d31-bd1b882b6033", "node_type": "1", "metadata": {"window": "I'd like to conclude by reiterati ng that we are taking action to mitigate \nthese inflationary impacts and supply chain constraints, and we're laser -focused on driving improved \nperformance across all of our businesses .  So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation .  You may now \ndisconnect.  \n \n \n \n \n ", "original_text": "Operator:   And with that, that does conclude today's call . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "039930b76b381569800ac467912004c784ce2758814d19bdf77db5a1e9e86a5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3be02d27-d638-483b-84c7-faf0c647cd80", "node_type": "1", "metadata": {"window": "Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation .  You may now \ndisconnect.  \n \n \n \n \n ", "original_text": "You may now \ndisconnect.  \n \n \n \n \n "}, "hash": "8c1f39f549b0576bf90cbcff3405c71f85f62efcb27cda2d4fde8b971cd86cd1", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for participation . ", "start_char_idx": 1047, "end_char_idx": 1077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3be02d27-d638-483b-84c7-faf0c647cd80": {"__data__": {"id_": "3be02d27-d638-483b-84c7-faf0c647cd80", "embedding": null, "metadata": {"window": "Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation .  You may now \ndisconnect.  \n \n \n \n \n ", "original_text": "You may now \ndisconnect.  \n \n \n \n \n ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d01fbdc2dfe02ef3ba165d9feffcd0f4b736c95a56634e21c097a83ecb36801c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bc690af-e017-4c37-b145-d483c4e180e9", "node_type": "1", "metadata": {"window": "So please stay safe , and we'll speak with you again soon . \n Take care everybody.  \n \n Operator:   And with that, that does conclude today's call .  Thank you for participation .  You may now \ndisconnect.  \n \n \n \n \n ", "original_text": "Thank you for participation . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71704672bdebb2a91d2f28a0cf9780ee90446857b9f59650f1d549aefce6accb", "class_name": "RelatedNodeInfo"}}, "text": "You may now \ndisconnect.  \n \n \n \n \n ", "start_char_idx": 1077, "end_char_idx": 1113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"8a18b715-4d21-4660-899a-d5bacabdd209": {"doc_hash": "2c5c376ac1adf29e88dfd0bf6738769911af3254e380e0936c8a307dd7570f92", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "487df8c4-d11a-4214-b81d-9f434234bcfe": {"doc_hash": "b0d3c5576d88773fafcfd614c1e9a798ad70128e223eeea6e5fefcc379804306", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "a2f53de9-142f-4ed0-a9df-998a4ad55fc6": {"doc_hash": "cdf81a080b0e8721dfeccf5a28f21095b4a81152390c661491bb4267efccfbd0", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "64f7b3ea-7c5b-4c6d-b74d-5a18a0cc68ba": {"doc_hash": "009b3b73d6380207cb8e3a4888bf9649f8ac8614ecf50f42d03e48d4a3346822", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "691f2ff0-f72d-4c90-8f4e-3c87313fbb39": {"doc_hash": "af61927028559bf19b2d81be2b3b02f3da0ee4242e8caadb095e036920381dd8", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "5b07050c-a339-4e4b-9c5a-9d195d01b30c": {"doc_hash": "ae5f3725c1c038f3ac1108268667ac6d8844975d34811d247ec03e1ab5104065", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "d6c0d5c5-cd5e-4c03-adb7-5018488f4c91": {"doc_hash": "ddb8f0e4e742ee20c63cbed4f71587e92dfaeb84eb47c1df3a87bb1dffcabda0", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "324b16d3-8f12-4bb2-ad4a-e66634fade20": {"doc_hash": "28d6ecf3ecf623dabd7ad0ed432bfd1b8325496f58f5e5a60bb5d6cb99436e00", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "5a84a070-cb03-4c79-aac8-62e3f2480743": {"doc_hash": "22a3cda1d604da0a041418b53389c5665d2b86ecd3b89ff22dfe1c72e21b3cbf", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "a3bdf4e7-2502-4577-a701-8b4354f0ccf7": {"doc_hash": "f075f831afc3bd205eb666cf4e004ec40d14ab5090032617fcfe93977e4eb14d", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "93c553a6-33aa-4bfe-93fa-c32a0954f7eb": {"doc_hash": "42f048df7e8eb7e6daba3af085777deb9e690d5cb1f61c628fcd571571f78423", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "5fda7b66-2aba-4ff6-8853-880f6881bef8": {"doc_hash": "01acf78a83eea235ef57efaa9e26c21ef9d0af3c5dced43a01b2359621468fa5", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "0b23bf48-be79-485b-a7df-c04747663807": {"doc_hash": "7131ee94464af3109cc7fe18d4d47e785be0b47517d31a4b0089ca744ff6fe1a", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "7b937d73-f2d0-4a8b-90bd-bf6cc47d563f": {"doc_hash": "a782a8b5767ac10956d1c1b9d24c1c4a24e1ebce9c33d5906770295ce116c49e", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "1c77b890-9816-4c5b-aa91-66e15e9f026b": {"doc_hash": "c28a1abe9b7df9818923ed9e9df3eeebeec8dc6e2afbad499db6526d51c8cd49", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "bc5f2b3b-a23a-4324-9710-f6cd84aa0de7": {"doc_hash": "022b314b4361c168a24690d0b7d67ba149ab9fc3f523193a1361936d9f27b9c8", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "ac7517dd-cd3d-4be9-b8fb-0039539e15aa": {"doc_hash": "c1b094b78747e2536f917d07dd221c846eb0ced8f8c2bbef9b54e6021f0ae970", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "e7f5187d-7ce8-4661-ad1e-9bede4c0b785": {"doc_hash": "f1b3cc6cb6827cfde4d91088cd2bea4ad10ee88ae5cf6716abd22a69c14def87", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "fa5ccd21-be07-4e1e-8e6e-1b3dcae6c1ca": {"doc_hash": "55a7b5380ebababcf21df78e40c7cd07918ee1d0378fdad237135cf0813ce0eb", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "f29ad5b1-38b8-4892-b043-eea95b4a5a09": {"doc_hash": "3619f1ed69e1a027fa4788bb4575cd9d24c37302bf772fba52c3723989e246c3", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "73568e45-f674-46d6-ac4e-d36e876e7967": {"doc_hash": "cf9624fe29ab89ac373a4612fcd4c4b83136e2090d974cf4c0293560acbb064b", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "cf7dc50b-84e3-45d9-999c-5f8382a0a154": {"doc_hash": "b25aff73838d7cfcfba58ce4787bd967c3a8ce9db75d611fce86f6620d68dabc", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "8ac430be-ec22-4401-a355-1698bbcc2e0c": {"doc_hash": "a5fbe009af5d68816514796a61e30fe3a52d68db6ad0bd5cf73d2f7d403a84d9", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "b1572aab-24fd-49b4-a652-cb67f7118f59": {"doc_hash": "7a021afe2aaf1c7e66cf59f8ed24269f5a37e368014d15218d4eb69c9df9fe93", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "e12d94b7-9fc8-43c7-993b-938810a830c9": {"doc_hash": "478437202f521b3ccba3484cee2521cc890f0fbf680dd93b5faf8451c8ea48b6", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "2873620b-8927-4df9-bc15-e7b66315db2c": {"doc_hash": "57336cb921ff77af717cd84f44e230071bf37adb300627175703fc2d116863a2", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "115aaf47-238e-4583-8356-543066f42e63": {"doc_hash": "509c25dceb21968b8c34bbc24cdc7389a19331911c0db96e87c72ac8e9fa322d", "ref_doc_id": "4e445af8-7e6a-4248-9fb0-0e69ef95c4bf"}, "df58a569-e898-4d33-94a8-1d1631e3622f": {"doc_hash": "b257cd9aed6af718268b494ef88e1310c5a3f8855e80b1140ca75f63c49128c8", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "3415a12b-2eef-4420-8b8f-8c708ff5f743": {"doc_hash": "d8d4237740b5ebf100e95128a7f01ad6ad44daf60b422ec8b1345431b1b2f809", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "2bd77940-a905-4195-a21f-c0d0a83c191a": {"doc_hash": "eb27ac6a7a6ff1276ee4c69debdc14edcb7b0d8b8cba0e92365f20862cff6dc5", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "3c40b3b1-cba2-4a8b-9405-555d43484e9d": {"doc_hash": "827b315f9f9a63f1c0453b73842af24d02f54f6a9741861df12df5b7d082c134", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "a0643812-8bfc-430b-b2bb-cfba089a60f2": {"doc_hash": "8beca54b7e79c56fbe25c8cf398840947273f0ac264f9df252d6fc1d31b241ff", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "ed32fa9a-92df-41cd-8481-9fd39f1254c6": {"doc_hash": "e95594e6e4b46c675f703b2b7900dd30afb550794b287426c31d7f300201d237", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "2659f564-2e2b-4a0b-949c-ff7ce23f2a57": {"doc_hash": "2c0408193eb7705352062441fa759162a02e9169cea6870f621571609daeb380", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "adfe9e05-4c02-4c00-87f1-ab2f2d39ae42": {"doc_hash": "731c71f2875d48478f0e7cb4b8af8bfab1a104c2bafe9b295188256f572dfdda", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "14fc9b48-9e70-4cab-8c67-841447068d25": {"doc_hash": "162da5be218c63d81c85446392ad3d3fc359a63e3220c0f360eb6619675bc6c5", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "f54e29a5-9fd2-44c2-8f1e-f8f8759fa234": {"doc_hash": "8ac9f5f507a54aa176edc6a5a3286771672af96652d79f6784e9eea1a5c708c4", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "fc3bdf0a-85f5-4cfb-8837-8510847fa604": {"doc_hash": "26339e4ff107be2ada9e3d1a54348c8e7baca8f7f6dfde75165b331b4deed16c", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "9ecadcf5-b601-4fbf-a667-1d6d46502703": {"doc_hash": "060c46d318da68082257c251e9defb5a496dc99990c849049a87eadde76ab79c", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "178db19e-8b00-4728-b552-2719cf15e950": {"doc_hash": "23ba873f9d311fbe1cfa760cb046006974685fd9aaffedad5c1d548abc664f58", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "e75d9633-8f59-4e31-a3fa-45c44eb13d9b": {"doc_hash": "572fb0014a5201c4d9efcdb79ca958f6f2fb83aa2f9ec7a6d3786acea9cf4fb8", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "18835c64-3fd1-41fb-b106-ddbabc01e082": {"doc_hash": "96f0c937bc425a54da7341890593483505dcbaab34e7e07a3ed52f0388cd6990", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "1ce275f5-377a-4daf-b70e-06fa9a8b521e": {"doc_hash": "fa1f461ea8962220e9e8c660ae4799d05f064d244e7c485ca69044e1e15146d8", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "25e3ac0f-441c-4a7e-b030-fd751f9eff63": {"doc_hash": "9c430ab7932148e42c84b8e81afae0f50228f5b0b55729c5e00a453211ac8312", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "55a321bd-fd6b-4373-acec-67641476366d": {"doc_hash": "405798d4e4dfe277342e209e630838c61192b943f3ca1df76576071b6bce1756", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "a5dbc850-e99e-433a-833f-96583de3fdf1": {"doc_hash": "6eec03332258274d30149aaedbdbb8b30f2cf04d236b8ad73efb40265d71cb41", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "95f06d92-6b27-4220-b9db-3802ad43e6e3": {"doc_hash": "805d2c09a8fcdd3cbd8cd848c29c0dae326a9ef8dad5486a609e1645bba866c0", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "8e1100ee-d3db-48aa-b41d-6da34b8484cc": {"doc_hash": "a2b380165a6f39a60e5033322eb1e52fc7e93d36df5ea559d5c74f8836da950d", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "7fbc93a5-3f1d-4440-b01f-630c6900560e": {"doc_hash": "f4c66816ac74c045b3d65fa566be875a032ea5159b06058c7d9930f65326d179", "ref_doc_id": "856c4011-9e85-4d6a-a778-2ec432012364"}, "21373f1b-42fb-4bf8-8711-f1e56bd4f857": {"doc_hash": "31adbee78dc711847dc9422554465029f8215ec58fa2c30c5f6e5fe9de2d32f8", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "fc563ad6-fd9e-4752-9aff-cba21639e134": {"doc_hash": "f4a7ff5567407754fcac0aa1c5b24cce8541dbd5683b339a2735204be04063a0", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "faad391e-873f-460b-9c7b-e8d27dc2f577": {"doc_hash": "1eadb73abcf961082fab0b8e764270aefc0f5ba68716c0d6977308311bf6bd8b", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "31a977e6-353c-4eb5-ae21-8147bc36b2d5": {"doc_hash": "0679d60188f992aed2acdc3511f6c40338fdcf980ebaffc64f4f74c8e87a368f", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "aaea3f17-e754-4ca9-b6c9-0a73ccbdbec0": {"doc_hash": "5181577678dfd5007fb40955cb6c3ba5c6ed5d124a563d8fc88104c01738de09", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "59a89ebc-d15c-4872-b4c9-5a3fdd2f4829": {"doc_hash": "e1b0da478a4150e5052ed27e2dbf9c3904bf81514f3a487944c79453565eca50", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "c396cdd2-5ada-4d1f-a69a-a532aff6d701": {"doc_hash": "440648e2eec0bad170e9061737caa8ec533f3d25740b71b81eb406f6055076e7", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "8e777dac-9cd9-4c05-a4d5-ce0b5131034b": {"doc_hash": "bf094b5f59848102172cd56d4c1e86998b7aea2b24ff56922d54ac969b4b5754", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "858ef2e5-c70d-4353-9fd9-83c10ad75ee1": {"doc_hash": "1d50a51aa8e5a4a82bdb3c8cf3a70fef252de876ed0ec14a5eacb870e8b3aa59", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "3177754c-55e9-4b26-87e8-d540e20a9223": {"doc_hash": "9789bef0a5ebd15f18c3ceab28a614d24dea6bc740b9420cb560bf7979a6cf28", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "ed0a2e98-b865-4d90-87e9-ff8c14dc7042": {"doc_hash": "1e3ced78a7d9182a0d69a1f54661403d053a149c5160e0046598950abf3947c3", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "b8afdf7c-4062-4ced-8f25-78305bc55560": {"doc_hash": "d0f56500dd68652e3569ae1305bf17845e426c2f22ad47334c47fffdf3340f70", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "5174be4e-a826-4536-9175-9187818bdd52": {"doc_hash": "37648912449fe18ee6529ebce3f11112f807828253a22ec98b58582d9b61ce75", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "1f591d9a-4d8a-43b1-bc06-204d6da7beac": {"doc_hash": "2e7483551e31646549418efb93e144c571bdfb4f8600d03704cc17028e8a5a1b", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "8bd99dae-d5c2-4aab-9680-c2e3751639a4": {"doc_hash": "b83f7e6146008b65da4ca2ec822fd75422fcb2b77d46ca4187862643a36fa999", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "9d528835-075e-43f9-9b3b-eab6684eaf0d": {"doc_hash": "cf675cd6052a081cece556224f9bd402f4d7d903d02e2a61fc602c66383bf387", "ref_doc_id": "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891"}, "d4d78b90-57d9-4968-9f3e-5c6518d6f017": {"doc_hash": "9846619f44743d03f39e682d9fb79e24092edfb0813bc89e080fdd4ba6045b24", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "a3f2de65-4b54-4263-a11a-90f40e97e842": {"doc_hash": "23bec7f2ce88addff989689193d2dfe5aacc0e636d48641fd255917c4add26f3", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "0fee0308-c83f-406c-8d2e-b375b2355412": {"doc_hash": "7b3a42ba8093878a23581be06e29986ec72206c58d870f3995a0fc976e88b30c", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "c16248e4-3da9-4ee5-8d66-4188f9dd591c": {"doc_hash": "d5bb6d53110e1996ac4a79e29c13a4355003c203e482684ff4017ed5998f6544", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "e7fdcab9-472a-492e-9b76-f2c60f9cf3a0": {"doc_hash": "77773bbba0b4492468348590d3409fa310050b9c6e55221459a4f8c223828ff3", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "2ff99423-1bea-413d-bb07-6d85298b2199": {"doc_hash": "7944513ff56e8078ce8ad727bf56892a2b68e2b02d4780f928e901de34cd3464", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "0c2a6902-8455-4758-9ca2-3db340c81a6c": {"doc_hash": "fd35bea7ccd037d654c8df38cc5ce32ca2d1fe81ebdd4429203682c22167cfde", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "40b305cc-c2f4-421e-a9df-4ba483169ea8": {"doc_hash": "30b5e1f9e04034a8ca7e184392283b17cfaf6874fe2aad92d1ca94a83a0afe90", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "bac86dce-6a31-4a20-8ddf-a5eede2f5bc7": {"doc_hash": "1c7c85be7d944b7edf8862aa833c121f7cfe64acaac17abfef52c0cae4785342", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "74054057-b06a-41ca-8d5f-e16c1c3e9547": {"doc_hash": "fd2d440b50bcde48fb4e6a71a92bd7b5e711eab82512778cd47b996c775581b8", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "27bfb175-a2c5-4f07-b45f-24bfd77b5770": {"doc_hash": "572899caa7b8db84046f049fd8b0363d75421ca66c9a24ab9a3d17c6ef6b4abf", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "20165d0c-8439-49af-8247-d33f1f560dde": {"doc_hash": "47fd8a3e23f988223712266cee2b458645780c91de69bb48fcdd5b021a71320f", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "4d924ab7-f2d2-4143-b244-8bdd79a75117": {"doc_hash": "80e0716d7aaee10fcc6ebdb89d03c64c0bd5200b5d9ba0df5a24b7bd2be5e065", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "e6cbac8f-13e7-4876-bc19-6addfc003f36": {"doc_hash": "9da7b2a08180ed7b18968225aaadefc8444b972fb25221b443b6766470cfb656", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "fd424dfe-38d3-4eff-be6b-01563c0a4a6f": {"doc_hash": "749734a15ffe387092dc15da20b8b9637fc4ef6678d50cdf0d564f3b6918fe1d", "ref_doc_id": "96fbe9de-9274-4aef-b03a-fe803e7f7f11"}, "4ea5d723-eb47-411e-91d6-2758f86aad24": {"doc_hash": "b7a407a4766ac8d58f23973ced2ac6caaffb1f89006b303692c0ed6be921a42e", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "c5a3fc2e-6b15-47c3-bf74-6f28b124cbe5": {"doc_hash": "fb566dfaec4ee17fedce7eff39862122ecaf41eda7c896048092e50c9dd7c25a", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "a8d38b99-e09e-49f8-a1ee-c34e2d8cd550": {"doc_hash": "db1746dc79d555a612b03ef3ca343e5d4951f2094738b13acf8dfa9899e1b9b0", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "5d864838-7d38-48c3-a65c-937708f63a5e": {"doc_hash": "00854f506e4b1658d1f0300bd9d13f28ec1e80232bce305821bc4f4f5b5b5660", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "b426a336-8e3f-4d3f-bbe0-b9af04dfbfb7": {"doc_hash": "d11265d95be0fdf7220049a829598a0549563ae314ec1e4f01570798d50ccc34", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "68ac87a8-8c5d-41a7-a188-123c36a5ef72": {"doc_hash": "585403237fdbddf7ff6cb09ead6176bde34b80df653aa540ce66d34f822be1ef", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "28f12405-2321-4a5b-9225-47f521d08235": {"doc_hash": "7c179c5a62e1622f1b6c3de7c0bb3ff08bdd6db0ff8253b19a2b7d45e3055478", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "7a12ab53-de5b-4423-aa92-be1368415e3b": {"doc_hash": "1ad26b6ae788d46621fdbd7d88b911b3cc60a4bea8a707b244e0c84fc0c7b9a9", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "b44fd569-7bdd-4a91-a855-514462d1fdaf": {"doc_hash": "b231d9e074cf7a69974d34036cf94dbc58fa319e3bf078b0925539d6b1be985b", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "ea69bdbb-f9e9-4aab-93a5-d276b1e3b7d3": {"doc_hash": "9b78fa23903cdbf3379a2ad14cb71373b317abd8c1d52ac3ebb4b92e9393626b", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "73803877-2b21-4cbe-a347-851cf6154e82": {"doc_hash": "fb78dc732ea6aaecb76beeac478dff46ad0a0b022321fdce65919f7b0069e3b5", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "f2d9068c-a3fd-4742-bca4-da160a406be5": {"doc_hash": "bcda3fb8f5333b62698ee537f8f50852610b31a69c356709c4e838b19bc36aec", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "1da8b24f-11de-48e1-8448-dd5a39f3338b": {"doc_hash": "d32b63649d2298ae92fb80a12e10714c0b9785b6e602d787dd76a4198f16bda4", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "77d4257f-97ba-40b3-9010-4eb9f762600d": {"doc_hash": "509d3f061cb510c06f78cc8d1a34571946982f4c21428c3add9cbcb41b1da0e6", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "7ee1d6c0-bebe-42d3-a481-dedcde0a9248": {"doc_hash": "8c41e1910459a65f9622ee547d74df7ce66d4773f744760df8d9c97edc5a87f4", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "82568a9a-755a-49e3-90c8-374a4e6b69ac": {"doc_hash": "4849a00d2c7b4faeabac302abc341c91b64e9769e27114eababd2e0052fbb4a0", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "e91d9c7b-edd8-43bd-af88-efb8289b6ff0": {"doc_hash": "314eacb060d600ff99fd3fce0bf5206ee0abaa3742736a308ecfc8002bfd32d5", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "6c86291e-b51b-45fe-9ae1-7833011504e8": {"doc_hash": "0dfc804e819e8db508dc74b6ba83cee4d7bfa6691d2113acd43e751fd54072f4", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "f528f00a-cac6-454c-badb-c7373a2f2379": {"doc_hash": "01df1af4740b63a3de25efdc8383b768f1656756284f04cb221931bf868e0891", "ref_doc_id": "a890dff1-9362-49d1-8301-69bcddb1f082"}, "721e79ba-2399-43f9-b912-9fe0c55bea14": {"doc_hash": "cc6c1be6a73d315896360bab438ea658fa3dd9ac537cc34404c9e30d7908efab", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "cb3e4932-54cf-4df6-810e-8ba11abdc4cf": {"doc_hash": "1883d4bd565184d1b7041f21c2df03e835bd3ddd53ed59efbeb48087393c4739", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "d3ab288a-3a9e-4761-bbd8-9ffad020c776": {"doc_hash": "7199066b80dc19f51f250dde1189d6ca8a1d756f9d11e862a70780d2c5720093", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "94c7cef1-8999-45cf-820d-d7a310d7da9e": {"doc_hash": "e2b9306d5ab604ecf1f04af03a5d32198c49deff60fa6f78f666cce2c9837646", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "2964809d-5ac1-4624-965f-4e9e3e23d62e": {"doc_hash": "d0f8443304bc8b63f7e223b25451e6ba1b2d0aa4c9cca66503bfe55fa1fb87db", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "741b2d65-3824-4a09-b6da-3ecf5922d3cb": {"doc_hash": "84d8fcf1e04d45c7f8a1abaaae69d96d43f7ca539d1be664006f019abd79c841", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "329d4c9e-9058-40f5-9b3c-d186325a8844": {"doc_hash": "3db711fd8ec46208f03d0ed3bff8c8e60d83d09482f56e27caed02bdac58b4b1", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "51bcb97d-6a93-49ed-b8ae-d0c7fdbfdb7f": {"doc_hash": "f34cbb7c64b47551ab39291c32f7775c47bf97d6c6fb4d40a87853a6675e20d3", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "212275ec-db62-427d-ac0c-5395ea088470": {"doc_hash": "eea43b93005c74f0a415707b320d7a9a000ba4086984ad21036c74108fe3cfcb", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "4ffa74d2-c536-4bd6-b5a9-1860e834f41f": {"doc_hash": "321213228ba60c9fc11cfe1f39ba1638ef71ea9af4ea194c46010586a3c3d803", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "349426f2-0907-4b6b-b869-6bad66cb1012": {"doc_hash": "42018a37bff5fc23d3f6bcffb3ac774cd22d25f2c5d64ecbbef30378a4dd5073", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "7bca876a-5602-41f1-a069-db912d029f7a": {"doc_hash": "d8953df0dd527972a274f344a8198c703f49b80217d8d23dcad91e404849fd2d", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "d8959190-322d-4f35-b26c-97adb59afbb7": {"doc_hash": "3787a004f66d1038a544ad5cd63b50cc07426239d2b8654d2200b14b2339ce7c", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "ac8e606b-ff42-45a2-8ca9-999a8898ef94": {"doc_hash": "ce11185c8e01694743ed491415ca148d22172d05e9b3835d62dc42a79589d93b", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "ed8e9ef7-75b0-4699-8cce-8f6b56c0b06f": {"doc_hash": "e3ac214c2d0bfb4dfd00c3fc636dc198bc91ea2c2e34194b367ccd8cfce6f33b", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "3aeaa93a-ba13-459b-86c9-86e7f0cd60fc": {"doc_hash": "17277ca885c05fdc929392cfee488a2e23a222fcdde3fee3ba10215752ab6fd0", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "f731da7c-3197-4619-b1bc-1bb43d22501f": {"doc_hash": "540d13c33fed66abf5464dadc17e35c781ed47b749a931a55b08f9e207f0da13", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "a2d7e07d-18ca-44c5-bde4-ead54894f792": {"doc_hash": "46978df74618a1f05284871632378410e96d73f72300806bdd7ff01bcf3df640", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "ca1af714-972d-416c-bec6-34d03839a18e": {"doc_hash": "563d078c87a533623dbffd1240e91d49a7a4e19ef240858420bdd718e51a723a", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "c72a4a32-bdaf-4cfa-bebf-c500fc1b1be0": {"doc_hash": "e2eef4bad227edd84a52bd6ac5774f1523a57594ec78774c472aa90c8288b18f", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "f471b982-3655-462a-b883-b084bb6e43a2": {"doc_hash": "987bc116a02c6461a218979c8765c556c2dbf5c90faa9727b48d055dd4a381f2", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "3cf4ff4b-e207-4d92-b2bb-a4cd92655dbe": {"doc_hash": "adcb77ebaf0b497fb2ecf01b467230d03c28e7384bcf6c66c9bb0926aed18b0b", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "43b8e7d5-c4b3-4865-bd71-53cf1da83a01": {"doc_hash": "1e97cdec905dd4af4fd2cfbd60e4cfc4554bc6f31465fc671b9f6889a50be096", "ref_doc_id": "dd3b63c9-237e-4ab4-bea3-ecfa138812ee"}, "f330ef66-a7ad-4e82-8b58-3d49b7458a5f": {"doc_hash": "d2d8f8d1a09978030093a15c5d0d608ee806095abf817f950ba216e1c4408b58", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "c8eb1929-fa61-4ee7-9305-3b691eec2b84": {"doc_hash": "591dab222d91a66f034f53d25cecbdaceeabd79b412bfa17cf093db105281a29", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "7bbcaa6c-59f6-41c7-b0c6-5770f82d0ab1": {"doc_hash": "9fb8ff969a6160581db6a8a93461c9cd170cdfbfe457ed9fec904004b6de7a9c", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "54819cc6-55d2-4b3f-bb4f-12f9f34760f0": {"doc_hash": "e905734dadafd63b3fe251734dea6a2ba02f03402e62864d49a622977d547371", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "c461a42f-79ee-4eaa-99f9-9b91acaf70d8": {"doc_hash": "23a1e7af9572ecca4c4b1537a362ea0be55a5e65489c0d4b75b494f34eda052a", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "bb948d6d-3d69-4a03-afe0-3d0071d4175e": {"doc_hash": "40738cfbff7a54eb60fc253f94ee548b7f5682383702b8f530369b2c72b19bdf", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "93aa5f14-fb31-4392-9bbe-5395d8ae5a2c": {"doc_hash": "fe2ffc5022b8a83793b9dae571648dceae95672bf59e65e66779484ea84c873b", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "5534d9b8-05fd-4c68-952f-b02c50854cd1": {"doc_hash": "11ae4bbd4a3fa85ff7ffabff3ebd80807d9c492d285c7755150683854eb950e5", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "5329afb4-8175-4f2f-a029-1c12a434a977": {"doc_hash": "b9bacdb6e2cb355d0f8183478877dfff9d0d44d5f060f29c44938390048b4b57", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "fa76cb72-27a7-4943-bf70-1f0c32959e82": {"doc_hash": "a779bd0c54c3ee5888cdec96c2111997d0fa4b7e3db91454395d103971b7dc46", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "40893f46-d54a-4780-adb0-a6bad706e396": {"doc_hash": "30c5d7b2dd5e020a0798610d2b5ea06c79edd2ac808dfd944042fe6e1659de95", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "40555185-108b-4948-814e-03ade797ce5e": {"doc_hash": "eff7e2961ca8e049b08be6e3681be0ca71137f11dfbd0768dd805235cf461ff3", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "ab752ea8-098d-4ce1-89c1-e8195d786a27": {"doc_hash": "5da47bde6036493d33ea72948f6363bdcc46c7b58508c45e516ad69961f41db6", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "bdaf5fd8-973f-4a8c-9cfc-e9d4ab385118": {"doc_hash": "0a8785ec1d1ab3c76daa74c299726bdeff4648753d98ba319c6d53ea34f37f30", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "9ecca4db-1a58-471b-82b8-a10b2b17942d": {"doc_hash": "2078e4ae8f8d47e10dec7799c7662b8c18ecc113953f4df68789ec5760155501", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "c9c873ca-14e1-440a-bdf6-b2f69d554397": {"doc_hash": "c10b720672299ea8d15fd376f522b3dd7b7da7e17394012e9c59364ac72335c2", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "d2eddb6e-e022-4dc8-8b53-7a9e0ac9fdf7": {"doc_hash": "3e383579a30ea38180d51b8110e9d1234a06448c7565cb4d176ed43a1b790bd9", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "ffbdb92c-3e13-42cb-8fe2-64856dcd6965": {"doc_hash": "05fa7d24edac9292f87ad743d4725dcd70a0823b54c6a5a3a9b97547c2b5acab", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "80eb4153-a141-4221-87cf-ba5d1bdb0fcd": {"doc_hash": "df4c6ffef29331e35c1a519e1b6e0669de4846b684d04c52b46834009cf62df7", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "b752b7f2-2695-4ec9-a9ff-55ec3fe08441": {"doc_hash": "7cd8b38dc4088736291e611a05163d12aa4efa9d5b4be07be1f948c7fbe8de1e", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "4140fdc4-742c-4952-ae84-1ffff832137a": {"doc_hash": "0ac9606f6763a0ebaa7d24c1355a840444d68868d17bd49f63ea5411211e645a", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "a499d427-1b34-4173-9746-e843baf520b7": {"doc_hash": "4f9d3171b639e704df20afe7736893c8a694baf529554514cc90044aa9e2c608", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "6a50eeeb-f988-4bbc-acf5-55820a3c58f6": {"doc_hash": "3d948232a3b58329bf3bc49d0f82690ac9ec17d1b4ecbcdc081d6299c5339425", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "b90bc32d-e3ec-4931-91a6-22a61a5e5551": {"doc_hash": "014ec1605efa93e3b16d63cd1ba3b87f1e8e5a825955a2822a320aee39983275", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "206b8b2c-107e-4ca3-99fb-dc18d2995378": {"doc_hash": "7c66151f6cff6a942a1644a39bb122f3fb38cf5f78d3b6b924a3a9298b7133fe", "ref_doc_id": "c9d1942c-2092-4906-89dd-7be3ae15f10a"}, "09281493-57a8-4ae8-ae97-182af622c839": {"doc_hash": "f020d1e3abbadb0404d6f270c9b940fdf92b01d10abf32332ca4a16b050a9f17", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "bf9f550c-7721-43cc-844f-322d3a9fb51e": {"doc_hash": "850353496e311173bb31ad3d142246107e2987dc1f72fc5f7bdf2cb44cc41f37", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "aab3681d-8bcb-43f3-abd6-cec49141770e": {"doc_hash": "5b6ee7da44c0d791a28c7657c6f441fe12000fc14d61220ed1a899631041548f", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "99e6b28e-9d8e-4359-922a-805b3668d3c1": {"doc_hash": "9881476c132c8fbf360839ee0607c22d6cbdaf472649079ccd9d8df71d7dd35c", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "9d9f6968-d4f0-461e-9a10-db22d21928a8": {"doc_hash": "5e1062bd5789a07ca56e6a0fd43f48d69ea8cb9bfde902efbc9bc12dd5a5e566", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "438388f6-e34b-4a63-8e48-628bbb0cf952": {"doc_hash": "2f537f17340d5070abdeb2b747c70c0571b9671212bc1dd81eea1c34740b8a41", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "af0499a9-39df-4b0d-9545-b8028f684e9f": {"doc_hash": "fbc94d68418f1186a9adc23a12d812e7740391627dc4915d3ba4d9295b49c0b1", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "1aba7f59-3a3d-4405-87fb-b93d6160e79c": {"doc_hash": "a01e4c2607dc37abd77beb3fda05adec95e6af803af5c9f9d4a29fdfbd531f41", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "34f63745-dcd7-418a-8b45-69eec821f3be": {"doc_hash": "812adef58e5519ec7459df0bb0a1435f8be4dd48e2abe4beb2e1073ddfec6401", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "238b0dc2-2b41-4f46-9ee8-a0722b653a32": {"doc_hash": "5288041b3d1ca1b9de9462da768e732ee18674d0a8a2839db4d006207e23c577", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "9ce3089a-fac6-4997-a6a1-513f2d985d20": {"doc_hash": "2e225bfb71f9b0f32aa56da6d8da0fd5c79c8e6c15c9c52eb3e573c69d0706bb", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "0adb7022-0512-4741-a726-5e5c0c998522": {"doc_hash": "be45b86d84a79798506b7d61398fc908641c60b84baaf4eceb69e5f86f5471f4", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "6c3d53bf-2598-42f3-9966-abca7ed6b3b5": {"doc_hash": "1a3642f9319f66ffffed3d82e10268c92d2ed6d9342bac9c6b632148b65ac5de", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "a66e2fff-7e15-4fed-b528-36352331fb33": {"doc_hash": "486be80e00fb4d268ef029d391a633cffd59896573432bfcf3356c5b7af4ba6c", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "797aeb11-e70e-48fb-bc0d-6915e3c1d41c": {"doc_hash": "924f253c97804a406a804e939c64f1c36d54f39b3ce5aa75bac26c25b64908df", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "8d848bde-7171-4da8-bf27-80902e24f99f": {"doc_hash": "37ba3a4efa9a1680017b575bf16634772fe5655210a7701caa538d0d34385560", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "0e69eaa6-0d75-4285-b6bf-663ecf99a029": {"doc_hash": "e7bcec943c1bc150f7a6d47ec3bb3cbb6098e13ca76ca64835f1d7f94b34b3a0", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "e715e99b-645c-4aa3-90e5-3ac4baab9128": {"doc_hash": "da310619fe5fea3981689b960079d2703f0b6fd7df015df738dbe5489ad3cde3", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "f830f858-d9db-4727-8ae6-a260988726c2": {"doc_hash": "7a217e718d157472b80eb3ab7bab52f1b4f497e8ed5dcab24dac1ab0849659ba", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "577d453d-e224-43b1-a74d-4c6d749b66b4": {"doc_hash": "aa67614627680c7248c34a96642e76136b81f79d0b3d6569aa421a916230480b", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "d9e5ceb1-6d54-48b8-9223-f89eaace0ea7": {"doc_hash": "d209de04b5b832803e0ddbb12046ee82c902cedba7af42292ce708ee02c2bdce", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "671b660e-13d1-4608-a240-c2e0a2fb0b05": {"doc_hash": "caeb807216867c06666c95f4a5a96e38b2b14ab13848a6d87cc7e4efea700243", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "65ff7c9e-95b4-4a9f-a992-84a553d78c53": {"doc_hash": "ba532eca0c7a2f0e0cb3cd4bda3a9e4e650fc11e2e0d48f7c9fde0f9cc2de69f", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "c3b82c03-f600-415c-849c-13f0d3346367": {"doc_hash": "eccb81916e8a5a26d4f21a96aef9b922f4aa94e82b20213ce3ff53874678395b", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "655a81a8-64ea-407c-8542-2db8a9fb97e6": {"doc_hash": "84d15ba8d405c8d2da24e6f53b8f3d8326373a9f13fb7ab56323c215fcc9d870", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "3d969bb9-be42-433e-9a42-84f338cd9292": {"doc_hash": "7d1cd9aa6825146d90a7e36a4052bcf4cd854adc26a2b51a49e03ec7113b28d3", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "47fa4d55-28ce-4f49-81b5-ef436f075391": {"doc_hash": "94e59e7965790e9a5b1984f346b351f706392439c002a72169acf6f439de1ae1", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "7078a04e-887a-4026-8bd9-7d955d8cbc2b": {"doc_hash": "a9e76263379c491d0dd5ca6bf6efbe5a637a834c756a5bfcaa515f56ddd0c31e", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "a5f94725-822b-4ed8-b136-f35f74495ffe": {"doc_hash": "d2be542ca5bf6ef920eef25ba5de6d24c25c6ebd309a5ebc0e6c20ec8a125199", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "67c17ff9-aef0-4d92-83c4-9332d5e5b4a7": {"doc_hash": "3b3cfd90ad4352ecf5f3e35087d7792c92853ced8660cdc16bd1eb4872ceee60", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "aa31de79-a464-4987-8ecb-cf7f3b2bfcb0": {"doc_hash": "f11a90c63d92898328f324356d2d58bd2efe1283360389d80dc12bec1a1eb845", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "57bafc9e-4eff-47cf-80f1-c04e460139eb": {"doc_hash": "59e8ba833ffda45654e1ee1c8d34358a3e539a9f28a7d6b64696a2fa890cb8c8", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "b9c6c827-2fe0-4816-83a0-d99f82edbfe2": {"doc_hash": "ec92df2ffe16e2c6f01fe259877247d765d4bf7f0c38664a3e0a4713ff039acd", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "1aa8f077-7243-49e4-a6b6-a6be18e9ea95": {"doc_hash": "82ac50f6110822ebbdbcbb91150e118c239644fda4533d240dc361ec0d213c5e", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "265632a6-5754-4549-a46d-06e44b6db58c": {"doc_hash": "9b85d1ff05a8cbcff5cd432cbb75f0678e306aded3cb4472d1f0eca27db99536", "ref_doc_id": "705f3567-1c04-4e8b-b1bd-a74dd72239a1"}, "6c7c1836-652c-4005-99c3-6dcd068e6c44": {"doc_hash": "0019045b1380897f099fcb8f604bee6ccaad9fa1ceaf9872e7e1060625fa30f1", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "4c8108aa-4e96-44a7-8a55-cd8c8c85a3db": {"doc_hash": "ef249afc9eff423ea97e07fce6bb73a74b561bdab4e9f127e45a129d0b331071", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "320cd030-07e3-4c2a-b121-cb5e342017e2": {"doc_hash": "e13dce7aa89f11713a1869a1074a56499799e8c566135b8f013e21093b961810", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "524d9df3-9fe3-4388-91cc-cd25e2b9e608": {"doc_hash": "9883134739d498b4f53fab6781adfde9a9eddb2899112182a491998d12e0774d", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "da8c6b86-07f4-4d8d-a23c-bcee2181bdea": {"doc_hash": "079ad7be0a4049a6eb38a3d2fbd5dc4c5398d9b2991bf4ebd8968ee9b78213d1", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "cbb4c677-2f32-4eea-b18a-771fbefa94c0": {"doc_hash": "8f8de898af226331cd462810c2345528673fe77fdb6dee88a1a200a189d80095", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "d0fee498-497f-43b5-9f3c-44a1f288c7ef": {"doc_hash": "9109c2fa40fd4633b538a12a25af8cd4aaad913d67a3237742131ca34d356ada", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "406685f8-de1f-486f-986f-0227c7831861": {"doc_hash": "b15511cb088a4f18ea4838c2f9cb401af6228d5f39be3e544a8bb45d088a340e", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "4b6b11c0-6230-4bf3-9d37-4ee9549ba7f8": {"doc_hash": "6d13b1784741058e345a59e65162c8efda76c93bf84894f1b947c4de7c0e01bb", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "55e0bf01-9bf0-4d0b-a441-c2355e3b570b": {"doc_hash": "24359f424f6c6d8fd393dd81ff8d2b081be141c46105746eb9f4150b8b56eaa5", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "eb2ae605-5318-48e0-8c5a-5847d1df53cd": {"doc_hash": "e5764322a817d0422ead02c8110c31cc7c658eb39c029bd416622ce27e31b0a7", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "b8962395-8001-4b5e-909b-4865de0de7c1": {"doc_hash": "6b7abf1abbb1a3efc0120b40843bf19dd979536ff7215c43e4a810f85b605ec7", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "0595ad51-ba69-4418-bb83-5808c84b98aa": {"doc_hash": "50592948531004e39c8d88ef857d07ed092bcfd3517095a77026b0f3e19aff03", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "d9078317-8511-416d-a6a5-9391dd35ade7": {"doc_hash": "cf9365a27ccd4f87730ddd0f8b5aee022b843c6beddeb748b446711b4c01479d", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "40ba7804-74eb-46ab-8d35-19ea7b48b48f": {"doc_hash": "e3141248befebaaf48030c434c6769f35ce4b155d9bf7ebe18882b95ba3c85f0", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "e8accf6c-a9a8-49c6-a438-43d63d4a5360": {"doc_hash": "b91471d15fd3038476da65a6632d473ab40c4dd6a1822395761211516a61779a", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "18de2489-bfd3-4d33-aafd-30623a95cbe7": {"doc_hash": "cbb1da1374d5ff68f1f6d8a4600e2af4a20a8337b37307dcea0d5a47a3af20bc", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "0fcd8fcb-2c9f-4765-8af7-6d4752a76f27": {"doc_hash": "fc9acd4fecd5d307c0fce8ae77ca29505e98e743d0d63c3b245da5d52e90574f", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "bfa84433-8a1b-47c1-bab4-406391bc3fe8": {"doc_hash": "9474c8b7975ea8f8e77f5b29272443ce24e4663c61a9ccbac05a1e1a1ecfeee4", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "e2364330-3920-4172-a225-d1b660d04022": {"doc_hash": "a1dfc046c6e5903e2302b46953190c364e77f19bb88ffa10a59cba1a60f53a27", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "ec84a815-65c9-4fa5-b150-ca98152e7e4a": {"doc_hash": "f19f5422b29e7f98baeb8087b765a1ad52a4c76bef171983c68aec3913547880", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "12deb404-bb80-4c62-9633-57cd790f7a34": {"doc_hash": "77f80ef7f46fa8555b363ba5c96afe761c7e74977f5f8f482f7644d3899391c9", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "fcbdc5d8-3d5f-4203-bba1-bf6b0402e1f1": {"doc_hash": "c4cf9d6dc9a6651958104c4b8c8f72becb81210c59c7e6d76cc65f8576d3f9d2", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "97588fc8-1492-4a80-b928-9042c440e571": {"doc_hash": "ea4692ee07661a215fa376293a3f39fec1fa4715c821c9ceee6710896b524b66", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "3248ffed-7540-4144-b784-9899015eca46": {"doc_hash": "8f1905a7413f4900d4ccc9128aa6f0420351bd7c5758015e4be45f8cd533c02a", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "844450bf-54b0-48cd-b312-14d976083a99": {"doc_hash": "6bbf8ab0a1b6095142e40ae4b74ed239708d88f30f44a29f7ec122f1601d50d7", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "5c59148e-ad22-4276-8ca4-14a507ae6250": {"doc_hash": "9c734a2a6dd084c4df2677710af4623521bb54843e21c88f793375c573374fec", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "2fbd0858-40f8-4517-aa66-61b5be12a91f": {"doc_hash": "90fd8bc4839dfacbf1604ef26dde88e91dd4d8ce7ac5af55154a5298e1aa9eae", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "53ca9fc8-ece1-40bf-8c56-50475386b1b2": {"doc_hash": "60c02612c1d1c1440813023038183321226ed3cf8b7a7964b475a0ff910855bd", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "ea32f2c0-529a-41e9-a5cb-e7b67cc23856": {"doc_hash": "5f26ae79ef79a97106528f256c17ddd818ca46c1564fdbc30c92df898cb5dbb8", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "dad0968d-eec6-4aff-bd22-6735edf5c67a": {"doc_hash": "8404ee5bc2c7ed82f052ff04c84a44184c03c305e1573486c01dd9ada2af62ad", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "fefff314-e519-4049-8cac-d5b43c562e7b": {"doc_hash": "72a75c9cc0931eef537599c930057e4f3921f0b81082bd8c3c83c5c8323a2472", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "624433a9-d947-4ca6-bb08-6ea8f79f7810": {"doc_hash": "988e366f782f44bef70b553d6bdf0ae00546d0ce83de81bb8aaf613fd9b33732", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "e30fa7cc-88ee-49d5-9ed2-778dc13e31f8": {"doc_hash": "5d28ad0f346a1728559b81fa43b41204f1f36265ff232ecaf8d0b9ecd92c5a33", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "a4e245a7-39be-4199-9cdd-f7ae86d549ab": {"doc_hash": "5cca6fc8fe5ce55df32d515dbb222c5024f16163b56957be6ad67eb3eb1e1f60", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "4a993d9b-4140-43ef-bc71-b3d09eebdb0d": {"doc_hash": "5f7c3f75134619f7df1b87b837c6365c9c74bd03d80608f67738bd66d406608b", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "e3661884-d59b-4b17-a41b-db31fe20b462": {"doc_hash": "c8444cc2fc8a002d6a47956db366e40ee28acfcb499971e429663ebbb1a2e37c", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "2bd6de5c-5e10-4a83-b7fc-66aef2f40476": {"doc_hash": "8a8a7ed1001f31497557dcef31f009dfc7362902ba288f39fc5aa463893612b0", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "cc2f3f35-00df-4665-8fa0-5912a19591c6": {"doc_hash": "2dc289bb4bf59b9072ad9071580a015c257684a80144e09f4f1b1889eec7d461", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "9f791413-b78d-4c38-8ee6-90d9f7014a7a": {"doc_hash": "adc61c032b978deec995cbf09237297195862b5156e086f373a176218b178a53", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "56d3608a-eaff-4c28-b6d5-80b8882b7add": {"doc_hash": "fcfcda75ecab9eb76fe62546987c5bfd4da0f8792087ff176852ffa823df1572", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "a3bd42d0-4188-4b3b-a995-6ad754856081": {"doc_hash": "def5659a260011a41caaee87a74b3aedcf046c81b3a95e3a0a2a8a228ba3ea95", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "5a44d87d-703d-42bc-9d77-8b1291bd70c1": {"doc_hash": "81e2eb4942727d2192dd40150a0007e2e27984aaab0c60039697047971966bc9", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "2ce3d17c-3c1a-4091-84ab-66ac074e4371": {"doc_hash": "915c500967617126feff36accecdda66722b7ff608cb12f2840cab601b36a408", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "a3e35f35-1ab2-4473-b500-30cd734331ac": {"doc_hash": "014342b768fb017fec44856826410403eed965f9eb2f1924a04a3f7c99e1e110", "ref_doc_id": "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2"}, "0d07168f-344c-4e91-8a23-ae87b7710090": {"doc_hash": "53b5c048579620132c76c49add309af90d079d1874ae404d5a4372fce78b8cec", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "51b25754-891d-4a33-bde9-dbbe0349e5a9": {"doc_hash": "3705c5d2659f5f006afb7420e7d52517fe01db9b51e0846b9f94d33ba141ea30", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "0c3dfcfb-61c7-49c6-83cb-af270bdb99a1": {"doc_hash": "246cd153dbd5ac3b65dafd10846fcf536794510a517e4a2cb767d2df21bd1bb8", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "deb05d14-b06d-410c-9b43-4e5eed5ed1e0": {"doc_hash": "91c546c8a782257bf87424c9e9554d87fbf67c8a3d93d5373286f46b58c7c86c", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "1dc1ef36-7bef-4ea5-97c1-4c6e34fce277": {"doc_hash": "a512640f96910e589895801fb3edeafc23171bc1aa43eb0142dc680e07753103", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "cd24591d-565e-46db-aed8-c77f2bd4598c": {"doc_hash": "06bb78e62c56ac65d3043d65d3ba8e228e1ff2ea10f4b55affe3393f4d4840de", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "409572ba-d848-4c0d-9966-f6a445aec269": {"doc_hash": "ed1a22f0fa98e12759c726ced83f8f3e501225d73e13472bca44909e0c90760b", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "2b88f1aa-f736-42b0-b514-f1e009cff485": {"doc_hash": "00fea60d9c613a1bb0ea929323d6602b069f9d6bd23179d6bbf88c204700bdc9", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "d45cc359-3228-4de6-a018-b2deadd9f2ea": {"doc_hash": "4e50175a6069cb8b3bc7f49ef14c73bd498083db53d360ac6d0505805a038531", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "0beafb5b-c328-4d79-b87b-f1f5d16db3b8": {"doc_hash": "1b291f375707c618d310656833913a59965aab669731d72b34a208b7548631de", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "4a1096b5-e3be-4eb2-acd5-b947525f519b": {"doc_hash": "76ff31897ba1aeefa51c8117b4c21607beddb2b34fe2a20b6a5436d270213443", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "4798d375-f06f-4d2d-b422-41e3bae67f66": {"doc_hash": "d4f498a7c391faff135195ab34e7a90c63c7910645c89e9c87adc0cd2e88e86f", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "ccb817c2-cbfa-45e4-9683-da7433fc6a04": {"doc_hash": "3f07fd79c225f87949b9948ea14201b87eb38b6351dc4aac0c4ff5699fc0f68b", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "8ec6b0d8-7f53-4d19-8f79-4d5c12a3e115": {"doc_hash": "decd6018e656465225122e74ab35e3aa493b5d0ddb7f01f2b7ed10bc654182ed", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "94a55e53-fa85-4357-95cd-c6943a29f52e": {"doc_hash": "8c5fb9d095a7347705b4a3d06a2b21dfa08575febc53723a09ef8e597b17d94c", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "6e6cb8d0-42ee-4084-9edb-081e60b92be5": {"doc_hash": "0843814bf0fe9a757a9b930e245261bc2a908640fafbc1b3d5a0affda7fe04e2", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "daf989b2-00f4-4ced-a5be-a77dc5d6d981": {"doc_hash": "6c5c2ad39fd8605107aa35ff9a3c56ed91d93e4f886e375205e6140177727bc0", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "4cc5bd73-39ec-4b59-ae9a-9d625c7fd052": {"doc_hash": "47a1b64a87c5426cbdeb2240f54d6a939cd0f9211704098d536ae7331d3e46f1", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "3c4d2cd4-831d-453c-9291-b291c10b0e65": {"doc_hash": "e4cd592b8177fce1f4c0a1e040bb400ab30fc8b30afb4d9c3226f234c1e2a791", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "3657af96-808a-443f-af9c-860f61d072f3": {"doc_hash": "f4d36a8e4a141b1b50c91834130571895d58ff0dc4e44c3395947a82e34aca04", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "62840c34-b24b-4f44-b199-6185a492358b": {"doc_hash": "13519ae55317945864b97ff1d9a7d580b28399cc54f3dbb6176354916fa2c90e", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "f3a802b9-fb04-4236-bee9-59a59a81a386": {"doc_hash": "699c7773c88fda033b6cd9c53b4e051caf3dc8ff0eba2a893dbac7d5b5ddffeb", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "ed23a65b-70b4-467d-b76e-f25c12a5f7e0": {"doc_hash": "a52b2d76b5fae2f8d6b404ce44192e1ed59bd1d0a5bdb99bfdb8da6952282477", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "edeac990-d822-4018-8c55-3202ce5489dd": {"doc_hash": "7e8eb9aa48a3c6883215f79fc90c14d893715b8ed5f4c5bb7207a8af05035d5c", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "b714f97f-f512-4311-b4ad-b10013bf6320": {"doc_hash": "bce95cc3020f77a5c6c46cdea8b1f8670d703e32f80072cb5082634c465d05d7", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "5872d0d5-f6d0-49f6-915e-36204fe0eb68": {"doc_hash": "239df5495c6f0cc8398b184bdb2c9a51407c311308ef8a4aa1565665a09e6f10", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "5f872346-ea36-4cf0-acb2-caeb3e46e20f": {"doc_hash": "2862edbc5d91b4cd600c0d6ae21291436166e6f39a0594dfbc4df776373f916b", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "ca96655c-64eb-42df-a28a-569772ee17db": {"doc_hash": "18851a1fc80384bf1cde0a6e8091e97b492f9e5f52153dbbd7cb1900690282d0", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "3c26a927-62ca-4065-ac80-6f390332956b": {"doc_hash": "b07f6a4ed220ac4c26cd0f96a01e14f213092484b074bba3ec59bd155e2e87a2", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "def9b295-91bd-4d4b-8278-0cfda143a631": {"doc_hash": "1bd8d82c27ccb2447948595c2e8bf8f07de534b87200e237865db4163b009855", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "8d9a2c8a-217a-4ad4-aec3-3561555200e8": {"doc_hash": "f169aaee81f49bd19772a6dc43b8e9d0bd6d7b23ec45283dfa926ea4e69d7c7d", "ref_doc_id": "8c4b1766-ca74-421e-9272-c22eb00993aa"}, "8bd3373b-c980-46be-892e-969dac8febe1": {"doc_hash": "41515baff7d28bc2f6531f533d12349fd3b93a8eb679a27acd14b56ee276f46a", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "4819d2ee-6ff1-4228-9e0e-e6de41f085a7": {"doc_hash": "88b2fdb7b8ebaecc62f9f3d38d977ffadc699db6922f4123e8f7a17b5108cde0", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "3725c1e6-dd8d-419e-806a-13e26c7c302c": {"doc_hash": "cadfca9b0cbaae14398745fef35b0550445e28234079c796d1c2b50eab36dcea", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "66c00aba-19d9-4a28-84e6-09919f0b5b33": {"doc_hash": "606f5f09f07fb9f2b10a8666574f2d5d053a43c146f6cdbf6a1bd47b12fed029", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "5512574d-dadf-4988-a287-628397c55fd6": {"doc_hash": "e9d61f32ed0a029191cd21a6f1d3e0ce07a434e915af50c3410e73c22e6dde13", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "57e6518d-e97b-4acb-b7f4-f56a74792df8": {"doc_hash": "0d366cfe93b9b9ae610b4e074da15a36abed0c1e19b40034a487062319f66950", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "fe2a32e6-dd1d-4731-8f87-64941a19a60a": {"doc_hash": "d57b064e7370f28f9e5d29d728d3fc7308d62631ebd0804e98259f19424be976", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "6ddb5c50-f827-4035-9b1b-d704ecfccb85": {"doc_hash": "ea3be38803484bf27beae379b109135548a0ff1c540fb44b555b82944f73c6ff", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "8f513455-9f31-495a-8383-243cf8aac3ab": {"doc_hash": "e7b6d7b83c7a1e9ab57c4e500def51f6cbed79f51f5aaabac1a0ae28ea7c2821", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "c2b371e4-ede5-42ab-b80f-91da42417016": {"doc_hash": "e2cf4c7a50b4dcd9b71340e662691dcde1f304c1f101854d9f364d55da4b58f9", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "985ba636-0675-4304-9a25-195671318bc7": {"doc_hash": "3692eccfcd463796235b88c3f009e85d60933268c3a7b8b74ef7bf98ea60b9c3", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "444b601d-c56a-4d54-9599-ab73775f7f6c": {"doc_hash": "f19c00a86c49d832dc9e23e0f72af6fbfd0a979e60e2094625f4f8ae584a8e2b", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "0fc1dd9f-8a58-471a-aef0-75cf2afaabdf": {"doc_hash": "162db3d45166a8cf12d4225f839aab6135e77ab397c4b6f375e985d4910f99d2", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "0ebee5d1-ac00-455b-ad3e-58a8ec7b6f46": {"doc_hash": "ffc919f2c30d835f0e9a32cd1766425e4b5d33b5070d4ad8fdcf0aff280cd0e7", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "29be5e65-ab08-4ad6-80b3-817174ca9e68": {"doc_hash": "6817b70e743f0f023ab1ca1fbc7e86c4f5f1dc36582d60cfeccd73237f98f076", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "c83568f4-0774-45d0-9a07-fdd629e0f2c4": {"doc_hash": "67659f2be39e5b1c1139087f6ad12430eccb1c964ca7a382d8ff52a69f5d8e4a", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "48393774-05b1-4a04-b804-6baace95b30c": {"doc_hash": "bca754988c6522216aad3c3108e30d55e6e98f0ad135ea5a2ecd3c5c815988c4", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "35525356-dc0d-48c8-b6a3-5eccec355b75": {"doc_hash": "94eb777198b923d73fa473dff1461ffed6731cc9f41d88ab0087c870c2cb1ebb", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "e7fee178-262f-412e-afac-cce1615417b1": {"doc_hash": "748f96c9e35a9a077c518de9326eb43eaa9095aaf2a5f551c16528227d1e995e", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "ccbf56b9-a0b8-43a0-a513-f4ce6215f4bf": {"doc_hash": "f7a156e85d06cef08e355d38cab64bf57c0694bfa203bf78274e285ca1c8e4a9", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "fdddc7b8-c3ab-4a60-a866-db9e6e3bf135": {"doc_hash": "4d62615ac21bc70e47dc8da269c2cf5e66047951566374024113ce0196970141", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "c3280658-e1a3-4022-a8c7-34e09e865af0": {"doc_hash": "8f49c759324331f16c7d48734b7f8f53ce9efd06c5a528a5bdabd9447ed51fb0", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "de68868f-8c8a-46c6-9a35-08fb243dea44": {"doc_hash": "fc0ce72db34a049acba3245e727e8367fb130d9d88b4b99a3fe6030f9c7d9429", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "e2be6c45-5c6f-4390-9637-72cedf94b162": {"doc_hash": "6d3e68f59532cc07c318b8ae414965c68b6834fdc9bbbb2c16d1af4ec29cf0fd", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "f4ebb2a2-e3dd-4c1b-94a8-acac6682bf5b": {"doc_hash": "bb76bf7ab272eaa3fc990e4044c1faa4704b98d1a040553bb209af0ac6f5a3c0", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "8440062c-68ff-47cc-83c9-bdcfc30835f1": {"doc_hash": "090493d4a31bfb953f935487466ab05c9d9967b6c011674d84a5e696fb5dd160", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "d2ce6169-6ace-432a-bf70-eb135c71e5da": {"doc_hash": "0db8d1cfec7e95e60abbfdd5d8459045e42904e27b524e82b522190ecb09b15e", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "96337448-f128-4180-9bd9-69050e746959": {"doc_hash": "5ed7f7d3af92bb68654896f6e062ebda7eb1837894904412a65b7a6d23be05fc", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "7e7a0334-cc8f-4da8-82ae-a4e121beebce": {"doc_hash": "af18cdcdafe3eea76969caea20dbe0cc9fbf11184d085a903ee6b5c04dfb1f18", "ref_doc_id": "9ee7b58f-008d-4a60-9057-6bfc82226f8f"}, "5b3584d3-9b8b-4adc-b92a-fde80a16190d": {"doc_hash": "e872544d51f40b2ae3efaee4f5f09ce13eca7027800cff8c996cc5b4440de1af", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "477ef5d9-fd5f-413c-b33e-6fd8d48b6438": {"doc_hash": "ea5f81226de4b2ed3c14df61a92cc70ad805fd40d95bdb797ebc624ef7bf9fb0", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "8a663665-f06b-41f9-ae17-3436c447a0fb": {"doc_hash": "3280ec50d0a78f3f625724b666bd8c13398f53a84e8dc16234d867fcbc67c0b6", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "9efd74a8-dcd4-4063-a7f7-114eaa925a9e": {"doc_hash": "77eb5ef89011403e4755148758f9210b1550506c0b0792176c98778b68668648", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "d55238ee-4d9f-4e10-9c8b-d7c1c71a11e2": {"doc_hash": "147b596c873b5e01c6b7e2538df8556f69c8428c2544431580eb83241ec9b0d3", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "64cfbdbd-7fa7-454d-947e-d0cabb098a54": {"doc_hash": "d2ff498975d0461f931ccfd7395184335618f8af214d9aec33c999a294924654", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "f0a70d93-a4bd-47cd-8255-01c1a42d2c47": {"doc_hash": "66c19726453283a673f69c1e5ac458a5eca7fdc2c31522773c062704e455ed2e", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "3d1882ed-e5c3-49d6-af7c-3513d0217ba8": {"doc_hash": "77f7e1c94a59b0acce12ced0148a69a1f7c202faa0856b2ab281375a772d70a0", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "3c880aab-49a5-4079-a799-43e8078dd9a9": {"doc_hash": "01d47a4e39427642163f61ae5db924d56eeb65467085fe9a69743a7035509755", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "817ecabd-73bf-4a33-8a03-f1a08847ef9a": {"doc_hash": "c41574eba9d4379d9cbc7b79b65cf23b399ecb52046196739ace6d4aa8e089b6", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "5c7cbd7e-d1d2-4103-bf95-9f35253d6f55": {"doc_hash": "16075495f27bf3461164c730de2ed54512731371751891c9b3f94ba0dc726fd9", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "09f30da6-22df-4319-abcc-b15efc440203": {"doc_hash": "499f5b4875550afd8398a68bbb07f0b74d298d304a9533b327df6a5b9c88b1d6", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "ed0de57d-b1fa-4823-b259-473492f54da8": {"doc_hash": "89ad68037f0b98f9b01e200e69f39a050c19b8890109534ae2fc09c0abf437a7", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "0c662fd7-7996-4f63-869f-6f3f4ef79322": {"doc_hash": "e632d2a9bbd57d0de2258c92e79dd479a0029451b21810a5a48d9b94c463897b", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "67319be8-de99-4f08-a884-4ffae21c90c9": {"doc_hash": "6e36d0391040e467fde06ae71f0aa5d6ec14946ad35c43f5687fbf47dd414351", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "da4756d7-8c0d-4b1c-9795-1a02404eb7ed": {"doc_hash": "7070c65ba3163321a50320534c14ad0af916a73770909cb46ddb12d8f83fd2cf", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "f5a66642-d5b2-4c03-891d-de07dd0fbe9f": {"doc_hash": "bff930118e8d090f4e528b0088cfe5c5728edaabbd215ed89245d2fbe6fa4a1c", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "9e7e4520-e385-4509-b7d2-7918517d1ad8": {"doc_hash": "f2a0a5fe473a3603d5823ab5b82901f4ce2d442a7da380718f4a7bf305a519c0", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "af88e9ec-f419-481f-9cb8-fd91f7d83952": {"doc_hash": "62dce944527dba70f60ebeeb5248c99ebf9a53e395413472efdebf80ee450c7e", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "1bcc3176-d3c7-4bae-a302-9ce001a97e42": {"doc_hash": "041589447aefc680787807d1b394956ca687bfa5d3269eacfdc3359c1adb6bf3", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "c6353a08-304a-4382-95df-6ad18c311f4a": {"doc_hash": "3dc036a4f336d798d89fbfa286b12d4621a81c68f858425e0ddb45094c49823a", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "9a95b8af-cec1-49a8-b63e-c54eb0de905f": {"doc_hash": "04c8add939c970e93d68ff8482b8784ef1fda0f2d7ef264e7e90bd83499d2b31", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "c0ca695a-ed8a-4795-9bec-c635a37d9540": {"doc_hash": "75753925fe363f2573a4530276f271a52ce18b48ef7593db9f39a58e28bc4d69", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "e3ed4f66-a831-4a1a-b523-85daa49d2afd": {"doc_hash": "1e87f9426e48962f34424ceddbc366a0ae1f85540649b7378803e43277d8cf30", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "2871197d-f858-450a-94b3-156f785288e4": {"doc_hash": "253c97b9635a05ea6650e16b03208ef497820cefbd12d3e5fa82e45b290c48d6", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "bca25f42-2f6b-477d-8451-f8a9dfa833a7": {"doc_hash": "dc6d4060401ac5309bef65a06fdb45dd9d96345cd348a751f29f3ea11271801b", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "3ddb4a68-7280-4ebd-81dc-b54f91235fa1": {"doc_hash": "40460fc79aa89b4b6c75900ac9b59134932e50bbfee445e2cf3fe7512459e941", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "aa35469a-7253-44d1-85b3-73ff8b40b759": {"doc_hash": "f75b158c3fa000ef0219f1575539bf3177380a68127ddd22db4a06a1a19dc234", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "9951aee1-1a45-4a3b-967f-dc83d9a556cc": {"doc_hash": "7e565190e24731c6456ed7966bb58e11cec076cd2a0446ba19c52a8ee84eae36", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "08b0c490-fd3c-4fe6-8b2e-b92e8ce6f54b": {"doc_hash": "bb573b61efc44bd45eba51a726376ac261e99be924de23cbd812d0d9bca95fd0", "ref_doc_id": "d70cd765-d00c-45c4-a597-e34c1fd5e714"}, "bb45d58e-8a9d-44e8-8207-5eee18ebeb2b": {"doc_hash": "a6e7b89ae6e6339c1545653d518c0703c7f58518c726140078f7b02ecb72dc50", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "11d5b1c0-f007-4974-a6bd-b65078219561": {"doc_hash": "852bb644234dac15c4c2fc63652800901451d0c60e84a7f4eea501ce168cccd9", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "71a36ced-3a8a-4db7-b7fd-739e60f3f32b": {"doc_hash": "16a46dc0a4b7b3ea4a4e96ab9a6bdde3a1fdd9b9180e9b58cabe139b825a0649", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "afdaebe8-46b8-49a7-8991-e3afb1ecdb1a": {"doc_hash": "6745d92e8c222d1c91365d331dbc3815b831904c8263356438710898f615b88d", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "589c5760-87c3-4ec6-b2d2-b8e448f83196": {"doc_hash": "12470928446b41777bbc2ea15318e6effdd60bb1e742e5f18241f39d088fd420", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "09933c53-3eba-42c1-816e-cd993e9c8a4d": {"doc_hash": "6b74b928c9015be79a6ff31844549c1bd8ecfa44c8dca5fdae4d405cf923df0a", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "c4e40dfc-d41c-4004-8f1f-f27b879f817d": {"doc_hash": "63b240c4a8127fee5230a70509e786a7da321a95f06c63598101ebfecb52afc0", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "2c2061d0-c3e2-4215-bc7c-cb0fdc47cc28": {"doc_hash": "5e44bc8bd0647bcbb6f57a59627c6b05031862cecf0929908950f1b1453f607c", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "53cc5cfb-36af-41f9-a871-eb50239fe5d4": {"doc_hash": "3a347c2cf233d630f292406e9521314d6b405b1209701260f4dacf17cf690583", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "463fcd49-d2aa-49eb-afff-0a81e523730a": {"doc_hash": "a33223ee245e5b51ea3fdc19b9dd373e8f95b49d3a6b98dbe4bd18fb0e81d470", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "75292374-cc01-4414-8d31-bd1b882b6033": {"doc_hash": "039930b76b381569800ac467912004c784ce2758814d19bdf77db5a1e9e86a5f", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "8bc690af-e017-4c37-b145-d483c4e180e9": {"doc_hash": "71704672bdebb2a91d2f28a0cf9780ee90446857b9f59650f1d549aefce6accb", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}, "3be02d27-d638-483b-84c7-faf0c647cd80": {"doc_hash": "d94d7032981d658f5f5718433b78717d66df181cd7a72717bf7f33279e41a20e", "ref_doc_id": "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7"}}, "docstore/ref_doc_info": {"4e445af8-7e6a-4248-9fb0-0e69ef95c4bf": {"node_ids": ["8a18b715-4d21-4660-899a-d5bacabdd209", "487df8c4-d11a-4214-b81d-9f434234bcfe", "a2f53de9-142f-4ed0-a9df-998a4ad55fc6", "64f7b3ea-7c5b-4c6d-b74d-5a18a0cc68ba", "691f2ff0-f72d-4c90-8f4e-3c87313fbb39", "5b07050c-a339-4e4b-9c5a-9d195d01b30c", "d6c0d5c5-cd5e-4c03-adb7-5018488f4c91", "324b16d3-8f12-4bb2-ad4a-e66634fade20", "5a84a070-cb03-4c79-aac8-62e3f2480743", "a3bdf4e7-2502-4577-a701-8b4354f0ccf7", "93c553a6-33aa-4bfe-93fa-c32a0954f7eb", "5fda7b66-2aba-4ff6-8853-880f6881bef8", "0b23bf48-be79-485b-a7df-c04747663807", "7b937d73-f2d0-4a8b-90bd-bf6cc47d563f", "1c77b890-9816-4c5b-aa91-66e15e9f026b", "bc5f2b3b-a23a-4324-9710-f6cd84aa0de7", "ac7517dd-cd3d-4be9-b8fb-0039539e15aa", "e7f5187d-7ce8-4661-ad1e-9bede4c0b785", "fa5ccd21-be07-4e1e-8e6e-1b3dcae6c1ca", "f29ad5b1-38b8-4892-b043-eea95b4a5a09", "73568e45-f674-46d6-ac4e-d36e876e7967", "cf7dc50b-84e3-45d9-999c-5f8382a0a154", "8ac430be-ec22-4401-a355-1698bbcc2e0c", "b1572aab-24fd-49b4-a652-cb67f7118f59", "e12d94b7-9fc8-43c7-993b-938810a830c9", "2873620b-8927-4df9-bc15-e7b66315db2c", "115aaf47-238e-4583-8356-543066f42e63"], "metadata": {"window": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 3, 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Second Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I'd like to turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "original_text": " \nPage 1 of 13 \n \nQ2 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "856c4011-9e85-4d6a-a778-2ec432012364": {"node_ids": ["df58a569-e898-4d33-94a8-1d1631e3622f", "3415a12b-2eef-4420-8b8f-8c708ff5f743", "2bd77940-a905-4195-a21f-c0d0a83c191a", "3c40b3b1-cba2-4a8b-9405-555d43484e9d", "a0643812-8bfc-430b-b2bb-cfba089a60f2", "ed32fa9a-92df-41cd-8481-9fd39f1254c6", "2659f564-2e2b-4a0b-949c-ff7ce23f2a57", "adfe9e05-4c02-4c00-87f1-ab2f2d39ae42", "14fc9b48-9e70-4cab-8c67-841447068d25", "f54e29a5-9fd2-44c2-8f1e-f8f8759fa234", "fc3bdf0a-85f5-4cfb-8837-8510847fa604", "9ecadcf5-b601-4fbf-a667-1d6d46502703", "178db19e-8b00-4728-b552-2719cf15e950", "e75d9633-8f59-4e31-a3fa-45c44eb13d9b", "18835c64-3fd1-41fb-b106-ddbabc01e082", "1ce275f5-377a-4daf-b70e-06fa9a8b521e", "25e3ac0f-441c-4a7e-b030-fd751f9eff63", "55a321bd-fd6b-4373-acec-67641476366d", "a5dbc850-e99e-433a-833f-96583de3fdf1", "95f06d92-6b27-4220-b9db-3802ad43e6e3", "8e1100ee-d3db-48aa-b41d-6da34b8484cc", "7fbc93a5-3f1d-4440-b01f-630c6900560e"], "metadata": {"window": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.   Consequently, we are urgently wo rking to mitigate the effect of these external \nmacroeconomic challenges on our business .  \n \n We are seeing progress in other areas of the Medical segment, including our lab business in growth \nareas , and we recently extended several key acute care distributio n customers.  Looking ahead, I'll \nelaborate on the actions we are taking to drive performance, particularly for Medical , after Jason \nreviews our Q2 results and updated outlook.  \n \n", "original_text": " \nPage 2 of 13 \n \nWhile we believe these impacts are temporary, the timing of when they will abate remains difficult to \npredict.  ", "page_label": "2", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ccb1a096-b8c4-44fb-b01f-c6fb5ca22891": {"node_ids": ["21373f1b-42fb-4bf8-8711-f1e56bd4f857", "fc563ad6-fd9e-4752-9aff-cba21639e134", "faad391e-873f-460b-9c7b-e8d27dc2f577", "31a977e6-353c-4eb5-ae21-8147bc36b2d5", "aaea3f17-e754-4ca9-b6c9-0a73ccbdbec0", "59a89ebc-d15c-4872-b4c9-5a3fdd2f4829", "c396cdd2-5ada-4d1f-a69a-a532aff6d701", "8e777dac-9cd9-4c05-a4d5-ce0b5131034b", "858ef2e5-c70d-4353-9fd9-83c10ad75ee1", "3177754c-55e9-4b26-87e8-d540e20a9223", "ed0a2e98-b865-4d90-87e9-ff8c14dc7042", "b8afdf7c-4062-4ced-8f25-78305bc55560", "5174be4e-a826-4536-9175-9187818bdd52", "1f591d9a-4d8a-43b1-bc06-204d6da7beac", "8bd99dae-d5c2-4aab-9680-c2e3751639a4", "9d528835-075e-43f9-9b3b-eab6684eaf0d"], "metadata": {"window": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n Segment profit increased 3% to $426 million driven by generics program performance .  This was \npartially offset by our previously discussed investments in technology enhancements and higher \noperations expenses, including cost supporting sales growth , such as transport ation and labor.  \n \n During the quarter , we were encouraged to seek  continued , broad -based improvements in \npharmaceutical demand consistent with our expectations, including a return of generics volumes to \napproximately pre -pandemic levels . ", "original_text": " \nPage 3 of 13 \n \nRevenue  increased 11% to $41 billion , driven primarily by branded pharmaceutical sales growth from \nlarge Pharmaceutical Distribution  and Specialty  customers.   \n \n", "page_label": "3", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "96fbe9de-9274-4aef-b03a-fe803e7f7f11": {"node_ids": ["d4d78b90-57d9-4968-9f3e-5c6518d6f017", "a3f2de65-4b54-4263-a11a-90f40e97e842", "0fee0308-c83f-406c-8d2e-b375b2355412", "c16248e4-3da9-4ee5-8d66-4188f9dd591c", "e7fdcab9-472a-492e-9b76-f2c60f9cf3a0", "2ff99423-1bea-413d-bb07-6d85298b2199", "0c2a6902-8455-4758-9ca2-3db340c81a6c", "40b305cc-c2f4-421e-a9df-4ba483169ea8", "bac86dce-6a31-4a20-8ddf-a5eede2f5bc7", "74054057-b06a-41ca-8d5f-e16c1c3e9547", "27bfb175-a2c5-4f07-b45f-24bfd77b5770", "20165d0c-8439-49af-8247-d33f1f560dde", "4d924ab7-f2d2-4143-b244-8bdd79a75117", "e6cbac8f-13e7-4876-bc19-6addfc003f36", "fd424dfe-38d3-4eff-be6b-01563c0a4a6f"], "metadata": {"window": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook .  We continue to expect low -double  digit revenue growth and \nmid-single digit segment profit growth.   \n \n For Medical , we now expect revenue to be down low -single to mid -single digits and segment profits  to \nbe down 30% to 45%.  \n \n Consistent with the financial update provided a few weeks ago, we expect increased inflationary \nimpacts and global supply chain constraints, as well as lower -than-expected pricing offsets, to result \nin an estimated incremental $ 150 to $175 million headwind to Medical segment profit for the full year. \n", "original_text": " \nPage 4 of 13 \n \nAs for the segments on slide 9\u2026 \n \nFor Pharma , no changes to our outlook . ", "page_label": "4", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a890dff1-9362-49d1-8301-69bcddb1f082": {"node_ids": ["4ea5d723-eb47-411e-91d6-2758f86aad24", "c5a3fc2e-6b15-47c3-bf74-6f28b124cbe5", "a8d38b99-e09e-49f8-a1ee-c34e2d8cd550", "5d864838-7d38-48c3-a65c-937708f63a5e", "b426a336-8e3f-4d3f-bbe0-b9af04dfbfb7", "68ac87a8-8c5d-41a7-a188-123c36a5ef72", "28f12405-2321-4a5b-9225-47f521d08235", "7a12ab53-de5b-4423-aa92-be1368415e3b", "b44fd569-7bdd-4a91-a855-514462d1fdaf", "ea69bdbb-f9e9-4aab-93a5-d276b1e3b7d3", "73803877-2b21-4cbe-a347-851cf6154e82", "f2d9068c-a3fd-4742-bca4-da160a406be5", "1da8b24f-11de-48e1-8448-dd5a39f3338b", "77d4257f-97ba-40b3-9010-4eb9f762600d", "7ee1d6c0-bebe-42d3-a481-dedcde0a9248", "82568a9a-755a-49e3-90c8-374a4e6b69ac", "e91d9c7b-edd8-43bd-af88-efb8289b6ff0", "6c86291e-b51b-45fe-9ae1-7833011504e8", "f528f00a-cac6-454c-badb-c7373a2f2379"], "metadata": {"window": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business.  We are vertically integrated with distribution through our \ncomprehensive Medical products portfolio, which is generally ori ented around the Operating Room \nand the Intensive Care Unit.  We also have an advantaged Lab products portfolio and higher margin \ngrowth businesses.  With our diverse customer base, we cross -sell products and services spanning \nour portfolio.  \n \n", "original_text": " \nPage 5 of 13 \n \nIn Medical, we\u2019re continuing to take action to drive performance and maximize the differentiated \nstrengths we have in this business. ", "page_label": "5", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "dd3b63c9-237e-4ab4-bea3-ecfa138812ee": {"node_ids": ["721e79ba-2399-43f9-b912-9fe0c55bea14", "cb3e4932-54cf-4df6-810e-8ba11abdc4cf", "d3ab288a-3a9e-4761-bbd8-9ffad020c776", "94c7cef1-8999-45cf-820d-d7a310d7da9e", "2964809d-5ac1-4624-965f-4e9e3e23d62e", "741b2d65-3824-4a09-b6da-3ecf5922d3cb", "329d4c9e-9058-40f5-9b3c-d186325a8844", "51bcb97d-6a93-49ed-b8ae-d0c7fdbfdb7f", "212275ec-db62-427d-ac0c-5395ea088470", "4ffa74d2-c536-4bd6-b5a9-1860e834f41f", "349426f2-0907-4b6b-b869-6bad66cb1012", "7bca876a-5602-41f1-a069-db912d029f7a", "d8959190-322d-4f35-b26c-97adb59afbb7", "ac8e606b-ff42-45a2-8ca9-999a8898ef94", "ed8e9ef7-75b0-4699-8cce-8f6b56c0b06f", "3aeaa93a-ba13-459b-86c9-86e7f0cd60fc", "f731da7c-3197-4619-b1bc-1bb43d22501f", "a2d7e07d-18ca-44c5-bde4-ead54894f792", "ca1af714-972d-416c-bec6-34d03839a18e", "c72a4a32-bdaf-4cfa-bebf-c500fc1b1be0", "f471b982-3655-462a-b883-b084bb6e43a2", "3cf4ff4b-e207-4d92-b2bb-a4cd92655dbe", "43b8e7d5-c4b3-4865-bd71-53cf1da83a01"], "metadata": {"window": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home.  We \nrecently announced an additional strategic investment in Med ically Home, a technology company that \nenables health systems and other partners, like Cardinal Health, to safely bring the hospital home, \nwhere patients increasingly prefer to receive their care.  Not only does this hospital at home model \nbenefit patients,  it also provides needed capacity for hospitals and delivers care in a lower cost \nsetting.  \n \n And in our higher -margin Medical Services businesses OptiFreight\u00ae Logistics and WaveMark, we \ncontinue to enable clinically integrated and digitally automated suppl y chains, and are seeing growth \ndriven by an expanded customer base and diversified solutions. ", "original_text": " \nPage 6 of 13 \n \nIn at-Home Solutions, we continue to see strong demand as care continues to shift into the home. ", "page_label": "6", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c9d1942c-2092-4906-89dd-7be3ae15f10a": {"node_ids": ["f330ef66-a7ad-4e82-8b58-3d49b7458a5f", "c8eb1929-fa61-4ee7-9305-3b691eec2b84", "7bbcaa6c-59f6-41c7-b0c6-5770f82d0ab1", "54819cc6-55d2-4b3f-bb4f-12f9f34760f0", "c461a42f-79ee-4eaa-99f9-9b91acaf70d8", "bb948d6d-3d69-4a03-afe0-3d0071d4175e", "93aa5f14-fb31-4392-9bbe-5395d8ae5a2c", "5534d9b8-05fd-4c68-952f-b02c50854cd1", "5329afb4-8175-4f2f-a029-1c12a434a977", "fa76cb72-27a7-4943-bf70-1f0c32959e82", "40893f46-d54a-4780-adb0-a6bad706e396", "40555185-108b-4948-814e-03ade797ce5e", "ab752ea8-098d-4ce1-89c1-e8195d786a27", "bdaf5fd8-973f-4a8c-9cfc-e9d4ab385118", "9ecca4db-1a58-471b-82b8-a10b2b17942d", "c9c873ca-14e1-440a-bdf6-b2f69d554397", "d2eddb6e-e022-4dc8-8b53-7a9e0ac9fdf7", "ffbdb92c-3e13-42cb-8fe2-64856dcd6965", "80eb4153-a141-4221-87cf-ba5d1bdb0fcd", "b752b7f2-2695-4ec9-a9ff-55ec3fe08441", "4140fdc4-742c-4952-ae84-1ffff832137a", "a499d427-1b34-4173-9746-e843baf520b7", "6a50eeeb-f988-4bbc-acf5-55820a3c58f6", "b90bc32d-e3ec-4931-91a6-22a61a5e5551", "206b8b2c-107e-4ca3-99fb-dc18d2995378"], "metadata": {"window": " \nPage 7 of 13 \n \nrobust PET diagno stics.  For example, with the FDA approval of Telix\u2019s radiopharmaceutical in Q2, we \nare positioned to drive nationwide accessibility and broad adoption of prostate -specific PET imaging \nfor physicians and eligible patients across the United States.  \n \n And in Outcomes, we are adding new payers and PBMs and expanding clinical solutions for both \nindependent pharmacies and retail chains.  Outcomes recently activated its 20 millionth user on its \ndigital patient engagement platform, which enables two -way communicatio n between pharmacies and \npatients to increase medication adherence.  \n \n", "original_text": " \nPage 7 of 13 \n \nrobust PET diagno stics. ", "page_label": "7", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "705f3567-1c04-4e8b-b1bd-a74dd72239a1": {"node_ids": ["09281493-57a8-4ae8-ae97-182af622c839", "bf9f550c-7721-43cc-844f-322d3a9fb51e", "aab3681d-8bcb-43f3-abd6-cec49141770e", "99e6b28e-9d8e-4359-922a-805b3668d3c1", "9d9f6968-d4f0-461e-9a10-db22d21928a8", "438388f6-e34b-4a63-8e48-628bbb0cf952", "af0499a9-39df-4b0d-9545-b8028f684e9f", "1aba7f59-3a3d-4405-87fb-b93d6160e79c", "34f63745-dcd7-418a-8b45-69eec821f3be", "238b0dc2-2b41-4f46-9ee8-a0722b653a32", "9ce3089a-fac6-4997-a6a1-513f2d985d20", "0adb7022-0512-4741-a726-5e5c0c998522", "6c3d53bf-2598-42f3-9966-abca7ed6b3b5", "a66e2fff-7e15-4fed-b528-36352331fb33", "797aeb11-e70e-48fb-bc0d-6915e3c1d41c", "8d848bde-7171-4da8-bf27-80902e24f99f", "0e69eaa6-0d75-4285-b6bf-663ecf99a029", "e715e99b-645c-4aa3-90e5-3ac4baab9128", "f830f858-d9db-4727-8ae6-a260988726c2", "577d453d-e224-43b1-a74d-4c6d749b66b4", "d9e5ceb1-6d54-48b8-9223-f89eaace0ea7", "671b660e-13d1-4608-a240-c2e0a2fb0b05", "65ff7c9e-95b4-4a9f-a992-84a553d78c53", "c3b82c03-f600-415c-849c-13f0d3346367", "655a81a8-64ea-407c-8542-2db8a9fb97e6", "3d969bb9-be42-433e-9a42-84f338cd9292", "47fa4d55-28ce-4f49-81b5-ef436f075391", "7078a04e-887a-4026-8bd9-7d955d8cbc2b", "a5f94725-822b-4ed8-b136-f35f74495ffe", "67c17ff9-aef0-4d92-83c4-9332d5e5b4a7", "aa31de79-a464-4987-8ecb-cf7f3b2bfcb0", "57bafc9e-4eff-47cf-80f1-c04e460139eb", "b9c6c827-2fe0-4816-83a0-d99f82edbfe2", "1aa8f077-7243-49e4-a6b6-a6be18e9ea95", "265632a6-5754-4549-a46d-06e44b6db58c"], "metadata": {"window": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad.  If \nyou're using a speakerphone, please make sure your mute function is turned off to allow your signal \nto reach our equipment.  \n \n And we'll go ahead and take  our first question from Charles Rhyee , with Cowen and Company.  \n Please, go ahead.  \n \n", "original_text": " \nPage 8 of 13 \n \nAnd if you would like to ask a question, please signal by pressing star 1 on your telephone keypad. ", "page_label": "8", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4726abb0-ca9a-4a2c-9d35-d5b3b1a5fdb2": {"node_ids": ["6c7c1836-652c-4005-99c3-6dcd068e6c44", "4c8108aa-4e96-44a7-8a55-cd8c8c85a3db", "320cd030-07e3-4c2a-b121-cb5e342017e2", "524d9df3-9fe3-4388-91cc-cd25e2b9e608", "da8c6b86-07f4-4d8d-a23c-bcee2181bdea", "cbb4c677-2f32-4eea-b18a-771fbefa94c0", "d0fee498-497f-43b5-9f3c-44a1f288c7ef", "406685f8-de1f-486f-986f-0227c7831861", "4b6b11c0-6230-4bf3-9d37-4ee9549ba7f8", "55e0bf01-9bf0-4d0b-a441-c2355e3b570b", "eb2ae605-5318-48e0-8c5a-5847d1df53cd", "b8962395-8001-4b5e-909b-4865de0de7c1", "0595ad51-ba69-4418-bb83-5808c84b98aa", "d9078317-8511-416d-a6a5-9391dd35ade7", "40ba7804-74eb-46ab-8d35-19ea7b48b48f", "e8accf6c-a9a8-49c6-a438-43d63d4a5360", "18de2489-bfd3-4d33-aafd-30623a95cbe7", "0fcd8fcb-2c9f-4765-8af7-6d4752a76f27", "bfa84433-8a1b-47c1-bab4-406391bc3fe8", "e2364330-3920-4172-a225-d1b660d04022", "ec84a815-65c9-4fa5-b150-ca98152e7e4a", "12deb404-bb80-4c62-9633-57cd790f7a34", "fcbdc5d8-3d5f-4203-bba1-bf6b0402e1f1", "97588fc8-1492-4a80-b928-9042c440e571", "3248ffed-7540-4144-b784-9899015eca46", "844450bf-54b0-48cd-b312-14d976083a99", "5c59148e-ad22-4276-8ca4-14a507ae6250", "2fbd0858-40f8-4517-aa66-61b5be12a91f", "53ca9fc8-ece1-40bf-8c56-50475386b1b2", "ea32f2c0-529a-41e9-a5cb-e7b67cc23856", "dad0968d-eec6-4aff-bd22-6735edf5c67a", "fefff314-e519-4049-8cac-d5b43c562e7b", "624433a9-d947-4ca6-bb08-6ea8f79f7810", "e30fa7cc-88ee-49d5-9ed2-778dc13e31f8", "a4e245a7-39be-4199-9cdd-f7ae86d549ab", "4a993d9b-4140-43ef-bc71-b3d09eebdb0d", "e3661884-d59b-4b17-a41b-db31fe20b462", "2bd6de5c-5e10-4a83-b7fc-66aef2f40476", "cc2f3f35-00df-4665-8fa0-5912a19591c6", "9f791413-b78d-4c38-8ee6-90d9f7014a7a", "56d3608a-eaff-4c28-b6d5-80b8882b7add", "a3bd42d0-4188-4b3b-a995-6ad754856081", "5a44d87d-703d-42bc-9d77-8b1291bd70c1", "2ce3d17c-3c1a-4091-84ab-66ac074e4371", "a3e35f35-1ab2-4473-b500-30cd734331ac"], "metadata": {"window": " \nPage 9 of 13 \n \nactively getting after this now .  So we're not going to have a strategy of just waiting for these to come \ndown .  So we are evolving our comm ercial and contracting strategies.  That is something we're actively \ndoing. ", "original_text": " \nPage 9 of 13 \n \nactively getting after this now . ", "page_label": "9", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8c4b1766-ca74-421e-9272-c22eb00993aa": {"node_ids": ["0d07168f-344c-4e91-8a23-ae87b7710090", "51b25754-891d-4a33-bde9-dbbe0349e5a9", "0c3dfcfb-61c7-49c6-83cb-af270bdb99a1", "deb05d14-b06d-410c-9b43-4e5eed5ed1e0", "1dc1ef36-7bef-4ea5-97c1-4c6e34fce277", "cd24591d-565e-46db-aed8-c77f2bd4598c", "409572ba-d848-4c0d-9966-f6a445aec269", "2b88f1aa-f736-42b0-b514-f1e009cff485", "d45cc359-3228-4de6-a018-b2deadd9f2ea", "0beafb5b-c328-4d79-b87b-f1f5d16db3b8", "4a1096b5-e3be-4eb2-acd5-b947525f519b", "4798d375-f06f-4d2d-b422-41e3bae67f66", "ccb817c2-cbfa-45e4-9683-da7433fc6a04", "8ec6b0d8-7f53-4d19-8f79-4d5c12a3e115", "94a55e53-fa85-4357-95cd-c6943a29f52e", "6e6cb8d0-42ee-4084-9edb-081e60b92be5", "daf989b2-00f4-4ced-a5be-a77dc5d6d981", "4cc5bd73-39ec-4b59-ae9a-9d625c7fd052", "3c4d2cd4-831d-453c-9291-b291c10b0e65", "3657af96-808a-443f-af9c-860f61d072f3", "62840c34-b24b-4f44-b199-6185a492358b", "f3a802b9-fb04-4236-bee9-59a59a81a386", "ed23a65b-70b4-467d-b76e-f25c12a5f7e0", "edeac990-d822-4018-8c55-3202ce5489dd", "b714f97f-f512-4311-b4ad-b10013bf6320", "5872d0d5-f6d0-49f6-915e-36204fe0eb68", "5f872346-ea36-4cf0-acb2-caeb3e46e20f", "ca96655c-64eb-42df-a28a-569772ee17db", "3c26a927-62ca-4065-ac80-6f390332956b", "def9b295-91bd-4d4b-8278-0cfda143a631", "8d9a2c8a-217a-4ad4-aec3-3561555200e8"], "metadata": {"window": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n I think the key is, as you think about the cadence of what this impact is on a net basis that $250 to \n$300 million, we have already incurred about $100 million of that year -to-date.  That $150 to $200 \nmillion that's remaining within our guidance, we see that peaking in the third quarter, and that's a \ncombination of not only the costs we expect to be at it's highest .  And then as they start to come down \nand it takes that delay to get it actually flowing through our inventory to our P&L, tha t then we'll start \nto benefit us later in the year . ", "original_text": " \nPage 10 of 13 \n \nthe costs are moving around a lot it is - provides more challenges as it relates to getting that pricing \nmore established.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9ee7b58f-008d-4a60-9057-6bfc82226f8f": {"node_ids": ["8bd3373b-c980-46be-892e-969dac8febe1", "4819d2ee-6ff1-4228-9e0e-e6de41f085a7", "3725c1e6-dd8d-419e-806a-13e26c7c302c", "66c00aba-19d9-4a28-84e6-09919f0b5b33", "5512574d-dadf-4988-a287-628397c55fd6", "57e6518d-e97b-4acb-b7f4-f56a74792df8", "fe2a32e6-dd1d-4731-8f87-64941a19a60a", "6ddb5c50-f827-4035-9b1b-d704ecfccb85", "8f513455-9f31-495a-8383-243cf8aac3ab", "c2b371e4-ede5-42ab-b80f-91da42417016", "985ba636-0675-4304-9a25-195671318bc7", "444b601d-c56a-4d54-9599-ab73775f7f6c", "0fc1dd9f-8a58-471a-aef0-75cf2afaabdf", "0ebee5d1-ac00-455b-ad3e-58a8ec7b6f46", "29be5e65-ab08-4ad6-80b3-817174ca9e68", "c83568f4-0774-45d0-9a07-fdd629e0f2c4", "48393774-05b1-4a04-b804-6baace95b30c", "35525356-dc0d-48c8-b6a3-5eccec355b75", "e7fee178-262f-412e-afac-cce1615417b1", "ccbf56b9-a0b8-43a0-a513-f4ce6215f4bf", "fdddc7b8-c3ab-4a60-a866-db9e6e3bf135", "c3280658-e1a3-4022-a8c7-34e09e865af0", "de68868f-8c8a-46c6-9a35-08fb243dea44", "e2be6c45-5c6f-4390-9637-72cedf94b162", "f4ebb2a2-e3dd-4c1b-94a8-acac6682bf5b", "8440062c-68ff-47cc-83c9-bdcfc30835f1", "d2ce6169-6ace-432a-bf70-eb135c71e5da", "96337448-f128-4180-9bd9-69050e746959", "7e7a0334-cc8f-4da8-82ae-a4e121beebce"], "metadata": {"window": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive .  So again, wouldn't say \nit's margin generating in and of itself .  However, by increasing the capacity on so me of these items, \nlike we mentioned, doubling our ability to manufacture our own gowns, that does give us more ability \nto sell our own product, which as we drive mix, that would increase our overall margin rate.  \n \n Operator:   And we'll move on to our next q uestion from Jailendra Singh with Credit Suisse . ", "original_text": " \nPage 11 of 13 \n \nsense, and freight is a big piece of it so that we can still stay cost competitive . ", "page_label": "11", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d70cd765-d00c-45c4-a597-e34c1fd5e714": {"node_ids": ["5b3584d3-9b8b-4adc-b92a-fde80a16190d", "477ef5d9-fd5f-413c-b33e-6fd8d48b6438", "8a663665-f06b-41f9-ae17-3436c447a0fb", "9efd74a8-dcd4-4063-a7f7-114eaa925a9e", "d55238ee-4d9f-4e10-9c8b-d7c1c71a11e2", "64cfbdbd-7fa7-454d-947e-d0cabb098a54", "f0a70d93-a4bd-47cd-8255-01c1a42d2c47", "3d1882ed-e5c3-49d6-af7c-3513d0217ba8", "3c880aab-49a5-4079-a799-43e8078dd9a9", "817ecabd-73bf-4a33-8a03-f1a08847ef9a", "5c7cbd7e-d1d2-4103-bf95-9f35253d6f55", "09f30da6-22df-4319-abcc-b15efc440203", "ed0de57d-b1fa-4823-b259-473492f54da8", "0c662fd7-7996-4f63-869f-6f3f4ef79322", "67319be8-de99-4f08-a884-4ffae21c90c9", "da4756d7-8c0d-4b1c-9795-1a02404eb7ed", "f5a66642-d5b2-4c03-891d-de07dd0fbe9f", "9e7e4520-e385-4509-b7d2-7918517d1ad8", "af88e9ec-f419-481f-9cb8-fd91f7d83952", "1bcc3176-d3c7-4bae-a302-9ce001a97e42", "c6353a08-304a-4382-95df-6ad18c311f4a", "9a95b8af-cec1-49a8-b63e-c54eb0de905f", "c0ca695a-ed8a-4795-9bec-c635a37d9540", "e3ed4f66-a831-4a1a-b523-85daa49d2afd", "2871197d-f858-450a-94b3-156f785288e4", "bca25f42-2f6b-477d-8451-f8a9dfa833a7", "3ddb4a68-7280-4ebd-81dc-b54f91235fa1", "aa35469a-7253-44d1-85b3-73ff8b40b759", "9951aee1-1a45-4a3b-967f-dc83d9a556cc", "08b0c490-fd3c-4fe6-8b2e-b92e8ce6f54b"], "metadata": {"window": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica .  Please go ahead.  \n \n Michael  Cherny :  Good morning .  Thanks for the details . ", "original_text": " \nPage 12 of 13 \n \n \nOperator:   And w e'll go ahead and move on to our next question from Micha el Cherny  with Bank of \nAmerica . ", "page_label": "12", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8907c44d-35d5-4c1c-94e7-c83f81f9c5e7": {"node_ids": ["bb45d58e-8a9d-44e8-8207-5eee18ebeb2b", "11d5b1c0-f007-4974-a6bd-b65078219561", "71a36ced-3a8a-4db7-b7fd-739e60f3f32b", "afdaebe8-46b8-49a7-8991-e3afb1ecdb1a", "589c5760-87c3-4ec6-b2d2-b8e448f83196", "09933c53-3eba-42c1-816e-cd993e9c8a4d", "c4e40dfc-d41c-4004-8f1f-f27b879f817d", "2c2061d0-c3e2-4215-bc7c-cb0fdc47cc28", "53cc5cfb-36af-41f9-a871-eb50239fe5d4", "463fcd49-d2aa-49eb-afff-0a81e523730a", "75292374-cc01-4414-8d31-bd1b882b6033", "8bc690af-e017-4c37-b145-d483c4e180e9", "3be02d27-d638-483b-84c7-faf0c647cd80"], "metadata": {"window": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels .  And we \nhave largely gotten back to that point at the end of the second quarter .  And so we're just not seeing a \nlot of variability there as well.  \n \n Operator:   And with that, that does conclude our question -and-answer session  for today . ", "original_text": " \nPage 13 of 13 \n \nOn the Pharma side, we continued to talk in today's prepared remarks, as well as a couple weeks \nago, just that we continue to see that widespread improvement back to pre -COVID l evels . ", "page_label": "13", "file_name": "CAH-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 177784, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}